Replimune Group, Inc.

TABLE OF CONTENTS
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended March 31, 2024
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to
Commission file number 001-38596
REPLIMUNE GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware
82-2082553
(State or other jurisdiction of

incorporation or organization)
(I.R.S. Employer 

Identification No.)
500 Unicorn Park Drive
Suite 303
Woburn MA 01801
(Address of principal executive offices)
(Zip Code)
(781) 222-9600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
REPL
The Nasdaq Stock Market LLC (Nasdaq Global
Select Market)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements. ☐
Indicate by check mark whether any of those corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No x
The aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $605.6 million, based on the closing price of the registrant’s Common
Stock on September 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter.
There were 61,415,105 shares of Common Stock outstanding as of May 13, 2024.
DOCUMENTS INCORPORATED BY REFERENCE
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended March 31, 2024. Portions of such definitive
proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.


TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
ANNUAL REPORT ON FORM 10-K
For the Year Ended March 31, 2024
Table of Contents
Page No.
PART I
1
Item 1.
Business
1
Item 1A.
Risk factors
24
Item 1B.
Unresolved staff comments
58
Item 1C.
Cybersecurity
58
Item 2.
Properties
58
Item 3.
Legal proceedings
59
Item 4.
Mine safety disclosures
59
PART II
60
Item 5.
Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities
60
Item 6.
Reserved
60
Item 7.
Management’s discussion and analysis of financial condition and results of operations
60
Item 7A.
Quantitative and qualitative disclosures about market risk
71
Item 8.
Financial statements and supplementary data
71
Item 9
Changes in and disagreements with accountants on accounting and financial disclosures
71
Item 9A.
Controls and procedures
71
Item 9B
Other Information
72
Item 9C
Disclosure regarding foreign jurisdictions that prevent inspections
73
PART III
74
Item 10.
Directors, executive officers and corporate governance
74
Item 11.
Executive compensation
74
Item 12.
Security ownership of certain beneficial owners and management and related stockholder matters
74
Item 13.
Certain relationships and related transactions, and director independence
74
Item 14.
Principal accountant fees and services
75
PART IV
76
Item 15.
Exhibits and financial statement schedules
76
Item 16.
10-K summary
76
SIGNATURES
i

TABLE OF CONTENTS
Special note regarding forward-looking statements
This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding our expectations about our cash
runway, the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of
our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and
the timing thereof, and other statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and
expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as
“outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,”
“estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks
and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated
in these statements. We believe these factors include, among other things:
•
the timing, progress, and results of preclinical studies and clinical trials for our product candidates, including the timing of initiation and
completion of studies or trials and related preparatory work and the period during which the results of the trials will become available;
•
our ability to obtain additional funding as necessary;
•
the timing, scope or likelihood of regulatory filings and approvals, including timing of our Biologics License Application, or BLA, and filing
for, and final approval by the U.S. Food and Drug Administration, or the FDA, of, RP1 or any of our other product candidates;
•
the timing, scope, or likelihood of foreign regulatory filings and approvals;
•
our ability to develop our product candidates for use in combination with other checkpoint blockade therapies, including anti-PD-1;
•
our ability to develop and advance any future product candidates into, and successfully complete, clinical trials;
•
our expectations regarding the size of the patient populations for RP1, RP2 and/or RP3 or any other product candidates from our RPx
platform if approved for commercial use;
•
our ability to successfully qualify, obtain approval for, and maintain successful operation, approval and qualification of our in-house
manufacturing operations;
•
our ability to obtain and maintain sufficient quantities of raw material supplies or access single or limited sources of goods or services needed
to build or maintain our product candidate supplies or otherwise operate our in-house manufacturing facility;
•
the costs of operating our in-house manufacturing facility;
•
our estimates regarding expenses and capital requirements;
•
the implementation of our business model and our strategic plans for our business, RP1 and our other product candidates;
•
the rate and degree of market acceptance and clinical utility of RP1 and our other product candidates;
•
the potential benefits of and our ability to establish or maintain future collaborations or strategic relationships;
•
our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;
•
our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights
covering RP1 and our other product candidates, claims others may make regarding rights in our intellectual property, and any potential
infringement, misappropriation or other violation of any third-party intellectual property rights;
•
our competitive position, and developments and projections relating to our competitors and our industry;
•
negative developments in the fields of immuno-oncology or oncolytic immunotherapy;
•
the impact of laws and regulations; and
•
the other risks and uncertainties described under “Risk factors.”
ii

TABLE OF CONTENTS
The forward-looking statements made in this Annual Report on Form 10-K relate only to events as of the date on which the statements are made.
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Annual
Report on Form 10-K. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time,
and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual
Report on Form 10-K. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,
future developments or otherwise, except to the extent required by applicable law. You should not rely on forward-looking statements as predictions of
future events. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place
undue reliance on our forward-looking statements.
iii

TABLE OF CONTENTS
PART I
Item 1.    Business
Overview
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the
lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and
intended to maximally activate the immune system against cancer.
Oncolytic immunotherapy is an emerging drug class, which we intend to establish as the second cornerstone of immune-based cancer treatments,
alongside checkpoint blockade. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well
as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms into a practical “off-the-shelf”
approach that is intended to maximize the immune response against a patient’s cancer and to offer significant advantages over other approaches to inducing
anti-tumor immunity, including personalized vaccine approaches. We believe that the bundling of multiple approaches for the treatment of cancer into
single therapies may improve patient outcomes and simplify the development path of our product candidates.
Our proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize
immunogenic cell death and the induction of a systemic anti-tumor immune response. Our RPx platform is intended to have unique dual local and systemic
activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor
microenvironment to ignite a strong and durable systemic response. Our product candidates are expected to be synergistic with most established and
experimental cancer treatment modalities, and, with an attractive safety profile our RPx platform is expected to have the versatility to be developed alone or
combined with a variety of other treatment options. We currently have three RPx product candidates in our portfolio, RP1 (vusolimogene oderparepvec),
our lead product candidate, RP2 and RP3. Although our fiscal year ends March 31st, our programs and program updates are reported on a calendar year
basis.
We are conducting a number of clinical trials of RP1, both as a monotherapy and in combination with anti-PD-1 therapy, with a focus on establishing a
major skin cancer franchise.
Our leading clinical trial of RP1 is our IGNYTE trial, a multi-cohort Phase 1/2 clinical trial being conducted in collaboration with Bristol Myers
Squibb Company, or BMS, under which BMS has granted us a non-exclusive, royalty-free license to, and is supplying at no cost, its anti-PD-1 therapy,
nivolumab, for use in combination with RP1. The leading tumor specific cohort in the IGNYTE trial is our registration directed Phase 2 expansion cohort
enrolling patients with anti-PD-1 failed cutaneous melanoma who are being treated with RP1 in combination with nivolumab. In December 2023, we
reported the full data set of 156 patients (140 patients from the registration-directed expansion cohort and 16 anti-PD1 failed cutaneous melanoma patients
from the prior phase 2 cohort), by investigator assessment, with an overall response rate, or ORR, of 31.4% and a complete response rate, or CR, of 12%.
RP1 combined with nivolumab continues to be well-tolerated, with mainly Grade 1-2 “on target” side effects, observed. Following a Type C meeting with
the U.S. Food and Drug Administration, or FDA, a Phase 3 study design was agreed. This confirmatory study, our IGNYTE-3 trial, is a randomized,
controlled, multicenter, open-label Phase 3 clinical study comparing RP1 in combination with nivolumab versus physician's choice treatment for patients
with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered
either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy. The FDA requested that the
IGNYTE-3 trial be underway at the time of a BLA submission under the accelerated approval pathway and we plan to enroll patients into this trial in the
second half of 2024. The FDA also indicated that all responding patients in the IGNYTE anti-PD-1 failed cohort of melanoma patients should be followed
for at least 6 months with assessments completed through independent central review using RECIST v1.1, in addition to modified RECIST used in the
study. Topline primary data from RP1 in combination with nivolumab in anti-PD-1 failed melanoma patients is expected in the second quarter of 2024 and
we plan to submit a BLA for this cohort in the second half of 2024.
In our non-melanoma skin cancer, or NMSC, cohort of the IGNYTE clinical trial, we provided a data update in December 2023 from the first 30
patients with at least 6 months of follow up including patients with cutaneous squamous cell carcinoma, or CSCC, Merkel cell carcinoma, or MCC, basal
cell carcinoma, and angiosarcoma in this cohort. The data showed that treatment with RP1 in combination with nivolumab led to an ORR of 30% which is
consistent with data from the anti-PD-1 failed melanoma cohort with approximately one-third of patients responding and 60% demonstrating clinical
benefit. The
1

TABLE OF CONTENTS
combination of RP1 and nivolumab was well tolerated in this patient population with a safety profile consistent with the overall experience seen with this
treatment regimen to date. Enrollment remains open in this cohort.
Furthering development of our RP1 clinical candidate, we have open for enrollment a Phase 1b/2 clinical trial of single agent RP1 in solid organ
transplant recipients with skin cancers, including CSCC, which is referred to herein as ARTACUS or the ARTACUS trial, which we believe to be
potentially registrational (subject to discussion with regulatory authorities). We are currently enrolling up to 65 patients in the ARTACUS trial to assess the
safety and efficacy of RP1 in liver, kidney, heart, lung, and hematopoietic cell transplant patients with skin cancers. In November 2023 we presented initial
data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancers at the Society for Immunotherapy of
Cancer’s, or SITC, 38th Annual Meeting. The data included 23 evaluable patients with CSCC (n=20) and MCC (n=3), demonstrating an ORR of 34.8%
with responses observed in 6 CSCC patients and 2 patients with MCC. Additional biomarker data collected showed an increase in CD+8 T, a type of
immune cell, and an increase in the expression of PD-L1, after treatment suggesting immune activation. RP1 monotherapy was well tolerated in these
patients and the safety profile was similar to that observed in our other RP1 clinical trials in patients who are not immune suppressed. No immune-mediated
adverse events or evidence of allograft rejection were observed. This data was also presented during oral presentation at the American Association of
Cancer Research, or AACR, 2024 Annual Meeting in April 2024. We continue to enroll patients into this trial.
As reported in December, our randomized, controlled Phase-2 clinical trial of RP1 with CSCC, referred to as CERPASS or the CERPASS trial, under
agreement with our partner Regeneron did not meet either of the two primary endpoints. RP1 in combination with cemiplimab increased the CRR versus
cemiplimab alone (38.1% vs. 25%, p=0.040), which was just short of the required threshold for statistical significance in this study. The ORR was
comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692). Notably, among the 83 patients
with locally advanced disease, the complete response rate in the RP1 plus cemiplimab group was 48.1% versus 22.6% in the cemiplimab only group. RP1
in combination with cemiplimab increased duration of response, or DOR, as compared to cemiplimab alone. The CERPASS trial will continue as planned
to assess DOR, progression free survival, or PFS, and overall survival, or OS, with greater maturity.
We are also developing or have been developing additional product candidates, RP2 and RP3, that have been further engineered to enhance anti-tumor
immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. In addition to the
expression of GALV-GP R(-) and human GM-CSF as in RP1, RP2 has been engineered to express an antibody-like molecule intended to block the activity
of CTLA-4, a protein that inhibits the full activation of an immune response, including to tumors. RP3 has been engineered with the intent to further
stimulate an anti-tumor immune response through activation of immune co-stimulatory pathways through the additional expression of the ligands for CD40
and 4-1BBL, as well as anti-CTLA-4 and GALV-GP R(-), but without the expression of GM-CSF.
We continue the development of our clinical candidate RP2 with a focus on establishing a rare cancer franchise.
Notably, as previously reported, from our Phase-1 clinical trial of RP2 alone and in combination with nivolumab, we have seen durable responses from
a monotherapy cohort in a variety of difficult to treat tumors as well as in combination with anti-PD1 and in particular in patients with uveal melanoma,
among other tumor types. In November 2023, we presented updated data from a cohort of metastatic uveal melanoma patients during a Plenary Session at
the 20th Annual International Society for Melanoma Research Congress. The updated data showed RP2 led to an ORR of 29.4 percent (5 of 17 patients;
one of the responding patients was treated with RP2 monotherapy and four of the responding patients were treated with RP2 combined with nivolumab),
including responses in patients with liver, lung, and bone metastases. The median DOR at the data cutoff was 11.47 months (range of 2.78 to 21.22 with
responses ongoing). Nearly all patients (15 of 17, 88.2%) in the study had progressed on or after immunotherapy with 12 of 17 patients (70.6%) having
previously received both anti-PD1 and anti-CTLA-4 therapies, including four of the responding patients. RP2 was generally well tolerated both as
monotherapy and in combination with nivolumab with no additive adverse events observed. The most common grade 1 or 2 treatment related adverse
events, or TRAEs, overall in both cohorts were pyrexia, chills, fatigue, hypotension and pruritis. Six patients had grade 3 TRAEs, including two cases of
hypotension and no patients had grade 4 or 5 TRAEs. Based on the data in this population, we are near final in the development of a registrational clinical
trial protocol with RP2 combined with nivolumab in advanced uveal melanoma following input from the FDA.
As previously announced, our development program in hepatocellular carcinoma, or HCC, that we are collaborating on with Roche for the supply of its
currently approved drugs, atezolizumab and bevacizumab, has been limited to the 2L setting and will use RP2 rather than RP3. The Phase 2 clinical trial
with RP2 in anti-PD1/PD-L1 progressed HCC with RP2 combined with atezolizumab and bevacizumab is expected to initiate in the second half of 2024.
2

TABLE OF CONTENTS
Although our RP2/3 development in squamous cell carcinoma of the head and neck and colorectal cancer, or CRC, have been discontinued, as
previously announced, we are continuing to treat patients who were already in screening or enrolled in these trials before the trials were discontinued.
RP1, RP2 and RP3 are administered by direct injection into solid tumors, guided either visually or by ultrasound, computerized tomography or other
imaging methods. We believe that direct injection maximizes virus-mediated tumor cell death, provides the most efficient delivery of virus-encoded
immune activating proteins into the tumor with the goal of activating systemic immunity, and limits the systemic toxicities that could be associated with
intravenous administration. Activation of systemic immunity through local administration is intended to lead to the induction of anti-tumor immune
responses leading to clinical response of tumors that have not themselves been injected.
Our approach — Oncolytic immunotherapy
Our product candidates are designed to induce a robust immune response against a patient’s cancer. To achieve this objective, we use oncolytic
immunotherapies that combine multiple mechanisms in a single product candidate. We believe our product candidates will initiate or enhance an immune
response in patients with no or minimal pre-existing cancer immunity, including to tumor neo-antigens, and thereby increase the effectiveness of immune
checkpoint blockade therapies.
Our product candidates are intended to act at several key points in the pathways involved in the initiation of an immune response. Following direct
injection into tumors, our viruses replicate in cancer cells and then lyse, or break them open, releasing tumor antigens, including neo-antigens specific to
the patient, which could otherwise be hidden from the immune system. This process of necrotic cell death releases intra-cellular markers of “danger,” the
danger associated molecular patterns, or DAMPs, while the virus produces pathogen associated markers of danger, or PAMPs. These trigger various
pathways of the innate immune system, including the STING pathway and pathways mediated through toll-like receptors, or TLRs, each resulting in the
production of interferon. Innate immune activation would be expected to itself provide anti-tumor effects, as interferon activates natural killer cells which
can destroy tumor cells. Innate immune activation would also be expected to help trigger adaptive anti-cancer immunity, in which antigen presenting cells,
or APCs, are attracted to the injected tumor. APCs internalize cancer antigens, including neo-antigens, and traffic back to the draining lymph nodes where
they present the antigens to T cells. Primed with the antigens, these T cells then proliferate and disperse systemically to seek and destroy cancer cells with
the same antigen profile throughout the body, resulting in the potential destruction of distant tumor deposits.
To further augment these intended effects, our product candidates are genetically encoded with multiple potent, cell-killing and immune-stimulating
proteins — in other words, our product candidates are “armed” with these therapeutic genes.
We believe that our ability to incorporate multiple mechanisms of action into a practical “off-the-shelf” approach to initiating or enhancing an anti-
tumor immune response, including to neo-antigens, will offer significant advantages over the various approaches to immune activation that are currently in
development, including personalized vaccine treatments. Tumor neo-antigens are uniquely present in tumors, rather than normal tissue, because they result
from the genetic changes that occur as cancer develops. Unlike the antigens present in normal tissue, the immune system identifies neo-antigens as foreign.
As a result, the immune system is able to mount an immune response to tumor neo-antigens in the same way that it would to the antigens contained in
disease-causing micro-organisms, which the immune system also identifies as foreign. Researchers believe immune responses to tumor neo-antigens are
particularly important in the immune system’s ability to combat cancer, and as a consequence various “personalized vaccine” approaches to generating
immune responses to tumor neo-antigens are in development. These approaches are generally both expensive and time consuming because a vaccine cannot
be designed and manufactured until a tumor biopsy is taken and analyzed in the laboratory to identify the mutated tumor antigens that will be targeted by
the treatment. We also believe that our “off-the-shelf” approach may offer significant advantages over other approaches to anti-cancer immune activation
that only target a single pathway of the immune system, as is the case with most of the other immuno-oncology therapies currently under development.
Importantly, our product candidates are intended to maximally activate an immune response against cancer, which we believe is the missing element
needed to allow anti-PD-1 or anti-PD(L)-1 therapy to treat more patients and tumor types, unlike some other therapies that are intended to act by blocking
additional defense mechanisms against an anti-tumor immune response once it has been initiated.
3

TABLE OF CONTENTS
Our Oncolytic Immunotherapy platform and product candidates
Our current product candidate pipeline is summarized in the table below:
The foundation of our oncolytic immunotherapy product candidates consists of a proprietary strain of HSV-1 that we have engineered to replicate
selectively in tumors and to express a fusogenic glycoprotein, a protein that triggers the fusion of the membranes between cells. HSV-1 is both highly cell
lytic and inflammatory, and also has a large carrying capacity, which makes it possible to incorporate multiple genes encoding therapeutic proteins. We
believe our combination of HSV-1 with the expression of the fusogenic glycoprotein increases the natural ability of HSV-1 to kill tumor cells and to induce
an anti-tumor immune response. The fusogenic functionality of our product candidates is intended not only to increase the number of tumor cells that are
killed, but also to cause highly immunogenic death of tumor cells. We believe that these factors will increase the potency of the systemic anti-tumor
immune response that is generated by our product candidates. With the intention of further amplifying the anti-tumor response, we have also engineered
product candidates that express a range of additional potent, immune activating genes encoding therapeutic proteins in tumors.
RP1 serves as our lead product candidate, with additional product candidates, RP2 and RP3, designed to express additional therapeutic proteins. We
believe that our development approach of further enhancing our product candidates with additional therapeutic proteins reduces clinical risk, as we are able
to study the safety profile of each therapeutic protein that is intended to provide more potent anti-tumor immune effects.
Lead product candidate: RP1
Our lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. RP1 has the
following properties:
•
we have deleted the ICP34.5-encoding gene, which enables tumor-selective virus replication;
•
we have deleted the ICP47-encoding gene, which is intended to prevent the inhibition of the antigen presentation pathway otherwise caused by
ICP47 binding to the transporter associated with antigen presentation. ICP47 deletion is also intended to result in the increased and earlier
expression of the HSV-1 US11 gene by placing the HSV-1 US11 gene under the control of ICP47 promoter which we believe will increase virus
replication in tumors without reducing tumor-selectivity; and
4

TABLE OF CONTENTS
•
we have inserted the sequences for GALV-GP R(-) and human GM-CSF, resulting in the expression of these therapeutic proteins with the intention
of increasing both the direct tumor cell killing and the potency of the anti-tumor immune response that is induced.
We have developed RP1 as a monotherapy and for use in combination with immune checkpoint blockade therapy, particularly therapies targeting PD-1
or PD-(L)-1. We believe that the robust release of tumor antigens and the highly immunogenic tumor cell death intended to be caused by RP1 will further
increase the previously observed synergy between oncolytic viruses and immune checkpoint blockade therapy.
Pipeline product candidates: RP2 and RP3
We have designed our RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response
otherwise caused by CTLA-4. We believe that RP2 may offer advantages compared with current CTLA-4 approaches, including ipilimumab. By expressing
anti-CTLA-4 only locally in the tumor and draining lymph nodes, we believe that activity will be retained, but that toxicity will be reduced. We expect that
our RP2 product candidate will be used as monotherapy and/or in combination with other treatment approaches, including anti-PD-1 therapy, which, when
used in combination, we believe will result in both synergy with the oncolytic immunotherapy and the expression of anti-CTLA-4 in the tumor.
We have designed our RP3 product candidate to express further immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and
GALV-GP R(-). These immune activating proteins are the ligands for two immune co-stimulatory pathways responsible for T cell proliferation and/or
activation, the CD40L and 4-1BBL pathways. As previously announced, we have discontinued development of RP3 at this time.
Intellectual property
We believe our rights under our issued patents and, anticipated future patents from our patent applications, will provide a competitive advantage. Our
success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate
without infringing the proprietary rights of others and to prevent others from infringing upon our proprietary rights. Our policy is to seek to protect our
proprietary position by, among other methods, filing United States and foreign patent applications related to our proprietary technology, inventions and
improvements that are important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to
develop and maintain our proprietary position.
For the core technology in our RPx platform and each of our product candidates, we initially filed six patent applications under the Patent Cooperation
Treaty, or PCT. All six of these PCT applications have entered the national phase and are in different stages of pending and/or issued in a range of
countries. Patent examination has started and continues in these national phase applications. Six U.S. patents have been granted by the applicable
authorities in the U.S. Four patents have been granted by the applicable authorities in each of the European Union and Japan. Three patents have been
granted by the applicable authorities in Hong Kong, two patents have been granted by the applicable authorities in each of China and Israel and one patent
has been granted by the applicable authorities in each of Singapore, India, Mexico and Australia. The granted U.S. patents include US patent numbers
10,570,377; 10,612,005; 10,626,377; 10,947,513; 11,427,810; and 11,473,063 and include description and claims directed to oncolytic virus compositions
of matter, pharmaceutical compositions encompassing an oncolytic virus and methods of use in treating cancer with oncolytic virus compositions. We have
successfully defended all oppositions that have been brought by third-parties against our issued patents to-date and have maintained our proprietary
position. We continue to vigorously pursue advancement and defense of our patents and patent applications through the respective patent offices in which
they are granted or pending throughout the world. See "Risk Factors - Risk Related to Intellectual Property."
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In many countries in which we
file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the patent term of a patent that
covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration of a portion of the patent term lost
during the U.S. clinical development and FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years
beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under clinical development in the
United States and the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in
Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA
approval, and if
5

TABLE OF CONTENTS
and when patents grant, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of
our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the
United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
We may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part,
by confidentiality agreements with our employees, consultants, scientific advisors and other contractors, as well as physical security of our premises and
our information technology systems.
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on
proprietary rights. We compete in the highly competitive markets that address cancer and face significant competition from many sources, including
pharmaceutical, biopharmaceutical and biotechnology companies, as well as universities and private and public research institutions. Many of our
competitors have significantly greater financial, manufacturing, marketing and drug development resources than we do. Large biopharmaceutical
companies in particular have extensive experience in clinical testing and in obtaining regulatory approvals for drugs and biologicals. These companies also
have significantly greater research capabilities than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies or universities and research institutions.
Our competitors fall primarily into the following groups of treatment:
•
traditional cancer therapies, including chemotherapy, surgery, radiation and targeted therapies;
•
approved immunotherapy antibodies and immunotherapy antibodies in clinical trials;
•
oncolytic immunotherapies, including T-Vec and other oncolytic immunotherapies in clinical trials;
•
therapies aimed at activating innate immunity such as those targeting STING and TLRs;
•
cancer vaccines including personalized vaccines and those targeting tumor neo-antigens; and
•
cell-based therapies, such as CAR-T, T cell receptor-based, and natural killer, or NK, cell therapies.
Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have
fewer side effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we may develop alone
or in combination with other therapies, especially if these get to market sooner than our products. These third parties also compete with us in recruiting and
retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies and technology licenses complementary to our programs or advantageous to our business.
Our oncolytic product candidates, if and when marketed, will compete with a number of drugs that are currently marketed or in development that also
target cancer but that utilize a different mechanism of action. To compete effectively with these agents, our product candidates will need to demonstrate
advantages that lead to improved clinical efficacy and safety compared with these competitors. At the same time, however, we believe that our oncolytic
product candidates, if and when ultimately marketed, would likely be used principally in combination with checkpoint blockade therapies in addition to
existing cancer therapies, including surgery, chemotherapy, radiation therapy and other biological therapies such as antibodies targeting particular surface
receptors. We therefore believe that our product candidates, if and when marketed, would largely complement rather than compete directly with some of
these existing treatment options.
We do, however, expect to face direct and increasing competition from a number of companies that are also seeking to develop cancer therapies based
on oncolytic viruses and other ways to prime the immune system, including neo-antigen vaccination. We believe that our ability to successfully compete
will depend, among other things, on our ability to:
•
expeditiously advance the development of our product candidates;
•
design, enroll patients in and successfully complete appropriate clinical trials in a timely fashion;
•
gain regulatory approval for our product candidates in their first indications as well as further indications;
•
establish collaborations and partnerships for the development and marketing of our product candidates;
•
commercialize our product candidates successfully, including demonstrating the safety and efficacy of our product candidates over currently
approved therapies to physicians, insurers and third-party payors;
6

TABLE OF CONTENTS
•
secure sufficient coverage from insurers and other payors;
•
secure, maintain and protect intellectual property rights based on our innovations; and
•
manufacture or otherwise obtain and sell commercial quantities of future products to the market.
Manufacturing and suppliers
We have established an operations leadership team with what we believe is extensive experience in manufacturing biologics based on viruses,
including oncolytic products and gene therapy products, and in the construction, validation, operation and approval of facilities for the manufacture and
filling of complex biological products. Our team has already developed a robust and reproducible manufacturing process for our product candidates. We are
also developing our product candidates for maximum practicality of use compared with some other oncolytic immunotherapies.
Traditionally, our third-party contract manufacturer in Europe had been responsible for the cGMP manufacture and filling of our product candidates for
use in our clinical trials. We have established our raw material supply chain for our product candidates as part of the process of establishing and qualifying
our own manufacturing facility and intend to enter into commercial supply, collaboration or similar agreements as needed to continue to operate the in-
house manufacturing of our product candidates for our clinical trials and, if approved, build commercial supply of our products.
Our approximately 63,000 square foot manufacturing facility in Framingham, Massachusetts is fully operational. We have completed the process of
transferring the manufacturing of RP1, RP2 and RP3 from our third-party contract manufacturer. Comparability analysis of RP1, RP2 and RP3 produced at
our Framingham facility with the contract manufacturer material used in our clinical studies is complete. The FDA and some European regulatory agencies
have approved the use of material produced at Framingham in ongoing and future clinical trials. We plan to operate our in-house manufacturing facility in
order to secure our product candidates for our ongoing and planned clinical studies and, if approved, commercial launch and supply. The facility has been
designed to allow us to produce enough material to cover full global commercialization of all our current product candidates. The facility is intended to
give us control over key aspects of the supply chain for our products and product candidates. We recently completed a successful Type C meeting with the
FDA that confirmed alignment on our chemistry, manufacturing, and controls, or CMC, plans to support our BLA submission for RP1 in the second half of
2024.
By establishing our own manufacturing facility, we aim to minimize or eliminate our reliance on contract manufacturing organizations, which typically
have limited capacity at commercial scale and long-lead time to conduct manufacturing campaigns. We believe that having control over the whole
manufacturing process will allow us to reduce cycle times and cost of goods for commercial production and to shorten overall timelines for new product
candidates in our development pipeline, as well as help us to develop drug formulations or presentations to simplify distribution and/or administration of
future oncolytic immunotherapies. We also believe that having a dedicated manufacturing facility will allow us to optimize commercial-scale processes and
to ensure security of supply to support market launch and commercialization of our product candidates, if approved.
Sales and marketing
None of our product candidates have been approved for sale. If and when our product candidates receive marketing approval, we intend to
commercialize them on our own in the United States and potentially with pharmaceutical or biotechnology partners in other geographies. We continue to
build our in-house sales, marketing and commercialization capabilities with the addition of sales, marketing, trade and distribution, as well as other related
expertise. Clinical data, the size of the opportunity for our product candidates, and the size of the commercial infrastructure required will influence our
commercialization plans and decision making.
Collaborations
BMS
In February 2018, we entered into a Clinical Trial Collaboration and Supply Agreement with BMS. Pursuant to the agreement, BMS is providing to us,
at no cost, nivolumab, its anti-PD-1 therapy, for use in combination with RP1 in our ongoing Phase 1/2 clinical trial. Under the agreement, we will sponsor,
fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted us a non-exclusive, non-transferrable, royalty-free license
(with a right to sublicense) under its intellectual property to use nivolumab in the clinical trial and has agreed to supply nivolumab, at no cost to us, for use
in the clinical trial. Both parties will own the study data produced in the clinical trial, other than study data related solely to nivolumab, which will belong
solely to BMS, or study data related solely to RP1, which will belong solely to us. In January 2020, this agreement was expanded to cover an additional
cohort of 125 patients with anti-PD-1 failed melanoma.
7

TABLE OF CONTENTS
Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been
delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis
otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party,
(y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to us to use
nivolumab in the clinical trial will terminate. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction
of this nature.
In April 2019, we entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to
which BMS will provide, at no cost to us, nivolumab for use in our Phase 1 clinical trial of RP2 in combination with nivolumab.
Regeneron
In May 2018, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron. Pursuant to the agreement we agreed to
undertake one or more clinical trials with Regeneron for the administration of our product candidates in combination with cemiplimab, an anti-PD-1
therapy developed by Regeneron, across multiple solid tumor types. The first of which, agreed in June 2018, is our ongoing clinical trial testing RP1 in
combination with cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted pursuant to an agreed study plan
which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and
a schedule of clinical obligations.
Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to
contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. The Company does not
expect any further reimbursements from Regeneron related to the initial study plan of June 2018 and the CERPASS trial. The agreement contains
representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based
covenants that restrict us from entering into a third-party arrangement with respect to the use of our product candidates in combination with an anti-PD-1
therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus,
in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a
future study plan, these covenants are only applicable to our ongoing Phase 2 clinical trial in CSCC.
The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the
parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or
(ii) in the event of a material breach.
Roche
In December 2022, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to our RP2 and RP3 programs
in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate in 30 patient cohort
signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following our re-prioritization of our
product development portfolio in December 2023, we have agreed with Roche to terminate the CRC collaboration and pursue the 2L cohort in HCC with
RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs, atezolizumab and bevacizumab for the 2L cohort in HCC but is
unlikely to share costs following our re-prioritization. We are in discussions with Roche about revising these agreements following our changes to our RP2
and RP3 development plans. Under the terms of the initial agreement we retained the responsibility of operating the clinical trials as well as retaining all the
rights to the development and commercialization of our product candidates. The agreement may be terminated by either party upon sixty days prior written
notice to the other party.
Incyte
In July 2023, we entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the
companies anticipate collaborating in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor)
and RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, we will supply
Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach
not reasonably cured within thirty days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices
of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety days of the effective date of the agreement. In addition, the
Company may terminate the agreement upon the inappropriate or unsafe use of the RP1
8

TABLE OF CONTENTS
product candidate. As of March 31, 2024, we and Incyte had not yet agreed on the protocol or budget. However, we and Incyte continue to discuss a
potential protocol and neither party has triggered termination of the agreement in accordance with the termination right described in clause (iv) above. The
parties are evaluating potential collaboration efforts pending further CERPASS data readout of RP1 in combination with cemiplimab and additional data for
Incyte's product candidate INCB99280.
Regulatory matters
Government authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other things, the
research, development, testing, approval, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import,
and export of biopharmaceutical products such as those we are developing. In addition, manufacturers of biopharmaceutical products participating in
Medicaid and Medicare are required to comply with mandatory price reporting, discount, and rebate requirements. The processes for obtaining regulatory
approvals in the United States and in foreign countries, along with compliance with applicable statutes and regulations, require the expenditure of
substantial time and financial resources. Regulatory requirements are also continually evolving. By example, the FDA and governmental authorities in
other countries have issued a growing body of guidance documents on various regulatory matters, including those specific to cell and gene therapy
development. While FDA’s guidance is not binding, it does provide FDA’s current interpretation and approach.
FDA and EU regulation
In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Services Act, or
PHSA, and their implementing regulations. The process required by the FDA before product candidates may be marketed in the United States generally
involves the following:
•
completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with good laboratory practice, or GLP,
regulations;
•
submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin at
United States clinical trial sites;
•
approval by an institutional review board, or IRB, for each clinical site, or centrally, before each trial may be initiated;
•
performance of adequate and well-controlled human clinical trials to establish the safety, purity, and potency of the proposed product candidate for
its intended use, performed in accordance with good clinical practices, or GCPs;
•
development and maintenance of manufacturing processes to ensure the product candidate’s identity, strength, quality, purity, and potency;
•
preparation and submission to the FDA of a BLA;
•
satisfactory completion of an FDA advisory committee review, if applicable;
•
satisfactory completion of an FDA inspection or remote regulatory assessment of the manufacturing facility or facilities at which the products are
produced to assess compliance with current good manufacturing practices, or cGMPs, and to assure that the facilities, methods, and controls are
adequate to preserve the therapeutics’ identity, strength, quality, purity, and potency as well as satisfactory completion of an FDA inspection or
remote regulatory assessment of selected clinical sites and selected clinical investigators to determine GCP compliance; and
•
FDA review and approval of the BLA to permit commercial marketing for particular indications for use.
The process in the European Union and other countries with developed regulatory regimes is broadly comparable.
Preclinical studies and IND submission
The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA’s and other
countries’ regulatory authorities’ pre-market approval requirements typically takes many years and the actual time required may vary substantially based
upon the type, complexity, and novelty of the product or disease. Preclinical studies include laboratory evaluation of chemistry, pharmacology, toxicity, and
product formulation, as well as animal studies to assess potential safety and efficacy. Such studies must generally be conducted in accordance with GLPs.
Prior to commencing the first clinical trial at a United States or other country’s investigational site with a product candidate, an IND sponsor must submit
the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data, any available clinical data or literature,
and proposed clinical study protocols among other things, to the FDA as part of an IND (or equivalent in other countries). Additional preclinical testing,
such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.
9

TABLE OF CONTENTS
An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, notifies the applicant of
safety concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the
FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during
trials due to safety concerns or non-compliance. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. A
separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.
Clinical trials
Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance
with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their
participation in any clinical trial, as well as review and approval of the study by an IRB. Investigators must also provide certain information to the clinical
trial sponsors to allow the sponsors to make certain financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety, the effectiveness criteria to be evaluated, and a
statistical analysis plan. A protocol for each clinical trial, and any subsequent protocol amendments, must be submitted to the FDA as part of the IND.
Sponsors will also be required to provide FDA with diversity action plans. In addition, an IRB at each study site participating in the clinical trial or a
central IRB must review and approve the plan for any clinical trial, informed consent forms, and communications to study subjects before a study
commences at that site. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable
in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial
while it is being conducted. Special clinical trial ethical considerations also must be taken into account if a study involves children. Once an IND is in
effect, each new clinical protocol and any amendments to the protocol must be added to the IND for FDA review and sent to the IRB for approval. If a
product candidate is being investigated for multiple intended indications, separate INDs may also be required. Progress reports detailing the results of the
clinical trials must also be submitted at least annually to the FDA and the IRB and more frequently if serious adverse events or other significant safety
information is found.
The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical
trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also
require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements or if the trial poses an
unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also
choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.
Information about certain clinical trials, including a description of the study and study results, must be submitted within specific timeframes to the
National Institutes of Health, or NIH, for public dissemination on their clinicaltrials.gov website. Manufacturers or distributors of investigational products
for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and
responding to requests for expanded access requests.
Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data
monitoring committee, or DMC, that regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of the trial. This
group may also review interim data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access to unblinded
data during the clinical trial and may advise the sponsor to halt the clinical trial if it determined there is an unacceptable safety risk for subjects or on other
grounds, such as no demonstration of efficacy.
Moreover, certain studies involving recombinant and synthetic nucleic acid molecules are subject to review by Institutional Biosafety Committees, or
IBCs, under the National Institutes of Health Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.
The manufacture of investigational biologics for the conduct of human clinical trials is subject to cGMP requirements. Investigational biologics and
active ingredients imported into the United States are also subject to regulation by the FDA. Further, the export of investigational products outside of the
United States is subject to regulatory requirements of the receiving country as well as United States export requirements under the FDCA.
In general, for purposes of BLA approval, human clinical trials are typically conducted in three sequential phases, which may overlap, be divided, or
be combined.
•
Phase 1 — Trials are initially conducted in healthy human volunteers or subjects with the target disease or condition and test the product candidate
for safety, dosage tolerance, structure-activity relationships, mechanism of action,
10

TABLE OF CONTENTS
absorption, metabolism, distribution, and excretion. If possible, Phase 1 trials may also be used to gain an initial indication of the activity of the
product candidate.
•
Phase 2 —  Trials are conducted in limited subject populations with a specified disease or condition to evaluate the effectiveness of the product
candidate for a particular indication or indications, identify optimal dosages, dosage tolerance and schedule, possible adverse effects and safety
risks, and expanded evidence of safety.
•
Phase 3 — These adequate and well controlled clinical trials are undertaken in expanded subject populations, generally at geographically dispersed
clinical trial sites, to generate enough data to provide statistically significant evidence of clinical efficacy and safety of the product for approval, to
establish the overall risk benefit profile of the product, and to provide adequate information for the labeling of the product. Typically, two Phase 3
trials are required by the FDA for product approval. Under some limited circumstances, however, approval may be based upon a single adequate
and well-controlled clinical trial plus confirmatory evidence or a single large multicenter trial without confirmatory evidence.
Additional kinds of data may also help to support a BLA, such as patient experience data and real-world evidence. Real world evidence may also be
used to assist in clinical trial design. For appropriate indications sought through supplemental BLAs, data summaries may provide marketing application
support. For genetically targeted products and variant protein targeted products intended to address an unmet medical need in one or more patient
subgroups with a serious or life threatening rare disease or condition, the FDA may allow a sponsor to rely upon data and information previously developed
by the sponsor or for which the sponsor has a right of reference, that was submitted previously to support an approved application for a product that
incorporates or utilizes the same or similar genetically targeted technology or a product that is the same or utilizes the same variant protein targeted drug as
the product that is the subject of the application. More recently, a program was established whereby a platform technology that is incorporated within or
utilized by an approved drug or biologic product may be designated as a platform technology, provided that certain conditions are met, in which case
development and approval of subsequent products using such technology may be expedited.
Further, under certain circumstances, manufacturers and sponsors of investigational biopharmaceutical product candidates can provide access to the
product candidates to certain qualifying patients outside of clinical trials. For instance, under the FDA’s expanded access program, with FDA approval and
subject to certain requirements, sponsors may provide access to product candidates to patients with serious or immediately life threatening diseases or
conditions for which there is no comparable or satisfactory alternative therapy, provided that the potential patient benefit justifies the risks, the risks are not
unreasonable in the context of the disease or condition to be treated, and the provision of the product candidate for the requested use will not interfere with
clinical investigations. The specific expanded access criteria and requirements depend on the number of expanded access patients. Sponsors and
investigators of expanded access programs must still comply with the FDA’s clinical trial guidelines and are subject to subject protection regulations.
Federal and state laws in the United States, referred to as right to try laws, also establish a separate mechanism through which certain patients with life
threatening diseases or conditions, who have exhausted all approved treatment options and are unable to participate in a clinical trial, may request access to
investigational product candidates that have completed a Phase 1 clinical trial. While certain criteria must be met for a patient to be eligible for access to
product candidates under right to try laws, these laws do not require the FDA to approve the use of the product candidate and do not require compliance
with the majority of the FDA’s clinical trial regulations.
The FDA may also require, or companies may conduct, additional clinical trials for the same indication after a product is approved to further assess the
product’s safety and effectiveness, and to ensure that population representative data is collected. These so-called Phase 4 trials may be made a condition to
be satisfied after approval. The results of Phase 4 trials can confirm or refute the effectiveness of a product candidate and can provide important safety
information.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other
things, manufacturers must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate
packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable
deterioration over its shelf life.
In relation to the clinical trial in the United Kingdom and in so far as trials will be conducted in other countries with a view to obtaining a marketing
authorization from the Medicines and Healthcare products Regulatory Agency, or MHRA, and the European Medicines Agency, there are broadly
equivalent GLP, GCP, cGMP and ethical approval requirements. In the European Union, these rules are memorialized in the form of Regulations, which are
directly enforceable in all EU member states or Directives, which may only be implemented nationally. However, enforcement of such rules is conducted
by the regulatory authority in which the trial is carried out, which is the MHRA in the United Kingdom. With the full departure of the United Kingdom
from the European Union in January 2021, the United Kingdom is not covered by the European Union
11

TABLE OF CONTENTS
Clinical Trial Regulation, in force since January 2022, which inter alia introduced a portal to streamline cross-border trial applications, and is instead
subject to rules equivalent to the previous 2001 EU Clinical Trials Regulation.
Combination Products
Biologic products may be regulated as combination products if they are intended for use in conjunction with medical devices, such as a delivery
device. In such cases, the use of the two products together (i.e., the biological product and the device) must be shown to be safe and effective for the
proposed intended use, and, the labeling of the two products must reflect their combined use. In some cases, the device component may require a separate
premarket submission; for example, when the device component is intended for use with multiple therapeutics. Sponsors of clinical studies using
investigational devices are required to comply with FDA’s investigational device exemption regulations. Once approved or cleared, the sponsor of the
device component submission (or the combination product submission, if both components are covered by one premarket submission) would need to
comply with FDA’s post-market device requirements, including establishment registration, device listing, device labeling, unique device identifier, quality
system regulations, medical device reporting, and reporting of corrections and removals. In the European Union there are specific quality requirements for
drug-device combinations.
BLA submission, review by the FDA, and marketing approval
Assuming successful completion of the required clinical and preclinical testing, the results of product development, including chemistry, manufacture,
and controls, non-clinical studies, and clinical trial results, including negative or ambiguous results as well as positive findings, are all submitted to the
FDA, along with the proposed labeling, as part of a BLA requesting approval to market the product for one or more indications. In most cases, the
submission of a BLA is subject to a substantial application user fee. These user fees must be paid at the time of the first submission of the application, even
if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances. One basis for a waiver of the
application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved
marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its
affiliates, is submitting its first marketing application.
In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a new active ingredient, indication, dosage form,
dosage regimen, or route of administration, must contain data that are adequate to assess the safety and effectiveness of the product for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe
and effective. Also, under the FDA Reauthorization Act of 2017, for applications for product candidates intended for the treatment of adult cancer which
are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place of the PREA
investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically
meaningful pediatric study data, using appropriate formulations, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request
of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers
from the pediatric data requirements.
The FDA also may require submission of a REMS to ensure that the benefits of the biologic outweigh the risks. The REMS plan could include
medication guides, physician communication plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk
minimization tools. An assessment of the REMS must also be conducted at set intervals. Following product approval, a REMS may also be required by the
FDA if new safety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the biologic outweigh the
risks.
Once the FDA receives an application, it has 60 days to review the BLA to determine if it is substantially complete to permit a substantive review
before it accepts the application for filing. The FDA may request additional information rather than accept a BLA for filing. In this event, the application
must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the
submission is accepted for filing, the FDA begins an in-depth substantive review.
Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of
completing its review of 90% of all applications within ten months from the 60-day filing date for its initial review of a BLA. The FDA does not always
meet its PDUFA goal dates for BLA submissions, and the review process may be extended if the FDA requests or the sponsor otherwise provides
additional information or clarification regarding the submission.
The FDA may also refer certain applications to an advisory committee. An advisory committee is typically a panel that includes clinicians and other
experts, and may at times includes patients, which review, evaluate, and make a recommendation
12

TABLE OF CONTENTS
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but
it considers such recommendations carefully when making decisions.
The FDA reviews applications to determine, among other things, whether a product is safe, pure and potent and whether the manufacturing methods
and controls are adequate to assure and preserve the product’s identity, strength, quality, potency, and purity. Before approving a BLA, the FDA typically
will inspect or conduct a remote regulatory assessment of the facility or facilities where the product is manufactured, referred to as a Pre-Approval
Inspection. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers
and subcontractors, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
Additionally, before approving a BLA the FDA will inspect or conduct a remote regulatory assessment of one or more clinical trial sites to assure
compliance with GCPs.
After evaluating the BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the
manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter, or CRL. A CRL
indicates that the review cycle of the application is complete and the application is not ready for approval, and describes all of the specific deficiencies that
the FDA identified in the BLA. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the BLA
and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. The deficiencies identified may be minor, for
example, requiring labeling changes, or major, for example, requiring additional clinical trials. If a CRL is issued, the applicant may either: resubmit the
BLA, addressing all of the deficiencies identified in the letter; withdraw the application; or request an opportunity for a hearing. The FDA has the goal of
reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the kind of resubmission. Even with
submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and
when those conditions have been met to the FDA’s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications.
Even if the FDA approves a product, it may limit the approved indications or populations for use of the product, require that contraindications,
warnings, or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including Phase 4 clinical trials,
be conducted to further assess a product’s safety and efficacy after approval, require testing and surveillance programs to monitor the product after
commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS which can
materially affect the potential market and profitability of the product. The FDA may also not approve label statements that are necessary for successful
commercialization and marketing.
After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling
claims, are subject to further testing requirements and FDA review and approval. The FDA may also withdraw the product approval if compliance with the
pre- and post-marketing regulatory standards are not maintained or if problems occur after the product reaches the marketplace. Further, should new safety
information arise, additional testing, product labeling, or FDA notification may be required.
While there is no direct equivalent to the separate route for biologics, broadly equivalent requirements and controls similarly apply to the submission
of pediatric testing and marketing authorization applications to the European Medicines Agency in the European Union and, post-approval, to the holding
of such marketing authorizations, including conditionality.
Additional FDA Expedited Review and Approval Programs
FDA’s fast track, priority review, accelerated approval, and breakthrough therapy programs are special programs and pathways at the agency that are
intended to facilitate and expedite product development and approval. Product candidates may be eligible for fast track designation if they are intended to
treat a serious or life-threatening disease or condition and demonstrate the potential to address an unmet medical need. If a sponsor applies for and receives
fast track designation, the designated product candidate may be eligible for more frequent FDA interactions as well as rolling review of sections of an
application before the application is complete. To qualify for rolling review, the applicant must provide and FDA must approve a schedule for the
submission of the full application. User fees must also be paid before FDA will commence its review of an application submitted on a rolling basis.
Priority review may be available to product candidates that are intended to treat serious conditions and, if approved, would provide significant
improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of the serious condition. If a product receives priority review, FDA’s
PDUFA review goal is shortened to six months following FDA acceptance of a BLA, rather than the standard review of ten months.
13

TABLE OF CONTENTS
Product candidates eligible for FDA’s accelerated approval pathway are those that are intended to treat serious or life-threatening illnesses that provide
meaningful therapeutic benefit to patients over existing treatments. Under this pathway, FDA may approve a marketing application based upon adequate
and well-controlled clinical trials that evaluate a product candidate’s effect on a surrogate endpoint, which is an endpoint that is reasonably likely to predict
clinical benefit, or a product’s effect on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality and that is reasonably likely
to predict an effect on irreversible morbidity or mortality, taking into account the severity, rarity, or prevalence of the condition and availability or lack of
alternative treatments. Products approved under the accelerated approval pathway must complete Phase 4 clinical trials to demonstrate the product’s clinical
benefit. By the date of approval of an accelerated approval product, FDA must specify the conditions for the required post approval studies, including
enrollment targets, the study protocol, milestones, and target completion dates. FDA may also, and frequently does, require that the confirmatory Phase 4
studies be commenced prior to FDA granting a product accelerated approval. If a Phase 4 study is not sufficiently advanced at the time of a marketing
application, FDA can issue a complete response letter rather than approve the product. Reports on the progress of the required Phase 4 confirmatory studies
must be submitted to FDA every 180 days after approval. If the confirmatory Phase 4 studies fail to verify the clinical benefit of the product, the FDA may
withdraw approval of the application through a statutorily defined streamlined process. Failure to conduct the required Phase 4 confirmatory studies or to
conduct such studies with due diligence, as well as failure to submit the required update reports can subject a sponsor to penalties. Promotional materials
for a drug or biologic approved under the accelerated approval pathway are subject to FDA prior review.
A third program that may be available is the breakthrough therapy program, which is for products that are intended, alone or in combination with one
or more other products, to treat a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Breakthrough therapy products may be
eligible for intensive FDA guidance on development programs as early as phase 1 clinical trials, FDA organization commitment to involve senior managers
and experienced review and regulatory management staff in a proactive collaborative, proactive, and cross-disciplinary reviews, and marketing application
rolling review.
FDA designations may be rescinded if the applicable qualifying criteria are no longer met.
Biosimilars and exclusivity
The Biologic Product Competition and Innovation Act, or BPCIA, created an abbreviated approval pathway for biological products shown to be
"biosimilar to" or "interchangeable with" an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product
requires a high similarity to the reference product notwithstanding minor differences in clinically inactive components, and no clinically meaningful
differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical
studies, animal studies, and at least one clinical trial, absent a waiver by the FDA. There must be no difference between the reference product and a
biosimilar in mechanism of action, conditions of use (though a biosimilar may be licensed for fewer indications than that of its reference product), route of
administration, dosage form, and strength. A biosimilar product may be deemed interchangeable with a prior approved product if it meets the higher hurdle
of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the
biosimilar and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished
efficacy relative to exclusive use of the reference biologic. The FDA has issued a number of guidance documents outlining its approach for review and
approval of biosimilars, including guidance documents on the demonstration of interchangeability and the licensure of biosimilar and interchangeable
products for fewer than all of the reference product’s licensed conditions of use.
A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can
be submitted for four years from the date of licensure of the reference product and not approved for another 8 years from the date of licensure of the
reference product. However, certain changes and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer,
licensor, predecessor in interest, or other related entity do not qualify for the twelve-year exclusivity period. The PHSA also includes provisions to protect
reference products that have patent protection. The biosimilar product sponsor and reference product sponsor may exchange certain patent and product
information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the
exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product
sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent.
The FDA maintains a publicly-available online database of licensed biological products, which is commonly referred to as the “Purple Book”. The
Purple Book lists product names, dates of licensure, and applicable periods of exclusivity. Further, pursuant to a statute to enable biological product patent
transparency, the reference product sponsor must provide patent information and patent expiry dates to the FDA following the exchange of patent
information between biosimilar and reference product sponsors. This information is then published in the Purple Book.
14

TABLE OF CONTENTS
In the European Union there is a period of 10 years (or 11 years for significant new indications) of data exclusivity so that those seeking to market
biosimilars cannot apply on an abridged basis for a marketing authorization for eight years from when the product was first marketed in the European
Union and cannot place it on the market for 10 or 11 years from such first marketing although the European Union has proposed legislation reducing these
exclusivity periods.
If approved, biologics may also be eligible for periods of United States patent term restoration. If a timely application is made and if granted, patent
term restoration extends the patent life of a single unexpired patent, that has not previously been extended, for a maximum of five years. The total patent
life with the extension also cannot exceed fourteen years from the product’s approval date. Subject to the prior limitations, the period of the extension is
calculated by adding half of the time from the effective date of an IND to the initial submission of a full marketing application, and all of the time between
the submission of the full marketing application and its approval. This period may also be reduced by any time that the applicant did not act with due
diligence.
In the European Union, a supplementary protection certificate, or SPC, can similarly extend a patent term for a maximum of five years. A further six-
month additional extension is available if the SPC relates to a medicinal product for which data has been submitted according to a Pediatric Investigation
Plan.
In an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and FDA have taken certain legislative and
regulatory steps. By way of example, measures have been proposed and implemented to facilitate product importation. Moreover, the 2020 Further
Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products, including those subject to REMS, provide
samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially
reasonable market-based terms. Failure to do so can subject the approved product sponsor to civil actions, penalties, and responsibility for attorney’s fees
and costs of the civil action.
Post-approval requirements
Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements related to manufacturing, recordkeeping, and reporting, including adverse experience reporting, deviation reporting, shortage
reporting, risk management plans, supply chain security, and periodic reporting, product distribution, advertising, marketing, promotion, certain electronic
records and signatures, and post-approval obligations imposed as a condition of approval, such as Phase 4 clinical trials, REMS, and surveillance to assess
safety and effectiveness after commercialization.
After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA notice or
review and approval. There also are continuing annual program user fee requirements for approved products. In addition, manufacturers and other entities
involved in the manufacture and distribution of approved therapeutics are required to register their establishments with the FDA and certain state agencies,
list their products, and are subject to periodic announced and unannounced inspections or remote regulatory assessment by the FDA and these state
agencies for compliance with cGMP and other requirements, which impose certain procedural and documentation requirements upon sponsors and third-
party manufacturers. The information that must be submitted to FDA regarding manufactured products was expanded through the Coronavirus Aid, Relief,
and Economic Security, or CARES, Act to include the volume of drugs produced during the prior year. Manufacturers must continue to expend time,
money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product
approvals, require label modifications or request product recalls, among other actions, if a company fails to comply with regulatory standards, if it
encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. Many states also regulate the
distribution of drug product samples and commercial product.
Changes to the manufacturing process are strictly regulated and often require prior FDA approval or notification before being implemented. FDA
regulations also require investigation and correction of any deviations from cGMP and specifications and impose reporting and documentation
requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend
time, money, and effort in the area of production and quality control to maintain cGMP compliance.
The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only
those claims relating to safety and efficacy, purity, and potency that are consistent with the FDA approved label. All promotional and advertising statements
must further be truthful and non-misleading, adequately substantiated, and must contain a fair balance between product benefit and risk information.
Recently, FDA has taken a few actions in the advertising and promotional spaces, including issuing a final rule and a guidance on risk and efficacy
disclosures in direct to consumer advertising, and a guidance on communication of off-label scientific information about approved products. Physicians, in
their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the
product’s labeling and that differ from those tested and approved by the
15

TABLE OF CONTENTS
FDA. Biopharmaceutical companies, however, are required to promote their products only for the approved indications and in accordance with the
provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a
company that is found to have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal and civil
penalties under the FDCA and False Claims Act, exclusion from participation in federal healthcare programs, mandatory compliance programs under
corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts.
Moreover, the Drug Quality and Security Act imposes obligations on manufacturers of biopharmaceutical products related to product tracking and
tracing. Among the requirements of this legislation, manufacturers are required to provide certain information regarding the products to individuals and
entities to which product ownership is transferred, are required to label products with a product identifier, and are required to keep certain records regarding
the product. The transfer of information to subsequent product owners by manufacturers will also be required to be done electronically and will be required
to be exchanged via an interoperable system at the package level (while this requirement was to go into effect in November 2023, FDA has stated that it
does not intend to take action to enforce requirements for the interoperable, electronic, package level product tracing until November 27, 2024).
Manufacturers must also verify that purchasers of the manufacturers’ products are appropriately licensed. Further, under this legislation, manufactures have
product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products
that would result in serious adverse health consequences or death to humans, as well as products that are the subject of fraudulent transactions or which are
otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. Similar requirements
additionally are imposed through this legislation on other companies within the biopharmaceutical product supply chain, such as distributors and
dispensers.
Adverse event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval of a
BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal
to approve pending applications, license suspension or revocation, imposition of a clinical hold or termination of clinical trials, warning letters, untitled
letters, cyber letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements
including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions,
refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate
integrity agreements, suspension and debarment from government contracts, refusal of orders under existing government contracts, exclusion from
participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and result
in adverse publicity, among other adverse consequences.
The FDA post-approval requirements are continually evolving. For example, in March 2020, the U.S. Congress passed the Coronavirus Aid, Relief,
and Economic Security Act, or CARES Act, which includes various provisions regarding FDA drug shortage and manufacturing volume reporting
requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain
redundancy and domestic manufacturing. As part of the CARES Act implementation, the FDA issued guidance on the reporting of the volume of drugs
produced, which reporting will require additional administrative efforts by drug manufacturers. In recent years, both the U.S. Congress and the President
have taken actions to encourage the use of domestic pharmaceutical suppliers and, there are also currently legislative proposals to limit the use of
equipment and services provided by certain Chinese “biotechnology companies of concern”.
Broadly equivalent requirements, controls and sanctions similarly apply to supply, QA, manufacture, labelling, advertising, pharmacovigilance and
tracing of medicinal products as imposed by European Union laws and enforced by European Union national regulatory authorities.
Additional controls for biologics and oncology programs
To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for
products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where
there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation
and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.
After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the
manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release
by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing the results of all of the
manufacturer’s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products before releasing the lots for
distribution by the manufacturer.
16

TABLE OF CONTENTS
In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological
products. There are also a number of additional standards that apply to oncolytic virus products. The FDA has issued various applicable guidance
documents on factors that the agency considers during product development including, but not limited to, preclinical assessments; chemistry manufacturing
and controls; and long-term patient and clinical study subject follow up and regulatory reporting. In the European Union, while there is no direct equivalent
to the separate route for biologics, the EMA issues scientific guidelines on biological medicinal products and the standard Common Technical Document
structure is modified for biologicals and plasma-derived products.
With respect to oncology product candidates, FDA has also established a number of different projects, intended to address different aspects of
oncology development. For instance, FDA’s Project Optimus is an initiative at FDA to reform dose optimization and selection. Project FrontRunner is
aimed at encouraging drug sponsors to potentially pursue the development of products for earlier clinical settings, rather than for the treatment of patients
who have received a number of different prior therapies. Project Confirm is a third FDA initiative, which aims to promote transparency regarding the
outcomes related to accelerated approval products.
Fraud and abuse, data privacy and security, and transparency laws and regulations
Our business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities following product
approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA,
including potentially the Department of Justice, the Department of Health and Human Services and its various divisions, including the Centers for
Medicare & Medicaid Services, or CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of
Defense, and state and local governments. Our business activities must comply with numerous healthcare laws, including but not limited to, anti-kickback
and false claims laws and regulations as well as data privacy and security laws and regulations, which are described below, as well as state and federal
consumer protection and unfair competition laws.
The federal Anti-Kickback Statute, which regulates, among other things, marketing practices, educational programs, pricing policies, and relationships
with healthcare providers or other entities, prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, or
receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or
arranging for or recommending the purchase, lease, or order, or the referral to another for the furnishing or arranging for the furnishing of any item or
service reimbursable under Medicare, Medicaid, or other federal healthcare programs, in whole or in part. The term “remuneration” has been interpreted
broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers
on one hand and prescribers, purchasers, and formulary managers, on the other, as well as to free trial and starter prescriptions provided through
pharmacies. There are certain statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. HHS recently
promulgated a regulation that is effective in two phases. First, the regulation excludes from the definition of “remuneration” limited categories of (a) PBM
rebates or other reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan reflected in point-of sale
reductions in price and (b) PBM service fees. Second, the regulation expressly provides that rebates to plan sponsors under Medicare Part D either directly
to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager will not be protected under the anti-kickback discount safe
harbor. Recent legislation has delayed implementation of the aforementioned regulation until January 1, 2032. The exceptions and safe harbors are drawn
narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject
to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or
regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of the facts and circumstances. Several courts have interpreted the statute’s intent requirement
to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, including purchases
of products paid by federal healthcare programs, the statute has been violated. The ACA modified the intent requirement under the Anti-Kickback Statute
to a stricter standard, such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have
committed a violation. In addition, the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a
whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act.
The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or
fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or
statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal
government. A claim includes “any request or demand” for money or property presented to the U.S. government. The civil False Claims Act has been used
to
17

TABLE OF CONTENTS
assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average
Manufacturer Price, improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses not
expressly approved by the FDA in a product’s label, and allegations as to misrepresentations with respect to products, contract requirements and services
rendered. In addition, private payers have filed follow-on lawsuits alleging fraudulent misrepresentation. Intent to deceive is not required to establish
liability under the civil False Claims Act. Civil False Claims Act actions may be brought by the government or may be brought by private individuals on
behalf of the government, called “qui tam” actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will
share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The civil False
Claims Act provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can
aggregate into hundreds of millions of dollars. For these reasons, since 2004, civil False Claims Act lawsuits against biopharmaceutical companies have
increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as much as $3.0 billion, regarding certain sales
practices and promoting off label uses. Civil False Claims Act liability may further be imposed for known Medicare or Medicaid overpayments that are not
refunded within 60 days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, judgment for
violating the civil False Claims Act may result in exclusion from participation in federal health care programs, suspension and debarment from government
contracts, and refusal of orders under existing government contracts.
The government may further prosecute conduct constituting a false claim under the criminal False Claims Act. The criminal False Claims Act prohibits
the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent. Unlike the civil False Claims Act, the
criminal False Claims Act requires proof of intent to submit a false claim.
The civil monetary penalties statute is another potential statute under which biopharmaceutical companies may be subject to enforcement. Among
other things, the civil monetary penalties statute imposes fines against any person who is determined to have knowingly presented, or caused to be
presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is
false or fraudulent.
Payment or reimbursement of prescription therapeutics, including, but not limited to, by Medicaid or Medicare requires manufacturers to submit
certified pricing information to CMS. The Medicaid Drug Rebate statute requires manufacturers to calculate and report price points, which are used to
determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for certain therapeutics. The
Medicaid Drug Rebate statute also imposes inflation penalties, and recent legislative changes have removed the caps limiting the magnitude of these
Medicaid penalties and the implementation of new inflation penalties applicable to the Medicare program. In addition to the Medicaid statutory rebate,
states are authorized to negotiate supplemental rebates on pharmaceuticals included in their formularies. For therapeutics paid under Medicare Part B,
manufacturers must also calculate and report their Average Sales Price, which is used to determine the Medicare Part B payment rate. For products
approved under a BLA (including biosimilars), or an NDA, the Veterans Health Care Act, or VHCA, requires manufacturers to calculate and report to the
Department Veterans Affairs, or VA, a different price called the Non-Federal Average Manufacturer Price, which is used to determine the maximum price
that can be charged to certain federal agencies, referred to as the Federal Ceiling Price, or FCP. Like the Medicaid rebate amount, the FCP includes an
inflation penalty. A Department of Defense regulation requires manufacturers to provide this discount on therapeutics dispensed by retail pharmacies when
paid by the TRICARE Program. All of these price reporting requirements create risk of inadvertently submitting false information to the government, and
potential FCA liability.
The VHCA also requires manufacturers of covered therapeutics participating in the Medicaid program to enter into Federal Supply Schedule contracts
with the VA through which their covered therapeutics must be sold to certain federal agencies at FCP. This necessitates compliance with applicable federal
procurement laws and regulations (e.g., Federal Acquisition Regulations), including submission of commercial sales and pricing information and
certification of compliance with the Trade Agreements Act, and subjects us to contractual remedies as well as administrative, civil, and criminal sanctions.
In addition, the VHCA requires manufacturers participating in Medicaid to agree to provide different mandatory discounts to certain Public Health Service
grantees and other safety net hospitals and clinics under the 340B program based on the manufacturer’s reported Medicaid pricing information. The 340B
program has its own regulatory authority to impose sanctions for non-compliance and adjudicate overcharge claims against manufacturers by the
purchasing entities.
The federal Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, also created federal criminal statutes that prohibit,
among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent
pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless
of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or
stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully
18

TABLE OF CONTENTS
falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these
criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have
committed a violation.
Under the federal Physician Payments Sunshine Act and its implementing regulations, manufacturers of biologics for which payment is available under
Medicare, Medicaid, or the Children’s Health Insurance Program (with certain exceptions) must make annual reports to CMS regarding payments and other
transfers of value made to or at the request of covered recipients, such as, but not limited to, physicians, physician assistants, nurse practitioners, clinical
nurse specialists, and certified registered nurse anesthetists and teaching hospitals, as well as ownership and investment interests held by physicians and
their immediate family. Certain payments for clinical trials are included within the ambit of this law. CMS makes the reported information publicly
available.
Further, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
HIPAA, as amended by the Health Information Technology for Economics and Clinical Health Act, or HITECH Act, and its respective implementing
regulations imposes requirements on covered entities relating to the privacy, security, and transmission of certain individually identifiable health
information known as protected health information. Among other things, the HITECH Act, through its implementing regulations, makes HIPAA’s security
standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered
entity’s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity
regulated by HIPAA. The HITECH Act also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates,
and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. HIPAA imposes certain privacy requirements with respect to
the use and disclosure of protected health information for research purposes, which will impact how we conduct our clinical trials. In addition, other federal
and state laws, such as the California Consumer Privacy Act, may govern the privacy and security of health and other information in certain circumstances,
many of which differ from each other in significant ways and may not be preempted by HIPAA, thus complicating compliance efforts. For example, certain
states, such as Washington, Nevada and Connecticut, have enacted new privacy laws with respect to health data that is not protected health information
governed by HIPAA.
Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed
by any third-party payor, including commercial insurers. Certain state laws also regulate manufacturers’ use of prescriber-identifiable data. Certain states
also require implementation of commercial compliance programs and compliance with the pharmaceutical industry’s voluntary compliance guidelines and
the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that
may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; or require manufacturers to track and
report information related to payments, gifts, and other items of value to physicians and other healthcare providers. Recently, states have enacted or are
considering legislation intended to make drug prices more transparent and deter significant price increases. These laws may affect our future sales,
marketing, and other promotional activities by imposing administrative and compliance burdens.
If our operations are found to be in violation of any of the laws or regulations described above or any other laws that apply to us, we may be subject
penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion
from participation in government healthcare programs, corporate integrity agreements, suspension and debarment from government contracts, and refusal
of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations.
To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for
instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance
programs and reporting of payments or transfers of value to healthcare professionals. In the European Union, the data privacy laws are generally perceived
to be stricter than those which apply in the United States and include specific requirements for the transfer of personal data outside the European Union to
the United States to ensure that European Union standards of data privacy will be applied to such data.
Coverage and reimbursement generally
The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part
on the extent to which governmental payor programs at the federal and state levels, including, but not limited to, Medicare and Medicaid, private health
insurers, and other third-party payors, provide coverage for and establish adequate reimbursement levels for our product candidates. Government
authorities, private health insurers, and other
19

TABLE OF CONTENTS
organizations generally decide which therapeutics they will pay for and establish reimbursement levels for healthcare. Medicare is a federally funded
program managed by CMS through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and
services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state
defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general
guidelines for Medicaid and each state creates specific regulations that govern its individual program, including supplemental rebate programs that restrict
coverage to therapeutics on the state Preferred Drug List. Similarly, government laws and regulations establish the parameters for coverage of prescription
therapeutics by health plans participating in state exchanges and Tricare, the health care program for military personnel, retirees, and related beneficiaries.
Some states have also created pharmacy assistance programs for individuals who do not qualify for federal programs. In the United States, private health
insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government provides
reimbursement through, amongst others, the Medicare or Medicaid programs for such products and services.
In the United States, the European Union, and other potentially significant markets for our product candidates, government authorities and third-party
payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and
therapies, which often has resulted in average selling prices lower than they would otherwise be and sometimes at or below the provider’s acquisition cost.
In the United States, it is also common for government and private health plans to use coverage determinations to leverage rebates from manufacturers in
order to reduce the plans’ net costs. These restrictions and limitations influence the purchase of healthcare services and products and lower the realization
on manufacturers’ sales of prescription therapeutics. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs.
Third-party payors may limit coverage to specific therapeutic products on an approved list, or formulary, which might not include all of the FDA-approved
products for a particular indication or might impose high copayment amounts to influence patient choice. Third-party payors also control costs by requiring
prior authorization or imposing other dispensing restrictions, such as, but not limited to step edits, before covering certain products and by broadening
therapeutic classes to increase competition. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-
effectiveness of medical products and services, in addition to their safety and efficacy. Absent clinical differentiators, third-party payors may treat products
as therapeutically equivalent and base formulary decisions on net cost. To lower the prescription cost, manufacturers frequently rebate a portion of the
prescription price to the third-party payors. Recently, purchasers and third-party payors have begun to focus on value of new therapeutics and sought
agreements in which price is based on achievement of performance metrics.
Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and
clinics and mandatory rebates on retail pharmacy prescriptions paid by Medicaid and Tricare. These restrictions and limitations influence the purchase of
healthcare services and products. Legislative proposals to reform healthcare or reduce costs under government programs may result in lower reimbursement
for our product candidates or exclusion of our product candidates from coverage. In addition, government programs like Medicaid include substantial
penalties for increasing commercial prices over the rate of inflation over the lifecycle of a product. All of these conditions can affect realization and return
on investment.
Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving
favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. In addition, many
government programs as a condition of participation mandate fixed discounts or rebates from manufacturers regardless of formulary position or utilization,
and then rely on competition in the market to attain further price reductions, which can greatly reduce realization on the sale.
Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the
European Union will put additional pressure on product pricing, reimbursement, and utilization, which may adversely affect our future product sales and
results of operations. These pressures can arise from rules and practices of managed care groups, competition within therapeutic classes, judicial decisions
and governmental laws and regulations related to, amongst others, Medicare, Medicaid, and healthcare reform, biopharmaceutical coverage and
reimbursement policies, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services
generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Sales of our product candidates will therefore depend
substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by health maintenance, managed care, pharmacy
benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, such as, but not limited to,
Medicare and Medicaid, private health insurers, and other third-party payors.
As a result of the above, we may need to conduct expensive pharmacoeconomic and/or health technology assessment studies in order to demonstrate
the medical necessity and cost-effectiveness of our products, in addition to the costs required to
20

TABLE OF CONTENTS
obtain the FDA and EMA approvals. Our product candidates may not be considered medically necessary or cost-effective, or the rebate percentages
required to secure coverage may not yield an adequate margin over cost.
Moreover, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-
party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in therapeutic
development. Legislative or regulatory proposals to reform healthcare or reduce costs under government insurance programs may result in lower
reimbursement for our products and product candidates or exclusion of our products and product candidates from coverage. The cost containment measures
that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved
product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our
product candidates in whole or in part.
The absence in Europe of any substantive harmonization of pricing and reimbursement regimes, including health technology assessment, means that
separate negotiations will need to take place with the relevant authorities in each member state and may include a variety of risk share agreements with
payors.
Healthcare reform measures
The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and
elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality,
and expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected
by major legislative initiatives, such as, but not limited to, the Inflation Reduction Act and the Bayh-Dole Act march-in rights expansion.
For example, on November 27, 2020, CMS issued an interim final rule implementing a Most Favored Nation payment model under which
reimbursement for certain Medicare Part B drugs and biologicals will be based on a price that reflects the lowest per capita Gross Domestic Product-
adjusted (GDP-adjusted) price of any non-U.S. member country of the Organization for Economic Co-operation and Development (OECD) with a GDP per
capita that is at least sixty percent of the U.S. GDP per capita. Any reduction in reimbursement from Medicare and other government programs may result
in a similar reduction in payments from private payors. This rule has now been rescinded, but similar programs have been described in recent legislative
proposals. Our results of operations could be adversely affected by current and future healthcare legislation and reforms.
Moreover, the ACA broadened access to health insurance, attempts to reduce or constrain the growth of healthcare spending, enhanced remedies
against fraud and abuse, added new transparency requirements for healthcare and health insurance industries, imposed new taxes and fees on the health care
industry, and imposed additional health policy reforms. The law expanded the eligibility criteria and mandatory eligibility categories for Medicaid
programs, thereby potentially increasing both the volume of sales and manufacturers’ Medicaid rebate liability. The law also expanded the 340B discount
program that mandates discounts to certain hospitals, community centers, and other qualifying providers, by expanding the categories of entities eligible to
purchase under the program. In addition, the ACA authorized civil monetary penalties for violating 340B pricing requirements, and regulations
implementing this authority became effective on January 1, 2019. The ACA revised the definition of “average manufacturer price”, or AMP, for reporting
purposes, which generally increased the amount of Medicaid rebates to states and created a separate AMP for certain categories of administered
therapeutics provided in non-retail outpatient settings. The law additionally extended manufacturer’s Medicaid rebate liability to covered therapeutics
dispensed to patients enrolled in Medicaid managed care organizations and increased the statutory minimum rebates a manufacturer must pay under the
Medicaid Drug Rebate program. The revisions to the AMP definition and Medicaid rebate formula can have the further effect of increasing the required
340B discounts. Further, the ACA required manufacturers of covered therapeutics to pay mandatory Medicare Part D coverage gap rebates, and the
Bipartisan Budget Act of 2018, increased the required percentage to 70% of the pharmacy charge to Medicare Part D patients while they are in the
coverage gap. Finally, the ACA imposes a significant annual fee on companies that manufacture or import branded prescription therapeutic products.
Substantial new provisions affecting compliance have also been enacted through the ACA and otherwise, including the reporting of therapeutic sample
distribution, which may require us to modify our business practices with healthcare practitioners. Although the ACA was recently amended to repeal the
individual insurance mandate, and efforts to repeal and replace portions of the law may continue, it is likely that pressure on biopharmaceutical pricing,
especially under the Medicare program, will continue, and may also increase our regulatory burdens and operating costs. Moreover, in the coming years,
additional changes could be made to governmental healthcare programs that could significantly impact the success of our product candidates.
The cost of biopharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the biopharmaceutical
industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and
additional legislative proposals. Our results of operations could be adversely affected by current and future healthcare reforms.
21

TABLE OF CONTENTS
Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare
providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in
the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product
candidates.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, as amended,
created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on
Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic
reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year.
The Bipartisan Budget Act of 2018 retained the federal budget “sequestration” Medicare payment reductions of 2%, at present that reduction has been
extended through 2030. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several categories of healthcare providers and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These and other healthcare
reform initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our financial
operations. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could further limit the prices we are able to charge, or the amounts of
reimbursement available, for our product candidates if approved and commercialized. The Bipartisan Budget Act also extended Manufacturer responsibility
for prescription costs in the Medicare Part D coverage gap to biosimilars, which had previously been exempt.
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of
anything of value, directly or indirectly, to any foreign official, political party, or candidate or representatives of international organizations for the purpose
of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business or obtaining an
improper advantage. The FCPA also obligates companies whose securities are listed in the United States to comply with books and records and accounting
control provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including
international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate
the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight by compliance
monitors, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.
Other foreign anti-corruption regimes are arguably of wider application. For instance, the U.K. Bribery Act 2010 applies to dealings with any decision
maker whether in the private or public sector in a position of trust.
Background on certain of our target indications
Set forth below is a description of certain of the target indications we currently intend to pursue with our product candidates.
Melanoma
Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. Metastatic
melanoma is the deadliest form of the disease and occurs when cancer spreads beyond the surface of the skin to other organs. The incidence of melanoma
has been increasing steadily for the last 30 years. In the United States, 91,270 new diagnoses of melanoma and more than 9,320 related deaths were
estimated to have occurred in 2018. Globally, the World Health Organization estimates that by 2035, melanoma incidence will reach 424,102, with 94,308
related deaths. Melanoma is mostly curable when treated in its very early stages; however, survival rates are roughly halved if regional lymph nodes are
involved.
Solid Organ Transplant Skin Cancers
Individuals who receive an organ transplant face a significantly higher risk, greater than 50 times higher, of developing skin cancer following the
transplant. These individuals are also on chronic immuno-suppressive treatments to reduce the risk of transplant rejection by their immune system. Adding
to this risk for these individuals, anti-PD-1/L1 based cancer treatment options, which are approved and/or used in other skin cancer settings carry a high
risk of transplant rejection, potentially leaving these patients without many treatment options. In the United States, transplant rates have increased by
roughly 50% over the last 8 years with an estimated 1,500 solid organ transplant patients with addressable skin cancer.
22

TABLE OF CONTENTS
Non-melanoma skin cancers
Non-melanoma skin cancer, or NMSC, are a collection of common cancer types which occurs mainly in fair-skinned populations. About 80% of all
NMSC are basal cell carcinomas, squamous cell carcinomas represent about 20%, with other diagnoses representing around 1%. Included in that 1% are
primary cutaneous lymphoma, sarcomas of the skin, Merkel cell carcinoma, and appendageal carcinoma. NMSC is often not routinely reported to cancer
registries; hence, accurate estimates of incidence are difficult to obtain. The World Health Organization estimates 2 to 3 million cases per year.
Cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma is the second most common form of skin cancer and is estimated to be responsible for at least 7,000 deaths each
year in the United States. It accounts for approximately 20% of all skin cancers in the U.S., with the number of newly diagnosed cases expected to rise
annually. When CSCC invades deeper layers of the skin or adjacent tissues, it is categorized as locally advanced. Once it spreads to other distant parts of
the body, it is considered metastatic. Cemiplimab was the first approved therapy in the United States for the treatment of locally advanced or metastatic
CSCC and has subsequently been approved in the European Union and Australia.
Uveal Melanoma
Uveal melanoma, or UM, represents the predominant primary intraocular malignancy among adults, comprising over 95% of cases. Globally, the
estimated annual incidence of UM is approximately 4,800 individuals, with an estimated 1,700 new diagnoses occurring in the United States each year.
Risk factors for developing UM include fair skin, light-colored eyes, congenital ocular melanocytosis, melanocytoma, and the BAP1-tumour predisposition
syndrome. Despite effective local treatments for the primary tumor, nearly 50% of UM patients develop metastatic disease with liver being the most
frequent (>90%) metastatic site. Many UMs metastasize at a very early clinical stage, suggesting micrometastases are already present by the time the tumor
is first recognized and treated. Historically, 1-year survival rate of patients with distant metastases is 15%, while reported median survival time is less than
1 year ranging from 4 to 15 months.
Human capital
As of March 31, 2024, we employed 331 employees, all of which are full-time employees. Of the 331 employees, 280 are in research and development
and 51 are in selling, general and administrative functions. We have never had a work stoppage, and none of our employees is represented by a labor
organization or under any collective bargaining arrangements. We consider our employee relations to be good.
We believe that developing a diverse and inclusive culture is important to attracting and retaining the top talent necessary to deliver on our growth
strategy. As such, we strive for, and are investing in, a work environment where our employees feel inspired and included.
We focus on identifying, attracting, retaining and developing highly talented and motivated employees. Our equity and cash incentive plans are aligned
to attract, retain and reward our employees through the granting of stock-based and cash-based compensation awards. We conduct annual internal and
external pay reviews to ensure fair and equitable pay for our employees, which includes an internal pay equity analysis, as well as the use of an external
compensation analysis expert for the review of our employees' pay against external market data. We believe motivating our employees to perform at their
highest level and take pride in achieving company goals increases stockholder value.
We are committed to our employees’ health, safety and well-being. Our work paradigm is flexible and designed to accommodate a range of work
profiles. Our workforce is a combination of full-time on-site, hybrid, and fully remote employees, including both at our manufacturing facility as well as in
our offices in Woburn and the United Kingdom. We offer a wide variety of competitive benefits to support our employees' physical, mental and financial
well-being. Our benefits package is comprehensive in coverage and offers options to support all employees in staying healthy, planning for their future and
developing their careers. Our management continues to assess and respond to the evolving needs of our workforce.
Corporate information
We are a Delaware corporation organized in July 2017. Our principal executive offices are located at 500 Unicorn Park Drive, Suite 303, Woburn, MA
01801, and our telephone number is (781) 222-9600. Our website is www.replimune.com. Information that is contained on, or that can be accessed through,
our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of
this Annual Report on Form 10-K.
23

TABLE OF CONTENTS
Available information
We make available free of charge on the investor relations portion of our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, Proxy Statements for our annual meetings of stockholders, and amendments to those reports, as soon as reasonably
practicable after we file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. These filings are available for download free
of charge on the investor relations portion of our website located at https://ir.replimune.com. The SEC also maintains a website that contains reports, proxy
and information statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is
https://www.sec.gov.
Item 1A.    Risk factors
Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with
all of the other information in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes and
“Management’s discussion and analysis of results of operations and financial condition.” If any of the following risks are realized, our business, financial
condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you
could lose part or all of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not
presently known to us or that we currently believe to be immaterial may also adversely affect our business.
Summary of risk factors
Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:
•
the timing, progress, and results of our preclinical studies and clinical trials for our product candidates, and the timing, scope or likelihood of
regulatory filings and approvals for any of our product candidates;
•
our ability to develop and advance any future product candidates based on our novel and proprietary RPx platform and successfully complete
clinical trials;
•
our ability to develop our product candidates for use in combination with other checkpoint blockade therapies, including anti-PD-1;
•
our ability to successfully commercialize any product candidate for which we receive regulatory approval and our expectations regarding the size
of the patient populations or the market acceptance of our product candidates if approved for commercial use;
•
our ability to compete with other biopharmaceutical companies, biotechnology companies and other third parties and risks associated with such
third parties developing or commercializing products more quickly or marketing them more successfully than us;
•
negative developments in the field of immuno-oncology including clinical or commercial developments that may be attributed to our product
candidates;
•
our history of losses, the likelihood that we will continue to incur substantial and increasing net losses in the future, and the likelihood that we will
require additional financing to achieve our goals;
•
our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering
our product candidates, claims others may make regarding rights in our intellectual property, and any potential infringement, misappropriation or
other violation or alleged violation of any third-party intellectual property rights;
•
our ability to successfully complete transfer of our product manufacturing to our in-house manufacturing facility from our contract manufacturers
including comparability analysis and to qualify, obtain approval for, and maintain successful operation, approval and qualification of our in-house
manufacturing operations;
•
our ability to obtain and maintain sufficient quantities of raw material supplies to build or maintain our product candidate supplies or otherwise
operate our in-house manufacturing facility;
•
the costs of operating our in-house manufacturing facility and our reliance on third-party collaborators and clinical trial service providers, which
may be single or of limited source;
•
our compliance with domestic and foreign laws, rules and regulations and the consequences in the event that we fail to comply with such laws,
rules and regulations;
24

TABLE OF CONTENTS
•
our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;
•
our competitive position, and developments and projections relating to our competitors and our industry;
•
our ability to access our existing cash, cash equivalents and investments due to conditions affecting the banking system and financial markets
could have a material adverse effect on our business and financial condition; and
•
•
the ongoing military conflicts between Russia-Ukraine and Israel-Hamas and the impact on the global economy and related governmental imposed
sanctions and potential material supplies and supply chain disruptions and global or national economic impacts such as inflation.
Risks related to product development
Our product candidates are in the early stages of development, are not approved for commercial sale and might never receive regulatory approval or
become commercially viable. We have never generated any revenue from product sales and may never be profitable.
All of our product candidates are in research or development. We have not generated any revenues from the sale of products and do not expect to do so
for at least the next several years, if ever. Our lead product candidate, RP1, and any other product candidates will require extensive preclinical and/or
clinical testing and regulatory approval prior to commercial use. Our research and development efforts may not be successful. Even if our clinical
development efforts result in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed at prices
that would permit us to operate profitably.
We will not be able to commercialize our product candidates if our preclinical studies do not produce successful results and/or our clinical trials do not
demonstrate the safety and efficacy of our product candidates.
Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the occurrence of unexpected or
unacceptable adverse events or the failure to demonstrate efficacy in clinical trials. Clinical development is expensive and can take many years to complete,
and its outcome is inherently uncertain.
The results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive of the results of
later stage clinical trials. Our product candidates may not perform as we expect, may ultimately have a different or no impact on tumors, may have a
different mechanism of action than we expect in humans, and may not ultimately prove to be safe and effective.
Preliminary and final results from preclinical studies and early stage trials, and trials in compounds that we believe are similar to ours, may not be
representative of results that are found in larger, controlled, blinded, and longer-term studies. Product candidates may fail at any stage of preclinical or
clinical development. Product candidates may fail to show the desired safety and efficacy traits even if they have progressed through preclinical studies or
initial clinical trials. Preclinical studies and clinical trials may also reveal unfavorable product candidate characteristics, including safety concerns. A
number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials, notwithstanding promising results in earlier
preclinical studies or clinical trials or promising mechanisms of action. In some instances, there can be significant variability in safety or efficacy results
between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols,
differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical
trial participants. Moreover, should there be an issue with the design of a clinical trial, our results may be impacted. We may not discover such a flaw until
the clinical trial is at an advanced stage.
We may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing
approval or commercialize our product candidates, including:
•
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may
be slower than we anticipate or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate, or may
elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product
candidates;
•
regulators or IRBs may not authorize us or our investigators to commence a clinical trial, conduct a clinical trial at a prospective trial site, or
amend trial protocols, or may require that we modify or amend our clinical trial protocols;
•
we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective
trial sites and/or contract research organizations, or CROs;
25

TABLE OF CONTENTS
•
clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of
statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development
programs;
•
our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us
in a timely manner, or at all, which may result in us having to repeat studies, engage in additional clinical trial site monitoring or take other
corrective actions;
•
we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including
noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side
effects, or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a chemically or
mechanistically similar therapeutic or therapeutic candidate;
•
changes in manufacturing facilities or the manufacturing process for our product candidates may impact how our product candidates perform in
clinical trials;
•
changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing
approval;
•
statutes or regulations could be amended or new ones could be adopted;
•
changes could be adopted in the regulatory review process for submitted product applications;
•
the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay
the substantial user fees required by the FDA upon the filing of a BLA or equivalent authorizations from comparable foreign regulatory
authorities;
•
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient
or inadequate or we may not be able to obtain them on favorable terms due to reasons, such as international trade policies and supply chain
disruptions;
•
we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data, or preclinical
trials, or we may abandon product development programs. For example, the FDA may determine that larger trials, Phase 3 trials, randomized and
controlled clinical trials, or clinical trials designed to replicate results found in our registrational or pivotal trials are required before we may file a
BLA or before the FDA will approve a marketing application;
•
we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and the FDA or
comparable foreign regulatory authorities may require changes to our study designs that make further study impractical or not financially prudent;
•
regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not support
product candidate approval;
•
we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;
•
patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the
need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration;
•
there may be regulatory questions or disagreements regarding interpretations of data and results;
•
the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of data from
preclinical studies and clinical trials or find that a product candidate’s benefits do not outweigh its safety risks;
•
the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;
•
the FDA or comparable foreign regulatory authorities may disagree with our intended indications;
•
the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing, testing, comparability
or quality processes or our manufacturing facilities for clinical and future commercial supplies;
26

TABLE OF CONTENTS
•
the data collected from our clinical trials, including our registration directed or registration intended trials may not be sufficient to the satisfaction
of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign
jurisdictions or to obtain regulatory approval in the United States or elsewhere;
•
the FDA may decide that our intended pathways, including accelerated approval, are not appropriate for any of our product candidates, requiring
that we conduct additional studies. For example, in recent years the accelerated approval pathway has come under significant FDA and public
scrutiny. Accordingly, depending on the results of our studies, the FDA may be more conservative in granting accelerated approval or, if granted,
may be more apt to withdrawal approval if clinical benefit is not confirmed. Even if accelerated approval is granted, payors, including
governmental payors, may be less welling to provide sufficient reimbursement for products approved via accelerated approval. Moreover,
accelerated approval is an evolving area, as evidenced by recent legislative changes to the program, including requirements that by the date of
approval of an accelerated approval product, the FDA must specify the conditions for the required post approval studies, explicit authorization for
the FDA to require that the confirmatory phase 4 studies be commenced prior to the FDA granting a product accelerated approval, a requirement
for the submission of progress reports on phase 4 studies, and statutorily specified streamlined withdrawal procedures if phase 4 studies do not
confirm efficacy and penalties for failing to conduct the required phase 4 confirmatory studies, failing to conduct such studies with due diligence,
as well as failing to submit the required update reports;
•
the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates or
necessary inspections before an approval can be issued may be delayed; and
•
we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive
therapies in development.
Our development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the
testing and approval process for any of our product candidates. We will be required to obtain additional funds to complete clinical trials and prepare for
possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials beyond what we currently have
planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant delays relating to any
preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow
our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our
business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of
marketing approval of any of our product candidates. If any of these occur, our business, financial condition, results of operations, stock price and prospects
may be materially harmed.
Topline data may not accurately reflect the complete results of a particular study or trial.
We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety
data. As topline or interim data, the results and related findings and conclusions are subject to change following a more comprehensive review of the data
related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not
have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline and interim results that we report may differ from future
results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.
Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data
we previously published. As a result, topline and interim data should be viewed with caution until the final data are available. Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the
importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug
candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based
on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to
include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions,
conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline and interim data that we report differ
from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and
commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.
We anticipate that our product candidates will be used in combination with third-party drugs, some of which are still in development, and we have
limited or no control over the supply, regulatory status, or regulatory approval of such drugs.
27

TABLE OF CONTENTS
Our product candidates may be administered in combination with checkpoint blockade drugs, a class of drugs that are intended to stop tumor cells
from “switching off” an immune system attack against themselves. We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1
therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1, our Phase 1/2 clinical trial with RP2 and our Phase 1 and Phase 2
clinical trials with RP3 where we decide to use nivolumab. We have also entered into a clinical collaboration agreement with Regeneron, which includes
the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted thereunder. Additionally, our signal finding study in HCC is being developed
in combination with atezolizumab and bevacizumab under a supply and clinical collaboration arrangement with Roche. We are using cemiplimab in the
CERPASS trial, our first planned clinical trial under the Regeneron agreement. We may enter into additional agreements for the supply of anti-PD-1
products for use in combination with and for the continued development of one or more of our product candidates. Our ability to develop and ultimately
commercialize our product candidates used in combination with nivolumab, cemiplimab, atezolizumab, bevacizumab or any other checkpoint blockade
therapy will depend on our ability to access such drugs on commercially reasonable terms for the clinical trials and their availability for use with the
commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of
such drugs on commercially reasonable terms or at all.
Any failure to maintain or enter into new successful commercial relationships, or the availability and expense of purchasing checkpoint blockade
therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as
commercially viable therapies. For instant, in recent years certain cancer related drugs have been in shortage. If any of these occur, our business, financial
condition, results of operations, stock price and prospects may be materially harmed.
Moreover, the development of our product candidates for use in combination with another product or product candidate may present challenges that are
not faced for single agent product candidates. While we have opened a clinical trial for use of RP1 as a monotherapy, we are generally developing RP1 and
our other product candidates for use in combination with anti-PD-1 or potentially anti-PD(L)-1 therapies and may develop RP1 or our other product
candidates for use with other therapies. Although we intend our IGNYTE anti-PD-1 failed melanoma trial cohort to be registration directed, the FDA may
require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It
is possible that the results of these trials could show that any positive previous trial results are attributable to the therapy with which our products were
combined and not our product candidates. Moreover, following product approval, the FDA may require that products used in conjunction with each other
be cross-labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy
such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial
prospects should we receive marketing approval. Such developments may include changes to the other product’s safety or efficacy profile, changes to the
availability of the approved product, and changes to the standard of care.
In the event that BMS, Regeneron, Roche or any future collaborator or supplier cannot continue to supply their products on commercially reasonable
terms or at all, we would need to identify alternatives for accessing an anti-PD-1 therapy. Additionally, should the supply of products from BMS,
Regeneron or any of our other current or future collaborators or suppliers be interrupted, delayed or otherwise be unavailable to us, our clinical trials may
be delayed, interrupted or halted. In the event we are unable to source a supply of an acceptable alternative anti-PD-1 therapy, or are unable to do so on
commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.
An underlying problem with our proprietary RPx platform would adversely affect our business and may require us to discontinue development of
product candidates based on the same or similar therapeutic approaches.
We have invested, and we expect to continue to invest, significant efforts and financial resources in the development of product candidates based on
our RPx platform. Our ability to generate any revenues from the sale of our product candidates will depend heavily on the successful development,
regulatory approval and commercialization of one or more of these product candidates using our RPx platform. Since all of the product candidates in our
current pipeline are based on our proprietary RPx platform, if any of our product candidates fail in development as a result of any underlying problem with
our proprietary RPx platform, then we may be required to discontinue development of all product candidates that are based on our RPx platform. If we
were required to discontinue development of our product candidates that are based on our RPx platform, or if any of them were to fail to receive regulatory
approval or achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability. We can provide no
assurance that we would be successful at developing other product candidates based on an alternative therapeutic approach from our RPx platform.
If we fail to develop additional product candidates, our commercial opportunity could be limited.
28

TABLE OF CONTENTS
While our lead product candidate is RP1, we intend to continue to pursue clinical development of additional product candidates, including RP2 and, in
the future potentially reinitiating development plans with RP3. Developing, obtaining marketing approval for, and commercializing additional product
candidates will require substantial additional funding and will be subject to the risks of failure inherent in medical product development. We cannot assure
our shareholders that we will be able to successfully advance any of these additional product candidates through the development process.
Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment of
solid tumors, we cannot assure our shareholders that any such product candidates will be successfully commercialized, widely accepted in the marketplace,
or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates,
our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially
harmed.
Risks related to regulatory approval
Even if our development efforts are successful, we may not obtain regulatory approval for any of our product candidates in the United States or other
jurisdictions, which would prevent us from commercializing our product candidates. Even if we obtain regulatory approval for our product candidates,
any such approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our
ability to successfully commercialize our product candidates.
We are not permitted to market or promote or sell any of our product candidates before we receive regulatory approval from the FDA or comparable
foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Securing marketing approval requires
the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the
product candidate’s safety and efficacy for that indication. Securing marketing approval also requires the submission of information about the product
manufacturing process to, and inspection or remote regulatory assessment of manufacturing facilities and clinical trial sites by, the regulatory authorities. If
we do not receive approval from the FDA and comparable foreign regulatory authorities for any of our product candidates, we will not be able to
commercialize such product candidates in the United States or in other jurisdictions. If significant delays in obtaining approval for and commercializing our
product candidates occur in any jurisdiction, our business, financial condition, results of operations, stock price and prospects will be materially harmed.
Even if our product candidates are approved, they may:
•
be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other conditions
of approval;
•
contain significant safety warnings, including boxed warnings, contraindications, and precautions;
•
not be approved with label statements necessary or desirable for successful commercialization; or
•
contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a REMS to monitor the
safety or efficacy of the products.
We have not previously submitted a BLA to the FDA, or a similar marketing application to comparable foreign regulatory authorities, for any product
candidate, and we can provide no assurance that we will ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable
for successful marketing, or at all.
The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently
unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our
product candidates as expected, and our ability to generate revenue may be materially impaired.
The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In
addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate’s clinical development and may vary among jurisdictions and there may be varying interpretations of data obtained from preclinical studies or
clinical trials, any of which may cause delays or limitations in the approval or a decision not to approve an application. These regulatory requirements may
require us to amend our clinical trial protocols, conduct additional preclinical studies or clinical trials that may require regulatory or IRB approval, or
otherwise cause delays in the approval or rejection of an application. Any delay in obtaining or failure to obtain required approvals could materially
adversely affect our ability to generate revenue from the
29

TABLE OF CONTENTS
particular product candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects.
If we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a product candidate does not
include the labeling claims necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such
product candidate may be harmed and our ability to generate revenues from that product candidate may be materially impaired.
The FDA or a comparable foreign regulatory authority may determine that our product candidates have undesirable side effects that could delay or
prevent their regulatory approval or commercialization.
There can be no assurance that undesirable side effects or serious adverse events will not be caused by or associated with RP1 or our other product
candidates as they continue through or enter clinical development. Serious adverse events or undesirable side effects caused by our product candidates
could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive
label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, if concerns are raised regarding
the safety of a new therapeutic as a result of undesirable side effects identified during clinical or preclinical testing, the FDA or comparable foreign
regulatory authority may order us to cease further development, decline to approve the product candidate or issue a letter requesting additional data or
information prior to making a final decision regarding whether or not to approve the product candidate. The FDA or comparable foreign regulatory
authorities, or IRBs and other reviewing entities, may also require, or we may voluntarily develop, strategies for managing adverse events during clinical
development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study’s design, or the monitoring of
safety data by a data monitoring committee, among other strategies. The FDA or comparable foreign regulatory authority requests for additional data or
information could also result in substantial delays in the approval of our product candidates.
Undesirable side effects caused by any of our product candidates could also result in denial of regulatory approval by the FDA or comparable foreign
regulatory authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the
indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications,
and precautions, a label without statements necessary or desirable for successful commercialization, or may result in requirements for costly post-marketing
testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from
commercializing and generating revenues from the sale of our product candidates. Undesirable side effects may limit the potential market for any approved
products or could result in the discontinuation of the sales and marketing of the product, or withdrawal of product approvals. Later discovered undesirable
side effects may further result in the imposition of a REMS, label revisions, post approval study requirements, or other testing and surveillance.
If any of our product candidates is associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may
need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. The therapeutic-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially
harm our business, financial condition, results of operations, stock price and prospects.
Changes in product candidate manufacturing or formulation may result in additional costs or delay.
As product candidates are developed through preclinical studies to later stage clinical trials towards approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods, facilities, equipment and formulation, are altered along the way in an effort to
optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical
trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, or notification to, or approval by
the FDA or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or
studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our
ability to commence product sales and generate revenue.
Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval
has been granted, and we may be subject to substantial fines, criminal penalties, injunctions,
30

TABLE OF CONTENTS
or other enforcement actions if we are determined to be promoting the use of our products for unapproved or “off label” uses, resulting in damage to
our reputation and business.
We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval.
Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA,
Department of Justice, Department of Health and Human Services’ Office of Inspector General, state attorneys general, members of Congress, and the
public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to
those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for desired uses or indications for our
product candidates, we may not market or promote them for those indications and uses, referred to as off label uses, and our business, financial condition,
results of operations, stock price and prospects may be materially harmed. We also must sufficiently substantiate any claims that we make for our products,
including claims comparing our products to other companies’ products, and must abide by the FDA’s strict requirements regarding the content of promotion
and advertising.
While physicians may choose to prescribe products for uses that are not described in the product’s labeling and for uses that differ from those tested in
clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications and uses that are not
specifically approved by the FDA. These off label uses are common across medical specialties and may constitute an appropriate treatment for some
patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice
of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off
label use.
If we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines.
The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off
label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied
large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off label promotion.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or
curtailed.
In the United States, engaging in the impermissible promotion of our products, following approval, for off label uses can also subject us to false claims
and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal
penalties and fines and agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products
and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state
healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These False
Claims Act lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth. In addition, False Claims Act
lawsuits may expose manufacturers to follow-on claims by private payers based on fraudulent marketing practices. This growth in litigation has increased
the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil
penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state
healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully
defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and
prospects.
In the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional
statements. If after one or more of our product candidates obtains marketing approval the FDA determines that our promotional activities violate its
regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other
enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests
for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement
actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies
in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions our business,
financial condition, results of operations, stock price and prospects will be materially harmed.
31

TABLE OF CONTENTS
Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may
result in significant additional expense and limit how we manufacture and market our products.
Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and
comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post approval clinical data, labeling, packaging,
distribution, adverse event reporting, shortage reporting, risk management plans, supply chain security, storage, recordkeeping, export, import, advertising,
marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information,
including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with current Good
Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records
and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post approval.
The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the
FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may
withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a
product’s indicated uses or marketing, or impose ongoing requirements for potentially costly post approval studies or post-market surveillance. Any such
restrictions could limit sales of the product.
We and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections or remote
regulatory assessments by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must
further notify the FDA, and depending on the nature of the change, obtain FDA preapproval for product and manufacturing changes.
In addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other problems with
our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield
various negative results, including:
•
restrictions on manufacturing, distribution, or marketing of such products;
•
restrictions on the labeling, including required additional warnings, such as black boxed warnings, contraindications, precautions, and restrictions
on the approved indication or use;
•
modifications to promotional pieces;
•
issuance of corrective information;
•
requirements to conduct post-marketing studies or other clinical trials;
•
clinical holds or termination of clinical trials;
•
requirements to establish or modify a REMS or similar strategy;
•
changes to the way the product candidate is administered;
•
liability for harm caused to patients or subjects;
•
reputational harm;
•
the product becoming less competitive;
•
warning, untitled, or cyber letters;
•
suspension of marketing or withdrawal of the products from the market;
•
regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or
other safety information about the product candidate;
•
refusal to approve pending applications or supplements to approved applications that we submit;
•
recalls of products;
•
fines, restitution or disgorgement of profits or revenues;
•
suspension or withdrawal of marketing approvals;
•
refusal to permit the import or export of our products;
32

TABLE OF CONTENTS
•
product seizure or detention;
•
FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from
federal healthcare programs, consent decrees, or corporate integrity agreements; or
•
injunctions or the imposition of civil or criminal penalties, including imprisonment.
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could
substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues
from its marketing and sale. Any of these events could further have other material and adverse effects on our operations and business and could adversely
impact our business, financial condition, results of operations, stock price and prospects.
The FDA’s policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates, limit the marketability of our product candidates, or impose additional regulatory
obligations on us. Changes in medical practice and standard of care may also impact the marketability of our product candidates.
If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are
not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement
action.
Should any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability. Further, the cost of
compliance with post approval regulations may have a negative effect on our operations and business and could adversely impact our business, financial
condition, results of operations, stock price and prospects.
We conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept
data from such trials.
We currently conduct clinical trials outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from
clinical trials conducted outside the United States or another jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where
data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the
application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were
performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need
for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site
inspection or other appropriate means. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical
powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the
applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign
regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign
regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay
aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in
the applicable jurisdiction.
Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining
marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.
Obtaining and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or
maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative
effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign
regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures
vary among jurisdictions and can involve requirements and administrative review periods different from and, in some cases, greater than, those in the
United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory
authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be
approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. Additionally, with the
full departure of the United Kingdom from the European Union in January 2021, commonly referred to as Brexit, there is continuing regulatory uncertainty.
Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives
33

TABLE OF CONTENTS
and regulations, and the degree to which the United Kingdom and European Union regulatory regimes align or diverge could materially impact the
execution of our clinical trials or approval of our product candidates in the United Kingdom or the European Union.
Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply
prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in
significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the
regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be harmed. If we obtain approval for any product candidate and ultimately commercialize that
product in foreign markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing
foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.
Risks related to commercialization
If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in
doing so, our business will be materially harmed.
If we are successful in obtaining marketing approval from applicable regulatory authorities for RP1 or any of our other product candidates, our ability
to generate revenues from our product candidates will depend on our success in:
•
launching commercial sales of our product candidates, whether alone or in collaboration with others;
•
receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain safety or other
limitations that would impede our ability to market the product candidates;
•
creating market demand for our product candidates through marketing, sales and promotion activities;
•
hiring, training, and deploying a sales force or contracting with third parties to commercialize product candidates in the United States;
•
manufacturing product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;
•
establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;
•
creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets where we receive
marketing approval;
•
maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
•
our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering
our product candidates, claims others may make regarding rights in our intellectual property, and any potential infringement, misappropriation or
other violation or alleged violation of any third-party intellectual property rights;
•
achieving market acceptance of our product candidates by patients, the medical community, and third-party payors;
•
achieving appropriate reimbursement for our product candidates;
•
effectively competing with other therapies; and
•
maintaining a continued acceptable safety profile of our product candidates following launch.
To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be
materially harmed.
We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other
research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more
successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or
eliminated.
The development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition
and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates, and will face competition with respect to
any product candidates that we may seek to develop or
34

TABLE OF CONTENTS
commercialize in the future, from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide.
There are a number of large biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of
products for the treatment of solid tumors, including oncolytic immunotherapy and cancer vaccine approaches. Potential competitors also include academic
institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish
collaborative arrangements for research, development, manufacturing, and commercialization.
While our product candidates are intended to be used in combination with other drugs with different mechanisms of action, if and when marketed they
will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively with these drugs, our
product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors when used alone or in combination
with other drugs.
Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we
may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign regulatory authority approval for
their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are
able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors coverage decisions or
third-party intellectual property rights that another may allege are violated by our product candidates.
Certain of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products
than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a
smaller number of our competitors. Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and
establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary
for, our programs. If we are unable to successfully compete with these companies our business, financial condition, results of operations, stock price and
prospects may be materially harmed.
If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our
product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.
We currently do not have a commercial infrastructure for the marketing, sale, and distribution of our product candidates. If and when our product
candidates receive marketing approval, we intend to commercialize our product candidates on our own in the United States and potentially with
pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products, we must build our marketing, sales, and
distribution capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. Should we decide to
move forward in developing our own marketing capabilities, we will incur expenses prior to product launch or even approval in order to recruit a sales
force and develop a marketing and sales infrastructure. If a commercial launch is delayed as a result of FDA or comparable foreign regulatory authority
requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales of our product candidates. Even if we
are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in
commercializing our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.
We may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product
candidates in the United States, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to
commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves,
which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties involved in our
commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.
We have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved in building
and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance plans, to market any
products we may develop is, and will continue to be expensive and time consuming and could delay any product launch, and we may not be able to
successfully develop this capability. We have and will continue to compete with other biopharmaceutical and biotechnology companies, including
oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and
35

TABLE OF CONTENTS
time consuming and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from
product development.
In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates in the United
States or elsewhere, which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations,
stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include:
•
the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;
•
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidates;
•
our inability to effectively oversee a geographically dispersed sales and marketing team;
•
the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;
•
an inability to secure adequate coverage and reimbursement by government and private health plans;
•
the clinical indications for which the products are approved and the claims that we may make for the products;
•
limitations or warnings, including distribution or use restrictions, contained in the products’ approved labeling;
•
any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a mandatory
REMS or voluntary risk management plan;
•
third-party intellectual property rights that another may allege are violated by our product candidates;
•
liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;
•
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with
more extensive product lines; and
•
unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.
Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product
candidate development.
There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that
such development problems can be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA
and foreign regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials, which could
significantly delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested
information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience
delays in developing a sustainable, reproducible and scalable manufacturing process, or developing or qualifying and validating product release assays,
other testing and manufacturing methods, and our equipment and facilities in a timely manner, which may prevent us from completing our clinical trials or
commercializing our product candidates on a timely or profitable basis, if at all.
In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine
the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential
products. The FDA and comparable foreign regulatory authorities have limited experience with the approval of oncolytic immunotherapies. Only one
oncolytic immunotherapy, T-Vec, has received FDA approval to date. Any product candidates that are approved may be subject to extensive post approval
regulatory requirements, including requirements pertaining to manufacturing, distribution, and promotion. We may need to devote significant time and
resources to compliance with these requirements.
If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales may be limited, and we may never
become profitable.
We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory
authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If
any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we could be prevented from or
significantly delayed in achieving profitability.
36

TABLE OF CONTENTS
Additionally, efforts to educate the medical community and third party payors on the benefits of our product candidates may require significant
resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could be
prevented from or significantly delayed in achieving profitability.
The degree of market acceptance of any of our product candidates will depend on a number of factors, some of which are out of our control, including
the following:
•
the efficacy of our product candidates in combination with marketed checkpoint blockade drugs;
•
the commercial success of the checkpoint blockade drugs with which our products are co-administered;
•
the prevalence and severity of adverse events associated with our product candidates or those products with which they are co-administered;
•
the clinical indications for which the products are approved and the approved claims that we may make for the products;
•
limitations or warnings contained in the product’s FDA-approved labeling or those of comparable foreign regulatory authorities, including
potential limitations or warnings for our product candidates that may be more restrictive than other competitive products;
•
changes in the standard of care for the targeted indications for our product candidates, which could reduce the marketing impact of any claims that
we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;
•
the relative convenience and ease of administration of our product candidates by direct injection into tumors, a less common method for the
administration of oncology therapies than systemic administration, which may result in slower adoption of our therapies;
•
the relative convenience and ease of administration of any products with which our product candidates are co-administered;
•
the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;
•
the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by
government healthcare programs, including Medicare and Medicaid;
•
the price concessions required by third party payors to obtain coverage;
•
the extent and strength of our marketing and distribution of our product candidates;
•
the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;
•
distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product candidates or to
which we agree as part of a REMS or voluntary risk management plan;
•
the timing of market introduction of our product candidates, as well as competitive products;
•
our ability to offer our product candidates for sale at competitive prices;
•
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
•
the extent and strength of our manufacturing operations and our third-party manufacturer and supplier support;
•
the actions of companies that market any products with which our product candidates are co-administered;
•
the approval of other new products;
•
adverse publicity about our product candidates or any products with which they are co-administered, or favorable publicity about competitive
products; and
•
potential product liability claims.
The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health
insurers establish adequate reimbursement levels and pricing policies.
Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as
government insurance programs, including, but not limited to, Medicare and Medicaid, private health
37

TABLE OF CONTENTS
insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and
services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers
will not offer adequate formulary coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly-approved drugs. Cost
control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our
sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any
denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue.
In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation,
regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and
state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may
further limit our commercial opportunity. For example, the Inflation Reduction Act of 2022, or IRA, includes several measures intended to lower the cost
of prescription drugs and related healthcare reforms, including limits on price increases, inflation and non-compliance penalties, and subjecting an
escalating number of drugs to annual maximum fair price negotiations with CMS. We cannot be sure whether additional legislation related to the IRA will
be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in
the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product
candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our
operations.
If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate and/or discount, or fees and
obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished.
The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for
our product candidates may be smaller than our estimates.
The potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our
product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market opportunity for
oncolytic immunotherapies is hard to estimate given that it is an emerging field with only one existing FDA-approved oncolytic immunotherapy, T-Vec,
which has yet to enjoy broad market acceptance. Our estimates of the potential market opportunities are predicated on many assumptions, which may
include industry knowledge and publications, third-party research reports, and surveys of clinics. Although we believe that our internal assumptions are
reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their
reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product
candidates could be smaller than our estimates of the potential market opportunities.
Negative developments in the field of immuno-oncology could damage public perception of our product candidates and negatively affect our business.
The commercial success of our product candidates will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in
clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative
developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in
demand for our product candidates. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical
trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our
competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be
discouraged from enrolling in our clinical trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.
As our product candidates consist of a modified virus, adverse developments in antiviral vaccines or clinical trials of other oncolytic immunotherapy
products based on viruses may result in a disproportionately negative effect for our product candidates as compared to other products in the field of
immuno-oncology that are not based on viruses. Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could
also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any
increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates.
Risks related to our financial position and need for additional capital
38

TABLE OF CONTENTS
We are a clinical stage biopharmaceutical company with a very limited operating history. We have incurred net losses since our inception and
anticipate that we will continue to incur substantial and increasing net losses in the foreseeable future. We may never achieve or sustain profitability.
We are a clinical stage biopharmaceutical company with a limited operating history, and we are early in our development efforts. We have no products
approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and
development and other expenses related to our ongoing operations. Investment in biopharmaceutical product development is highly speculative because it
entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an
acceptable safety profile, gain marketing approval and become commercially viable. We have financed our operations to date primarily through the sale of
equity securities, including the sale of our common stock and pre-funded warrants in public and private offerings. Since our inception, most of our
resources have been dedicated to the preclinical and clinical development of our proprietary RPx platform, including our lead product candidate, RP1, and
our other product candidates. The size of our future net losses will depend, in part, on our future expenses and our ability to generate revenue, if any.
We are not profitable and have incurred losses in each period since our inception. For the years ended March 31, 2024 and 2023, we reported a net loss
of $215.8 million and $174.3 million, respectively. At March 31, 2024, we had an accumulated deficit of $701.3 million. We expect to continue to incur
significant losses for the foreseeable future, and, notwithstanding our discontinuation of certain development efforts, as previously announced, we expect
these losses to increase as we continue our research and development of, and seek marketing approvals for, RP1, our other product candidates and any
additional product candidates we may develop.
Even if we succeed in receiving marketing approval for and commercialize RP1 or our other product candidates, we will continue to incur substantial
research and development and other expenditures to develop and market additional potential products. We may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of
future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an
adverse effect on our stockholders’ equity and working capital.
Our ability to generate revenue from product sales and become profitable will depend significantly on our success in achieving a number of goals.
We have no products approved for commercial sale and do not anticipate generating any revenue from product sales until after we have received
marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate revenue and achieve profitability depends significantly
on our success in achieving a number of goals, including:
•
completing research regarding, and preclinical and clinical development of, RP1 and our other product candidates;
•
obtaining marketing approvals for RP1 and our other product candidates for which we complete clinical trials;
•
developing a sustainable and scalable manufacturing process for RP1 and our other product candidates, including establishing and maintaining
commercially viable supply and manufacturing relationships with third parties;
•
launching and commercializing RP1 and our other product candidates for which we obtain marketing approvals, either directly or with a
collaborator or distributor;
•
obtaining market acceptance of RP1 and our other product candidates as viable treatment options;
•
addressing any competing technological and market developments;
•
identifying, assessing, acquiring and developing new product candidates;
•
negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
•
obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and
•
attracting, hiring, and retaining qualified personnel.
Even if our product candidates or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant
costs associated with commercializing any such product candidate. Our expenses could increase beyond expectations if we are required by the FDA or
comparable foreign regulatory authorities to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in
addition to those that we currently anticipate.
39

TABLE OF CONTENTS
If we are successful in obtaining regulatory approvals to market RP1 or our other product candidates, our revenue will be dependent, in part, upon the
size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any price,
and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication
approved by regulatory authorities is narrower than we expect, the labels for our product candidates contain significant safety warnings, regulatory
authorities impose burdensome or restrictive distribution requirements, or the reasonably accepted patient population for treatment is narrowed by
competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not
able to generate revenue from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability.
We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all,
could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
Our operations have consumed substantial amounts of cash since inception. At March 31, 2024, our cash and cash equivalents and short-term
investments were $420.7 million. We expect to continue to spend substantial amounts to continue the clinical and preclinical development of RP1 and our
other product candidates. Accordingly, we will need to obtain additional funds to achieve our business objectives. If we are able to gain marketing approval
of any product candidate, we will require significant additional amounts of cash in order to launch and commercialize such product. In addition, other
unanticipated costs may arise.
Our future capital requirements depend on many factors, including:
•
the scope, progress, results and costs of researching and developing RP1 and our other product candidates, and conducting preclinical studies and
clinical trials;
•
the timing of, and the costs involved in, obtaining marketing approvals for RP1 and our other product candidates if clinical trials are successful;
•
the success of any collaborations;
•
the cost of commercialization activities for any approved product, including marketing, sales and distribution costs;
•
the cost and timing of operating our manufacturing facility;
•
the cost of manufacturing RP1 and our other product candidates for clinical trials in preparation for marketing approval and commercialization;
•
our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;
•
the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and
the outcome of such litigation;
•
the timing, receipt, and amount of sales of, or royalties on, our future products, if any; and
•
the emergence of competing cancer therapies and other adverse market developments.
We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product revenue
to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity
offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. Based on our
current operating plan, we expect that our existing cash and cash equivalents and short-term investments, as of March 31, 2024 will enable us to fund our
planned operating expenses and capital expenditure requirements into the second half of calendar 2026. We have based this estimate on assumptions that
may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, because the design and outcome of our
planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the
development and commercialization of RP1 or our other product candidates.
We maintain our cash at financial institutions, often in balances that exceed federally insured limits.
Most of our cash, cash equivalents and short-term investments are held in accounts with banking institutions. The balances of some of these accounts
have in the past, and may in the future, exceed the Federal Deposit Insurance Corporation, or the FDIC, insurance limits. If such banking institutions were
to fail, we could lose all or a portion of those amounts held in excess
40

TABLE OF CONTENTS
of such insurance limitations. In March 2023, the FDIC took control of Silicon Valley Bank, or SVB, where we previously held a portion of our cash. The
Federal Reserve subsequently announced that account holders would be made whole and we were able to access all of our cash held at SVB. However, the
FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with
respect to a future bank failure, account holders’ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss
that we may experience in the future or inability for a material time period to access our cash, short-term investments and cash equivalents could have an
adverse effect on our ability to pay our operational expenses, fund our operations or make other payments, which could adversely affect our business.
Risks related to intellectual property
If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual
property rights are inadequate, our competitive position could be harmed.
Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States
and other countries with respect to our technology and proprietary RPx platform, including our lead product candidate, RP1, and our other product
candidates. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third
parties, all of which offer only limited protection.
The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and
have in recent years been the subject of much litigation and subject to change with regulatory agencies and court decisions. As a result, the issuance, scope,
validity, enforceability and commercial value of our licensed patents and any patents we own in the future are highly uncertain. The steps we have taken to
protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information, use by third parties of our products or
infringement of our intellectual property rights, both inside and outside of the United States.
Our pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues
from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our issued patents and
issued patents that we license from third parties or that we may own in the future may be challenged in the courts or patent offices inside or outside of the
United States. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of
patent protection that may be obtained if these applications issue. The scope of a patent may also be interpreted or reinterpreted after issuance. The rights
that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. In
addition, defending against challenges in respect of the inventorship, scope, validity or enforceability of our patents may be expensive, time consuming,
difficult and in some cases may not be possible. Although we enter into nondisclosure and confidentiality agreements with parties who have access to
confidential or patentable aspects of our research and development output, such as our employees, consultants, collaborators, and other third parties, any of
these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. In addition, the patent prosecution process is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain,
enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. If we are unable to obtain and maintain patent
protection for our technology or inventions, or for RP1 or our other product candidates, or if the scope of the patent protection obtained is not sufficient,
our competitors could develop and commercialize products similar or superior to ours, and our ability to successfully commercialize RP1 or our other
product candidates and future technologies or inventions may be adversely affected.
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for
which we intend to seek approval as biological products may face competition sooner than anticipated. Given the amount of time required for the
development, testing and regulatory review of our product candidates, such as RP1 and our other product candidates, patents protecting such product
candidates might expire before or shortly after such product candidates are commercialized.
Filing, prosecuting and defending patents on our technology or inventions in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries or religions outside the United States can be less protective of our products than those in the United
States. In addition, the laws and practices of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in
the United States. Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing
our ability to protect RP1 and our other product candidates. Consequently, we may not be able to prevent third parties from practicing our inventions in all
countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.
Competitors may use our technologies or inventions in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own
products and may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the
United States. These products
41

TABLE OF CONTENTS
may compete with our products and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so
competing.
Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming,
difficult and in some cases may not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of
our intellectual property rights, even in relation to issued patent claims, and proving any such infringement or misappropriation may be even more difficult.
If we are unable to obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material
adverse effect on our business, financial condition, results of operations, stock price and prospects.
In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and
proprietary information. Although we enter into confidentiality agreements with our employees, consultants, collaborators, suppliers, manufacturers and
other third parties who have access to our trade secrets, and our agreements with employees also provide that any inventions conceived by the individual in
the course of rendering services to us shall be our exclusive property, we may not obtain these agreements in all circumstances, and individuals with whom
we have these agreements may not comply with their terms or may have conflicting agreements with third parties. In addition, in the event of unauthorized
use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for
our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by
third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. If any of our trade secrets,
know-how or confidential or proprietary information were to be lawfully obtained, patented or independently developed by a competitor or other third
party, we would have no right to prevent them from using that technology or information to compete with us and may be blocked from using such trade
secrets, know-how or confidential or proprietary information ourselves. The disclosure of our trade secrets or the independent development of our trade
secrets by a competitor or other third party would impair our competitive position and may materially harm our business, financial condition, results of
operations, stock price and prospects.
Third parties may in the future initiate legal proceedings alleging that we are infringing their intellectual property rights, and we may become involved
in lawsuits or other administrative procedures to protect or enforce our intellectual property, which could be expensive, time consuming and
unsuccessful and have a material adverse effect on the success of our business.
Our commercial success depends on our ability and the ability of our current or future collaborators to develop, manufacture, market and sell RP1 and
our other product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual
property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents
and other intellectual property rights. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property
rights with respect to our current and any other future product candidates. For example, we are aware of U.S. Patent 10,034,938 (the '938 Patent) held by
Amgen Inc., which includes claims purported to cover methods and kits for treating stage IIIb to IV melanoma by the administration of (i) an effective
amount of an anti-PD-1 antibody or anti-CTLA-4 antibody; and (ii) a herpes simplex virus, wherein the herpes simplex virus lacks a functional ICP34.5
encoding gene and a functional ICP47 encoding gene, and comprises a gene encoding human GM-CSF. In November 2022, we filed a petition for inter
partes review with the Patent Trial and Appeal Board, or PTAB, of the United States Patent and Trademark Office, or USPTO, seeking to invalidate certain
claims of United States Patent 10,034,938, or the ‘938 Patent. In August 2023 we entered into a Settlement Agreement with Amgen and mutually agreed to
terminate our challenges to their patents. In connection with the Settlement Agreement, we entered into a License and Covenant Agreement with Amgen in
which we agreed to pay Amgen low single-digit royalty payments on net sales of our products that, but for the license, could be found to infringe a valid
Amgen patent on a country-by-country and product-by-product basis.
Third parties may assert infringement or other intellectual property claims against us based on existing patents or patents that may be filed and/or
granted in the future. At times we may attempt to initiate litigation or other administrative procedures to invalidate or otherwise limit the scope of a third
party’s intellectual property and these attempts may not be successful. If we are found to infringe a third party’s intellectual property rights, and we are
unsuccessful in demonstrating that such intellectual property rights are invalid, unenforceable or otherwise not infringed, we could be required to obtain a
license from such third-party to continue developing, manufacturing and commercializing RP1 and our other product candidates. Such a license may not be
available on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and
other third parties access to the same technologies and inventions licensed to us, and it could require us to make substantial licensing and royalty payments.
We also could be forced, including by court order, to cease developing, manufacturing, and commercializing RP1 or our other product candidates or we
could be found liable for significant monetary damages if we are found to have willfully infringed a patent or other intellectual property right. Any of the
42

TABLE OF CONTENTS
foregoing could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. Any claims by third
parties that we have misappropriated their know-how, confidential or proprietary information or trade secrets could have a similar material adverse effect
on our business, financial condition, results of operations, stock price and prospects.
If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology or inventions,
the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. If a third party were to prevail on a legal
assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on RP1 and our other product
candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, stock price and
prospects.
Many of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we take steps to ensure that our employees do not use, claim as
theirs, or misappropriate the intellectual property, confidential or proprietary information, know-how or trade secrets of others in their work for us, we may
be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual property, including trade secrets,
know-how or other confidential or proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend
against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such
third-party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all.
In addition, we are developing certain of our product candidates in combination with products, which are or may be covered by patents or licenses held
by third parties, and to which we do not have a license other than for use in connection with the applicable clinical trial. We also may develop our product
candidates in combination with products developed by additional companies that are covered by patents or licenses held by those entities to which we do
not have a license. In the event that a labeling instruction is required in product packaging recommending that combination, we could be accused of, or held
liable for, infringement of the third-party patents covering the product candidate or product recommended for administration with RP1 or our other product
candidates. In such a case, we could be required to obtain a license from the other company or institution to use the required or desired package labeling,
which license may not be available on commercially reasonable terms, or at all.
Competitors may infringe any future licensed patents or any patent we own in the future or misappropriate or otherwise violate our intellectual
property rights. We may also be required to defend against claims of infringement and our licensed patents and any patents we own in the future may
become involved in priority or other intellectual property related disputes. To counter infringement or unauthorized use, litigation may be necessary in the
future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual
property rights or the proprietary rights of others.
These proceedings can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially
greater resources to conduct intellectual property related litigations or proceedings than we can. We may not have sufficient financial or other resources to
conduct such litigation or proceedings adequately. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or
misappropriating our intellectual property. An adverse result in any litigation or other intellectual property related proceeding could put one or more of our
patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation in the United States, there is a risk that some of our trade secrets, know-how, or proprietary or confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings,
motions or other interim proceedings or developments in any such proceedings. If securities analysts or investors perceive these results to be negative, it
could have a material adverse effect on the price of shares of our common stock. Any of the foregoing may have a material adverse effect on our business,
financial condition, results of operations, stock price and prospects.
Risks related to manufacturing and our reliance on third parties
We have agreements with BMS and Regeneron, and in the future may have agreements with other companies, to obtain the supply of anti-PD-1
therapies for the development of our product candidates. If our relationships with BMS, Regeneron, or any future collaborator or supplier are not
successful, we may be delayed in completing the development of our product candidates.
43

TABLE OF CONTENTS
We have entered into arrangements with BMS and Regeneron as part of our clinical development programs where nivolumab or cemiplimab,
respectively, are intended to be used for these clinical programs. BMS is providing nivolumab, its anti-PD-1 therapy, for use in our ongoing IGNYTE
Phase 1/2 trials with RP1, our Phase 1/2 clinical trial with RP2 and our Phase 1 and Phase 2 clinical trials with RP3 where we intend to use nivolumab and
may potentially do so for other clinical trials in the future; Regeneron is providing cemiplimab, its anti-PD-1 therapy, for use in our ongoing CERPASS
Phase 2 clinical trial and may potentially do so for other clinical trials in the future. We may also enter into agreements with additional companies for the
supply of anti-PD-1 therapies for use in the development of RP1 and our other product candidates, similar to our agreement with Roche. The outcome of
these clinical trials is dependent, in part, both on the performance of our partners’ products and product candidates and also on our partners’ ability to
deliver sufficient quantities of adequately produced product. Should any of our partners’ products or product candidates fail to produce the results that we
anticipate, we may have to re-run clinical trials for RP1 or our other product candidates or may otherwise be delayed in the commercialization of RP1 or
our other product candidates. Similarly, should any partner fail to provide us with a product or product candidate that suits our requirements, we may have
to re-run clinical trials for RP1 or our other product candidates or may be otherwise delayed in the commercialization of RP1 or our other product
candidates. Additionally, we are subject to specific risks associated with our collaboration partners, including possible discrepancies as to the timing, nature
and the extent of development plans, contract interpretations, and the costs and allocation of costs related to the conduct of our clinical trials. If we and any
collaboration partner are unable to agree or fail to perform our respective obligations or effectively manage our relationship, our clinical trials performed
under such collaboration could incur additional costs, be delayed or could result in costly or time-consuming legal proceedings that could have an adverse
effect on a collaboration or on our business.
Our collaboration agreements with any future partners may not be successful, which could adversely affect our ability to develop and commercialize
our product candidates.
We may in the future seek collaboration arrangements with other parties for the development or commercialization of our product candidates. The
success of any collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion
in determining the efforts and resources that they will apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding
clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate
and, in some cases, termination of the collaboration arrangement.
Collaborations with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such
termination or expiration could adversely affect us financially and could harm our business reputation.
Any future collaborations we might enter into may pose a number of risks, including the following:
•
collaborators may not perform their obligations as expected;
•
collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to
continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or
available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
•
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate,
repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
•
collaborators could fail to make timely regulatory submissions for a product candidate;
•
collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable
regulatory requirements, which could subject them or us to regulatory enforcement actions;
•
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under
terms that are more economically attractive than ours;
•
product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or
products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;
•
a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such product candidate or product;
44

TABLE OF CONTENTS
•
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional
responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and
expensive;
•
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to
invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and
•
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.
If any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our
collaborators subsequently terminates its agreement with us, we may not receive any future clinical trial materials supply, research funding or milestone or
royalty payments under such potential future collaboration. If we do not receive the funding we expect under the agreements, our development of our
product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.
Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might de-emphasize or terminate development or
commercialization of any product candidate it licenses to us. If one of our collaborators terminates its agreement with us, we may find it more difficult to
attract new collaborators and our reputation in the business and financial communities could be adversely affected.
We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend
upon, among other things, our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator’s evaluation of a number of factors.
If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the
development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional
expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have
sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product
candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.
We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third
parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory
requirements, we may be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the
future.
We rely on third-party CROs, study sites, and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product
candidates and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates. We expect to
continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our
preclinical studies and clinical trials. Although we have agreements governing their activities, we have limited influence over their actual performance and
control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines
could substantially harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of
our product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these
agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements our
product development activities would be delayed and our business, financial condition, results of operations, stock price and prospects may be materially
harmed.
Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring
that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties
does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in
accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials are conducted in accordance with
GLP regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly
45

TABLE OF CONTENTS
referred to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate
and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic
inspections or remote regulatory assessment of trial sponsors, clinical investigators, and trial sites. If we or any of our third parties fail to comply with
applicable GCPs, the applicable study protocols and plans, or other regulatory requirements, we or they may be subject to enforcement or other legal
actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional studies.
In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Failure to comply with these
regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in
accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is
compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or
terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates; we may not be able to, or may
be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions. As a
result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to
generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the
future, our business, financial condition, results of operations, stock price and prospects may be materially harmed.
If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on
commercially reasonable terms. Switching or adding additional third parties involves additional cost and may result in delays that could compromise our
ability to meet our desired development timelines.
We also rely on other third parties to store and distribute our products for the clinical trials that we conduct. Any performance failure on the part of our
distributors could delay clinical development, marketing approval, or commercialization of our product candidates, which could result in additional losses
and deprive us of potential product revenue.
If the manufacturers upon which we rely fail to produce our raw materials or product candidates in the volumes that we require on a timely basis, or
fail to comply with stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization
of, or be unable to meet demand for, our product candidates and may lose potential revenues.
We continue to rely on third-party contract manufacturers to manufacture our raw materials and clinical trial product supplies. As a result, there can be
no assurance that our clinical development will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices.
We currently have only one in-house manufacturing site approved for use in our clinical trials. In addition, we do not have any long-term commitments
from our suppliers of raw materials or clinical trial material or guaranteed prices for our product candidates or their components. There are a limited
number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing and filling our viral product for us and willing to
do so. If our existing third-party manufacturers of raw materials or our product candidates, or the third parties that we engage in the future, should cease to
work with us, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to
advance our clinical trials while we identify and qualify replacement suppliers. Any replacement of our contract manufacturer could require significant
effort and expertise because there may be a limited number of qualified replacements. Any delays in obtaining adequate supplies of our raw materials or
product candidates that meet the necessary quality standards may delay our development or commercialization.
If our manufacturers of raw materials, equipment or process consumables do not perform as agreed or encounter difficulties in production costs and
yields, quality control, shortages of qualified personnel or key raw materials, compliance with strictly enforced federal, state, and foreign regulations, or
other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized.
In addition, if our Framingham manufacturing site cannot successfully manufacture material that conforms to our specifications and the strict
regulatory requirements of the FDA or other regulatory authorities, we will not be able to secure or maintain regulatory approval for our manufacturing
facilities. Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party to implement and that
may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility. Any such remedial measures
imposed upon us
46

TABLE OF CONTENTS
or third parties with whom we contract could materially harm our business. Any delays in obtaining raw materials, products or product candidates that
comply with the applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization.
We are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, but, other than through our contractual
arrangements, we have little control over our raw materials or process consumables manufacturers’ compliance with these regulations and standards. If the
FDA or a comparable foreign regulatory authority does not approve these facilities for manufacturing or supply, or if it withdraws any such approval in the
future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or
market our product candidates, if approved. We must also receive FDA approval for the use of any new manufacturers for clinical or commercial supply,
including our own manufacturing facility.
A failure to comply with the applicable regulatory requirements, including periodic regulatory inspections or remote regulatory assessments, may
result in regulatory enforcement actions against our manufacturers or us (including fines and civil and criminal penalties, including imprisonment)
suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination
of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal
to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, corporate
integrity agreements, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities. If the safety of any quantities
supplied is compromised due to our or our manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory
approval for or successfully commercialize our product candidates.
The transition of our manufacturing operations to our new facility may result in further delays or expenses, and we may not experience the anticipated
operating efficiencies.
Our approximately 63,000 square foot manufacturing facility in Framingham, Massachusetts is now fully operational. We have completed the process
of transferring the manufacturing of RP1, RP2 and RP3 from our third-party contract manufacturer. Comparability analysis of RP1, RP2 and RP3 produced
at our in-house Framingham facility with the contract manufacturer material used in our clinical trials is complete. The FDA and some European regulatory
agencies have approved the use of material produced at our Framingham facility in ongoing and future clinical trials. The Framingham facility is intended
to give us control over key aspects of the supply chain for our products and product candidates. However, we may not experience the anticipated operating
efficiencies as we commence manufacturing operations at our in-house facility. Any such delays may disrupt or delay the supply of our product candidates
if we have not maintained a sufficient backup supply of our product candidates through third-party manufacturers. Moreover, changing manufacturing
facilities may also require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the regulatory
authorities, and obtain regulatory authority approval for our in-house facility, which may be delayed or which we may never receive. We will further need
to comply with the FDA’s and applicable state and foreign regulatory authorities’ cGMP requirements for the production of our product candidates for
clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable state and foreign regulatory authority licensing requirements
and inspections. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements. If we are
not able to comply with the applicable regulatory requirements or produce product that meets our requirements and specifications, we will be subject to the
same risks that we would be subject to should third party manufacturers be unable to comply with the applicable regulatory requirements or produce
product meeting our requirements or specifications, as described above. If we fail to achieve the operating efficiencies that we anticipate, our
manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results.
In operating our own manufacturing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas
relating to operations, quality, raw material supply, regulatory, facilities and information technology. Further, should corrective or preventative actions be
required, we will be fully responsible for these. If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively
manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from our in-house facility, which may
negatively affect our product development timeline, product candidate supplies and, if approved, our commercial product supplies. If we experience any
unanticipated shortages of key raw materials, or other difficulties related to our raw material supply, we may not be able to effectively manage our ongoing
manufacturing timelines and costs which may negatively affect our product development schedule and our ability to provide clinical trial supplies to
patients in our clinical trials, and if approved, commercial product supplies.
47

TABLE OF CONTENTS
Any problems or delays we experience in preparing for commercial scale manufacturing of a product candidate or component may result in a delay in
product development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to
manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of
clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations,
stock price and prospects.
Any such problems could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates, if
approved, and may materially harm our business, financial condition, results of operations, stock price and prospects.
Risks related to legal and compliance matters
We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the
commercialization of any approved products and/or our product candidates.
The use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of
product liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials, including liability
relating to the actions and negligence of our investigators, and will face an even greater risk if we commercially sell any product candidates that we may
develop. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in
the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims
might be brought against us by consumers, healthcare providers or others using, administering or selling our products. If we cannot successfully defend
ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful
defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in:
•
loss of revenue from decreased demand for our products and/or product candidates;
•
impairment of our business reputation or financial stability;
•
costs of related litigation;
•
substantial monetary awards to patients or other claimants;
•
diversion of management attention;
•
withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;
•
the inability to commercialize our product candidates;
•
significant negative media attention;
•
decreases in our stock price;
•
initiation of investigations and enforcement actions by regulators; and
•
product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval.
We believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse us or may
not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the
future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We
intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA or comparable foreign regulatory approval for our
product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for
marketing, or at all. Failure to obtain and retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of
products we develop. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed
our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and prospects.
We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anticorruption laws, as well as import and export control
laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or
criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations,
stock price and prospects.
48

TABLE OF CONTENTS
Our operations are subject to anticorruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010, or the
Bribery Act, and other anticorruption laws that apply in countries where we do business. We also may participate in collaborations and relationships with
third parties whose actions, if noncompliant, could potentially subject us to liability under the FCPA, Bribery Act or local anticorruption laws.
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the
United States and the United Kingdom and authorities in the European Union, including applicable import and export control regulations, economic
sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the
trade control laws.
We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anticorruption laws or other legal
requirements, including trade control laws. If we are not in compliance with applicable anticorruption laws or trade control laws, we may be subject to
criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our
business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anticorruption
laws or trade control laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, financial condition, results
of operations, stock price and prospects.
If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we
could face substantial penalties and our business, financial condition, results of operations, stock price and prospects will be materially harmed.
We are subject to many federal and state healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts,
the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, HIPAA, the FCPA, the ACA, and similar
state laws. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors,
certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients’
rights are and will be applicable to our business. We will be subject to healthcare fraud and abuse and patient privacy regulation by both the federal
government and the states and foreign jurisdictions in which we conduct our business. In the European Union, the data privacy laws are generally stricter
than those that apply in the United States and include specific requirements for the collection of personal data of European Union persons or the transfer of
personal data outside of the European Union to the United States to ensure that European Union standards of data privacy will be applied to such data.
If we or our operations are found to be in violation of any federal or state healthcare law, or any other laws or regulations that apply to us, we may be
subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment from government
contracts, refusal of orders under existing government contracts, exclusion from participation in U.S. federal or state health care programs, corporate
integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our
business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management’s attention from the operation of our business.
We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect
our ability to market our products, obtain collaborators, and raise capital.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post approval activities and affect our
ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures
that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for
any approved products, which could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of
operations.
Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to
generate revenue, and we could be prevented from or significantly delayed in achieving profitability.
Compliance with the Drug Supply Chain Security Act (DSCSA) requirements may increase our operational expenses and impose significant
administrative burdens. As a result of these and other new proposals, either in the present or future, we may determine to change our current manner of
operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial
condition, results of operations, stock price and prospects.
49

TABLE OF CONTENTS
Our employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our
business.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial
partners, principal investigators, CMOs, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations,
comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required by federal
programs, report financial information or data accurately or disclose unauthorized activities to us. This misconduct could also involve the improper use or
misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us even if the government considers the claim unmeritorious and
declines to intervene, which could require us to incur costs defending against such a claim. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of
operations, stock price and prospects, including the imposition of significant fines or other sanctions.
Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have
a material adverse effect on the success of our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use,
storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We would incur
substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines,
penalties and other sanctions, investigation and cleanup costs and third party claims. In the event of contamination or injury resulting from our use of
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties.
Although we maintain workers’ compensation insurance to cover costs and expenses, we may incur due to injuries to our employees resulting from the
use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.
We are subject to stringent and changing obligations related to privacy and security. Our actual or perceived failure to comply with such obligations
could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could
negatively affect our operating results and business.
In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of,
transmit, and share (collectively, processing) sensitive information, including personal data, proprietary and confidential business data, trade secrets,
intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities
subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy
and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.
In the United States, numerous federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including
personal data privacy laws, health information privacy laws, data breach notification laws, personal data privacy laws, and consumer protection laws. For
example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable
health information. We may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are
subject to privacy and security requirements under HIPAA, as amended by HITECH, and its implementing rules and regulations. Depending on the facts
and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information maintained by a
HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
Additionally, the California Consumer Privacy Act, or CCPA, imposes obligations on covered businesses. These obligations include, but are not
limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA also
allows for statutory fines for noncompliance (up to $7,500 per violation) and includes a private right of action for certain data breaches. Although there are
some exemptions for clinical trial data and health information, the CCPA may impact our business activities and increase our compliance costs and
potential
50

TABLE OF CONTENTS
liability. Similar laws have passed in Virginia, Utah, Connecticut and Colorado, and have been proposed in other states and at the federal level, reflecting a
trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would
make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection
laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.
Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the
European Union’s General Data Protection Regulation, or EU GDPR, and the United Kingdom’s GDPR, or UK GDPR, impose strict requirements for
processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well
as fines up to the greater of €20 million or 4% of annual global revenue. Further, individuals may initiate litigation related to processing of their personal
data.
Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer
information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other jurisdictions outside of the United
States). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards
or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area, or EEA, that the
European Commission does not consider to provide an adequate level of data privacy and security, such as the United States. The European Commission
released a set of “Standard Contractual Clauses,” or SCCs, that are designed to be a valid mechanism to facilitate personal data transfers out of the EEA to
these jurisdictions. The SCCs, though approved by the European Commission as a suitable alternative, have faced challenges in European courts, and may
be further challenged, suspended or invalidated. Other countries in Europe, such as the UK, similarly restrict personal data transfers outside of those
jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid
compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against
processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could
significantly and negatively impact our business operations, limiting our ability to collaborate with parties that are subject to such cross-border data transfer
or localization laws; or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense.
See Part I, Item 1C, Cybersecurity, in this Annual Report on Form 10-K for more information regarding our cybersecurity risk management, strategy,
and governance.
Risks related to our operations
We will need to expand the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
As our clinical development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales,
marketing, financial and other personnel. Our future financial performance and our ability to commercialize RP1 and our other product candidates will
depend, in part, on our ability to effectively manage any future growth, which would impose significant additional responsibilities on members of
management and may divert their attention away from day-to-day activities.
We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants
to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing, as well as support for our
financial reporting and accounting functions. If the services of independent organizations, advisors and consultants become unavailable to us or we are
unable to effectively manage our outsourced activities, or if the quality or accuracy of such services is compromised for any reason, our clinical trials may
be extended, delayed or terminated, we may not comply with our financial reporting and accounting obligations on a timely basis and we may not be able
to obtain marketing approval of RP1 and our other product candidates or otherwise advance our business.
If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize RP1 and our other product candidates and,
accordingly, may not achieve our research, development and commercialization goals.
Our future success depends on our ability to retain our key employees and consultants, and to attract and motivate highly qualified personnel.
51

TABLE OF CONTENTS
Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain
highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive leadership team, as well as our other scientific,
manufacturing, quality and medical personnel. The loss of the services of our key personnel and any of our other executive officers, key employees, and
scientific and medical advisors, without our inability to find suitable replacements, could result in delays in product development and harm our business.
Changes in our management team resulting from the hiring or departure of executives and key employees from time to time could disrupt our business.
Over the a past fiscal year, there have been changes to our executive leadership team. For example, in March 2024, we announced the appointment of
Sushil Patel, our former Chief Strategy Officer, as our Chief Executive Officer and the appointment of Philip Astley-Sparke, our former Chief Executive
Officer to Executive Chairman of our Board of Directors. Also announced was the appointment of our former Chairman of the Board of Directors, Dieter
Weinand, to the Lead Independent Director of our Board of Directors, the transition of Pamela Esposito, Tanya Lewis and Robert Coffin, our former Chief
Business Officer, Chief Development Operations Officer and President, Chief Research and Development Officer, respectively, to non-employee advisory
roles and the retirement, effective May 31, 2024, of Colin Love, our Chief Operating Officer. These changes and any future significant leadership changes
or senior management transitions involve inherent risk. For example, Robert Coffin, Pamela Esposito and Colin Love had been employed by us for a
significant period of time and, without their advisory services may result in a loss of personnel with a deep institutional knowledge. Any failure to ensure
an effective transition, including the effective onboarding, assimilation, and retention of our management team and key employees, could hinder our
strategic planning, business execution and future performance. In addition, executive leadership transition periods, including the transition we currently
effected, can be disruptive and may result in a loss of personnel with deep technical knowledge, or result in changes to business strategy or objectives, and
may negatively impact our operations and relationships with employees and third-parties due to increased or unanticipated expenses, operational
inefficiencies, uncertainty regarding changes in strategy, decreased employee morale and productivity, and increased turnover.
To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option and restricted stock
unit grants that vest over time and, in some instances, based on performance metrics. The value to employees of these equity grants that vest over time may
be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative
offers from other companies. Although we have employment agreements with our key employees, these employment agreements generally provide for at-
will employment, which means that any of our employees could leave our employment at any time, with or without notice.
If we fail to establish and maintain proper and effective internal control over financial reporting our ability to produce accurate and timely financial
statements could be impaired.
We are required to maintain internal control over financial reporting. We must perform system and process design evaluation and testing of the
effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial
reporting, as required by Section 404 of the Sarbanes-Oxley Act. We continue to be engaged in a process to document and evaluate our internal control
over financial reporting, which is both costly and challenging. In this regard, we will need to continue to incur substantial professional fees and internal
costs for our accounting and finance functions, expend significant management efforts, continue to implement plans developed to address areas that we
have identified as requiring improvement, validate through testing that controls are functioning as documented and implement a continuous reporting and
improvement process for internal control over financial reporting.
If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper
and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our
investors could lose confidence in our reported financial information, the market price of our stock could decline and we could be subject to sanctions or
investigations by the SEC, Nasdaq or other regulatory authorities.
We believe that any internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. We may discover weaknesses in our system of internal financial and accounting controls and procedures
that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect
all errors and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.
These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized
override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be
detected.
52

TABLE OF CONTENTS
Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems.
In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of,
transmit, and share (collectively, processing) sensitive information, including personal data, proprietary and confidential business data, trade secrets,
intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. The secure maintenance of this
information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized
access and use by third parties with a wide range of motives and expertise, including organized criminal groups, “hacktivists,” patient groups, disgruntled
current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information
technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.
The pervasiveness of cybersecurity incidents in general and the risks of cyber-crime are complex and continue to evolve. There can be no assurance
that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Our internal
computer systems and those of our contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or
inappropriate access or use, natural disasters, pandemics, terrorism, war and telecommunication and electrical failures. Such events could cause interruption
of our operations. For example, the loss of pre-clinical trial data or data from clinical trials for our product candidates could result in delays in our
regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent
that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or
inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur
notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees,
stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the
development and potential commercialization of our product candidates could be delayed. For additional information, see the Risk Factor captioned, “We
are subject to stringent and changing obligations related to privacy and security. Our actual or perceived failure to comply with such obligations could
lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively
affect our operating results and business.”
Risks related to our common stock and general risks
An active trading market for our common stock may not be sustained.
Our common stock began trading on the Nasdaq Global Select Market on July 20, 2018 and we can provide no assurances that we will be able to
continue to maintain an active trading market on the Nasdaq Global Select Market or any other exchange in the future. In the absence of an active trading
market for shares of our common stock, our stockholders may not be able to sell their common stock at or above the price at which such stockholder
acquired our common stock or at the time that they would like to sell. An inactive market may also impair our ability to raise capital by selling shares and
may impair our ability to use our shares as consideration in commercial transactions.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock.
Our stock price has been and is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not
be able to sell your common stock at or above the price at which it was acquired. The market price for our common stock may be influenced by many
factors, including:
•
the success of competitive products or technologies;
•
results of clinical trials of RP1 and our other product candidates or those of our competitors;
•
regulatory or legal developments in the United States and other countries;
•
developments or disputes concerning patent applications, issued patents or other proprietary rights;
•
the recruitment or departure of key personnel;
•
the level of expenses related to the development of RP1 and our other product candidates or clinical development programs;
53

TABLE OF CONTENTS
•
the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;
•
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
•
variations in our financial results or those of companies that are perceived to be similar to us;
•
changes in the structure of healthcare payment systems;
•
market conditions in the pharmaceutical and biotechnology sectors;
•
general economic, industry and market conditions;
•
political and economic instability, the possibility of an economic recession, international hostilities, governmental restrictions and sanctions,
inflation, global supply chain disruptions, trade relationships and military and political alliances; and
•
the other factors described in this “Risk factors” section.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to
fall below expectations or our guidance.
Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating
results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant
upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on
development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration
agreements and sales of our products, if approved. These upfront and milestone payments may vary significantly from period to period and any such
variance could cause a significant fluctuation in our operating results from one period to the next.
In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the
award as determined by our board of directors, and recognize the cost as an expense over the employee’s requisite service period. As the variables that we
use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility, the magnitude of the expense that
we must recognize may vary significantly.
Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to
predict, including the following:
•
timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which
will change from time to time;
•
the total expenses we incur in connection with equipping and operating our manufacturing facility;
•
our ability to engage clinical trial sites in the U.S. and in foreign territories, obtain the approval for conducing our clinical trials in foreign
territories from their regulatory authorities, as well as our ability to enroll the number of patients necessary in our clinical trials and the timing of
enrollment;
•
the cost of manufacturing our current and any future product candidates, which may vary depending on the FDA’s and comparable foreign
regulatory authorities’ guidelines and requirements, the quantity of production and the terms of any agreements with manufacturers;
•
expenditures that we will or may incur to acquire or develop additional product candidates and technologies;
•
the timing and outcomes of clinical and preclinical studies for RP1 and our other product candidates or competing product candidates;
•
competition from existing and potential future products that compete with RP1 and our other product candidates, and changes in the competitive
landscape of our industry, including consolidation among our competitors or partners;
•
any delays in regulatory review or approval of RP1 or our other product candidates;
•
the level of demand for RP1 and our other product candidates, if approved, which may fluctuate significantly and be difficult to predict;
•
the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future
products that compete with RP1 and our other product candidates;
•
our ability to commercialize RP1 and our other product candidates, if approved, inside and outside of the United States, either independently or
working with third parties;
54

TABLE OF CONTENTS
•
the success of and our ability to establish and maintain collaborations, licensing or other arrangements;
•
our ability to adequately support future growth;
•
potential unforeseen business disruptions that increase our costs or expenses;
•
natural disasters, public health crises, political crises, negative global climate patterns, or other catastrophic events, the possibility of an economic
recession, international hostilities, including, but not limited to, those resulting from the ongoing military conflicts between Russia-Ukraine and
Israel-Hamas, acts of terrorism, governmental restrictions and sanctions, inflation, global supply chain disruptions, trade relationships and military
and political alliances;
•
future accounting pronouncements or changes in our accounting policies; and
•
the changing and volatile global economic environment.
These factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating
results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.
This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any
period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the
forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a
stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.
We have broad discretion in how we use our cash, cash equivalents and investments, and may not use these resources effectively, which could affect
our results of operations and cause our stock price to decline.
Our management has considerable discretion in the application of our cash, cash equivalents and investments. We intend to use our resources to fund
our preclinical and clinical development programs as well as for general corporate purposes, including working capital requirements and other operating
expenses. As a result, investors will be relying upon management’s judgment with only limited information about our specific intentions for the use of our
resources. We may use our resources for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their
use, we may invest our cash, cash equivalents and investments in a manner that does not produce income or that loses value.
We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring
or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, which may
never occur, as the only way to realize any return on their investment.
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the expiration of
contractual or legal restrictions on resale lapse, the market price of our common stock could decline. These sales may make it more difficult for us to sell
equity or equity related securities in the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisition.
In addition, a significant number of shares of common stock that are either subject to outstanding options and restricted stock units, reserved for future
issuance under our equity incentive plans or subject to outstanding warrants are eligible for sale in the public market to the extent permitted by the
provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act, including our ESPP if activated. If these additional shares of
common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.
Certain holders of shares of our common stock, or their permitted transferees, are entitled to rights with respect to the registration under the Securities
Act of shares of our common stock pursuant to the amended and restated investors’ rights agreement by and among us and certain of our stockholders.
Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except
for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common
stock.
We may sell up to $100.0 million of shares of our common stock in “at-the-market” offerings pursuant to a Sales Agreement entered into on August 3,
2023 with Leerink Partners LLC, and amended on May 16, 2024, or the 2023 Sales Agreement. The sale of a substantial number of shares of our common
stock pursuant to the 2023 Sales Agreement, or
55

TABLE OF CONTENTS
anticipation of such sales, could cause the trading price of our common stock to decline or make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise desire. In addition, issuances of any shares of our common stock sold pursuant to the
2023 Sales Agreement will have a dilutive effect on our existing stockholders.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or
product candidates.
To the extent that we raise additional capital through the sale of common stock or securities convertible, exercisable or exchangeable into common
stock, our existing stockholders’ interest will be diluted. Debt financing, if available, would increase our fixed payment obligations and may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends.
If we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market one
or more of our product candidates or technologies that we would otherwise prefer to develop and market ourselves.
If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt
or assume contingent liabilities, and subject us to other risks.
We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights,
technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:
•
increased operating expenses and cash requirements;
•
the assumption of additional indebtedness or contingent liabilities;
•
the issuance of our equity securities;
•
assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new
personnel;
•
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
•
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
•
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance
status, and their existing products or product candidates and marketing approvals; and
•
our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even
to offset the associated acquisition and maintenance costs.
In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire
intangible assets that could result in significant future amortization expense or intangible asset impairment charges. Moreover, we may not be able to locate
suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the
development of our business. Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and prospects.
Unfavorable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock
price and prospects.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The most recent
global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in
a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining
economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all
of the ways in which the economic climate and financial market conditions could adversely impact our business.
Global financial markets have been experiencing extreme disruption in recent months, including, among other things, extreme volatility in securities
prices. We are unable to predict the likely duration and severity of the current disruptions in financial markets and adverse economic conditions throughout
the world. These economic developments affect businesses such as ours and those of third parties on which we rely in a number of ways that could result in
unfavorable consequences to us.
56

TABLE OF CONTENTS
Current economic conditions or a deepening economic downturn in the United States and elsewhere may reduce our ability to access capital, which could
negatively impact our short-term and long-term liquidity.
Although we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents or short-term
investments, we cannot assure you that deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash
equivalents or short-term investments, or our ability to meet our financing objectives. Furthermore, our stock price may decline due, in part, to the volatility
of the stock market and general economic downturns.
Exchange rate fluctuations may materially affect our results of operations and financial conditions.
Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S. dollar and the British pound and the
euro, may adversely affect us. Although we are based in the United States, we have significant research and development operations in the United
Kingdom, and source consulting and other services in the United Kingdom and the European Union. As a result, our business and the price of our common
stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from
period to period. Currently, we do not have any exchange rate hedging arrangements in place.
Unfavorable global economic conditions and geopolitical events could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The financial
markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing military
conflicts between Russia-Ukraine and Israel-Hamas, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in
response to such conflicts may also adversely impact our clinical trials, the financial markets and the global economy, and any economic countermeasures
by the affected countries or others could exacerbate market and economic instability. A weak or declining economy or political disruption, including any
international trade disputes, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Although we do not
currently operate in Russia or Ukraine, if the conflict broadens it may impact countries or territories in which we do operate or intend to operate, which
could have a negative impact on our ability to achieve our objectives or timelines.
The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our
financial results.
There has been increasing public focus by investors, customers, environmental activists, the media and governmental and nongovernmental
organizations on a variety of environmental, social and other sustainability matters. We experience pressure to make commitments relating to sustainability
matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not
effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our
reputation and financial results may suffer. We may experience increased costs in order to execute upon our sustainability goals and measure achievement
of those goals, which could have a materially adverse impact on our business and financial condition. In addition, this emphasis on environmental, social
and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to
comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted.
The Hercules Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to
occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to
meet this obligation.
On October 6, 2022 we and certain of our subsidiaries entered into a Loan and Security Agreement, or the Loan Agreement with Hercules Capital,
Inc., or Hercules, in its capacity as administrative agent and collateral agent and as a lender, which such agreement was subsequently amended in June 2023
and December 2023. The Hercules Loan Agreement contains certain affirmative and negative covenants that could prevent us from taking certain actions
without the consent of our lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be
advantageous to us and our stockholders. The Hercules Loan Agreement also contains customary affirmative and negative covenants that, among other
things, may limit our ability, subject to certain exceptions, to incur indebtedness, grant liens, enter into a merger or consolidation, enter into transactions
with affiliates, or sell all or a portion of our property, business or assets. The Hercules Loan Agreement contains customary events of default. Upon the
occurrence and continuation of an event of default, all
57

TABLE OF CONTENTS
amounts due under the Hercules Loan Agreement become (in the case of an insolvency or bankruptcy event), or may become (in the case of all other events
of default and at the option of Hercules), immediately due and payable. If an event of default under the Hercules Loan Agreement should occur, we could
be required to immediately repay any outstanding indebtedness. If we are unable to repay such debt, the lenders would be able to foreclose on the secured
collateral, including our cash accounts, and take other remedies permitted under the Hercules Loan Agreement. Even if we are able to repay any
indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned.
Item 1B.    Unresolved staff comments
None.
Item 1C.    Cybersecurity
We have policies, procedures, and processes for assessing, identifying, and managing cybersecurity risks, which are built into our overall information
technology function and are designed to help protect our information assets and operations from internal and external cyber threats as well as secure our
networks and systems. Such processes include procedural and technical safeguards, response plans, regular vulnerability and penetration tests on our
systems and product applications, incident simulations, and routine review of our policies and procedures to identify risks and improve our practices. Our
security incident response plan is designed to help coordinate our response to, and recovery from, cybersecurity incidents, and includes processes to assess
the severity of, escalate, contain, investigate, and remediate incidents as well as to comply with applicable legal obligations. We maintain cyber insurance
coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks, and other
related breaches.
We engage certain external parties to enhance our cybersecurity processes and strategies. Depending on the nature of the services provided, the
sensitivity and quantity of information processed, and the identity of the service provider, we evaluate the security and risk posture according to the
perceived level of risk and in accordance with industry standard best practices.
Our audit committee of the Board of Directors provides direct oversight over cybersecurity risk and provides applicable updates to the Board of
Directors regarding such oversight. Members of management responsible for data privacy, technology, and information security risks join our audit
committee meetings from time to time to discuss these risks, risk management activities, incident response plans, best practices, the effectiveness of our
security measures, and other related matters.
Our Chief Information Officer, who reports to our Chief Financial Officer, leads the operational oversight of company-wide cybersecurity strategy,
policy, standards, and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.
Specific cybersecurity related responsibilities include overseeing our processes and strategies for the detection, mitigation, and remediation of
cybersecurity incidents. Our Chief Information Officer has extensive experience assessing and managing cybersecurity and risk programs having served in
relevant positions of increasing responsibility for over 25 years at several private and public companies.
In an effort to deter and detect cyber threats, we provide all employees with routine response and prevention training, which covers timely and relevant
topics, including social engineering, phishing, password protection, confidential data protection, asset use, and mobile security, and educates employees on
the importance of reporting all incidents promptly. We also use technology-based tools to mitigate cybersecurity threats and risks and to bolster our
employee-based cybersecurity programs.
Despite our cybersecurity efforts, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse
effect on us. See Part I, Item 1A, Risk Factors, in this Annual Report for a discussion of cybersecurity risks.
Item 2.    Properties
Our corporate headquarters are located in Woburn, Massachusetts, where we occupy approximately 18,712 square feet pursuant to a lease expiring in
2029, with an option to extend by an additional five years. We also lease an approximately 12,000 square-foot facility in Oxfordshire, United Kingdom,
containing research and development, laboratory and office space. This lease expires in April 2031 and we have the right to terminate it in April 2026. In
October 2021 and March 2023, the Company entered into additional agreements to lease approximately 2,951 and 2,058 square feet, respectively, of
research and development, office and laboratory space in Abingdon, Oxfordshire, United Kingdom. These lease agreements are both for five years and
expire in October 2026 and March 2028, respectively, with no right to renewal.
58

TABLE OF CONTENTS
In June 2018, we entered into an agreement to lease approximately 63,000 square feet of office, manufacturing and laboratory space in Framingham,
Massachusetts. Pursuant to the lease agreement, the lease term commenced in December 2018 and the rent commenced in August 2019. The initial lease
term is ten years from the rent commencement date and includes two optional five-year extensions.
We believe that our current facilities are suitable and adequate to meet our current and planned needs. Our leases can be renewed, and we believe that
suitable alternative spaces will be available as needed in the future, on commercially reasonable terms. We do not own any real property.
Item 3.    Legal proceedings
We are not currently a party to any material legal proceedings.
Item 4.    Mine safety disclosures
Not applicable.
59

TABLE OF CONTENTS
PART II
Item 5.    Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities
Our common stock has been listed on the Nasdaq Global Select Market under the symbol “REPL” since July 20, 2018. Prior to that date, there was no
public trading market for our common stock.
Holders of common stock
As of the close of business on May 13, 2024, there were approximately 9 holders of record of our common stock. This number does not reflect
beneficial owners whose shares are held in street name.
Dividend policy
We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in
the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to
declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements,
contractual restrictions, business prospects, general business conditions and other factors that our board of directors may deem relevant.
Securities authorized for issuance under equity compensation plans
Information regarding our equity compensation plans and the securities authorized for issuance thereunder is set forth herein under Part III, Item 12
below.
Recent sales of unregistered securities
None.
Purchases of equity securities by the Issuer and affiliated purchasers
None.
Item 6.    Reserved
Item 7.    Management’s discussion and analysis of financial condition and results of operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated
financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical
information, some of the statements contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including
information with respect to our plans and strategy for our business, constitute forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have based these
forward-looking statements on our current expectations and projections about future events. The following information and any forward-looking statements
should be considered in light of factors discussed elsewhere in this Annual Report on Form 10-K, particularly including those risks identified in Part I,
Item 1A “Risk factors” and our other filings with the SEC.
We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition
and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual
Report on Form 10-K. Statements made herein are as of the date of the filing of this Annual Report on Form 10-K with the SEC and should not be relied
upon as of any subsequent date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate
are consistent with the forward-looking statements contained in this Annual Report on Form 10-K, they may not be predictive of results or developments in
future periods. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements
to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based or that may affect the
likelihood that actual results will differ from those set forth in the forward-looking statements.
Overview
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the
lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary
60

TABLE OF CONTENTS
oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Oncolytic immunotherapy is an emerging drug class, which we intend to establish as the second cornerstone of immune-based cancer treatments,
alongside checkpoint blockade. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well
as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms into a practical “off-the-shelf”
approach that is intended to maximize the immune response against a patient’s cancer and to offer significant advantages over other approaches of inducing
anti-tumor immunity, including personalized vaccine approaches. We believe that the bundling of multiple approaches for the treatment of cancer into
single therapies may improve patient outcomes and simplify the development path of our product candidates.
Financial
Since our inception, we have devoted substantially all of our resources to developing our proprietary RPx platform, building our intellectual property
portfolio, conducting research and development of our product candidates, business planning, raising capital and providing selling, general and
administrative support for our operations. To date, we have incurred significant operating losses and we have financed our operations primarily with
proceeds from the sale of equity securities and to a lesser extent the proceeds from the issuance of debt securities. Our ability to generate product revenue
sufficient to achieve profitability will depend on the successful development and eventual commercialization, if approved, of one or more of our product
candidates. We do not have any products approved for sale and have not generated any revenue from product sales.
Since our initial public offering, or IPO, on July 20, 2018, we have raised an aggregate of approximately $849.1 million in net proceeds to fund our
operations, of which $101.2 million was from our IPO, $706.0 million was from four separate follow-on offerings, or the Public Offerings, that we closed
in November 2019, June 2020, October 2020 and December 2022, respectively, and $41.9 million was from at-the-market offerings.
Our net losses were $215.8 million and $174.3 million for the years ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an
accumulated deficit of $701.3 million. These losses have resulted primarily from costs incurred in connection with research and development activities and
selling, general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses
for at least the next several years.
We anticipate that our expenses and capital requirements will fluctuate from period to period depending upon the Company's development programs
and priorities. We expect to continue to incur costs in connection with our ongoing development activities, including further advancement of any preclinical
activities and clinical trials of our product candidates across our platform, and if and as we:
•
conduct our current and future clinical trials;
•
further preclinical development of our platform;
•
operate our in-house manufacturing facility;
•
seek to identify and develop additional product candidates;
•
seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;
•
establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
•
until our manufacturing facility is fully validated, continued limited manufacturing by third parties for clinical development;
•
maintain, expand and protect our intellectual property portfolio;
•
hire and retain additional clinical, quality control, scientific and selling, general and administration personnel;
•
acquire or in-license other drugs, technologies or intellectual property rights; and
•
add operational, financial and management information systems and personnel, including personnel to support our research and development
programs, any future commercialization efforts and operations as a public company.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or
amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not
become profitable. If we fail to become profitable or are
61

TABLE OF CONTENTS
unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or
terminate our operations.
As of March 31, 2024, we had cash and cash equivalents and short-term investments of $420.7 million. Based on our current operating plan, we
believe that our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure
requirements through at least 12 months from the issuance of the consolidated financial statements included in this Annual Report on Form 10-K.
See “Results of Operations — Liquidity and capital resources” and “Risk factors — Risks related to our financial position and need for additional
capital.”
Components of our results of operations
Revenue
To date, we have not generated any revenue from product sales as we do not have any approved products and do not expect to generate any revenue
from the sale of products in the near future. If our development efforts for RP1 or any other product candidates that we may develop in the future are
successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future
from a combination of product sales or payments from those collaborations or license agreements.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development
of our product candidates, and include:
•
expenses incurred under agreements with third parties, including CROs, that conduct research, preclinical activities and clinical trials on our
behalf as well as CMOs that manufacture our raw materials and/or product candidates for use in our preclinical and clinical trials;
•
salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development
functions;
•
costs of outside consultants engaged in research and development functions, including their fees, stock-based compensation and related travel
expenses;
•
the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;
•
costs related to compliance with regulatory requirements in connection with the development of our product candidates; and
•
facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating
costs.
We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to
completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the
individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued
research and development expenses.
Our direct external research and development expenses are tracked on a program-by-program basis and consist of costs, such as fees paid to
consultants, contractors, CMOs, and CROs in connection with our preclinical and clinical development activities. We do not allocate personnel costs, costs
associated with our discovery efforts, laboratory supplies or other indirect costs, to specific product development programs because these costs are
deployed across multiple product development programs and, as such, are not separately classified. Non-employee costs associated with our manufacturing
facility including depreciation, amortization and facility costs are appropriately allocated to development programs based on the percentage of time spent
per program.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher
development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We
expect that our research and development expenses will continue to increase for the foreseeable future as we continue enrollment and initiate additional
clinical trials and continue to discover and
62

TABLE OF CONTENTS
develop additional product candidates. The successful development and commercialization of our product candidates is highly uncertain. This is due to the
numerous risks and uncertainties associated with product development and commercialization, including the following:
•
the scope, rate of progress, expense and results of our ongoing clinical trials, as well as future clinical trials or other product candidates and other
research and development activities that we may conduct;
•
the number and scope of preclinical and clinical programs we decide to pursue;
•
our ability to maintain our current research and development programs and to establish new ones;
•
uncertainties in clinical trial design;
•
the rate of enrollment in clinical trials;
•
the successful completion of clinical trials with safety, tolerability, and efficacy profiles that are satisfactory to the FDA or any comparable foreign
regulatory authority;
•
the receipt of regulatory approvals from applicable regulatory authorities;
•
our success in operating our manufacturing facility, or securing manufacturing supply through relationships with third parties;
•
our ability to obtain and maintain patents, trade secret protection, and regulatory exclusivity, both in the United States and internationally;
•
our ability to maintain, expand and protect our rights in our intellectual property portfolio;
•
the commercialization of our product candidates, if and when approved;
•
the acceptance of our product candidates, if approved, by patients, the medical community, and third-party payors;
•
our ability to successfully develop our product candidates for use in combination with third-party products or product candidates;
•
negative developments in the field of immuno-oncology;
•
competition with other products; and
•
significant and changing government regulation and regulatory guidance.
A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs
and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to
conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we
experience significant trial delays due to patient enrollment or other reasons, we could be required to expend significant additional financial resources and
time on the completion of clinical development. We may never succeed in obtaining regulatory approval for any of our product candidates.
Selling, general and administrative expenses
Selling, general and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in
our executive, finance, corporate, commercial, and business development and administrative functions. Selling, general and administrative expenses also
include professional fees for legal, patent, accounting, auditing, tax and consulting services, pre-commercial planning, marketing and strategic planning,
business development, travel expenses, and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and
maintenance of facilities and other operating costs.
We expect that our selling, general and administrative expenses will continue to increase in the future as we increase our selling, general and
administrative headcount to support our continued research and development and pre-launch activities to prepare for potential commercialization of our
product candidates. We also expect to continue to incur increased expenses, including accounting, audit, legal, regulatory and tax-related services
associated with maintaining compliance with exchange listing and SEC requirements; director and officer insurance costs; and investor and public relations
costs.
Other income (expense), net
Research and development incentives
63

TABLE OF CONTENTS
Research and development incentives consists of reimbursements of research and development expenditures. We participate, through our subsidiary in
the United Kingdom, in the research and development program provided by the United Kingdom tax relief program, such that a percentage of up to 14.5%
of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as other
income.
Investment income
Investment income consists of income earned on our cash and cash equivalents and short-term investments.
Interest expense on finance lease liability
Interest expense on finance lease liability consists of amortization of finance charges under our financing lease.
Interest expense on debt obligations
Interest expense on debt obligations consists of the amortization of debt discount and cash paid for interest under the Hercules Loan Agreement.
Other income (expense), net
Other income (expense), net consists primarily of realized and unrealized foreign currency transaction gains and losses.
Income taxes
During the year ended March 31, 2024 and 2023, the Company recorded an income tax provision of $0.4 million and $0.3 million, respectively, related
to U.S. current taxes primarily due to the transfer pricing arrangement between the U.S. and the U.K., as well as unfavorable adjustments related to stock
compensation, resulting in U.S. taxable income reduced by certain prior year available net operating losses.
Results of operations
Comparison of the years ended March 31, 2024 and 2023
The following table summarizes our results of operations for the years ended March 31, 2024 and 2023:
Year Ended March 31,
Change
2024
2023
$
%
(Amounts in thousands)
Operating expenses:
Research and development
$
174,963 
$
126,527 
$
48,436 
38 %
Selling, general and administrative
59,810 
50,553 
9,257 
18 %
Total operating expenses
234,773 
177,080 
57,693 
33 %
Loss from operations
(234,773)
(177,080)
(57,693)
33 %
Other income (expense):
Research and development incentives
1,920 
2,914 
(994)
(34)%
Investment income
23,356 
10,006 
13,350 
133 %
Interest expense on finance lease liability
(2,163)
(2,197)
34 
(2)%
Interest expense on debt obligations
(4,497)
(1,963)
(2,534)
129 %
Other income (expense)
771 
(5,676)
6,447 
(114)%
Total other income (expense), net
19,387 
3,084 
16,303 
529 %
Loss before income taxes
$
(215,386)
$
(173,996)
$
(41,390)
24 %
Income tax provision
408 
288 
120 
42 %
Net loss
$
(215,794)
$
(174,284)
$
(41,510)
24 %
64

TABLE OF CONTENTS
Research and development expenses
Research and development expenses for the year ended March 31, 2024 were $175.0 million, compared to $126.5 million for the year ended March 31,
2023. The following table summarizes our research and development expenses for the years ended March 31, 2024 and 2023:
Year Ended March 31,
Change
2024
2023
$
%
Direct research and development expenses by program:
RP1
51,492 
39,641 
11,851 
30 %
RP2
10,701 
3,632 
7,069 
195 %
RP3
13,162 
13,349 
(187)
(1)%
Unallocated research and development expenses:
Personnel related (including stock-based compensation)
80,395 
53,634 
26,761 
50 %
Other
19,213 
16,271 
2,942 
18 %
Total research and development expenses
$
174,963 
$
126,527 
$
48,436 
38 %
The total increase of $48.4 million was due to an increase of approximately $18.7 million in direct research costs related to our ongoing clinical trials
and increased patient enrollment for RP1, RP2 and RP3, including an increase of approximately $13.3 million in the areas of CRO costs, investigator costs,
and imaging costs. The costs for RP1 also increased compared to the prior year as we prepared the primary analysis and preparations for a potential BLA
filing for CERPASS as well as the initial full data presentation for IGNYTE and preparations for a potential BLA submission for IGNYTE. In addition, we
focused on an updated data presentation on the ARTACUS trial. Furthermore, we continued to ramp up activities to develop RP2 throughout the year ended
March 31, 2024 as compared to the prior year, whereas activities for RP3 remained consistent year over year as a result of the deprioritization of
development efforts on this product candidate during the later part of fiscal 2024.
The increase of $29.7 million in our unallocated expenses was due primarily to a $26.8 million increase in personnel-related costs, including a $22.1
million increase in payroll and fringe benefits and a stock-based compensation increase of $4.7 million. The increase in personnel-related costs largely
reflected the hiring of additional personnel in our research and development functions as we expand the development plan in multiple indications.
Personnel related costs for the years ended March 31, 2024 and 2023 included stock-based compensation expense of $14.7 million and $10.1 million,
respectively.
Selling, general and administrative expenses
Selling, general and administrative expenses were $59.8 million for the year ended March 31, 2024, compared to $50.6 million for the year ended
March 31, 2023. The increase of $9.3 million is primarily the result of an increase of $6.3 million in personnel related costs, including an increase of $5.0
million in payroll and fringe benefits and a stock-based compensation increase of $1.3 million. The increase in personnel related costs was driven by the
continued hiring of additional personnel within our selling, general and administrative functions, specifically focusing on commercial planning and
building of our initial commercial infrastructure. Personnel related costs for the year ended March 31, 2024 and 2023 included stock-based compensation
expense of $19.4 million and $18.1 million, respectively.
Total other income (expense), net
Other income for the year ended March 31, 2024 was $19.4 million compared to $3.1 million for the year ended March 31, 2023. The net change of
$16.3 million is primarily attributable to an increase of $13.4 million in investment income in the current year as compared to the prior year as a result of
increases in interest rates throughout the year, as well as a $6.4 million decrease in expense due to the changes in foreign exchange rates of the Great
British Pound to United States Dollar. These increases were partially offset by an increase in expense of $2.5 million of interest expense on debt
obligations, as the Company drew down an additional term loan advance of $15.0 million in December 2023 from the debt agreement with Hercules.
Income tax provision
Income tax provision for the year ended March 31, 2024 was $0.4 million compared to $0.3 million for the year ended March 31, 2023. The income tax
provision for the current year is attributable to U.S. current taxes primarily due to the transfer pricing arrangement between the U.S. and the U.K., as well
as unfavorable adjustments related to stock compensation, resulting in U.S. taxable income reduced by certain prior year available net operating losses.
65

TABLE OF CONTENTS
Liquidity and capital resources
Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from
our operations. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we
do not expect to generate revenue from sales of any products for the foreseeable future, if at all.
Sources of liquidity
To date, we have financed our operations primarily with proceeds from the sale of equity securities and, to a lesser extent, proceeds from borrowing
under a secured loan facility. Through March 31, 2024, we had received net proceeds of $935.9 million through the sale of equity securities, as well as net
$42.8 million from our incurrence of debt under the Hercules Loan Agreement. As of March 31, 2024, we had cash and cash equivalents and short-term
investments of $420.7 million.
Cash flows
The following table summarizes our cash flows for each of the periods presented:
Year Ended March 31,
2024
2023
(Amounts in thousands)
Net cash used in operating activities
$
(185,467)
$
(128,050)
Net cash provided by (used in) investing activities
97,201 
(142,502)
Net cash provided by financing activities
16,283 
311,303 
Effect of exchange rate changes on cash and cash equivalents
(86)
(109)
Net increase (decrease) in cash and cash equivalents
$
(72,069)
$
40,642 
Operating activities
During the year ended March 31, 2024, net cash used in operating activities was $185.5 million, primarily resulting from our net loss of $215.8
million, which was partially offset by non-cash charges of $24.8 million, consisting primarily of stock-based compensation expense of $34.1 million offset
by $12.3 million related to the net amortization of premiums and discounts on short-term investments. Additionally, there was an increase in cash of $5.5
million related to changes in our operating assets and liabilities. Changes in our operating assets and liabilities for the year ended March 31, 2024 consisted
primarily of a $9.2 million increase in accrued expenses and other current liabilities, a $2.8 million decrease in accounts payable, and a net $2.4 million
change in operating and financing right-of-use assets and lease liabilities.
During the year ended March 31, 2023, net cash used in operating activities was $128.1 million, primarily resulting from our net loss of $174.3
million, partially offset by non-cash charges of $31.1 million, consisting primarily of stock-based compensation expense of $28.1 million, and an increase
in cash of $15.1 million related to changes in our operating assets and liabilities. Changes in our operating assets and liabilities for the year ended March
31, 2023 consisted primarily of a $11.4 million increase in accrued expenses and other current liabilities, a net $2.4 million change in operating and
financing right-of-use assets and lease liabilities, and a $2.0 million increase in accounts payable.
Investing activities
During the year ended March 31, 2024, net cash provided by investing activities was $97.2 million, consisting of $592.4 million in proceeds from sales
and maturities of short-term investments, partially offset by $489.5 million in purchases of available for sale securities and $5.7 million in purchases of
property, plant and equipment.
During the year ended March 31, 2023, net cash used in investing activities was $142.5 million, consisting of $583.4 million in purchases of available
for sale securities and $2.3 million in purchases of property, plant and equipment, offset by $443.2 million in proceeds from sales and maturities of short-
term investments.
Financing Activities
During the year ended March 31, 2024, net cash provided by financing activities was $16.3 million, consisting primarily of $15.0 million in proceeds
from the incurrence of debt under the Hercules Loan Agreement, as well as approximately $1.8 million in proceeds from the exercise of stock options.
66

TABLE OF CONTENTS
During the year ended March 31, 2023, net cash provided by financing activities was $311.3 million, consisting primarily of $149.9 million in
proceeds from the issuance of common stock, $92.8 million from the issuance of pre-funded warrants to purchase common stock, $37.4 million from the
issuance of common stock through sales under our at-the-market facilities, $28.2 million in proceeds from the incurrence of debt under the Hercules Loan
Agreement, as well as approximately $3.4 million in proceeds from the exercise of stock options.
Funding requirements
Our plan of operation is to continue implementing our business strategy, continue research and development of RP1 and our other product candidates
and continue to expand our research pipeline and our internal research and development capabilities. We expect our expenses to increase substantially in
connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates and if and as we:
•
conduct our current and future clinical trials with RP1, RP2 and RP3;
•
further preclinical development of our RPx platform;
•
operate, qualify and maintain our in-house manufacturing facility and qualify and maintain our product candidates made therein for use in our
clinical trials;
•
seek to identify and develop additional product candidates;
•
seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;
•
establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
•
until our planned manufacturing facility is fully validated, continued limited manufacturing by third parties for clinical development;
•
maintain, expand and protect our intellectual property portfolio;
•
acquire or in-license other drugs, technologies or third-party intellectual property; and
•
add operational, financial and management information systems and personnel, including personnel to support our research and development
programs, any future commercialization efforts and operations as a public company.
As of March 31, 2024, we had cash and cash equivalents and short-term investments of $420.7 million. Based on our current operating plan, we
believe that our existing cash, cash equivalents and short-term investments as of March 31, 2024, will enable us to fund operations into the second half of
2026. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
expect.
Because of the numerous risks and uncertainties associated with the development of RP1 and other product candidates and programs, and because the
extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the
timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product
candidates. Our future capital requirements will depend on many factors, including those described in this section and above under “— Operating expenses 
— Research and development expenses.”
Developing novel biopharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and
uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any
product candidates or generate revenue from the sale of any products for which we may obtain marketing approval. In addition, our product candidates, if
approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of therapies that we do not expect to be
commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.
Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds.
To the extent that we raise additional capital through the sale of our equity or convertible debt securities, our shareholders’ interest may be diluted, and the
terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common
stockholder. Additional debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability
to take specific actions, such as incurring debt, adversely impact our ability to conduct our business, and may require the issuance of warrants, which could
potentially dilute your ownership interest.
67

TABLE OF CONTENTS
If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to
us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third
parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization
efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Contractual obligations and commitments
We have entered into arrangements that contractually obligate us to make payments that will affect our liquidity and cash flows in future periods. Our
contractual obligations include those related to our operating and financing leases, long-term debt, as well as costs associated with contracts entered into in
the normal course of business with CROs, CMOs and other third parties for clinical trials and preclinical research studies and testing.
Lease Commitments
As of March 31, 2024, the aggregate amount of future lease payments is approximately $52.9 million, with $3.9 million due within one year. For
additional information on our leases and timing of future payments, see Note 13 Commitments and contingencies, of the "notes to Consolidated Financial
Statements" contained in Part II, Item 8 of this Annual Report on Form 10-K.
Loan Agreement
Our commitments due for our term loan under our arrangement with Hercules include principal payments of $45.0 million as of March 31, 2024.
Borrowings under the term loan agreement are repayable in monthly interest-only payments through September 2026, and the agreement has a maturity
date of October 2027. Our remaining commitments, based on our current draws, are due through October 2027, and include principal and interest payments
of $62.2 million, and an additional fee upon maturity of the loan of $2.2 million. See Note 7, Long term debt, of the "notes to Consolidated Financial
Statements" contained in Part II, Item 8 of this Annual Report on Form 10-K for further discussion of the Hercules term loan.
Other Obligations
Manufacturing and research commitments include agreements that are enforceable and legally binding on us and that specify all significant terms,
including fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. As of
March 31, 2024, the aggregate amount of non-cancelable purchase obligations related to such manufacturing commitments are approximately $0.9 million
and all of this balance is due within one year.
Collaborations
BMS
In February 2018, we entered into a Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company, or BMS. Pursuant to the
agreement, BMS is providing to us, at no cost, nivolumab, its anti-PD-1 therapy, for use in combination with RP1 in our ongoing Phase 1/2 clinical trial.
Under the agreement, we will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted us a non-exclusive,
non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to use nivolumab in the clinical trial and has agreed to
supply nivolumab, at no cost to us, for use in the clinical trial. Both parties will own the study data produced in the clinical trial, other than study data
related solely to nivolumab, which will belong solely to BMS, or study data related solely to RP1, which will belong solely to us. In January 2020, this
agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma.
Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been
delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis
otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party,
(y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to us to use
nivolumab in the clinical trial will terminate. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction
of this nature.
68

TABLE OF CONTENTS
In April 2019, we entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to
which BMS will provide, at no cost to us, nivolumab for use in our Phase 1 clinical trial of RP2 in combination with nivolumab.
Regeneron
In May 2018, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron. Pursuant to the agreement we agreed to
undertake one or more clinical trials with Regeneron for the administration of our product candidates in combination with cemiplimab, an anti-PD-1
therapy developed by Regeneron, across multiple solid tumor types, the first of which is our ongoing Phase 2 clinical trial testing RP1 in combination with
cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted pursuant to an agreed study plan which, among other
things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a schedule of
clinical obligations.
Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to
contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. The Company does not
expect any further reimbursements from Regeneron related to the initial study plan of June 2018 and the CERPASS trial. The agreement contains
representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based
covenants that restrict us from entering into a third-party arrangement with respect to the use of our product candidates in combination with an anti-PD-1
therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus,
in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a
future study plan, these covenants are only applicable to our ongoing Phase 2 clinical trial in CSCC.
The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the
parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or
(ii) in the event of a material breach.
Roche
In December 2022, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to our RP2 and RP3 programs
in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate in 30 patient cohort
signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following our re-prioritization of our
product development portfolio in December 2023, we have agreed with Roche to terminate the CRC collaboration and pursue the 2L cohort in HCC with
RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs, atezolizumab and bevacizumab for the 2L cohort in HCC but is
unlikely to share costs following our re-prioritization. We are in discussions with Roche about revising these agreements following our changes to our RP2
and RP3 development plans. Under the terms of the initial agreement we retained the responsibility of operating the clinical trials as well as retaining all the
rights to the development and commercialization of our product candidates. The agreement may be terminated by either party upon sixty days prior written
notice to the other party.
Incyte
In July 2023, we entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the
companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and RP1
in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, we will supply Incyte with
RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach not
reasonably cured within thirty days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices of
the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety days of the effective date of the agreement. In addition, the
Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. As of March 31, 2024, we and Incyte had not
yet agreed on the protocol or budget. However, we and Incyte continue to discuss a potential protocol and neither party has triggered termination of the
agreement in accordance with the termination right described in clause (iv) above. The parties are evaluating potential collaboration efforts pending further
CERPASS data readout of RP1 in combination with cemiplimab and additional data for Incyte's product candidate INCB99280.
Critical accounting policies and estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with generally accepted accounting principles in the United
69

TABLE OF CONTENTS
States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements.
We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions.
While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements appearing elsewhere in this
Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the
preparation of our consolidated financial statements.
Accrued research and development expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses.
This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on
our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise
notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when
contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in the
consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development
expenses include fees paid to:
•
CROs in connection with performing research activities and conducting preclinical studies and clinical trials on our behalf;
•
CMOs in connection with the production of preclinical and clinical trial materials;
•
investigative sites or other service providers in connection with clinical trials;
•
vendors in connection with preclinical and clinical development activities; and
•
vendors related to product manufacturing and development and distribution of preclinical and clinical supplies.
We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes
and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of
these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which
payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we
estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance
of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect
our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the
actual status and timing of services performed and/or timing of receiving invoices for actual services performed may vary and may result in reporting
amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued
research and development expenses.
Stock-based compensation
We issue stock-based awards to employees, directors, consultants and non-employees in the form of stock options, restricted stock units, and
performance-based restricted stock units, or PSUs. We measure such stock-based awards in accordance with ASC 718, Compensation — Stock
Compensation, which requires all stock-based awards to be recognized in the consolidated statements of operations and comprehensive loss based on their
fair value on the date of the grant and the related compensation expense for those awards is recognized over the requisite service period, which is generally
the vesting period of the respective award. We have, to date, issued stock-based awards with service-based and performance-based vesting conditions.
Expense for stock-based awards with service-based vesting conditions is recorded using the straight-line method and for PSUs with performance-based
vesting conditions, the expense is recorded using the graded vesting method. The fair value of each stock option grant is estimated on the date of grant
using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility,
the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield.
See Note 10 of the "Notes to Consolidated Financial Statements" contained in Part II, Item 8 of this Annual Report on Form 10-K
70

TABLE OF CONTENTS
for more information. Forfeitures are accounted for as they occur. The fair value of each RSU and PSU is estimated on the date of grant based on the fair
value of our common stock on that same date.
We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s payroll
costs are classified or in which the award recipient’s service payments are classified.
Recently issued accounting pronouncements
Refer to Note 2, summary of significant accounting policies of the “Notes to Consolidated Financial Statements” contained in Part II, Item 8 of this
Annual Report on Form 10-K for a description of recent accounting pronouncements that are applicable to our business and may potentially have an impact
on our financial position and results of operations.
Item 7A.    Quantitative and qualitative disclosures about market risks
Interest rate sensitivity
As of March 31, 2024, we had cash and cash equivalents and short-term investments of $420.7 million, which consisted of cash equivalents, U.S.
Treasury securities and U.S. government agency securities. Our primary exposure to market risk relates to fluctuations in interest rates, which are affected
by changes in the general level of U.S. interest rates. Given the short-term nature of our cash, cash equivalents and marketable securities, we do not expect
that a sudden change in market interest rates would have a material impact on our financial condition and/or results of operations.
Foreign currency exchange risk
Our headquarters are located in the United States, where the majority of our selling, general and administrative expenses are incurred in U.S. dollars.
The majority of our research and development costs are incurred by our subsidiary in Oxfordshire, United Kingdom, whose functional currency is the
British pound. We are exposed to foreign exchange rate risk. During the year ended March 31, 2024, we recorded net foreign currency transaction gains of
$0.8 million whereas for the year ended March 31, 2023, we recognized a net foreign currency transaction loss of $5.7 million. These gains and losses are
primarily related to unrealized and realized foreign currency gains and losses as a result of transactions entered into by our United Kingdom subsidiary in
currencies other than the British pound, primarily the euro. These foreign currency transaction losses were recorded as a component of other income
(expense), net in our consolidated statements of operations. We believe that a 10% change in the exchange rate between the British pound and the euro
would not have a material impact on our financial position or results of operations.
As we continue to grow our business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency
exchange rates, which could adversely impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to
mitigate our exposure to foreign currency exchange risk.
Item 8.    Financial statements and supplementary data
See the consolidated financial statements filed as part of this Annual Report on Form 10-K as listed under Item 15 below.
Item 9.    Changes in and disagreements with accountants on accounting and financial disclosures
None.
Item 9A.    Controls and procedures
Evaluation of disclosure controls and procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures
that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its
principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with
the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of
our disclosure controls and procedures as of March 31, 2024. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2024.
71

TABLE OF CONTENTS
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how
well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;
over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.
Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Management’s report on internal control over financial reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-
15(f) under the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and
includes those policies and procedures that:
(i)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have
a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
Management of the Company has assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2024. In
making its assessment of internal control over financial reporting, management used the criteria established in Internal Control — Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that
our internal control over financial reporting was effective as of March 31, 2024.
This annual report does not include an audit report of the Company’s registered public accounting firm regarding internal control over financial
reporting. Management’s report was not subject to audit by the Company’s registered public accounting firm pursuant to rules of the Securities and
Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.
Changes in internal control over financial reporting
There have been no changes in our internal control over financial reporting during the fourth quarter of the fiscal year ended March 31, 2024 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information
Rule 10b5-1 Plan Trading Arrangements
During the three months ended March 31, 2024, each of the following officers adopted a “Rule 10b5-1 trading arrangement” (as defined in Item 408
of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c)
72

TABLE OF CONTENTS
under 
the 
Exchange 
Act 
and 
our 
policies 
on 
insider 
trading:
Name & Title
Date Adopted
Aggregate Number of Shares of Common
Stock to be Purchased or Sold Pursuant to
Trading Arrangement
Expiration Date
Pamela Esposito
Chief Business Officer
2/21/2024
Indeterminable
November 14, 2024
Konstantinos Xynos
Chief Medical Officer
2/13/2024
Indeterminable
February 18, 2025

Date of adoption of Rule 10b5-1 trading arrangements is in accordance with both the Company’s insider trading policy and applicable SEC rules
and regulations.

 The first trade pursuant to the Rule 10b5-1 trading arrangement will be, in accordance with both the Company’s insider trading policy and
applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement.

 The Rule 10b5-1 trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the
date listed in the table. The arrangement also provides for automatic expiration in the event of liquidation, dissolution, bankruptcy, insolvency, or
death of the adopting person.

The Rule 10b5-1 trading arrangement includes the sale of shares to be received upon future vesting of certain outstanding equity awards, net of
any shares withheld by us to satisfy applicable taxes. The number of shares to be withheld, and thus the exact number of shares to be sold pursuant
to the Rule 10b5-1 trading arrangement, can only be determined upon the occurrence of the future vesting events. For purposes of this disclosure,
we have reported the gross number of shares to be received upon the future vesting of such equity awards, before subtracting any shares to be
withheld by us to satisfy applicable taxes in connection with such future vesting events.


Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K.

Item 9C. Disclosure Regarding Jurisdictions That Prevent Inspections
Not Applicable.
 (1)
(3)
(2)
(4)
(2)
(4)
(1) 
(2)
(3)
(4) 
73

TABLE OF CONTENTS
PART III
Item 10.    Directors, executive officers and corporate governance
The text of our Code of Business Conduct and Ethics, which applies to our directors and employees (including our principal executive officer,
principal financial officer, and principal accounting officer or controller, and persons performing similar functions), is posted in the “Corporate
Governance” section of our website, www.replimune.com. A copy of the Code of Business Conduct and Ethics can be obtained free of charge on our
website. We intend to disclose on our website any amendments to, or waivers from, our Code of Business Conduct and Ethics that are required to be
disclosed pursuant to the rules of the Securities and Exchange Commission and Nasdaq. The information contained on our website is not considered part
of, or incorporated by reference into, this Annual Report on Form 10-K or any other filing that we make with the Securities and Exchange Commission.
The remaining information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A,
which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended March 31,
2024.
Item 11.    Executive compensation
The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which
proxy statement will be filed with the Securities and Exchange commission not later than 120 days after the close of our fiscal year ended March 31, 2024.
Item 12.    Security ownership of certain beneficial owners and management and related stockholder matters
Securities authorized for issuance under equity compensation plans
The following table provides information as of March 31, 2024, regarding our common stock that may be issued under (1) the 2017 Equity
Compensation Plan, or the 2017 Plan; (2) the 2018 Omnibus Incentive Compensation Plan, or the 2018 Plan; or (3) the Employee Stock Purchase Plan, or
the ESPP.
Number of Securities to be
Issued Upon Exercise of
Outstanding Options,
Warrants and Rights
(a)
Weighted-Average Exercise
Price of Outstanding Options,
Warrants and Rights
(b)
Number of Securities
Remaining Available for
Future Issuance Under Equity
Compensation Plans (excluding
securities reflected in column
(a))
(c)
Plan Category:
Equity compensation plans approved by stockholders
2017 Plan
1,136,195 
3.12 
— 
2018 Plan
7,183,561 
18.64 
2,284,141 
ESPP
2,738,208 
Total
8,319,756 
5,022,349 
_________________
(1) Includes 2,229,143 shares of common stock subject to outstanding restricted and performance stock units.
The remaining information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A,
which proxy statement will be filed with the Securities and Exchange commission not later than 120 days after the close of our fiscal year ended March 31,
2024.
Item 13.    Certain relationships and related transactions, and director independence
The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which
proxy statement will be filed with the Securities and Exchange commission not later than 120 days after the close of our fiscal year ended March 31, 2024.
(1)
74

TABLE OF CONTENTS
Item 14.    Principal accountant fees and services
The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which
proxy statement will be filed with the Securities and Exchange commission not later than 120 days after the close of our fiscal year ended March 31, 2024.
75

TABLE OF CONTENTS
PART IV
Item 15.    Exhibits and financial statement schedules
(a) 1.    Consolidated financial statements.
For a list of the consolidated financial statements included herein, see Index on page F-1 of this report.
2.
Financial statement schedules.
All required information is included in the financial statements or notes thereto.
3.
List of exhibits.
The documents listed in the exhibit index immediately preceding the signature page of this Annual Report on Form 10-K are incorporated by reference
or are filed or furnished with this Annual Report on Form 10-K, in each case as indicated therein.
Item 16.    10-K summary
None.
76

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
Index to Consolidated Financial Statements
For the Years Ended March 31, 2024 and 2023
Page
Report of independent registered public accounting firm (PCAOB ID 238)
F-2
Consolidated balance sheets
F-4
Consolidated statements of operations
F-5
Consolidated statements of comprehensive loss
F-6
Consolidated statements of stockholders’ equity
F-7
Consolidated statements of cash flows
F-8
Notes to consolidated financial statements
F-9
F - 1

TABLE OF CONTENTS
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Replimune Group, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Replimune Group, Inc. and its subsidiaries (the “Company”) as of March 31, 2024
and 2023, and the related consolidated statements of operations, of comprehensive loss, of stockholders’ equity and of cash flows for the years then ended,
including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of March 31, 2024 and 2023, and the results of its operations and its cash flows for
the years then ended in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the
Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we
plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on
the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis
for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was
communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below,
providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Accrued Research and Development Costs
As described in Notes 2 and 6 to the consolidated financial statements, the Company has entered into various research and development-related
contracts with companies both inside and outside of the United States. When billing terms under these contracts do not coincide with the timing of when
the work is performed, management is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. The
Company records accruals for estimated ongoing research costs. Within accrued expenses and other current liabilities, total accrued research and
development costs amounted to $16.4 million as of March 31, 2024. Accrual estimates are based on a number of factors, including management’s
assessment of progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the
research organization or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the
contracts. Significant judgments and estimates are made by management in determining the accrued balances at the end of any reporting period.
The principal considerations for our determination that performing procedures relating to accrued research and development costs is a critical audit
matter are (i) the significant judgment by management in developing the estimate of the accrued research and development costs and (ii) a high degree of
auditor judgment and effort in performing procedures related to the accrued research and development costs.
F - 2

TABLE OF CONTENTS
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the
consolidated financial statements. These procedures included, among others, (i) testing management’s process for developing the estimate of accrued
research and development costs; (ii) evaluating the appropriateness of the methodology used by management to develop the estimate; (iii) evaluating the
reasonableness of management’s estimate of accrued external research and development costs by (a) testing the completeness and accuracy of costs
incurred, on a sample basis, by tracing information to the underlying contracts, purchase orders, invoices and information received from the research
organization or other companies, as applicable, and (b) evaluating the reasonableness of the estimated costs incurred for the services that have not been
invoiced, on a sample basis, by tracing to underlying supporting documentation, such as underlying contracts, purchase orders and information received
from research organizations or other companies, as applicable.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
May 16, 2024
We have served as the Company’s auditor since 2018.
F - 3

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share amounts)
March 31,

2024
March 31,

2023
Assets
Current assets:
Cash and cash equivalents
$
74,457 
$
146,590 
Short-term investments
346,211 
436,796 
Research and development incentives receivable
4,922 
2,939 
Prepaid expenses and other current assets
8,077 
6,278 
Total current assets
433,667 
592,603 
Property, plant and equipment, net
10,483 
7,479 
Restricted cash
1,700 
1,636 
Right-to-use asset – operating leases
4,635 
5,208 
Right-to-use asset – financing leases
37,237 
39,665 
Total assets
$
487,722 
$
646,591 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
2,578 
$
5,364 
Accrued expenses and other current liabilities
33,981 
24,704 
Operating lease liabilities, current
1,161 
1,118 
Financing lease liabilities, current
2,718 
2,639 
Total current liabilities
40,438 
33,825 
Operating lease liabilities, non-current
3,771 
4,389 
Financing lease liabilities, non-current
23,410 
23,965 
Long term debt, net of discount
44,809 
28,648 
Other liabilities, non-current
786 
472 
Total liabilities
$
113,214 
$
91,299 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2024 and March 31, 2023;
61,415,105 and 56,676,313 shares issued and outstanding as of March 31, 2024 and March 31, 2023,
respectively
61 
57 
Additional paid-in capital
1,070,874 
1,034,994 
Accumulated deficit
(701,282)
(485,488)
Accumulated other comprehensive income (loss)
4,855 
5,729 
Total stockholders’ equity
374,508 
555,292 
Total liabilities and stockholders’ equity
$
487,722 
$
646,591 
The accompanying notes are an integral part of these consolidated financial statements.
F - 4

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share amounts)
Year Ended March 31,
2024
2023
Operating expenses:
Research and development
$
174,963 
$
126,527 
Selling, general and administrative
59,810 
50,553 
Total operating expenses
234,773 
177,080 
Loss from operations
(234,773)
(177,080)
Other income (expense):
Research and development incentives
1,920 
2,914 
Investment income
23,356 
10,006 
Interest expense on finance lease liability
(2,163)
(2,197)
Interest expense on debt obligations
(4,497)
(1,963)
Other income (expense)
771 
(5,676)
Total other income, net
19,387 
3,084 
Loss before income taxes
$
(215,386)
$
(173,996)
    Income tax provision
408 
288 
Net loss
$
(215,794)
$
(174,284)
Net loss per common share, basic and diluted
$
(3.24)
$
(2.99)
Weighted average common shares outstanding, basic and diluted
66,569,894 
58,213,010 
The accompanying notes are an integral part of these consolidated financial statements.
F - 5

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Amounts in thousands)
Year Ended March 31,
2024
2023
Net loss
$
(215,794)
$
(174,284)
Other comprehensive loss:
Foreign currency translation (loss) gain
(826)
5,483 
Net unrealized (loss) gain on short-term investments, net of tax of $0
(48)
1,219 
Comprehensive loss
$
(216,668)
$
(167,582)
The accompanying notes are an integral part of these consolidated financial statements.
F - 6

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except share amounts)
Common stock
Additional paid-in
capital
Accumulated
deficit
Accumulated other
comprehensive
income (loss)
Total
stockholders’
equity
Shares
Amount
Balances as of March 31, 2022
47,338,660 
$
47 
$
723,359 
$
(311,204)
$
(973)
$
411,229 
Issuance of common stock through ATM sales,
net of offering costs
2,026,438 
2 
37,436 
— 
— 
37,438 
Issuance of prefunded warrants to purchase
common stock
— 
— 
92,778 
— 
— 
92,778 
Issuance of common stock, net of issuance costs
and underwriter fees
6,810,658 
7 
149,847 
— 
— 
149,854 
Foreign currency translation adjustment
— 
— 
— 
— 
5,483 
5,483 
Unrealized gain on short-term investments
— 
— 
— 
— 
1,219 
1,219 
Exercise of stock options
296,876 
1 
3,443 
— 
— 
3,444 
Vesting of RSUs
203,681 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
28,131 
— 
— 
28,131 
Net loss
— 
— 
— 
(174,284)
— 
(174,284)
Balances as of March 31, 2023
56,676,313 
$
57 
$
1,034,994 
$
(485,488)
$
5,729 
$
555,292 
Foreign currency translation adjustment
— 
— 
— 
— 
(826)
(826)
Unrealized loss on short-term investments
— 
— 
— 
— 
(48)
(48)
Exercise of pre-funded warrants
4,202,622 
4 
(4)
— 
— 
— 
Exercise of stock options
164,221 
— 
1,759 
— 
— 
1,759 
Vesting of RSUs
371,949 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
34,125 
— 
— 
34,125 
Net loss
— 
— 
— 
(215,794)
— 
(215,794)
Balances as of March 31, 2024
61,415,105 
$
61 
$
1,070,874 
$
(701,282)
$
4,855 
$
374,508 
The accompanying notes are an integral part of these consolidated financial statements.
F - 7

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Year Ended March 31,
2024
2023
Cash flows from operating activities:
Net loss
$
(215,794)
$
(174,284)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
34,125 
28,131 
Depreciation and amortization
2,655 
2,447 
Net amortization of premiums and discounts on short-term investments
(12,326)
(5,638)
Noncash interest expense
1,161 
494 
Unrealized foreign currency transaction losses
(771)
5,676 
Changes in operating assets and liabilities:
Research and development incentives receivable
(1,916)
(61)
Prepaid expenses and other current assets
(1,778)
(1,059)
Operating lease, right-of-use-asset
615 
225 
Finance lease, right-of-use-asset
2,428 
2,428 
Accounts payable
(2,794)
1,981 
Accrued expenses and other current liabilities
9,234 
11,376 
Operating lease liabilities
(620)
(238)
Other non-current liabilities
314 
472 
Net cash used in operating activities
(185,467)
(128,050)
Cash flows from investing activities:
Purchases of property, plant and equipment
(5,662)
(2,270)
Purchase of short-term investments
(489,516)
(583,412)
Proceeds from sales and maturities of short-term investments
592,379 
443,180 
Net cash provided by (used in) investing activities
97,201 
(142,502)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of underwriting fees and discounts
— 
149,854 
Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and discounts
— 
92,778 
Proceeds from issuance of common stock through ATM sales, net of offering costs
— 
37,438 
Proceeds from long-term debt, net of debt issuance costs
15,000 
28,154 
Principal payment of finance lease obligation
(476)
(365)
Proceeds from exercise of stock options
1,759 
3,444 
Net cash provided by financing activities
16,283 
311,303 
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(86)
(109)
Net (decrease) increase in cash, cash equivalents and restricted cash
(72,069)
40,642 
Cash, cash equivalents and restricted cash at beginning of period
148,226 
107,584 
Cash, cash equivalents and restricted cash at end of period
$
76,157 
$
148,226 
Supplemental disclosure of cash flow information:
Cash paid during the period for interest
3,044 
$
1,066 
Cash paid for income taxes
300 
— 
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable
$
101 
$
103 
Lease assets obtained in exchange for new operating lease liabilities
$
— 
$
290 
The accompanying notes are an integral part of these consolidated financial statements.
F - 8

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
1.
Nature of the business
Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat
cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries:
Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to,
development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with
government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These
efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if
the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Basis of presentation
The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the
satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net
losses of $215.8 million and $174.3 million for the years ended March 31, 2024 and 2023, respectively. In addition, as of March 31, 2024, the Company
had an accumulated deficit of $701.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance
date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to
fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.
2.
Summary of significant accounting policies
Principles of consolidation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America, or GAAP, and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune
US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions.
Use of estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements
include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its
estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the
circumstances.
Foreign currency and currency translation
The functional currency for the Company’s wholly owned foreign subsidiary, Replimune UK, is the British pound. Assets and liabilities of Replimune
UK are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average
exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in
the consolidated statements of stockholders’ equity as a component of accumulated other comprehensive income (loss). Adjustments that arise from
exchange rate changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the
consolidated statements of operations as incurred.
F - 9

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Concentrations of credit risk and of significant suppliers
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as
short-term investments. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits. We limit our exposure
to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with
maturities that maintain safety and liquidity. To date, the Company has not experienced any losses on such accounts.
The Company relies, and expects to continue to rely, on a small number of vendors to manufacture and supply raw materials and supply services for its
development programs. These programs could be adversely affected by a significant interruption in these services or the availability of raw materials.
Cash and cash equivalents
The Company considers all highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. Cash
equivalents consisted of money market funds as of March 31, 2024 and 2023, respectively. As of March 31, 2024 and 2023, the amount of cash equivalents
included in cash and cash equivalents totaled $41.1 million and $121.5 million, respectively.
Restricted cash
The Company holds restricted cash in segregated bank accounts in connection with a letter of credit. As of March 31, 2024 and 2023, restricted cash
consisted of $1.7 million, held for the benefit of the landlords in connection with our leases and for the Company's credit card program in the United
Kingdom. These amounts have been classified as non-current assets on the Company’s consolidated balance sheets.
Short-term investments
The Company’s short-term debt security investments are classified as available-for-sale and are carried at fair value, with the unrealized gains and non-
credit related losses reported as a component of accumulated other comprehensive income (loss) and included in stockholders’ equity. Realized gains and
losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other
income (expense), net in the consolidated statements of operations.
For available-for-sale debt securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will
be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the
security’s amortized cost basis is written down to fair value through a charge to interest income. For available-for-sale debt securities that do not meet the
aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the
Company considers such factors as, among other things, the severity of the impairment, any changes in interest rates, how long the market value of the
investment has been less than its original cost, the Company’s ability and intent to retain the short-term debt security investment for a period of time
sufficient to allow for any anticipated recovery in fair value and market conditions in general. The credit-related portion of unrealized losses, and any
subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance
for credit losses is included in other comprehensive loss on the statements of comprehensive loss.
No credit-related losses or impairments have been recognized on the Company's investments in available-for-sale debt securities during the years
ended March 31, 2024 or 2023.
The Company’s short-term investments as of March 31, 2024 and 2023 had maturities of less than two years. The Company has classified its
investments with maturities beyond one year as short term, based on their highly liquid nature and because they represent the investment of cash that is
available for current operations.
Property, plant and equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized
using the straight-line method over the estimated useful lives of the respective assets as follows:
F - 10

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Estimated Useful life
Office equipment
5 years
Computer equipment and software
3 years
Plant, manufacturing and laboratory equipment
5 years
Capitalized software
3 to 5 years
Leasehold improvements
Lesser of lease term or 10 years
Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines
once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts
and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.
Capitalized software as a service costs represent implementation costs incurred during the application development stage and are included in "property,
plant and equipment, net" on the Company's consolidated balance sheet. Such costs are amortized on a straight-line basis over the term of the associated
arrangement plus any reasonably certain renewal period. Costs incurred during the preliminary project stage and the post-implementation-operation stage
are expensed as incurred.
Impairment of long-lived assets
Long-lived assets consist of property, plant and equipment, right-to-use-asset - operating leases, and right-to-use-asset - financing leases. Long-lived
assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance
of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the
assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash
flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized
when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss
would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the
Company has not recorded any impairment losses on long-lived assets.
Fair value measurements
Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and
minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three
levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•
Level 1 — Quoted prices in active markets for identical assets or liabilities.
•
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted
prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by
observable market data.
•
Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or
liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The Company’s short-term investments and cash equivalents are carried at fair value, determined according to the fair value hierarchy described above
(see Note 3). The carrying values of research and development incentives receivable, prepaid expenses and other current assets, accounts payable and
accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. Furthermore, the
carrying value of the Company’s long-term
F - 11

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
debt approximates its fair value at each balance sheet date due to its variable interest rate, which approximates a market interest rate.
Debt issuance costs
Debt issuance costs consist of payments made to secure commitments under certain debt financing arrangements. These amounts are recognized as
interest expense over the period of the financing arrangement using the effective interest method. If the financing arrangement is canceled or forfeited, or if
the utility of the arrangement to the Company is otherwise compromised, these costs are recognized as interest expense immediately. The Company’s
consolidated financial statements present debt issuance costs related to a recognized debt liability as a direct reduction from the carrying amount of that
debt liability.
Segment information
The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The
Company’s current focus is on developing oncolytic immunotherapies for the treatment of cancer.
Research and development costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and
development activities, including salaries, stock-based compensation and benefits, facilities costs and laboratory supplies, depreciation and external costs of
outside vendors engaged to conduct preclinical development, clinical development activities and clinical trials as well as to manufacture clinical trial
materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and
capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected
that the goods will be delivered or the services rendered. Upfront payments for materials and supplies acquired for particular research and development
activities that have no alternative future use in other research and development projects or otherwise, and therefore have no separate economic value, are
expensed as research and development costs at the time the costs are incurred.
Research contract costs and accruals
The Company has entered into various research and development-related contracts with companies both inside and outside of the United States. These
agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for
estimated ongoing research costs. Accrual estimates are based on a number of factors, including management’s assessment of progress towards completion
of the research and development activities, invoicing to date under the contracts, communication from the research organization or other companies of any
actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. When billing terms under these contracts do
not coincide with the timing of when the work is performed, management is required to make estimates of outstanding obligations to those third parties as
of the end of the reporting period. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period.
Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual
costs.
Patent costs
All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified as selling, general and administrative expenses.
Stock-based compensation
The Company accounts for share-based payment awards granted to employees, consultants, and non-employees and directors using the fair value of
the Company’s common stock on the grant date and compensation expense is recognized for those awards over the requisite service period, which is
generally the vesting period of the respective award. The grant date fair value is utilized for restricted stock units, or RSUs and performance stock units, or
PSUs and is based on the closing price of the Company's common stock on the date of grant. For PSUs, the cost is measured at the grant date based on the
fair value of the award and is recognized over any relevant service period as expense when the achievement of the performance condition is probable. The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing
F - 12

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the
risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield (see Note 10). Forfeitures
are accounted for as they occur. To date, the Company has issued stock-based awards with service-based vesting conditions and records the related expense
for these awards using the straight-line method. The Company has also issued PSUs with performance-based vesting conditions and records the expense for
these awards using the graded vesting method.
The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Research and development incentives and receivable
The Company, through its subsidiary in the United Kingdom, receives reimbursements of certain research and development expenditures as part of a
United Kingdom government’s research and development tax reliefs program. Under the program, a percentage of qualifying research and development
expenses incurred by the Company’s subsidiary in the United Kingdom are reimbursed up to 14.5%.
Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are
likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement
available to the Company based on available information at the time.
The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated
conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and
development incentives as other income. The research and development incentives receivable represents an amount due in connection with the above
program. The Company recorded other income from research and development incentives of $1.9 million and $2.9 million during the years ended
March 31, 2024 and 2023, respectively, in the consolidated statements of operations and a research and development incentives receivable of $4.9 million
and $2.9 million as of March 31, 2024 and 2023, respectively, on the consolidated balance sheets.
Comprehensive loss
Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than
those with stockholders. For the year ended March 31, 2024, comprehensive loss included $0.8 million of foreign currency translation losses. For the year
ended March 31, 2023, comprehensive loss included $5.5 million of foreign currency translation gains and $1.2 million of unrealized gains on short-term
investments, net of tax.
Income taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for
the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred
tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in
the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the
extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be
realized, a valuation allowance is established through a charge to income tax provision. Potential for recovery of deferred tax assets is evaluated by
estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon
external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to
determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest
amount that has a greater than
F - 13

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or
unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net income (loss) per share
Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock
outstanding for the period. Diluted net income (loss) per common share is computed by dividing the diluted net income (loss) by the weighted average
number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock
equivalents.
In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are
not assumed to have been issued if their effect is anti-dilutive.
Recently Issued Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2023-09, “Income Taxes (Topic
740): Improvements to Income Tax Disclosures.” This ASU updates income tax disclosure requirements primarily by requiring specific categories and
greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods
beginning after December 15, 2024 and is applicable to the Company’s fiscal year beginning April 1, 2025, with early application permitted. The Company
is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.
In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". The
amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable
segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal
years beginning after December 15, 2024. The Company is currently evaluating the potential impact of this adoption on the consolidated financial
statements and related disclosures.
3.
Fair value of financial assets and liabilities
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis:
Fair Value Measurements as of March 31, 2024 Using:
Level 1
Level 2
Level 3
Total
Cash equivalents:
Money market funds
$
— 
$
41,077 
$
— 
$
41,077 
Short-term investments:
US Government Agency bonds
— 
199,821 
— 
199,821 
US Treasury bonds
— 
146,390 
— 
146,390 
$
— 
$
387,288 
$
— 
$
387,288 
Fair Value Measurements as of March 31, 2023 Using:
Level 1
Level 2
Level 3
Total
Cash equivalents:
Money market funds
$
— 
$
121,455 
$
— 
$
121,455 
Short-term investments:
US Government Agency bonds
— 
240,355 
— 
240,355 
US Treasury bonds
— 
196,441 
— 
196,441 
$
— 
$
558,251 
$
— 
$
558,251 
F - 14

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
3.    Fair value of financial assets and liabilities (Continued)
The underlying securities held in the money market funds held by the Company are all government backed securities. During the years ended
March 31, 2024 and 2023, there were no transfers between levels.
Valuation of cash equivalents and short-term investments
Money market funds, U.S. Treasury bonds and U.S. Government Agency bonds were valued by the Company using quoted prices in active markets for
similar securities, which represent a Level 2 measurement within the fair value hierarchy. Cash equivalents consisted of money market funds at March 31,
2024 and March 31, 2023.
4.
Short-term investments
As of March 31, 2024 and 2023, the Company's available-for-sale investments by type, consisted of the following:
March 31, 2024
Amortized cost
Gross unrealized
gains
Gross unrealized
losses
Credit Losses
Fair value
US Government agency bonds
$
199,905 
$
33 
$
(117)
$
— 
$
199,821 
US Treasury bonds
146,417 
11 
(38)
$
— 
146,390 
$
346,322 
$
44 
$
(155)
$
— 
$
346,211 
March 31, 2023
Amortized cost
Gross unrealized
gains
Gross unrealized
losses
Credit Losses
Fair value
US Government agency bonds
$
240,371 
$
187 
$
(203)
$
— 
$
240,355 
US Treasury bonds
196,488 
77 
(124)
— 
196,441 
$
436,859 
$
264 
$
(327)
$
— 
$
436,796 
As of March 31, 2024, available-for-sale securities consisted of investments that mature within one year. As of March 31, 2023, available-for-sale securities
consisted of investments that mature within one year, with the exception of certain U.S. Government agency bonds and U.S. Treasury bonds which had
maturities between one and two years and an aggregate fair value of $15.1 million.
5.
Property, plant and equipment, net
Property, plant and equipment, net consisted of the following:
March 31,

2024
March 31,

2023
Office equipment
$
1,464 
$
1,240 
Computer equipment
1,975 
1,806 
Plant and laboratory equipment
10,423 
9,186 
Leasehold improvements
1,886 
1,706 
Capitalized software
3,515 
— 
Construction in progress
1,117 
783 
20,380 
14,721 
Less: Accumulated depreciation and amortization
(9,897)
(7,242)
$
10,483 
$
7,479 
Depreciation and amortization expense was $2.7 million and $2.4 million for the years ended March 31, 2024 and 2023, respectively, and recorded
within research and development and selling, general and administrative expenses in the consolidated statement of operations.
F - 15

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
6.
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following:
March 31,

2024
March 31,

2023
Accrued research and development costs
$
16,376 
$
11,261 
Accrued compensation and benefits costs
13,906 
9,909 
Accrued professional fees
369 
540 
Other
3,330 
2,994 
$
33,981 
$
24,704 
7.
Long-term debt
Hercules Loan Agreement
On October 6, 2022, the Company entered into a Loan and Security Agreement (the “Loan Agreement”), with Hercules Capital, Inc., as administrative
agent, collateral agent and as a lender (“Hercules”). Pursuant to the Loan Agreement, the Company can borrow term loans in an aggregate maximum
principal amount of up to $200.0 million under multiple tranches (the “Term Loan Facility”). Under the Loan Agreement, the Company borrowed an initial
amount of $30.0 million on the Closing Date, and at the Company's sole option, could have drawn, but did not draw, an additional $30.0 million on or prior
to September 30, 2023. The Company can also draw as additional term loan advances in an aggregate principal amount of up to $115.0 million during the
term of the Term Loan Facility subject to achievement of specified performance milestones, and two additional term loan advances up to an aggregate
principal amount of $25.0 million subject to certain terms and conditions, on or prior to the end of the interest-only period. The Company intends to use the
proceeds of the Term Loan Facility for working capital and general corporate purposes.
The Loan Agreement was subsequently amended (the "Amendment") on June 28, 2023 pursuant to which the Company agreed to draw an initial term
loan advance in an aggregate principal amount not less than $30.0 million, provided that the aggregate amount of the term loan advances made under
tranche 1 do not exceed $30.0 million, which reflects a decrease of $30.0 million from the $60.0 million in the original Loan Agreement for tranche 1. The
total amount of the Loan Agreement, as well as the outstanding balance of the loan, is unchanged, but the option to borrow additional funds were
redistributed from tranche 1 to tranche 2. The impact of this amendment is not a modification, as it does not relate to outstanding debt, but is rather an
amendment that provides for a future potential benefit. There was no material impact to the financial statements as a result of the Amendment.
A second amendment was made to the Loan Agreement (the "Second Amendment") on December 22, 2023 pursuant to which the Company agreed to draw
a term loan advance in an aggregate principal amount not less than $15.0 million, provided that the aggregate amount of the term loan advances made
under tranche 2 do not exceed $15.0 million on or prior to December 31, 2023. The Second Amendment re-allocated the total future consideration of the
Loan Agreement to the future tranches extending through September 2026, subject to the terms and conditions of the Loan Agreement. The Second
Amendment did not change the total aggregate maximum principal amount to be drawn under the Loan Agreement, which remains as up to $200.0 million.
The Company evaluated the Second Amendment as a modification under relevant accounting guidance, and based on that analysis and the immaterial
change in cash flows on current outstanding debt, it was determined that there was no material accounting impact. Upon closing of the Second
Amendment, the Company drew down the tranche 2 amount of $15.0 million.
The Term Loan Facility will mature on October 1, 2027 (the “Maturity Date”). The outstanding principal balance of the Term Loan Facility bears
interest payable in cash at a floating rate per annum equal to the greater of (i) 7.25% and (ii) the sum of the Prime Rate (which is capped at 7.25%) and
1.75%. Accrued interest is payable monthly following the funding of each term loan advance. In addition, the principal balance of the Term Loan Facility
will bear “payment-in-kind” interest at the rate of 1.50% (“PIK Interest”), which PIK Interest will be added to the outstanding principal balance of the Term
Loan Facility on each interest payment date.
F - 16

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
7.    Long-term debt (Continued)
Borrowings under the Loan Agreement are repayable in monthly interest-only payments through September 2026. After the interest-only payment
period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until October 2027. At the
Company's option, the Company may prepay all or a portion of the outstanding borrowings, subject to a prepayment fee of 3.0% of the principal amount if
prepayment occurs during the 12 months following the Closing Date, 2.0% after 12 months following the Closing Date but prior to 36 months following
the Closing Date, and 1.0% thereafter.
The Loan Agreement contains customary facility fees, events of default and representations, warranties and affirmative and negative covenants,
including a financial covenant requiring the Company to maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent
(the “Unrestricted Cash”) at all times commencing on January 1, 2024. In addition, the Loan Agreement also contains a financial covenant that beginning
on the later of (i) July 1, 2024 and (ii) the date on which the aggregate outstanding principal amount of the Term Loan Facility is equal to or greater than
$100.0 million, the Company is required to satisfy one of the following requirements: (1) achieve a minimum amount of trailing three-month net product
revenue tested on a monthly basis, (2) maintain a market capitalization in excess of $1.2 billion and Unrestricted Cash in an amount no less than 50% of the
outstanding amount under the Term Loan Facility, or (3) maintain Unrestricted Cash in an amount no less than 85% of the outstanding amount under the
Term Loan Facility.
The Company paid a $0.5 million facility charge and incurred debt issuance costs of $1.5 million upon closing of the Loan Agreement. The Loan
Agreement also provides for a final payment, payable upon maturity or the repayment of the obligations in full or in part (on a pro rata basis), equal to
4.95% of the aggregate principal amount of Term Loans advanced to the Borrower and repaid on such date, which is being accrued on the Company's
consolidated balance sheet. As of March 31, 2024 and 2023, the amount accrued for the final payment was $0.5 million and $0.2 million, respectively.
Unamortized debt issuance costs are recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the
effective-interest method. In addition, unamortized deferred financing costs of $1.2 million and $1.4 million were recorded in other assets as of March 31,
2024 and 2023, respectively, related to the Company's right to borrow additional amounts from Hercules in the future and amortized to interest expense
over the relevant draw period on a straight-line basis. Interest expense for the twelve months ended March 31, 2024 and 2023 was $4.5 million and $2.0
million, respectively.
The summary of obligations under the term loan as of March 31, 2024 and 2023 consisted of the following (in thousands):
March 31, 2024
March 31, 2023
Principal loan balance
$
45,749  $
30,222 
Facility charge and diligence fee
(266)
(315)
Unamortized issuance costs
(1,191)
(1,410)
Accumulated end of term fee
517 
151 
Long term debt, net
$
44,809  $
28,648 
The annual principal payments by fiscal year due under the Loan Agreement as of March 31, 2024 were as follows:
March 31, 2024
2025
— 
2026
— 
2027
20,145 
Thereafter
27,769 
Total
$
47,914 
The table of future payments of long-term debt excludes the end of term charge of $2.2 million, which is due upon the maturity of the loan.
8.
Stockholders’ Equity
F - 17

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
8.    Stockholders’ Equity (Continued)
Common stock
As of March 31, 2024 and 2023, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to
150,000,000 shares of common stock, par value $0.001 per share.
The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted share units, the number of
shares remaining available for grant under the Company’s 2018 Omnibus Incentive Compensation Plan and the Company’s Employee Stock Purchase Plan
(see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:
March 31, 2024
March 31, 2023
Stock options, issued and outstanding
8,652,256 
7,454,828 
Restricted and performance stock units
2,397,890 
1,351,280 
Stock options and restricted stock units, future issuance
2,284,141 
2,209,597 
Employee stock purchase plan, available for future grants
2,738,208 
2,076,603 
Pre-IPO warrants to purchase common stock
497,344 
497,344 
Pre-funded warrants
5,281,616 
9,484,238 
Total shares of common stock reserved for future issuance
21,851,455 
23,073,890 
Undesignated preferred stock
As of March 31, 2024 and 2023, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to
10,000,000 shares of undesignated preferred stock, par value $0.001 per share. There were no undesignated preferred shares issued or outstanding as of
March 31, 2024 and 2023.
ATM program
On August 11, 2020, the Company and SVB Leerink (the "Agent") entered into a sales agreement, which was subsequently amended on October 21,
2020 (as amended, the “2020 Sales Agreement”), pursuant to which the Company could sell, from time to time, at its option, up to an aggregate of $62.5
million of shares of the Company’s common stock through the Agent, as the Company’s sales agent.
During the fiscal year ended March 31, 2023, the Company settled transactions that occurred pursuant to the 2020 Sales Agreement, whereby the
Company issued and sold an aggregate of 1,686,438 shares of its common stock, resulting in gross proceeds of $32.0 million, before deducting fees of $1.0
million.
On June 23, 2022, the 2020 Sales Agreement was terminated by the execution by the Company and the Agent of a new sales agreement (the “2022
Sales Agreement”). Under the 2022 Sales Agreement, the Company may sell, from time to time, at its option, up to an aggregate $100.0 million of shares
of the Company's common stock through the Agent, as the Company's sales agent.
During the year ended March 31, 2023, pursuant to the 2022 Sales Agreement, the Company issued and sold an aggregate of 340,000 shares of its
common stock, resulting in gross proceeds of $6.7 million, before deducting fees of $0.3 million.
On August 3, 2023, the 2022 Sales Agreement was terminated by the execution by the Company and Leerink Partners LLC (formerly known as SVB
Securities LLC) (the "Current Agent") of a new sales agreement, which was subsequently amended on May 16, 2024 (as so amended, the "2023 Sales
Agreement"). Under the 2023 Sales Agreement, the Company may sell, from time to time, at its option, up to an aggregate of $100.0 million of share of the
Company's common stock, $0.001 par value shares (the "Shares"), through the Current Agent, as the Company's sales agent.
Any Shares to be offered and sold under the 2023 Sales Agreement will be issued and sold (i) by methods deemed to be an “at the market offering”
(“ATM”) as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or if authorized by the Company, in negotiated
transactions or block trades, and (ii) pursuant to a registration statement on Form S-3 filed by the Company with the Securities and Exchange Commission
on August 3, 2023, as amended for an offering of various
F - 18

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
8.    Stockholders’ Equity (Continued)
securities, including shares of the Company’s common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more
public offerings.
Subject to the terms of the 2023 Sales Agreement, the Current Agent will use reasonable efforts to sell the Shares from time to time, based upon the
Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company
will pay the Current Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares. The Company has also agreed to provide the
Current Agent with customary indemnification rights.
During the year ended March 31, 2024, the Company did not issue or sell any shares under the 2023 Sales Agreement. The Company cannot provide
any assurances that it will issue any additional Shares pursuant to the 2023 Sales Agreement.
Equity offerings
In December 2022, the Company completed a public offering of (a) 6,810,658 shares of the Company’s common stock, inclusive of the underwriters
30-day option to purchase up to an additional 1,436,172 shares of the Company’s common stock, at a public offering price of $23.50 per share and (b) pre-
funded warrants to purchase 4,200,000 shares of the Company’s common stock at a public offering price of $23.4999 per warrant. The Company received
aggregate net proceeds of approximately $242.6 million after deducting underwriting discounts, commissions and other offering expenses payable by the
Company of approximately $16.1 million.
9. Pre-funded Warrants
Between November 2019 and December 2022, the Company completed public offerings including an option to purchase pre-funded warrants to
purchase shares of the Company's common stock. As of March 31, 2024, the total amount of pre-funded warrants issued was 9,484,238 of which 4,202,622
have been exercised and 5,281,616 remained outstanding.
The remaining outstanding pre-funded warrants described above are exercisable at any time after the date of issuance. Unless otherwise modified by a
holder of a pre-funded warrant, no holder may exercise a pre-funded warrant if such holder, together with its affiliates, would beneficially own more than
9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of a pre-funded
warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company.
The 5,281,616 shares of the Company's common stock underlying the above described pre-funded warrants, are not included in the number of issued
and outstanding shares of the Company’s common stock outstanding as reported on the consolidated balance sheet, though they are included in the
Company's annual pool increase calculation as well as the weighted average outstanding common stock in the calculation of basic and diluted net loss per
share, as noted below in Note 11.
During the year ended March 31, 2024, a holder of the Company's pre-funded warrants exercised 4,202,622 of its pre-funded warrants and the
Company issued 4,202,622 shares of common stock in exchange thereof.
10. Stock-based compensation
Stock-based compensation expense
The following table summarizes the classification of stock-based compensation expense in the consolidated statements of operations for the years
ended March 31, 2024 and 2023 as follows:
Year ended March 31,
2024
2023
Research and development
$
14,745 
$
10,074 
Selling, general and administrative
19,380 
18,057 
$
34,125 
$
28,131 
The following table summarizes stock-based compensation expense by award type for the years ended March 31, 2024 and 2023 as follows:
F - 19

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
10.    Stock-based compensation (Continued)
Year ended March 31,
2024
2023
Stock options
$
21,594 
$
19,521 
Restricted and performance stock units
12,531 
8,610 
$
34,125 
$
28,131 
2015 Enterprise Management Incentive Share Option Plan
The 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the “2015 Plan”) provided for Replimune UK to grant incentive
stock options, non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options are
granted only to the Company’s employees, including officers and directors who are also employees. Non-statutory stock options are granted to employees,
members of the board of directors, outside advisors and consultants of the Company.
2017 Equity Compensation Plan
In July 2017, in conjunction with reorganization by Replimune Limited, pursuant to which each shareholder thereof exchanged their outstanding shares
in Replimune Limited for shares in Replimune Group, Inc., on a one-for-one basis (the "Reorganization"), the 2015 Plan was terminated, and all awards
were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the “2017 Plan”). Subsequent to the Reorganization, no
additional grants have been or will be made under the 2015 Plan and any outstanding awards under the 2015 Plan have continued, and will continue with
their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a
modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award.
The Company’s 2017 Plan provides for the Company to grant incentive stock options or non-statutory stock options, stock awards, stock units, stock
appreciation rights and other stock-based awards. Incentive stock options were granted under the 2017 Plan only to the Company’s employees, including
officers and directors who were also employees. Restricted stock awards and non-statutory stock options were granted under the 2017 Plan to employees,
officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under
the 2017 Plan was 2,659,885, of which none remained available for future grants as of March 31, 2024. Shares with respect to which awards have expired,
terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2018 Plan
referenced below. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of
shares of common stock available for the grant of awards.
2018 Omnibus Incentive Compensation Plan
On July 9, 2018, the Company’s board of directors adopted, and the Company’s stockholders approved the 2018 Omnibus Incentive Compensation
Plan (the “2018 Plan”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public
offering. The 2018 Plan provides for the issuance of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation
rights and other stock-based awards. The number of shares initially reserved for issuance under the 2018 Plan is 3,617,968 shares. If any options or stock
appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or
are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards, including
outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the
Company’s common stock subject to such grants will be available for purposes of our 2018 Plan. The number of shares reserved for issuance under the
2018 Plan will increase automatically on the first day of each April equal to 4.0% of the total number of shares of Company stock outstanding on the last
trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded
warrants described in Note 9 to these consolidated financial statements, or such lesser amount as determined by the Board. On April 1, 2023, the number of
shares reserved for issuance under the 2018 Plan automatically increased by 2,646,422 shares pursuant to the terms of the 2018 Plan and based on total
number of shares of Company stock
F - 20

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
10.    Stock-based compensation (Continued)
outstanding on March 31, 2023. As of March 31, 2024, 2,284,141 shares remained available for future grants under the 2018 Plan.
The 2015 Plan, the 2017 Plan and the 2018 Plan are administered by the board of directors or, at the discretion of the board of directors, by a
committee of the board of directors. However, the board of directors shall administer and approve all grants made to non-employee directors. The exercise
prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the exercise price per share of incentive stock
options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted
to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not
be greater than five years for an incentive stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options
awarded under both plans expire ten years after the grant date, unless the board of directors sets a shorter term. Vesting periods for both plans are
determined at the discretion of the board of directors. Incentive stock options granted to employees and non-statutory options granted to employees,
officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. In 2021 the board of directors initiated
the award of RSUs, under the 2018 Plan in addition to stock option awards available as part of the Company’s equity incentive for employees, officers,
advisors and consultants of the Company. The RSUs typically vest over four approximately equal annual installments with the first such installment
occurring on a designated vesting date that is approximately on the one year anniversary date of the date of grant and the subsequent installments occurring
on the subsequent three annual anniversaries of the designated vesting date. In 2024 the Board of Directors approved the award of PSUs, under the 2018
Plan in addition to the aforementioned stock option awards and RSUs available as part of the Company’s equity incentive for employees, officers, advisors
and consultants of the Company. The PSUs will vest in connection with the timely achievement of a specified corporate milestone, and the expense
recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The timing of
recognition of this stock-based compensation expense is subject to our judgment as to when the performance conditions are considered probable of being
achieved. The Company granted 368,980 PSUs under the 2018 Plan during the year ended March 31, 2024.
Employee Stock Purchase Plan
On July 9, 2018, the Company’s board of directors adopted and the Company’s stockholders approved the Employee Stock Purchase Plan (the
“ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s IPO. The total shares of common
stock initially reserved for issuance under the ESPP is limited to 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of
the ESPP (excluding any extensions), an additional number of shares of the Company’s common stock equal to 1% of the total number of shares
outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise
of those pre-funded warrants described in Note 9 to these consolidated financial statements, or 697,224 shares, whichever is less (or such lesser amount as
determined by the Company’s board of directors) will be added to the number of shares authorized under the ESPP. In accordance with the terms of the
ESPP, on April 1, 2023, the number of shares reserved for issuance under the ESPP automatically increased by 661,605, for a total of 2,738,208 shares
reserved for the ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed
the number of shares then available for issuance under the ESPP, then the plan administrator will allocate the available shares pro-rata and refund any
excess payroll deductions or other contributions to participants. The Company’s ESPP is not currently active.
Out-of-Plan Inducement Grant
From time to time, the Company grants equity awards to newly hired executives as a material inducement to enter into employment with the Company.
The grants constitute "employment inducement grants" in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules and was issued outside of the 2018
Plan and each of the other stock incentive plans described above. The inducement grants typically include nonqualified stock options to purchase shares of
the Company's common stock, as well as restricted stock unit grants representing shares of the Company's common stock. These stock option and restricted
stock unit inducement grants have terms and conditions consistent with those set forth under the 2018 Plan and vest under the same respective vesting
schedules as stock option and restricted stock unit awards granted under the 2018 Plan. The inducement grants are included in the stock option and RSU
award tables below. During the years ended March 31, 2024 and 2023, the Company granted 125,000 and 82,500 nonqualified stock options to purchase
shares of the Company's common stock, respectively, and 83,330 and 55,000 restricted stock units, respectively, under employment inducement grants.
F - 21

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
10.    Stock-based compensation (Continued)
Stock option valuation
The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. As the Company has limited company-specific
historical and implied volatility information, the expected stock volatility is based on a combination of Replimune volatility and the historical volatility of a
publicly traded set of peer companies. For options with service-based vesting conditions, the expected term of the Company’s stock options has been
determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-
employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact
that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock
options granted to employees and directors:
Year ended March 31,
2024
2023
Risk-free interest rate
3.75 %
2.83 %
Expected term (in years)
6.0
6.0
Expected volatility
74.2 %
75.2 %
Expected dividend yield
0 %
0 %
Stock options
A summary of stock option activity under the Company’s equity incentive plans for the year ended March 31, 2024 is as follows:
Number of Shares
Weighted Average
Exercise Price
Weighted Average
Contractual Term
(Years)
Aggregate Intrinsic
Value
Outstanding as of March 31, 2023
7,454,828 
$
17.24 
6.88 $
31,244 
Granted
2,394,124 
16.90 
Exercised
(164,221)
10.71 
Cancelled
(1,032,475)
20.05 
Outstanding as of March 31, 2024
8,652,256 
16.94 
6.61 $
5,748 
Options exercisable as of March 31, 2024
5,483,718 
$
15.65 
5.40 $
5,738 
Options vested and expected to vest as of March 31, 2024
8,652,256 
$
16.94 
6.61 $
5,748 
As of March 31, 2024, there was $33.0 million of unrecognized compensation cost related to unvested common stock options, which is expected to be
recognized over a weighted average period of 2.5 years.
The weighted average grant-date fair value of stock options granted during the years ended March 31, 2024 and 2023 was $11.41 and $12.80,
respectively. The aggregate intrinsic value of stock options exercised during the years ended March 31, 2024 and 2023 was $1.4 million and $2.7 million,
respectively.
Restricted and performance stock units
In January 2024, the Board approved a one-time PSU award under the 2018 Plan for all employees at the VP level and below as of January 31, 2024,
subject to non-market performance and service conditions. The grants will become vested upon the achievement of the approval of the Company’s first
Biologics License Application (“BLA”) for RP1 by the Food and Drug Administration (“FDA”) no later than June 30, 2026. The grant date fair value for
the PSUs is determined based on the market price of the Company's common stock on the grant date and is recognized over the requisite service period if
and when the achievement of such performance condition is determined to be probable by the Company. The Company reassesses the
F - 22

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
10.    Stock-based compensation (Continued)
probability of achieving the performance condition at each reporting period. As of March 31, 2024, the Company has not recognized any expense related to
PSUs.
A summary of the changes in the Company’s RSUs and PSUs during the year ended March 31, 2024 is as follows:
Number of Shares
Weighted Average
Grant Date Fair Value
Outstanding as of March 31, 2023
1,351,280 
$
24.38 
Granted
1,771,872 
15.07 
Vested
(371,949)
25.26 
Cancelled
(353,313)
20.25 
Outstanding as of March 31, 2024
2,397,890 
$
17.97 
At March 31, 2024, there was $29.9 million of total unrecognized compensation cost related to unvested awards, which will be recognized over a
weighted-average period of 2.5 years. Of the $29.9 million of total unrecognized compensation cost, performance based awards tied to the achievement of a
company milestone account for approximately $2.9 million. The performance based awards will vest upon achievement of the performance milestone. The
remaining $27.0 million in unrecognized compensation cost is related to restricted stock units which vest over time.
11. Net loss per share
The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in
thousands, except per share amounts):
Year ended March 31,
2024
2023
Numerator:
Net loss
$
(215,794)
$
(174,284)
Denominator:
Weighted average common shares outstanding, basic and diluted
66,569,894 
58,213,010 
Net loss per share, basic and diluted
$
(3.24)
$
(2.99)
The 5,281,616 shares of the Company's common stock issuable upon exercise of Pre-Funded Warrants described in Note 9 to these consolidated
financial statements are included as outstanding common stock in the calculation of basic and diluted net loss per share.
The Company’s potentially dilutive securities, which include stock options, unvested restricted and performance stock units and warrants to purchase
common stock have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the
weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the
following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the
periods indicated because including them would have had an anti-dilutive effect:
Year ended March 31,
2024
2023
Options to purchase common stock
8,652,256 
7,454,828 
Unvested restricted and performance stock units
2,397,890 
1,351,280 
Warrants to purchase common stock
497,344 
497,344 
12. Significant agreements
Agreement with Bristol-Myers Squibb Company
F - 23

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
12.    Significant agreements (Continued)
In February 2018, the Company entered into an agreement with Bristol-Myers Squibb Company (“BMS”). Pursuant to the agreement, BMS will
provide to the Company, at no cost, nivolumab, its anti-PD-1 therapy, for use in the Company’s ongoing clinical trial of RP1. Under the agreement, the
Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted the Company a non-exclusive, non-
transferrable, royalty-free license (with a right to sublicense) under its intellectual property to use nivolumab in the clinical trial and agreed to supply
nivolumab, at no cost to the Company, for use in the clinical trial. Both parties will own the study data produced in the clinical trial, other than study data
related solely to nivolumab, which will belong solely to BMS, or study data related solely to RP1, which will belong solely to us. In January 2020, this
agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma.
Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been
delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis
otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party,
(y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to the Company to
use BMS’s nivolumab in the clinical trial will terminate.
In April 2019, the Company entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above,
pursuant to which BMS will provide to the Company, at no cost, nivolumab for use in the Company’s Phase 1 clinical trial of RP2 in combination with
nivolumab.
Agreement with Regeneron Pharmaceuticals, Inc.
In May 2018, the Company entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron. Pursuant to the agreement the
Company agreed to undertake one or more clinical trials with Regeneron for the administration of the Company's product candidates in combination with
cemiplimab, an anti-PD-1 therapy developed by Regeneron, across multiple solid tumor types. The first of which, agreed in June 2018, is the Company's
ongoing clinical trial testing RP1 in combination with cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted
pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and
include the protocol, the budget and a schedule of clinical obligations.
Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to
contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. The Company does not
expect any further reimbursements from Regeneron related to the initial study plan of June 2018 and the CERPASS trial. The agreement contains
representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based
covenants that restrict the Company from entering into a third-party arrangement with respect to the use of its product candidates in combination with an
anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an
HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually
agreed in a future study plan, these covenants are only applicable to the Company's ongoing Phase 2 clinical trial in CSCC.
The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the
parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (ii)
in the event of a material breach
The agreement with Regeneron is accounted for under ASC 808, Collaborative Arrangements (“ASC 808”), as both parties are active participants and
each party pays its own compound costs and share equally in development costs. The Company accounts for costs incurred as part of the study, including
costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company
recognizes any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the
consolidated statement of operations.
In July 2022, Regeneron informed the Company that the costs of the study have reached the initial budget for the initial study plan of June 2018 and
that Regeneron's reimbursement of CERPASS study costs to the Company have completed in the period ending June 30, 2022 in relation to the initial study
budget. As a result of this notice from, and the ongoing
F - 24

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
12.    Significant agreements (Continued)
communications with, Regeneron, the Company has not recorded any cost-sharing reimbursements from Regeneron in prepaid expenses and other current
assets in the consolidated balance sheet or as an offset to research and development expense within the consolidated statement of operations since
Regeneron informed it that Regeneron’s reimbursement of CERPASS study costs have completed. The Company does not expect any further
reimbursements from Regeneron related to the initial study plan of June 2018.
The Company did not record any costs as an offset to research and development expenses during the year ended March 31, 2024 and recorded $1.1
million during the year ended March 31, 2023. During the years ended March 31, 2024 and 2023, the Company did not make any payments to Regeneron
under the terms of the agreement. During the years ended March 31, 2024 and 2023, the Company received payments under the terms of the agreement
from Regeneron of $0.0 million and $3.1 million, respectively. There were no outstanding receivables from Regeneron associated with this agreement at
March 31, 2024 or 2023.
Roche
In December 2022, the Company entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to the Company's
RP2 and RP3 programs in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate
in 30 patient cohort signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following the
Company's re-prioritization of its product development portfolio in December 2023, the Company has agreed with Roche to terminate the CRC
collaboration and pursue the 2L cohort in HCC with RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs,
atezolizumab and bevacizumab for the 2L cohort in HCC but is unlikely to share costs following the Company's re-prioritization. The Company is in
discussions with Roche about revising these agreements following the Company's changes to its RP2 and RP3 development plans. Under the terms of the
initial agreement the Company retained the responsibility of operating the clinical trials as well as retaining all the rights to the development and
commercialization of its product candidates. The agreement may be terminated by either party upon sixty days prior written notice to the other party.
The agreement with Roche is accounted for under ASC 808, Collaborative Arrangements (“ASC 808”), as both parties are active participants and each
party pays its own compound costs and shares equally in development costs in accordance with and up to the amount in the agreed upon first study plan.
The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development
expenses within the consolidated statement of operations. The Company recognizes any amounts received from Roche in connection with this agreement as
an offset to research and development expense within the consolidated statement of operations.
During the years ended March 31, 2024 and 2023, the Company did not make any payments to Roche under the terms of the agreement. The Company
recorded $2.7 million and $0.9 million as an offset to research and development expenses during the years ended March 31, 2024 and 2023, respectively.
During the years ended March 31, 2024 and 2023, the Company received payments under the terms of the agreement from Roche of $1.7 million and
$0.0 million, respectively. As of March 31, 2024 and 2023, the Company recorded $1.8 million and $0.9 million as receivables from Roche in connection
with this agreement, respectively.
Incyte
In July 2023, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement,
the companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and
RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, the Company will
supply Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material
breach not reasonably cured within thirty days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business
practices of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety days of the effective date of the agreement. In
addition, the Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. As of March 31, 2024, the
Company and Incyte had not yet agreed on the protocol or budget. However, the Company and Incyte continue to discuss a potential protocol and neither
party has triggered termination of the agreement in accordance with the termination right described in clause (iv) above. The parties are evaluating potential
collaboration efforts pending further CERPASS data readout of RP1 in combination with cemiplimab and additional data for Incyte's product candidate
INCB99280. During the year ended March 31, 2024, the Company did not make any payments to, or
F - 25

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
12.    Significant agreements (Continued)
receive any payments from, Inctye under the terms of the agreement. Additionally, no costs were recorded to research and development expenses during the
year ended March 31, 2024 related to this agreement.
Amgen
In August 2023 the Company entered into a Settlement Agreement with Amgen and mutually agreed to terminate the Company's challenges to
Amgen's patents. In connection with the Settlement Agreement, the Company entered into a License and Covenant Agreement with Amgen in which the
Company agreed to pay Amgen low single-digit royalty payments on net sales of its products that, but for the license, could be found to infringe a valid
Amgen patent on a country-by-country and product-by-product basis.
13. Commitments and contingencies
Leases
The Company leases real estate assets and equipment, and determination if an arrangement is a lease occurs at inception. For leases with terms greater
than 12 months, the Company records a related right-of-use (“ROU”) asset and lease liability at the present value of lease payments over the term. Many
leases include fixed rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when
appropriate. The Company’s leases do not provide an implicit rate, and thus the Company estimated the incremental borrowing rate in calculating the
present value of the lease payments. The Company has elected not to record a ROU asset and lease obligation for short-term leases (with terms less than
12 months) or separate non-lease components from associated lease components for its real estate lease assets. As a result, all contract consideration is
allocated to the single lease component.
The Company’s leases have remaining lease terms of five years to fifteen years. Some of the Company's leases include one or more options to renew
with renewal terms that can extend the lease for additional years, or options to terminate the leases, both at the Company’s discretion. The Company’s lease
terms include options to extend or terminate leases when the Company concludes it is reasonably certain that it would exercise those options. Lease
expense for minimum lease payments is recognized on a straight-line basis based on the fixed components of a lease arrangement. The Company amortizes
this expense over the term of the lease beginning with the date of initial possession, which is the date the Company can enter the leased space and begin to
make improvements in preparation for its intended use. Variable lease components represent amounts that are not fixed in nature and are not tied to an
index or rate, and are recognized as incurred.
F - 26

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
13.    Commitments and contingencies (Continued)
The table below presents the lease-related costs which are included in the consolidated statements of operations for the years ended as of March 31,
2024 and 2023:
Year ended March 31,
2024
2023
Lease cost
Finance lease costs:
Amortization of right-to-use asset
$
2,428 
$
2,428 
Interest on lease liabilities
2,163 
2,197 
Operating lease costs
1,122 
1,018 
Total lease cost
$
5,713 
$
5,643 
The following table summarizes the classification of lease costs in the consolidated statement of operations for the years ended March 31, 2024 and
2023 as follows:
Year ended March 31,
2024
2023
Finance Lease Costs
Research and development
$
2,428 
$
2,071 
Selling, general and administrative
— 
358 
Other income, net
2,163 
2,197 
Operating Lease Costs
Research and development
911 
421 
Selling, general and administrative
211 
596 
Total lease cost
$
5,713 
$
5,643 
The following table summarizes the maturity of the Company’s lease liabilities on an undiscounted cash flow basis and a reconciliation to the
operating and financing lease liabilities recognized on our balance sheet as of March 31, 2024:
March 31, 2024
Operating leases
Financing lease
Total
2025
$
1,161 
$
2,718 
$
3,879 
2026
1,170 
2,799 
3,969 
2027
1,136 
2,883 
4,019 
2028
1,085 
2,969 
4,054 
2029
1,004 
3,058 
4,062 
Thereafter
923 
31,995 
32,918 
Total lease payments
6,479 
46,422 
52,901 
Less: interest
1,547 
20,294 
21,841 
Total lease liabilities
$
4,932 
$
26,128 
$
31,060 
F - 27

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
13.    Commitments and contingencies (Continued)
The following table provides lease disclosure as of and for the year ended March 31, 2024:
March 31, 2024
March 31, 2023
Leases
Right-to-use operating lease asset
$
4,635 
$
5,208 
Right-to-use finance lease asset
37,237 
39,665 
Total lease assets
$
41,872 
$
44,873 
Operating lease liabilities, current
$
1,161 
$
1,118 
Finance lease liabilities, current
2,718 
2,639 
Operating lease liabilities, non-current
3,771 
4,389 
Finance lease liabilities, non-current
23,410 
23,965 
Total lease liabilities
$
31,060 
$
32,111 
Other information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
$
1,059 
$
1,014 
Operating cash flows from finance leases
$
2,163 
$
2,197 
Financing cash flows from finance leases
$
476 
$
365 
Right-to-use asset obtained in exchange for new operating lease liabilities
$
— 
$
290 
Weighted-average remaining lease term – operating leases
5.6 years
6.6 years
Weighted-average remaining lease term – financing leases
15.3 years
16.3 years
Weighted-average discount rate – operating leases
10.3 %
10.3 %
Weighted-average discount rate – financing leases
8.3 %
8.3 %
The variable lease costs and short-term lease costs were insignificant for the years ended March 31, 2024 and 2023, respectively.
Manufacturing commitments
The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of March 31, 2024 and
2023, the Company had committed to minimum payments under these arrangements totaling $0.9 million and $1.0 million.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and
other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property
infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive
management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise
by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make
under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such
indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to
such obligations in its consolidated financial statements as of March 31, 2024 or 2023.
Legal proceedings
The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.
14.    Benefit plans
F - 28

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
The Company established a defined-contribution savings plan under Section 401(k) of the Code (the “401(k) Plan”). The 401(k) Plan covers
substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a
pre-tax basis. Matching contributions to the 401(k) Plan may be made at the discretion of the Company’s board of directors. During the years ended
March 31, 2024 and 2023, the Company made contributions totaling $2.1 million and $1.3 million, respectively, to the 401(k) Plan.
We provide a pension contribution plan for our employees in the United Kingdom, pursuant to which we match our employees’ contributions each year
in amounts up to 8% of their annual base salary.
15.    Income taxes
Loss before income taxes for the years ended March 31, 2024 and 2023 were as follows:
Year Ended March 31,
2024
2023
United States
$
(19,367)
$
(18,367)
United Kingdom
(196,019)
(155,629)
Total
$
(215,386)
$
(173,996)
During the year ended March 31, 2024 and 2023, the Company recorded an income tax provision of $0.4 million and $0.3 million, respectively, related
to U.S. current taxes primarily due to the transfer pricing arrangement between the U.S. and the U.K., as well as unfavorable adjustments related to stock
compensation, resulting in U.S. taxable income reduced by certain prior year available net operating losses.
Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of
sufficient taxable income within the carryforward period. As of March 31, 2024 and 2023, the Company performed an evaluation to determine whether a
valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for
the current and preceding years. It was determined that it was not possible to reasonably quantify future taxable income and determined that it is more
likely than not that all of the deferred tax assets will not be realized. Accordingly, a full valuation allowance was maintained as of March 31, 2024 and
2023.
A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the years ended March 31, 2024 and 2023 is as
follows:
Year Ended March 31,
2024
2023
U.S. federal statutory income tax rate
-21.0 %
-21.0 %
State taxes, net of federal benefit
-0.3 %
-0.6 %
Research and development
0.7 %
1 %
Stock compensation
3.0 %
-0.1 %
Foreign tax rate differential
-3.6 %
1.8 %
Change in tax rates
0.0 %
-6.0 %
Change in valuation allowance
21.4 %
23.6 %
Other
0.0 %
1.5 %
0.2 %
0.2 %
F - 29

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
15.    Income taxes (Continued)
Components of the Company’s deferred tax assets as of March 31, 2024 and 2023 were as follows:
Year Ended March 31,
2024
2023
Deferred tax assets:
Net operating loss carryforwards
$
141,911 
$
93,788 
Property, plant and equipment
4,706 
4,535 
Capitalized start-up costs
1,199 
1,301 
Stock compensation
13,798 
14,757 
Accrued expenses
3,221 
2,906 
Lease liability
7,938 
7,964 
Other
39 
24 
Total deferred tax assets
172,812 
125,275 
Valuation allowance
(161,890)
(113,889)
Net deferred tax assets
10,922 
11,386 
Deferred tax liabilities:
Right of use asset
(10,922)
(11,386)
Total deferred tax liabilities
(10,922)
(11,386)
Net deferred tax assets (liabilities)
$
— 
$
— 
As of March 31, 2024, the Company had U.S. federal operating loss carryforwards of approximately $32.0 million, which can be carried forward
indefinitely subject to 80% limitation of taxable income when utilized. As of March 31, 2024, the Company had U.S. state operating loss carryforwards of
$60.1 million, which will begin to expire in 2039. As of March 31, 2024, the Company had U.K. operating loss carryforwards of approximately $528.7
million, which can be carried forward indefinitely. Such U.S. federal and state, as well as U.K., net operating loss carryforwards are based on tax returns
filed and does not reflect uncertain tax positions in the U.S. and offsetting positions in the U.K. related to the transfer pricing arrangement.
Utilization of the U.S. federal and state net operating loss carryforwards may be subject to a substantial annual limitation under Section 382 of the
Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes that have occurred previously or that
could occur in the future. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future
taxable income and tax liabilities, respectively. The Company has not completed a study to assess whether a change of ownership has occurred, or whether
there have been multiple ownership changes since its formation, due to the significant cost and complexity associated with such a study. Any limitation
may result in expiration of a portion of the net operating loss carryforwards before utilization.
Changes in the valuation allowance for deferred tax assets during the years ended March 31, 2024 and 2023 related primarily to the increase in net
operating loss carryforwards were as follows:
Year Ended March 31,
2024
2023
Valuation allowance as of beginning of year
$
113,889 
$
74,892 
Increases recorded to income tax provision
45,941 
41,063 
Increases (decreases) recorded to equity
2,060 
(2,066)
Valuation allowance as of end of year
$
161,890 
$
113,889 
Changes in the Company's gross unrecognized tax benefits from uncertain tax positions consisted of the following:
F - 30

TABLE OF CONTENTS
REPLIMUNE GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
15.    Income taxes (Continued)
Year Ended March 31,
2024
2023
Unrecognized tax benefits as of beginning of year
$
8,757 
$
— 
(Decreases) increases for tax positions taken during prior years
(90)
8,757 
Unrecognized tax benefits as of end of year
$
8,667 
$
8,757 
The Company's unrecognized tax benefits primarily relate to the Company's transfer pricing arrangements.
The Company's unrecognized tax benefits, if recognized, would not impact the effective tax rate and income tax provision due to the Company's
valuation allowance.
As of March 31, 2024 and 2023, the Company had not accrued interest or penalties related to uncertain income tax positions.
The Company files income tax returns in the U.S., Massachusetts and the U.K. In the normal course of business, the Company is subject to
examination by U.S. federal and state as well as U.K. jurisdictions, where applicable. There are currently no pending income tax examinations. The
Company is open to future U.S. federal income tax examination from 2020 to the present and in the U.K. from 2022 to the present. Although, carryforward
attributes may still be adjusted upon examination if they either have been or will be used in a future period.
As of March 31, 2024 and 2023, income taxes on outside basis differences, primarily related to undistributed earnings, of the Company’s subsidiary
have not been provided for as the Company intends to indefinitely reinvest its outside basis differences, and the undistributed earnings were in a cumulative
and overall deficit.
16.    Geographic information
The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the
Company’s long-lived assets held in different geographic regions is presented in the tables below:
March 31, 2024
March 31, 2023
United States
$
8,992 
$
5,836 
United Kingdom
1,491 
1,643 
$
10,483 
$
7,479 
17.    Subsequent events
In April 2024, the Company granted an equity award to a newly hired executive as a material inducement to enter into employment with the Company. The
grant constitutes an "employment inducement grant" in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules and was issued outside of the 2018
Plan and each of the other stock incentive plans described above. The inducement grant included a nonqualified stock option to purchase up to 75,000
shares of the Company's common stock, as well as a restricted stock unit grant representing 50,000 shares of the Company's common stock. These stock
option and restricted stock unit inducement grants have terms and conditions consistent with those set forth under the 2018 Plan and vest under the same
respective vesting schedules as stock option and restricted stock unit awards granted under the 2018 Plan.
F - 31

TABLE OF CONTENTS
Exhibit index
Exhibit Number
Exhibit Description
Incorporated by Reference
Form
Date
Number
3.1
Third Amended and Restated Certificate of Incorporation of the Registrant
(conformed to include the Certificate of Amendment to the Third Amended and
Restated Certificate of Incorporation filed on September 9, 2019).
10-K
June 3, 2020
3.1
3.2
Amended and Restated By-laws of the Registrant.
8-K
July 24, 2018
3.2
4.1
Form of Common Stock Certificate of the Registrant.
S-1/A
July 10, 2018
4.1
4.2
Amended and Restated Investors’ Rights Agreement, dated July 10, 2017, by and
among the Registrant and the investors set forth therein.
S-1
June 22, 2018
4.2
4.3*
Description of the Registrant’s Securities registered pursuant to Section 12 of the
Securities Exchange Act of 1934.
4.4
Form of Pre-Funded Warrant (2019).
8-K
November 18, 2019
4.1
4.5
Form of Pre-Funded Warrant (2020).
8-K
June 10, 2020
4.1
4.6
Form of Pre-Funded Warrant (2022)
8-K
December 12, 2022
4.1
4.7
Form of Indenture to be entered into between the Registrant and a trustee acceptable
to the Registrant.
S-3
August 8, 2019
4.4
10.1†
Form of Indemnification Agreement by and between the Registrant and its directors
and officers.
S-1/A
July 10, 2018
10.1
10.2†
2017 Equity Compensation Plan and Sub-Plan for U.K. Employees and forms of
agreements thereunder.
S-1/A
June 26, 2018
10.2
10.3†*
2018 Omnibus Incentive Compensation Plan and Sub-Plan for U.K. Employees and
forms of agreements thereunder.
10-K
May 19, 2022
10.3
10.4†*
Form of Performance Stock Unit Award Agreement under 2018 Omnibus Incentive
Compensation Plan for U.S. Employees.
10.5†*
Form of Performance Stock Unit Award Agreement under 2018 Omnibus Incentive
Compensation Plan and Sub-Plan for U.K. Employees.
10.6†*
Form of Inducement Stock Option Grant Agreement.
10.7†*
Form of Inducement Restricted Stock Unit Grant Agreement.
10.8†
Employee Stock Purchase Plan.
S-1/A
July 10, 2018
10.4
10.9†
Amended and Restated Employment Agreement, dated as of November 2, 2021, by
and between Robert Coffin and Replimune, Inc.
10-Q
November 4, 2021
10.2
10.10†
Employment Agreement, effective as of November 1, 2015, by and between Pamela
Esposito and Replimune, Inc.
S-1
June 22, 2018
10.7
10.11†
Employment Agreement, dated as of September 16, 2015, by and between Colin
Love and Replimune Limited.
S-1/A
July 10, 2018
10.9
10.12†
Employment Agreement, dated as of November 27, 2019, by and between Jean
Franchi and Replimune, Inc.
8-K
December 9, 2019
10.1
10.13†*
Employment Agreement, dated as of May 10, 2021, by and between Tanya Lewis
and Replimune, Inc.
10-K
May 20, 2021
10.12
10.14†
Separation Agreement and Release, dated as of December 23, 2019, by and between
Howard Kaufman and Replimune, Inc.
10-Q
February 13, 2020
10.2
10.15†
Separation Agreement and Release, dated as of April 3, 2020, by and between
Stephen Gorgol and Replimune, Inc.
10-K
June 3, 2020
10.13

TABLE OF CONTENTS
Exhibit Number
Exhibit Description
Incorporated by Reference
Form
Date
Number
10.16
Lease, dated as of April 1, 2016, by and between Cummings Properties, LLC and the
Registrant.
S-1
June 22, 2018
10.8
10.17
Lease, dated as of April 4, 2016, by and between MEPC Milton Park No. 1 Limited
and MEPC Milton Park No. 2 Limited, and Replimune Limited.
S-1
June 22, 2018
10.9
10.18
Deed of Variation, dated June 29, 2020, by and among MEPC Milton Park No. 1
Limited and MEPC Milton Park No. 2 Limited, and Replimune Limited.
10-Q
August 7, 2020
10.3
10.19‡
Clinical Trial Collaboration and Supply Agreement, dated as of February 26, 2018,
by and between Bristol-Myers Squibb Company and the Registrant.
S-1/A
July 10, 2018
10.12
10.20‡
Master Clinical Trial Collaboration and Supply Agreement, dated as of May 29,
2018, by and between Regeneron Pharmaceuticals, Inc. and the Registrant.
S-1/A
July 17, 2018
10.13
10.21
Indenture of Lease, dated as of June 22, 2018, by and between CRP/King 33 NY
Ave. Owner, L.L.C. and the Registrant.
S-1
June 22, 2018
10.12
10.22
Lease, dated as of June 7, 2019, by and between ND/CR Unicorn LLC and the
Registrant.
8-K
June 13, 2019
10.1
10.23
Payoff Letter to Loan and Security Agreement by and among the Registrant,
Replimune, Inc., Replimune Limited and Hercules Capital, Inc., dated December 15,
2020.
10-Q
February 4, 2021
10.1
10.24
Clinical Trial Collaboration and Supply Agreement (RP-2), dated as of April 12,
2019, by and between Bristol-Myers Squibb Company and Replimune, Inc.
10-K
June 3, 2020
10.22
10.25
Lease Agreement, dated as of October 29, 2021, by and among Replimune Limited,
MEPC Milton Park No. 1 Limited, and MEPC Milton Park No. 2 Limited.
10-Q
February 3, 2022
10.3
10.26*
Lease Agreement, dated as of March 23, 2023, by and among Replimune Limited,
MEPC Milton Park No. 1 Limited, and MEPC Milton Park No. 2 Limited.
10-K
May 18, 2023
10.34
10.27†*
Separation Agreement and Release, dated as of August 25, 2021, by and between
Andrea Pirzkall and Replimune, Inc., as amended.
10-K
May 19, 2022
10.27
10.28
Second Amendment to Loan and Security Agreement, dated as of December 22,
2023, by and among Replimune Group Inc., Replimune, Inc., Replimune Limited
and Hercules
10-Q
February 8, 2024
10.1
10.29†
Employment Agreement, dated as of December 1, 2022, by and between
Konstantinos Xynos and Replimune, Inc.
10-Q
February 9, 2023
10.2
10.30†
Amendment to Amended and Restated Employment Agreement, dated as of
December 30, 2022, by and between Sushil Patel and Replimune, Inc.
10-Q
February 9, 2023
10.3
10.31†
Employment Agreement, dated as of December 30, 2022, by and between
Christopher Sarchi and Replimune, Inc.
10-Q
February 9, 2023
10.4
10.32†*
Employment Agreement, dated as of August 31, 2023, by and between Emily Hill
and Replimune, Inc.
10-Q
November 7, 2023
10.1
10.33†*
Second Amended and Restated Employment Agreement, dated as of March 25,
2024, by and between Replimune, Inc. and Sushil Patel.
10.34†*
Second Amended and Restated Employment Agreement, dated as of March 25,
2024, by and between Replimune, Inc. and Philip Astley-Sparke.
10.35†*
Separation and Transition Agreement, dated as of March 25, 2024, by and between
Robert Coffin and Replimune, Inc.

TABLE OF CONTENTS
Exhibit Number
Exhibit Description
Incorporated by Reference
Form
Date
Number
10.36†*
Consulting Agreement, dated as of March 25, 2024, by and between Robert Coffin
and Replimune, Inc.
10.37†
Separation Agreement and Release, dated as of May 18, 2023 by and between Jean
Franchi and Replimune, Inc.
10-Q
August 3, 2023
10.2
10.38†
Consulting Agreement, dated as of May 18, 2023 by and between Jean Franchi and
Replimune, Inc.
10-Q
August 3, 2023
10.3
10.39†*
Separation Agreement and Release, dated as of March 26, 2024, by and between
Pamela Esposito and Replimune, Inc.
10.40†*
Consulting Agreement, dated as of March 26, 2024, by and between Pamela
Esposito and Replimune, Inc.
10.41†*
Separation Agreement and Release, dated as of March 31, 2024, by and between
Tanya Lewis and Replimune, Inc.
10.42†*
Consulting Agreement, dated as of March 31, 2024, by and between Tanya Lewis
and Replimune, Inc.
10.43*
Replimune Group, Inc. Clawback Policy
21.1*
Subsidiaries of the Registrant.
23.1*
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting
Firm.
31.1*
Certification of the Chief Executive Officer, as required by Section 302 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
31.2*
Certification of the Chief Financial Officer, as required by Section 302 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
32.1**
Certification of the Chief Executive Officer, as required by Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
32.2**
Certification of the Chief Financial Officer, as required by Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
101.INS*
Inline XBRL Instance Document.
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
___________________
*    Filed herewith.
**    Furnished and not filed herewith.
†    Indicates management contract or compensatory plan.
‡    Indicates confidential treatment has been requested with respect to specific portions of this exhibit. Omitted portions have been filed with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

TABLE OF CONTENTS
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
REPLIMUNE GROUP, INC.
Date: May 16, 2024
By:
/s/ SUSHIL PATEL
Sushil Patel
Chief Executive Officer and Director
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons in the capacities and on the dates
indicated.
Name
Title
Date
/s/ SUSHIL PATEL
Chief Executive Officer and Director
(Principal Executive Officer)
May 16, 2024
Sushil Patel
/s/ EMILY HILL
Chief Financial Officer, (Principal Financial Officer)
May 16, 2024
Emily Hill
/s/ ANDREW SCHWENDENMAN
Chief Accounting Officer, 

(Principal Accounting Officer)
May 16, 2024
Andrew Schwendenman
/s/ PHILIP ASTLEY-SPARKE
Director
May 16, 2024
Philip Astley-Sparke
/s/ ROBERT COFFIN
Director
May 16, 2024
Robert Coffin
/s/ KAPIL DHINGRA
Director
May 16, 2024
Kapil Dhingra
/s/ HYAM LEVITSKY
Director
May 16, 2024
Hyam Levitsky
/s/ CHRISTY OLIGER
Director
May 16, 2024
Christy Oliger
/s/ PAOLO PUCCI
Director
May 16, 2024
Paolo Pucci
/s/ JOSEPH SLATTERY
Director
May 16, 2024
Joseph Slattery
/s/ VELEKA PEEPLES-DYER
Director
May 16, 2024
Veleka Peeples-Dyer
/s/ DIETER WEINAND
Director
May 16, 2024
Dieter Weinand

DESCRIPTION OF THE REGISTRANT’S SECURITIES
 
REGISTERED PURSUANT TO SECTION 12 OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
The following description sets forth certain material terms and provisions of Replimune Group, Inc.’s (“we,” “us,” and “our”) securities that are
registered under Section 12 of the Securities Exchange Act of 1934, as amended.
 
DESCRIPTION OF CAPITAL STOCK
 
The following description is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Third
Amended and Restated Certificate of Incorporation, as amended (our “Certificate of Incorporation”), and our Amended and Restated By-laws (our
“Bylaws”), each of which are incorporated by reference or filed as an exhibit to our Annual Report on Form 10-K of which this Exhibit 4.3 is a part. The
terms of these securities also may be affected by the Delaware General Corporation Law (the “DGCL”).
 
Authorized Capital Stock
 
The Company’s authorized capital stock consists of 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of
undesignated preferred stock, par value $0.001 per share.
 
Common Stock
 
Subject to any preferential rights that may be applicable to any outstanding shares of preferred stock from time to time, holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any
cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally
available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights,
conversion rights or other subscription rights or redemption or sinking fund provisions.
 
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining
after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.
 
Preferred Stock
 
Pursuant to our Certificate of Incorporation, our board of directors has the authority, without further action by our stockholders, to designate up to
10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences
and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the
number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock.
 
The DGCL provides that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental
changes in the rights of holders of that preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of
designation.
 
Pre-Funded Warrants
 
In November 2019, we issued and sold pre-funded warrants to purchase an aggregate of 2,200,000 shares of our common stock at an offering price
of $13.6099 per pre-funded warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. In June 2020, we issued and sold pre-
funded warrants to purchase an aggregate of 1,521,738 shares of our common stock at an offering price of $22.999 per pre-funded warrant and, in October
2020, we issued and sold pre-funded warrants to purchase an aggregate of 1,562,500 shares of our common stock at an offering price of $39.999 per pre-
funded warrant, in each case, in an underwritten public offering pursuant to a shelf registration on Form S-3 (the “2020 Pre-Funded Warrants”).
 
Each pre-funded warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.0001 per share. The pre-funded
warrants do not expire and may be exercised at any time after their original issuance. Under the pre-funded warrants, we may not effect the exercise of any
pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant, which, upon giving effect to such exercise,

would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the
number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities
beneficially owned by the holder of the pre-funded warrant (together with its affiliates) to exceed 9.99% of the combined voting power of all of our
securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the
pre-funded warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 days’ prior notice from the
holder to us; provided, that a holder of a 2020 Pre-Funded Warrant may not increase such percentage to a percentage in excess of 19.99%.The exercise
price of the pre-funded warrants and the number of shares of our common stock issuable upon exercise of the pre-funded warrants is subject to appropriate
adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our
common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The exercise price will not be adjusted
below the par value of our common stock.
  
Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws
 
The provisions of Delaware law and of our Certificate of Incorporation and Bylaws may have the effect of discouraging, delaying or preventing a
change in control or an unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that might result in the payment
of a premium over the market price for the shares held by stockholders. These provisions are summarized in the following paragraphs.
 
Classified Board of Directors. Our Certificate of Incorporation and Bylaws provide that our board of directors is divided into three classes of
directors, with the directors in each class serving staggered three-year terms and with the number of directors in each class to be as nearly equal as possible.
The classification of our board of directors has the effect of requiring at least two annual stockholder meetings, instead of one, to replace a majority of the
members of our board of directors.
 
Authorized but Unissued or Undesignated Capital Stock. Our authorized capital stock consists of 150,000,000 shares of common stock and
10,000,000 shares of preferred stock. The authorized but unissued (and in the case of preferred stock, undesignated) stock may be issued by our board of
directors in one or more transactions. In this regard, our Certificate of Incorporation grants our board of directors broad power to establish the rights and
preferences of authorized and unissued preferred stock. The issuance of shares of preferred stock pursuant to our board of directors’ authority described
above could decrease the amount of earnings and assets available for distribution to holders of common stock and adversely affect the rights and powers,
including voting rights, of such holders and may have the effect of delaying, deferring or preventing a change in control. Our board of directors does not
currently intend to seek stockholder approval prior to any issuance of preferred stock, unless otherwise required by law.
 
Special Meetings of Stockholders. Our Certificate of Incorporation provides that special meetings of the stockholders may be called only by or at
the direction of our board of directors. Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such
meeting.
 
Requirements for Advance Notification of Stockholder Nominations and Proposals. Our Bylaws establish advance notice procedures with respect
to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of
directors or a committee of our board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply
with advance notice requirements and provide us with certain information. Additionally, vacancies and newly created directorships may be filled only by a
vote of a majority of the directors then in office, even though less than a quorum, and not by the stockholders. Our Bylaws allow the presiding officer at a
meeting of the stockholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain
business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from
conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.
 
Stockholder Action by Written Consent. Our Certificate of Incorporation prohibits the taking of any action of our stockholders by written consent
without a meeting.
 
Amendments to Our Certificate of Incorporation and Bylaws. The DGCL provides that, unless a corporation’s certificate of incorporation provides
otherwise, the affirmative vote of holders of shares constituting a majority of the votes of all shares entitled to vote may approve amendments to the
certificate of incorporation. Our Certificate of Incorporation and Bylaws provide that the affirmative vote of holders of at least 75% of the outstanding
shares of capital stock, voting together as a single class, and entitled to vote in the election of directors, will be required to amend, alter, change or repeal
our Certificate of Incorporation and Bylaws. This requirement of a

supermajority vote to approve amendments to our Certificate of Incorporation and Bylaws could enable a minority of our stockholders to exercise veto
power over such amendments.
 
No Cumulative Voting. The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless the corporation’s
certificate of incorporation provides otherwise. Our Certificate of Incorporation does not expressly provide for cumulative voting.
 
Delaware Anti-Takeover Statute. We are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general,
Section 203 prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years
after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A “business combination” includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An “interested stockholder”
is a person who, together with affiliates and associates, owns, or within three years of the date on which it is sought to be determined whether such person
is an interested stockholder, did own, 15% or more of the corporation’s outstanding voting stock. These provisions may have the effect of delaying,
deferring, or preventing a change in our control.
  
Registration Rights
 
Certain holders of our common stock, or their transferees, are entitled to registration rights with respect to registration of the resale of such shares
under the Securities Act of 1933, as amended, pursuant to the amended and restated investors’ rights agreement, by and among us and certain of our
investors.
 
Stock Exchange Listing
 
Our common stock is listed on the Nasdaq Global Select Market under the symbol “REPL.”
 
Transfer Agent and Registrar
 
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

April 2024
U.S. PSU Form
REPLIMUNE GROUP, INC.
2018 OMNIBUS INCENTIVE COMPENSATION PLAN
PERFORMANCE STOCK UNIT SUMMARY OF GRANT
    Replimune Group, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2018 Omnibus Incentive
Compensation Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), this performance stock unit
award representing the target number of performance stock units set forth below (the “Performance Stock Units”) that may
become earned and vested by the Participant based on the level of achievement of the Performance Goals. The actual number of
Performance Stock Units earned and vested will be based on the actual Performance Level achieved with respect to the
Performance Goals set forth on Schedule A. The Performance Stock Units are subject in all respects to the terms and conditions
set forth herein, in the Performance Stock Unit Award Agreement attached hereto as Exhibit A (the “Performance Stock Unit
Award Agreement”) and the Plan, each of which is incorporated herein by reference and made part hereof. Unless otherwise
defined herein, capitalized terms used in this Performance Stock Unit Summary of Grant (the “Summary of Grant”) and the
Performance Stock Unit Award Agreement shall have the meanings set forth in the Plan.
Participant:
%%FIRST_NAME%-% %%LAST_NAME%-%
Date of Grant:
%%OPTION_DATE,'Month DD, YYYY'%-%
Target Award of Performance Units
Granted:
%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Performance Period:
As set forth on Schedule A, the period beginning on Date of Grant and ending on
June 30, 2026 (the “Performance Period”).
Performance Goals:
The Performance Goals are based on the Performance Measure set forth on Schedule
A.
        
DB1/ 144206349.5


Vesting Schedule:
The Performance Stock Units will become earned and vested based on the
Performance Measure being achieved within a respective Performance Goal and the
Participant’s continued employment or approved service with the Employer through
the date that is the date that achievement of the applicable Performance Goal is
publicly announced (the “Vesting Date”).
The number of Performance Stock Units set forth above is equal to the target number
of Performance Stock Units that the Participant will earn and become vested in for
100% achievement of the Performance Goal (referred to as the “Target Award”). The
actual number of Performance Stock Units the Participant will become earned and
vested in may be greater than the Target Award, or may be zero, and will be based on
the Performance Level achieved, if any, by the Company with respect to the
Performance Goals, as set forth on Schedule A. Performance Level is measured based
on the Target, Intermediate and Maximum Performance Levels set forth on Schedule
A. Each Performance Level is calculated as a percentage of Target Performance
Level. The Target Performance Level is 100% of the Target Award, the Intermediate
Performance Level is 125% of the Target Award and the Maximum Performance
Level is 150% of the Target Award. Failure to achieve the Performance Measure at
the Target Performance Level within the Performance Goal will result in no
Performance Stock Units being earned and vested. The Target, Intermediate and
Maximum Performance Level achievements are binary events and there is no
interpolation between Performance Levels. Any fractional Performance Stock Units
resulting from the vesting of the Performance Stock Units in accordance with the
terms herein shall be rounded down to the nearest whole number.
In the event a Change of Control occurs while the Participant is employed by, or
providing approved service to, the Employer during the Performance Period, the
Performance Stock Units will vest as if Target Performance Level had been achieved,
such that the Target Award is deemed fully earned and vested as of the date of the
Change of Control.
Issuance Schedule:
The Participant will receive a distribution with respect to the Performance Stock
Units earned and vested pursuant to this Performance Stock Unit Award, if any,
within 60 days following the Vesting Date (the “Payment Date”); and in no event later
than March 15 of the calendar year following the Vesting Date. Distribution will be
made with respect to the Performance Stock Units on the Payment Date in shares of
Company Stock, with each Performance Stock Unit earned and vested equivalent to
one share of Company Stock. In no event shall any fractional shares be issued.
Although performance may be achieved at or above the Target Performance Level
during the Performance Period, the Participant must be employed by, or providing
approved service to, the Employer on the Vesting Date in order to earn and vest in the
Performance Stock Units, unless the Committee determines otherwise.
    
Participant Acceptance:    
    By electronic acceptance, the Participant agrees to be bound by the terms and conditions of the Plan, the Performance Stock
Unit Award Agreement and this Summary of Grant and accepts the Performance Stock Units following the date of the
Company’s notification to the Participant of the award of the Performance Stock Units (the “Notification Date”). The Participant
will accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the
Plan, this Summary of Grant or the Performance Stock Unit Award Agreement. The Participant hereby acknowledges the receipt
of a copy of the official prospectus for the Plan, which is available electronically in the Participant’s online account or by
accessing the Company’s intranet at www.replimune.com. Paper copies of the Plan and the official Plan prospectus are available
by contacting the Chief Financial Officer of the Company at +1.781.222.9600.
2
DB1/ 144206349.5


SCHEDULE A
PERFORMANCE GOALS
        The number of Performance Stock Units that may become earned and vested shall be determined based on the actual
Performance Level achieved with respect to the timing of approval of the Company’s first Biologics License Applicable for RP1
by the U.S. Food and Drug Administration (“BLA Approval”). The chart below sets forth the Performance Goals at each
Performance Level for receipt of BLA Approval:
Performance Measure
Performance Level
Performance Goals
Performance Stock Units
Earned and Vested as a
Percentage of Target
Award
BLA Approval*
Target
After December 31, 2025 and on or before
June 30, 2026
100%
Intermediate
After October 31, 2025 and on or before
December 31, 2025
125%
Maximum
After the Date of Grant and on or before
October 31, 2025
150%
    
*    The actual number of Performance Stock Units earned and vested will be based on the actual Performance Level achieved, as
set forth in the chart above. If the actual Performance Level achieved does not meet the Target Performance Level Performance
Goal, then no Performance Stock Units will be earned and vested pursuant to this Award. The maximum number of Performance
Stock Units that may become earned and vested pursuant to this Award is capped at 150% of the Target Award. Any fractional
Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance with the terms herein shall be
rounded down to the nearest whole number.
    
3
DB1/ 144206349.5


REPLIMUNE GROUP, INC.
PERFORMANCE STOCK UNIT AWARD AGREEMENT
(Pursuant to the Company’s 2018 Omnibus Incentive Compensation Plan)
This PERFORMANCE STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of the Date of Grant set
forth in the Summary of Grant is delivered by Replimune Group, Inc., (the “Company”) to the individual named in the Summary
of Grant (the “Participant”).
RECITALS
1.
The Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan (the “Plan”) provides for the grant of restricted
stock units that are payable if specified performance goals are met (referred to herein as “Performance Stock Units”), in
accordance with the terms and conditions of the Plan. The Committee has decided to make this grant of Performance Stock Units
as an inducement for the Participant to promote the best interests of the Replimune Group, Inc. (the “Company”) and its
stockholders. This Agreement is made pursuant to the Plan and is subject in its entirety to all applicable provisions of the Plan.
Unless otherwise defined herein, capitalized terms used in this Performance Stock Unit Award Agreement and the Summary of
Grant shall have the meanings set forth in the Plan. Subject to the terms, restrictions and conditions set forth in the Summary of
Grant, this Agreement and the Plan, the Company hereby grants to the Participant the right to receive the shares of Company
Stock in the amount and on the terms set forth in the Summary of Grant upon achievement of the Performance Goals as set forth
in the Summary of Grant and satisfaction of the requirements of the Vesting Schedule set forth in the Summary of Grant. No
shares of Company Stock shall be issued to the Participant on the Date of Grant.
2.
Stock Unit Account. Performance Stock Units represent hypothetical shares of Company Stock, and not actual shares of
stock. The Company shall establish and maintain a Performance Stock Unit account, as a bookkeeping account on its records, for
the Participant and shall record in such account the target number of Performance Stock Units granted to the Participant. No
shares of Company Stock shall be issued to the Participant at the time the grant is made, and the Participant shall not be, and shall
not have any of the rights or privileges of, a stockholder of the Company with respect to any Performance Stock Units recorded
in the Performance Stock Unit account. The Participant shall not have any interest in any fund or specific assets of the Company
by reason of this award or the Performance Stock Unit account established for the Participant.
3.
Vesting.
(a)
The Performance Stock Units subject to this Agreement will become earned based on the actual level of
performance achieved with respect to the Performance Goals for the Performance Period on the terms set forth in the Summary of
Grant and provided that the Participant satisfies the requirements of the Vesting Schedule set forth in the Summary of Grant. Any
fractional Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance with the terms
herein shall be rounded down to the nearest whole number.
(b)
If the Participant’s employment or service terminates on account of the Participant’s death or Disability before the
Vesting Date, any unvested Performance Stock Units
-1-
DB1/ 144206349.5


shall become fully vested upon such termination of employment or service and at the Target Performance Level.
(c)
Except as set forth in Section 3(b) above, if the Participant ceases to be employed by, or provide approved service
to, the Employer for any reason prior to the applicable Vesting Date, the Participant shall forfeit all rights to receive shares of
Company Stock hereunder and the Participant will not have any rights with respect to any portion of the Performance Stock Units
that have not yet become vested as of the date the Participant ceases to be employed by, or provide approved service to, the
Employer, irrespective of the level of achievement of the Performance Goals. No payment shall be made with respect to any
unvested Performance Stock Units that terminate as described in this Section 3.
4.
Issuance.
(a)
Shares of Company Stock equal to the number of Performance Stock Units that the Participant earns upon
achievement of the Performance Goals and becomes vested in pursuant to the Vesting Schedule, in each case, as set forth in the
Summary of Grant shall be issued to the Participant as set forth in the Summary of Grant and a certificate representing the
Company Stock shall be issued to the Participant, free of the restrictions under Section 9 of this Agreement.
(b)
All obligations of the Company under this Agreement shall be subject to the rights of the Employer as set forth in
the Plan to withhold amounts required by law to be withheld for any federal (including FICA), state, local and other taxes with
respect to the payment of the Performance Stock Units (“Withholding Taxes”). The Participant irrevocably (i) has elected, as of
the Date of Grant to sell shares of Company Stock in an amount having an aggregate Fair Market Value equal to the Withholding
Taxes, and to allow the Company’s designated broker to remit the cash proceeds of such sale to the Employer (a “Sell to Cover”)
and (ii) directs the Employer to make a cash payment to satisfy the Withholding Taxes from the cash proceeds of such sale
directly to the appropriate taxing authorities. To the extent the Sell to Cover does not cover all Withholding Taxes due, the
Participant shall be required to pay to the Employer, or make other arrangements satisfactory to the Employer to provide for the
payment of, any Withholding Taxes that the Employer is required to withhold with respect to the Performance Stock Units.
(c)
The obligation of the Company to deliver the Company Stock to the Participant following the applicable Vesting
Date shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be
deemed appropriate to comply with relevant securities laws and regulations.
5.
No Stockholder Rights. Neither the Participant, nor any person entitled to receive payment in the event of the Participant’s
death, shall have any of the rights and privileges of a stockholder with respect to shares of Company Stock, including voting,
dividend rights or dividend equivalent rights, until certificates for shares have been issued upon payment of Performance Stock
Units. The Participant acknowledges that no election under Section 83(b) of the Code is available with respect to Performance
Stock Units.
6.
Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of which are incorporated herein by
reference, and in all respects shall be interpreted in accordance with the Plan. The grant and payment of the Performance Stock
Units are subject to the
-2-
DB1/ 144206349.5


provisions of the Plan and to interpretations, regulations and determinations concerning the Plan established from time to time by
the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (a) rights and
obligations with respect to Withholding Taxes, (b) the registration, qualification or listing of the shares of Company Stock, (c)
changes in capitalization of the Company and (d) other requirements of applicable law. The Committee shall have the authority to
interpret and construe the Performance Stock Units pursuant to the terms of the Plan, and its decisions shall be conclusive as to
any questions arising hereunder.
7.
No Employment or Other Rights. The grant of the Performance Stock Units shall not confer upon the Participant any right
to be retained by or in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to
terminate the Participant’s employment or service at any time. The right of any Employer to terminate at will the Participant’s
employment or service at any time for any reason is specifically reserved.
8.
Company Policies. The Participant agrees that payment to the Participant shall be made in such manner and on such terms
and conditions as may be required by the Committee and the Employer shall be entitled to set off against the amount of any such
payment any amounts otherwise owed to the Participant by the Employer, to the extent permitted by applicable law. In addition,
the Participant agrees that the Performance Stock Units shall be subject to any applicable clawback or recoupment policies, share
trading policies and other policies that may be implemented by the Board or imposed under applicable rule or regulation from
time to time.
9.
Assignment and Transfers. Except as the Committee may otherwise permit pursuant to the Plan, the rights and interests of
the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the
death of the Participant, by will or by the laws of descent and distribution. In the event of any attempt by the Participant to
alienate, assign, pledge, hypothecate, or otherwise dispose of the Performance Stock Units or any right hereunder, except as
provided for in this Agreement, or in the event of the levy or any attachment, execution or similar process upon the rights or
interests hereby conferred, the Company may terminate the Performance Stock Units by notice to the Participant, and the
Performance Stock Units and all rights hereunder shall thereupon become null and void. The rights and protections of the
Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and
affiliates. This Agreement may be assigned by the Company without the Participant’s consent.
10.
Applicable Law; Jurisdiction. The validity, construction, interpretation and effect of this Agreement shall be governed by
and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws provisions
thereof. Any action arising out of, or relating to, any of the provisions of this Agreement shall be brought only in the United
States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will not accept jurisdiction, in
any court of general jurisdiction in Boston, Massachusetts, and the jurisdiction of such court in any such proceeding shall be
exclusive. Notwithstanding the foregoing sentence, on and after the date a Participant receives shares of Company Stock
hereunder, the Participant will be subject to the jurisdiction provision set forth in the Company’s bylaws.
11.
Notice. Any notice to the Company provided for in this instrument shall be addressed to the Company in care of the Chief
Financial Officer at the corporate headquarters of the Company, and any notice to the Participant shall be addressed to such
Participant at the current
-3-
DB1/ 144206349.5


address shown on the payroll of the Employer, or to such other address as the Participant may designate to the Employer in
writing. Any notice shall be delivered by hand, or enclosed in a properly sealed envelope addressed as stated above, registered
and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or by the postal authority
of the country in which the Participant resides or to an internationally recognized expedited mail courier.
-4-
DB1/ 144206349.5


April 2024
U.K. PSU Form
REPLIMUNE GROUP, INC.
2018 OMNIBUS INCENTIVE COMPENSATION PLAN
PERFORMANCE STOCK UNIT SUMMARY OF GRANT
    Replimune Group, Inc., a Delaware corporation (the “Company” or “Employer”), pursuant to its 2018 Omnibus Incentive
Compensation Plan and the Sub-Plan for U.K. Employees thereunder (together, the “Plan”), hereby grants to the individual listed
below (the “Participant”), this performance stock unit award representing the target number of performance stock units set forth
below (the “Performance Stock Units”) that may become earned and vested by the Participant based on the level of achievement
of the Performance Goals. The actual number of Performance Stock Units earned and vested will be based on the actual
Performance Level achieved with respect to the Performance Goals set forth on Schedule A. The Performance Stock Units are
subject in all respects to the terms and conditions set forth herein, in the Performance Stock Unit Award Agreement attached
hereto as Exhibit A (the “Performance Stock Unit Award Agreement”) and the Plan, each of which is incorporated herein by
reference and made part hereof. Unless otherwise defined herein, capitalized terms used in this Performance Stock Unit Summary
of Grant (the “Summary of Grant”) and the Performance Stock Unit Award Agreement shall have the meanings set forth in the
Plan.
Participant:
%%FIRST_NAME%-% %%LAST_NAME%-%
Date of Grant:
%%OPTION_DATE,'Month DD, YYYY'%-%
Target Award of Performance Units
Granted:
%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Performance Period:
As set forth on Schedule A, the period beginning on Date of Grant and ending on
June 30, 2026 (the “Performance Period”).
Performance Goals:
The Performance Goals are based on the Performance Measure set forth on Schedule
A.
        
DB1/ 144206349.5


Vesting Schedule:
The Performance Stock Units will become earned and vested based on the
Performance Measure being achieved within a respective Performance Goal and the
Participant’s continued employment or approved service with the Employer through
the date that is the date that achievement of the applicable Performance Goal is
publicly announced (the “Vesting Date”).
The number of Performance Stock Units set forth above is equal to the target number
of Performance Stock Units that the Participant will earn and become vested in for
100% achievement of the Performance Goal (referred to as the “Target Award”). The
actual number of Performance Stock Units the Participant will become earned and
vested in may be greater than the Target Award, or may be zero, and will be based on
the Performance Level achieved, if any, by the Company with respect to the
Performance Goals, as set forth on Schedule A. Performance Level is measured based
on the Target, Intermediate and Maximum Performance Levels set forth on Schedule
A. Each Performance Level is calculated as a percentage of Target Performance
Level. The Target Performance Level is 100% of the Target Award, the Intermediate
Performance Level is 125% of the Target Award and the Maximum Performance
Level is 150% of the Target Award. Failure to achieve the Performance Measure at
the Target Performance Level within the Performance Goal will result in no
Performance Stock Units being earned and vested. The Target, Intermediate and
Maximum Performance Level achievements are binary events and there is no
interpolation between Performance Levels. Any fractional Performance Stock Units
resulting from the vesting of the Performance Stock Units in accordance with the
terms herein shall be rounded down to the nearest whole number.
In the event a Change of Control occurs while the Participant is employed by, or
providing approved service to, the Employer during the Performance Period, the
Performance Stock Units will vest as if Target Performance Level had been achieved,
such that the Target Award is deemed fully earned and vested as of the date of the
Change of Control.
Issuance Schedule:
The Participant will receive a distribution with respect to the Performance Stock
Units earned and vested pursuant to this Performance Stock Unit Award, if any,
within 60 days following the Vesting Date (the “Payment Date”); and in no event later
than March 15 of the calendar year following the Vesting Date. Distribution will be
made with respect to the Performance Stock Units on the Payment Date in shares of
Company Stock, with each Performance Stock Unit earned and vested equivalent to
one share of Company Stock. In no event shall any fractional shares be issued.
Although performance may be achieved at or above the Target Performance Level
during the Performance Period, the Participant must be employed by, or providing
approved service to, the Employer on the Vesting Date in order to earn and vest in the
Performance Stock Units, unless the Committee determines otherwise.
    
Participant Acceptance:    
    By electronic acceptance, the Participant agrees to be bound by the terms and conditions of the Plan, the Performance Stock
Unit Award Agreement and this Summary of Grant and accepts the Performance Stock Units following the date of the
Company’s notification to the Participant of the award of the Performance Stock Units (the “Notification Date”). The Participant
will accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the
Plan, this Summary of Grant or the Performance Stock Unit Award Agreement. The Participant hereby acknowledges the receipt
of a copy of the official prospectus for the Plan, which is available electronically in the Participant’s online account or by
accessing the Company’s intranet at www.replimune.com. Paper copies of the Plan and the official Plan prospectus are available
by contacting the Chief Financial Officer of the Company at +1.781.222.9600.
2
DB1/ 144206349.5


SCHEDULE A
PERFORMANCE GOALS
        The number of Performance Stock Units that may become earned and vested shall be determined based on the actual
Performance Level achieved with respect to the timing of approval of the Company’s first Biologics License Applicable for RP1
by the U.S. Food and Drug Administration (“BLA Approval”). The chart below sets forth the Performance Goals at each
Performance Level for receipt of BLA Approval:
Performance Measure
Performance Level
Performance Goals
Performance Stock Units
Earned and Vested as a
Percentage of Target
Award
BLA Approval*
Target
After December 31, 2025 and on or before
June 30, 2026
100%
Intermediate
After October 31, 2025 and on or before
December 31, 2025
125%
Maximum
After the Date of Grant and on or before
October 31, 2025
150%
    
*    The actual number of Performance Stock Units earned and vested will be based on the actual Performance Level achieved, as
set forth in the chart above. If the actual Performance Level achieved does not meet the Target Performance Level Performance
Goal, then no Performance Stock Units will be earned and vested pursuant to this Award. The maximum number of Performance
Stock Units that may become earned and vested pursuant to this Award is capped at 150% of the Target Award. Any fractional
Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance with the terms herein shall be
rounded down to the nearest whole number.
    
3
DB1/ 144206349.5


REPLIMUNE GROUP, INC.
PERFORMANCE STOCK UNIT AWARD AGREEMENT
(Pursuant to the Company’s 2018 Omnibus Incentive Compensation Plan)
This PERFORMANCE STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of the Date of Grant set
forth in the Summary of Grant is delivered by Replimune Group, Inc., (the “Company”) to the individual named in the Summary
of Grant (the “Participant”).
RECITALS
1.
The Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan and the Sub-Plan for U.K. Employees
thereunder (together, the “Plan”) provides for the grant of restricted stock units that are payable if specified performance goals are
met (referred to herein as “Performance Stock Units”), in accordance with the terms and conditions of the Plan. The Committee
has decided to make this grant of Performance Stock Units as an inducement for the Participant to promote the best interests of
the Replimune Group, Inc. (the “Company”) and its stockholders. This Agreement is made pursuant to the Plan and is subject in
its entirety to all applicable provisions of the Plan. Unless otherwise defined herein, capitalized terms used in this Performance
Stock Unit Award Agreement and the Summary of Grant shall have the meanings set forth in the Plan. Subject to the terms,
restrictions and conditions set forth in the Summary of Grant, this Agreement and the Plan, the Company hereby grants to the
Participant the right to receive the shares of Company Stock in the amount and on the terms set forth in the Summary of Grant
upon achievement of the Performance Goals as set forth in the Summary of Grant and satisfaction of the requirements of the
Vesting Schedule set forth in the Summary of Grant. No shares of Company Stock shall be issued to the Participant on the Date
of Grant.
2.
Stock Unit Account. Performance Stock Units represent hypothetical shares of Company Stock, and not actual shares of
stock. The Company shall establish and maintain a Performance Stock Unit account, as a bookkeeping account on its records, for
the Participant and shall record in such account the target number of Performance Stock Units granted to the Participant. No
shares of Company Stock shall be issued to the Participant at the time the grant is made, and the Participant shall not be, and shall
not have any of the rights or privileges of, a stockholder of the Company with respect to any Performance Stock Units recorded
in the Performance Stock Unit account. The Participant shall not have any interest in any fund or specific assets of the Company
by reason of this award or the Performance Stock Unit account established for the Participant.
3.
Vesting.
(a)
The Performance Stock Units subject to this Agreement will become earned based on the actual level of
performance achieved with respect to the Performance Goals for the Performance Period on the terms set forth in the Summary of
Grant and provided that the Participant satisfies the requirements of the Vesting Schedule set forth in the Summary of Grant. Any
fractional Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance with the terms
herein shall be rounded down to the nearest whole number.
(b)
If the Participant’s employment or service terminates on account of the Participant’s death or Disability before the
Vesting Date, any unvested Performance Stock Units
-1-

shall become fully vested upon such termination of employment or service and at the Target Performance Level.
(c)
Except as set forth in Section 3(b) above, if the Participant ceases to be employed by, or provide approved service
to, the Employer for any reason prior to the applicable Vesting Date, the Participant shall forfeit all rights to receive shares of
Company Stock hereunder and the Participant will not have any rights with respect to any portion of the Performance Stock Units
that have not yet become vested as of the date the Participant ceases to be employed by, or provide approved service to, the
Employer, irrespective of the level of achievement of the Performance Goals. No payment shall be made with respect to any
unvested Performance Stock Units that terminate as described in this Section 3.
(d)
For purposes of this Agreement, the Participant’s employment or service will be deemed to terminate on the date
that the Participant ceases to be actively employed by, or providing services to, the Employer and shall not be extended by any
notice period mandated or implied under local law (i) during or for which the Participant receives pay in lieu of notice or
severance pay or is on garden or similar leave or (ii) during which the Participant remains employed or providing services, but is
not actively working. The Company shall have the sole discretion to determine when the Participant is no longer in active
employment or service for purposes of this Agreement, without reference to any other agreement, written or oral, including the
Participant’s contract of employment or service.
4.
Issuance.
(a)
Shares of Company Stock equal to the number of Performance Stock Units that the Participant earns upon
achievement of the Performance Goals and becomes vested in pursuant to the Vesting Schedule, in each case, as set forth in the
Summary of Grant shall be issued to the Participant as set forth in the Summary of Grant and a certificate representing the
Company Stock shall be issued to the Participant, free of the restrictions under Section 9 of this Agreement.
(b)
All obligations of the Company under this Agreement shall be subject to the rights of the Employer as set forth in
the Plan to withhold amounts required by law to be withheld, collected or accounted for with respect to any income tax (including
U.S. federal, state, and local tax and/or foreign income tax), employment tax (including FICA), payroll tax, social security tax,
social insurance, national insurance and other contributions, payment on account obligations, national and local tax or other
amounts required to be withheld, collected or accounted for by the Employer in connection with any taxable event with respect to
the payment of the Performance Stock Units (“Withholding Taxes”). The Participant irrevocably (i) has elected, as of the Date of
Grant, to sell shares of Company Stock in an amount having an aggregate Fair Market Value equal to the Withholding Taxes, and
to allow the Company’s designated broker to remit the cash proceeds of such sale to the Employer (a “Sell to Cover”) and (ii)
directs the Employer to make a cash payment to satisfy the Withholding Taxes from the cash proceeds of such sale directly to the
appropriate taxing authorities. To the extent the Sell to Cover does not cover all Withholding Taxes due, the Participant shall be
required to pay to the Employer, or make other arrangements satisfactory to the Employer to provide for the payment of, any
Withholding Taxes that the Employer is required to withhold with respect to the Performance Stock Units.
-2-

(c)
Regardless of any action the Employer takes with respect to any such Withholding Taxes, the Participant
acknowledges that the ultimate liability for all such Withholding Taxes legally due by the Participant is and remains the
Participant's responsibility and may exceed the amount withheld by the Employer. The Participant further acknowledges that the
Employer (i) makes no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any
aspect of the Performance Stock Units, including the grant, vesting or payment of the Performance Stock Units and the
subsequent sale of any shares of Company Stock acquired upon payment of the Performance Stock Units and (ii) does not
commit to, and is under no obligation to, structure the terms of the grant or any aspect of the Performance Stock Units to reduce
or eliminate the Participant's liability for Withholding Taxes. Further, if the Participant has become subject to tax in more than
one jurisdiction between the date of grant and the date of any relevant taxable event, then the Participant acknowledges that the
Employer may be required to collect, withhold or account for Withholding Taxes in more than one jurisdiction.
(d)
As a condition to participation in the Plan and the grant of the Performance Stock Units, the Participant hereby
agrees to accept all liability for and pay all secondary Class 1 National Insurance Contributions which would otherwise be
payable by the Company (or any successor or any subsidiary employing or retaining or previously employing or retaining the
Participant) with respect to the payment of the Performance Stock Units or any other event giving rise to taxation in respect of the
Performance Stock Units (the "Employer NICs"). The Participant agrees that to the extent requested by the Company, the
Participant will execute, within the time period specified by the Company, a joint election, and any other consent or elections
required to effect the transfer of the Employer NICs. The Participant further agrees to execute such other joint elections as may
be required between the Participant and any successor to the Company and/or the Participant's employer. The Participant further
agrees that the Company and/or the Participant's employer may collect the Employer NICs by any of the means set forth in this
Agreement.
(e)
The Participant indemnifies the Company and the Employer for any Withholding Taxes that may be payable with
respect to the full number of shares of Company Stock vested and issued (including those shares of Company Stock that are
deemed issued).
(f)
The obligation of the Company to deliver the Company Stock to the Participant following the applicable Vesting
Date shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be
deemed appropriate to comply with relevant securities laws and regulations.
5.
No Stockholder Rights. Neither the Participant, nor any person entitled to receive payment in the event of the Participant’s
death, shall have any of the rights and privileges of a stockholder with respect to shares of Company Stock, including voting,
dividend rights or dividend equivalent rights, until certificates for shares have been issued upon payment of Performance Stock
Units. The Participant acknowledges that no election under Section 83(b) of the Code is available with respect to Performance
Stock Units.
6.
Grant Subject to Plan Provisions. This grant is made pursuant to the Plan, the terms of which are incorporated herein by
reference, and in all respects shall be interpreted in accordance with the Plan. The grant and payment of the Performance Stock
Units are subject to the provisions of the Plan and to interpretations, regulations and determinations concerning the Plan
established from time to time by the Committee in accordance with the provisions of the Plan,
-3-

including, but not limited to, provisions pertaining to (a) rights and obligations with respect to Withholding Taxes, (b) the
registration, qualification or listing of the shares of Company Stock, (c) changes in capitalization of the Company and (d) other
requirements of applicable law. The Committee shall have the authority to interpret and construe the Performance Stock Units
pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.
7.
No Employment or Other Rights. The grant of the Performance Stock Units shall not confer upon the Participant any right
to be retained by or in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to
terminate the Participant’s employment or service at any time. Subject to the terms of any employment agreement between the
Participant and the Employer and applicable law, the right of any Employer to terminate at will the Participant’s employment or
service at any time for any reason is specifically reserved.
8.
Company Policies. The Participant agrees that payment to the Participant shall be made in such manner and on such terms
and conditions as may be required by the Committee and the Employer shall be entitled to set off against the amount of any such
payment any amounts otherwise owed to the Participant by the Employer, to the extent permitted by applicable law. In addition,
the Participant agrees that the Performance Stock Units shall be subject to any applicable clawback or recoupment policies, share
trading policies and other policies that may be implemented by the Board or imposed under applicable rule or regulation from
time to time.
9.
Assignment and Transfers. Except as the Committee may otherwise permit pursuant to the Plan, the rights and interests of
the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the
death of the Participant, by will or by the laws of descent and distribution. In the event of any attempt by the Participant to
alienate, assign, pledge, hypothecate, or otherwise dispose of the Performance Stock Units or any right hereunder, except as
provided for in this Agreement, or in the event of the levy or any attachment, execution or similar process upon the rights or
interests hereby conferred, the Company may terminate the Performance Stock Units by notice to the Participant, and the
Performance Stock Units and all rights hereunder shall thereupon become null and void. The rights and protections of the
Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and
affiliates. This Agreement may be assigned by the Company without the Participant’s consent.
10.
No Entitlement or Claims for Compensation. In connection with the acceptance of the grant of the Performance Stock
Units under this Agreement, the Participant acknowledges the following:
(a)
the Plan is established voluntarily by the Company, the grant of the Performance Stock Units under the Plan is
made at the discretion of the Committee and the Plan may be modified, amended, suspended or terminated by the Company at
any time;
(b)
the grant of the Performance Stock Units under the Plan is voluntary and occasional and does not create any
contractual or other right to receive future grants of equity awards, or benefits in lieu of them, even if equity awards have been
granted repeatedly in the past;
-4-

(c)
all decisions with respect to future grants of awards, if any, will be at the sole discretion of the Committee;
(d)
the Participant is voluntarily participating in the Plan;
(e)
the Performance Stock Units and any shares of Company Stock acquired under the Plan are extraordinary items
that do not constitute compensation of any kind for services of any kind rendered to the Employer or any affiliate and which are
outside the scope of the Participant's employment contract, if any;
(f)
the Performance Stock Units and any shares of Company Stock acquired under the Plan are not to be considered
part of the Participant's normal or expected compensation or salary for any purpose, including, but not limited to, calculating any
severance, resignation, termination, payment in lieu of notice, redundancy, end of service payments, bonuses, long-service
awards, pension or retirement or welfare benefits or similar payments;
(g)
the Performance Stock Units and the shares of Company Stock underlying the Performance Stock Units are not
intended to replace any pension rights or compensation;
(h)
the grant of the Performance Stock Units and the Participant's participation in the Plan will not be interpreted to
form an employment contract or relationship with the Employer;
(i)
the future value of the shares of Company Stock underlying the Performance Stock Units is unknown and cannot
be predicted with certainty. If the Performance Stock Units are paid pursuant to this Agreement, the value of the acquired shares
of Company Stock may increase or decrease;
(j)
the Participant understands that the Company is not responsible for any foreign exchange fluctuation between the
United States Dollar and the Participant's local currency that may affect the value of the Performance Stock Units or the
underlying shares of Company Stock;
(k)
the Participant shall have no rights, claim or entitlement to compensation or damages as a result of the
Participant's cessation of employment or service for any reason whatsoever, whether or not in breach of contract or local labor
law, insofar as these rights, claim or entitlement arise or may arise from the Participant's ceasing to have rights under or be
entitled to the Performance Stock Units as a result of such cessation or loss or diminution in value of the Performance Stock
Units or any of the shares received upon payment of the Performance Stock Units as a result of such cessation, and the
Participant irrevocably releases his or her Employer from any such rights, entitlement or claim that may arise. If, notwithstanding
the foregoing, any such right or claim is found by a court of competent jurisdiction to have arisen, then, by signing this
Agreement, the Participant shall be deemed to have irrevocably waived his or her entitlement to pursue such rights or claim; and
(l)
the Participant has no right to compensation or damages on account of any loss in respect of the Performance
Stock Units where the loss arises or is claimed to arise in whole or part from: (i) the termination of Participant's office or
employment; or (ii) notice to terminate Participant's office or employment. This exclusion of liability shall apply however
termination of office or employment, or the giving of notice, is caused, and however compensation or damages are claimed. For
the purpose of the Plan, the implied duty of trust and confidence is expressly excluded.
-5-

11.
Data Privacy.
(a)
The Participant hereby acknowledges and understands the collection, use, disclosure and transfer, in
electronic or other form, of his or her personal data as described in this Agreement by and among, as applicable, his or
her employer, the Company and its affiliates for the exclusive purpose of implementing, administering and managing his
or her participation in the Plan.
(b)
The Participant understands that the Company and its affiliates (including his or her employer), as
applicable, hold certain personal information about him or her regarding the Participant's employment, the nature and
amount of the Participant's compensation and the fact and conditions of the Participant's participation in the Plan,
including, but not limited to, his or her name, home address, telephone number and e-mail address, date of birth, social
insurance number or other identification number, salary, nationality, job title, any equity or directorships held in the
Company and its affiliates, details of all stock units or any other entitlement to equity awarded, canceled, exercised,
vested, unvested or outstanding in his or her favor, for the purpose of implementing, administering and managing the
Plan (the “Data”).
(c)
The Participant understands that the Data may be transferred to the Company, its affiliates and any third
parties assisting in the implementation, administration, and management of the Plan, that these recipients may be located
in his or her country, or elsewhere, and that the recipient's country may have a lower standard of data privacy laws and
protections than the Participant's country of residence. The Participant understands that he or she may request a list with
the names and addresses of any potential recipients of the Data by contacting the Participant's local human resources
representative. The Participant understands that the recipients receive, possess, use, retain and transfer the Data, in
electronic or other form, for the purposes of implementing, administering and managing his or her participation in the
Plan, including any requisite transfer of such Data as may be required to a broker or other third party. The Participant
understands that the Data will be held only as long as is necessary to implement, administer and manage his or her
participation in the Plan. The Participant understands that he or she may, at any time, view the Data, request additional
information about the storage and processing of the Data, require any necessary amendments to the Data, object to or
request restriction of the processing of his or her Data or refuse or withdraw any consents provided to the Company
herein, in any case without cost, by contacting in writing his or her local human resources representative. The Participant
understands, however, that objecting to or requesting restriction of the processing of his or her Data may affect his or her
ability to participate in the Plan. For more information on the processing of his or her Data and other personal data, the
Participant is referred to the Privacy Notice provided to him or her by his or her employer.
12.
Applicable Law; Jurisdiction. The validity, construction, interpretation and effect of this Agreement shall be governed by
and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws provisions
thereof. Any action arising out of, or relating to, any of the provisions of this Agreement shall be brought only in the United
States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will not accept jurisdiction, in
any court of general jurisdiction in Boston, Massachusetts, and the jurisdiction of such court in any such proceeding shall be
exclusive. Notwithstanding the
-6-

foregoing sentence, on and after the date a Participant receives shares of Company Stock hereunder, the Participant will be
subject to the jurisdiction provision set forth in the Company’s bylaws.
13.
Notice. Any notice to the Company provided for in this instrument shall be addressed to the Company in care of the Chief
Financial Officer at the corporate headquarters of the Company, and any notice to the Participant shall be addressed to such
Participant at the current address shown on the payroll of the Employer, or to such other address as the Participant may designate
to the Employer in writing. Any notice shall be delivered by hand, or enclosed in a properly sealed envelope addressed as stated
above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or by
the postal authority of the country in which the Participant resides or to an internationally recognized expedited mail courier.
-7-

U.S. Form NQSO Inducement Grant (April 2024)
REPLIMUNE GROUP, INC.
NONQUALIFIED STOCK OPTION GRANT AGREEMENT
Participant:
%%FIRST_NAME%-% %%LAST_NAME%-%
Date of Grant:
%%OPTION_DATE,'Month DD, YYYY'%-%
Shares subject to the Option:
%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
Option Price:
%%OPTION_PRICE,'$999,999,999.99'%-%
RECITALS
Pursuant to the terms of the employment engagement between Replimune, Inc. (the “Company”) and the Participant (as it
may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of an option to
acquire shares of Company common stock, $0.001 par value per share (“Company Stock”) to the Participant on the terms and
subject to the conditions set forth herein. The Committee has decided to make this nonqualified stock option grant as an
inducement material for the Participant to enter into employment with the Company and to align the Participant’s interests with
those of the Company and its stockholders. The grant of the option provided for herein is intended to constitute an “employment
inducement grant” as described in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, and is not being
issued under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as amended from time to time (the “Plan”).
Capitalized terms used herein and not otherwise defined will have the meanings set forth in the Plan.
1.
Grant of Option.
(a)
Grant. In accordance with the employment inducement grant exception to the shareholder-approval requirements
of the Nasdaq Stock Market set forth in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, the Company
hereby grants to the Participant a nonqualified stock option (the “Option”) to purchase the number of shares of Company Stock
set forth above (“Shares”) at the per-Share Exercise Price set forth above, on the terms and subject to the conditions set forth in
this Nonqualified Stock Option Grant Agreement (this “Agreement”) and, subject to Section 1(c) below, otherwise on terms
identical to the terms provided in the Plan. In the event of any conflict between this Agreement and the Plan, this Agreement shall
control. The Option is not intended to qualify as an incentive stock option pursuant to Section 422 of the Code. The Option shall
become exercisable according to Section 2 below. The Company shall timely file with the Securities and Exchange Commission
a registration statement on Form S-8 registering the Shares issuable pursuant to this Option.
DB1/ 119262344.2


(b)
Inducement Award. The Participant acknowledges that the grant of the Option hereunder satisfies in full the
Company’s obligation to provide the Participant with an option grant as described in the Employment Agreement. The Participant
acknowledges that the grant of the Option hereunder is intended to be in consideration for, in part, the restrictive covenants set
forth in the Employment Agreement.
(c)
Incorporation by Reference. It is understood that the Option is not being granted pursuant to the Plan; provided,
however, that this Agreement shall be construed and administered in a manner consistent with the provisions of the Plan as if
granted pursuant thereto, the terms of which are incorporated herein by reference (including, without limitation, any
interpretations, amendments, rules and regulations promulgated by the Committee from time to time pursuant to the Plan, which
shall be deemed to apply to the Option granted hereunder without any further action of the Committee, unless expressly provided
otherwise by the Committee). The Committee shall have final authority to interpret and construe the terms of this Agreement and
the Plan’s terms as they are incorporated herein by reference and deemed to apply to the Option granted hereunder, and to make
any and all determinations under them, and its decision shall be binding and conclusive upon the Participant and the Participant’s
beneficiaries in respect of any questions arising under the Plan or this Agreement. The Participant acknowledges that the
Participant has received a copy of the Plan, the official prospectus for the Plan, which is available by accessing the Company’s
intranet at www.replimune.com, and the official prospectus for this Agreement. The Participant also acknowledges that the
Participant had an opportunity to review the Plan and agrees to be bound by all the terms and provisions of the Plan, as
incorporated into this Agreement. Paper copies of the Plan, the official Plan prospectus and the prospectus for this Agreement are
available by contacting the Chief Financial Officer or the General Counsel of the Company. For the avoidance of doubt, neither
the Option granted hereunder nor any Shares issued upon the exercise of the Option shall reduce the number of Shares available
for issuance pursuant to Grants granted under the Plan.
2.
Exercisability of Option.
(a)
The Option shall become vested and exercisable according to the vesting table in Exhibit A, detailing the vesting
dates (each, an individual “Vesting Date”), provided that the Participant continues to be employed by, or provide approved
service to, the Employer from the Date of Grant until the applicable Vesting Date.
(b)
The vesting and exercisability of the Option is cumulative, but shall not exceed 100% of the Shares subject to the
Option.
(c)
If the Participant’s employment or service terminates on account of the Participant’s death or Disability before the
last Vesting Date, any unvested and unexercisable portion of the Option shall become fully vested and exercisable upon such
termination of employment or service.
(d)
In the event of a Change of Control, the provisions of the Plan applicable to a Change of Control shall apply to the
Option, and, in the event of a Change of Control, the Committee may take such actions as it deems appropriate as described in the
Plan.
-2-
DB1/ 119262344.2


In addition, if the Company is not the surviving corporation (or survives only as a subsidiary of another corporation) as a
result of the Change of Control and the Option is assumed by, or replaced with an award with comparable terms by, the surviving
corporation (or parent or subsidiary of the surviving corporation) and the Participant’s employment or service is terminated by the
Employer without Cause or by the Participant for Good Reason (if applicable) upon or within 12 months following a Change of
Control and before the Option is fully vested and exercisable in accordance with the vesting schedule set forth in Section 2(a)
above, any unvested and unexercisable portion of the Option shall become fully vested and exercisable upon such termination of
employment or service. In the event that the surviving corporation (or a parent or subsidiary of the surviving corporation) does
not assume or replace the Option with a grant that has comparable terms, and the Participant is employed by, or providing
services to, the Employer on the date of the Change of Control, any unvested and unexercisable portion of the Option shall
become fully vested and exercisable upon the date of the Change of Control.
3.
Term of Option.
(a)
The Option shall have a term of ten years from the Date of Grant and shall terminate at the expiration of that
period, unless it is terminated at an earlier date pursuant to the provisions of this Agreement or the applicable terms of the Plan.
Notwithstanding the foregoing, in the event that on the last business day of the term of the Option, the exercise of the Option is
prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider
trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition, unless
the Committee determines otherwise.
(b)
The Option shall automatically terminate upon the happening of the first of the following events:
(i)
The expiration of the 90-day period after the Participant ceases to be employed by, or provide service to,
the Employer, if the termination is for any reason other than Disability, death or Cause.
(ii)
The expiration of the one-year period after the Participant ceases to be employed by, or provide service to,
the Employer on account of the Participant’s Disability.
(iii)
The expiration of the one-year period after the Participant ceases to be employed by, or provide service to,
the Employer, if the Participant dies while employed by, or providing service to, the Employer or the Participant dies
within 90 days after the Participant ceases to be so employed by or to provide services to the Employer for any reason
other than Disability, death or Cause.
(iv)
The date on which the Participant ceases to be employed by, or provide service to, the Employer for Cause.
In addition, notwithstanding the prior provisions of this Section 3, if the Participant engages in conduct that constitutes
Cause after the Participant’s employment or service terminates, the Option shall immediately terminate.
-3-
DB1/ 119262344.2


Notwithstanding the foregoing, in no event may the Option be exercised after the date that is immediately before the tenth
anniversary of the Date of Grant, except as provided under Section 3(a) above. Any portion of the Option that is not exercisable
at the time the Participant ceases to be employed by, or provide approved service to, the Employer shall immediately terminate.
4.
Exercise Procedures.
(a)
Subject to the provisions of Sections 2 and 3 above, the Participant may exercise part or all of the exercisable
Option by giving the Company or its delegate written notice of intent to exercise, specifying the number of Shares as to which the
Option is to be exercised and such other information as the Company or its delegate may require.
The Participant shall pay the Exercise Price (i) in cash or check, (ii) unless the Committee determines otherwise, by
delivering shares of Company Stock owned by the Participant, which shall be valued at their Fair Market Value on the date of
exercise, or by attestation (in accordance with procedures prescribed by the Company) to ownership of shares of Company Stock
having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) if permitted by the Committee, by
payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or (iv) by such
other method as the Committee may approve, to the extent permitted by applicable law. The Committee may impose from time to
time such limitations as it deems appropriate on the use of shares of Company Stock to exercise the Option.
(b)
The obligation of the Company to deliver Shares upon exercise of the Option shall be subject to all applicable
laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate by the Committee,
including such actions as Company counsel shall deem necessary or appropriate to comply with relevant securities laws and
regulations.
(c)
All obligations of the Company under this Agreement shall be subject to the rights of the Employer as set forth in
the Plan to withhold amounts required to be withheld for any taxes, if applicable. The Participant shall be required to pay to the
Employer, or make other arrangements satisfactory to the Employer to provide for the payment of, any federal, state, local or
other taxes that the Employer is required to withhold with respect to the Option.
(d)
Upon exercise of the Option (or portion thereof), the Option (or portion thereof) will terminate and cease to be
outstanding.
5.
Restrictions on Exercise. Except as the Committee may otherwise permit, only the Participant may exercise the Option
during the Participant’s lifetime and, after the Participant’s death, the Option shall be exercisable (subject to the limitations
specified in the Plan) solely by the legal representatives of the Participant, or by the person who acquires the right to exercise the
Option by will or by the laws of descent and distribution, to the extent that the Option is exercisable pursuant to this Agreement.
-4-
DB1/ 119262344.2


6.
No Employment or Other Rights. The grant of the Option shall not confer upon the Participant any right to be retained by
or in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to terminate the
Participant’s employment or service at any time. The right of any Employer to terminate at will the Participant’s employment or
service at any time for any reason is specifically reserved.
7.
No Stockholder Rights. Neither the Participant, nor any person entitled to exercise the Participant’s rights in the event of
the Participant’s death, shall have any of the rights and privileges of a stockholder with respect to the Shares subject to the
Option, until certificates for Shares have been issued upon the exercise of the Option.
8.
Assignment and Transfers. Except as the Committee may otherwise permit, the rights and interests of the Participant
under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of the
Participant, by will or by the laws of descent and distribution. In the event of any attempt by the Participant to alienate, assign,
pledge, hypothecate, or otherwise dispose of the Option or any right hereunder, except as provided for in this Agreement, or in
the event of the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, the Company
may terminate the Option by notice to the Participant, and the Option and all rights hereunder shall thereupon become null and
void. The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the
Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned by the Company without the Participant’s
consent.
9.
Applicable Law. The validity, construction, interpretation and effect of this Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws provisions thereof.
10.
Notice. Any notice to the Company provided for in this instrument shall be addressed to the Company in care of the Chief
Financial Officer at the corporate headquarters of the Company, and any notice to the Participant shall be addressed to such
Participant at the current address shown on the payroll of the Employer, or to such other address as the Participant may designate
to the Employer in writing. Any notice shall be delivered by hand or enclosed in a properly sealed envelope addressed as stated
above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or by
the postal authority of the country in which the Participant resides or to an internationally recognized expedited mail courier.
11.
Company Policies. The Participant agrees that payment by the Participant shall be made in such manner and on such
terms and conditions as may be required by the Committee and the Employer shall be entitled to set off against the amount of any
such payment any amounts otherwise owed to the Participant by the Employer. In addition, the Participant agrees that the Option
shall be subject to any applicable clawback or recoupment policies, share trading policies and other policies that may be
implemented by the Board or imposed under applicable rule or regulation from time to time.
-5-
DB1/ 119262344.2


12.
Application of Section 409A of the Code. This Agreement is intended to be exempt from section 409A of the Code and to
the extent this Agreement is subject to section 409A of the Code, it will in all respects be administered in accordance with section
409A of the Code.
By electronic acceptance, the Participant hereby accepts the Option described in this Agreement, and agrees to be bound
by the terms of this Agreement. The Participant hereby agrees that all decisions and determinations of the Committee with
respect to the Option shall be final and binding.
-6-
DB1/ 119262344.2


Exhibit A
Vesting Schedule
Shares Vesting
Vesting Date
-7-
DB1/ 119262344.2


-8-
DB1/ 119262344.2


U.S. Form RSU Inducement Grant (April 2024)
REPLIMUNE GROUP, INC.
RESTRICTED STOCK UNIT GRANT AGREEMENT
Participant:
%%FIRST_NAME%-% %%LAST_NAME%-%
Date of Grant:
%%OPTION_DATE,'Month DD, YYYY'%-%
Restricted Units Granted:
%%TOTAL_SHARES_GRANTED,'999,999,999'%-%
RECITALS
Pursuant to the terms of the employment engagement between Replimune, Inc. (the “Company”) and the Participant (as it
may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of restricted
stock units to the Participant on the terms and subject to the conditions set forth herein. The Committee has decided to make this
grant of restricted stock units as an inducement material for the Participant to enter into employment with the Company and to
align the Participant’s interests with those of the Company and its stockholders. The grant of the restricted stock units provided
for herein is intended to constitute an “employment inducement grant” as described in Rule 5635(c)(4), or any successor
provision, of the Nasdaq Listing Rules, and is not being issued under the Replimune Group, Inc. 2018 Omnibus Incentive
Compensation Plan, as amended from time to time (the “Plan”). Capitalized terms used herein and not otherwise defined will
have the meanings set forth in the Plan.
1.
Grant of Stock Units.
(a)
Grant. In accordance with the employment inducement grant exception to the shareholder-approval requirements
of the Nasdaq Stock Market set forth in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, the Company
hereby grants to the Participant the number of restricted stock units set forth above (the “Stock Units”), on the terms and subject
to the conditions set forth in this Restricted Stock Unit Grant Agreement (this “Agreement”) and, subject to Section 1(c) below,
otherwise on terms identical to the terms provided in the Plan. In the event of any conflict between this Agreement and the Plan,
this Agreement shall control. Each Stock Unit represents the right of the Participant to receive a share of common stock, $0.001
par value per share, of the Company (“Company Stock”) on the applicable payment date set forth in Section 5 below. The
Company shall timely file with the Securities and Exchange Commission a registration statement on Form S-8 registering the
shares of Company Stock represented by the Stock Units.
(b)
Inducement Award. The Participant acknowledges that the grant of the Stock Units hereunder satisfies in full the
Company’s obligation to provide the Participant a restricted stock unit grant as described in the Employment Agreement. The
Participant acknowledges that the grant of the Stock Units hereunder is intended to be in consideration for, in part, the restrictive
covenants set forth in the Employment Agreement.
DB1/ 119264074.2


(c)
Incorporation by Reference. It is understood that the Stock Units are not being granted pursuant to the Plan;
provided, however, that this Agreement shall be construed and administered in a manner consistent with the provisions of the
Plan as if granted pursuant thereto, the terms of which are incorporated herein by reference (including, without limitation, any
interpretations, amendments, rules and regulations promulgated by the Committee from time to time pursuant to the Plan, which
shall be deemed to apply to the Stock Units granted hereunder without any further action of the Committee, unless expressly
provided otherwise by the Committee). The Committee shall have final authority to interpret and construe the terms of this
Agreement and the Plan’s terms as they are incorporated herein by reference and deemed to apply to the Stock Units granted
hereunder, and to make any and all determinations under them, and its decision shall be binding and conclusive upon the
Participant and the Participant’s beneficiaries in respect of any questions arising under the Plan or this Agreement. The
Participant acknowledges that the Participant has received a copy of the Plan, the official prospectus for the Plan, which is
available by accessing the Company’s intranet at www.replimune.com, and the official prospectus for this Agreement. The
Participant also acknowledges that the Participant had an opportunity to review the Plan and agrees to be bound by all the terms
and provisions of the Plan, as incorporated into this Agreement. Paper copies of the Plan, the official Plan prospectus, and the
official prospectus for this Agreement are available by contacting the Chief Financial Officer or the General Counsel of the
Company. For the avoidance of doubt, neither the Stock Units granted hereunder nor any shares of Company Stock issued upon
settlement of such Stock Units shall reduce the number of shares of Company Stock available for issuance pursuant to Grants
granted under the Plan.
2.
Stock Unit Account. Stock Units represent hypothetical shares of Company Stock, and not actual shares of stock.
The Company shall establish and maintain a Stock Unit account, as a bookkeeping account on its records, for the Participant and
shall record in such account the number of Stock Units granted to the Participant. No shares of Company Stock shall be issued to
the Participant at the time the grant is made, and the Participant shall not be, and shall not have any of the rights or privileges of,
a stockholder of the Company with respect to any Stock Units recorded in the Stock Unit account. The Participant shall not have
any interest in any fund or specific assets of the Company by reason of this award or the Stock Unit account established for the
Participant.
3.
Vesting.
(a)
The Stock Units shall become vested according to the vesting table in Exhibit A, detailing the vesting dates (each,
an individual “Vesting Date”), provided that the Participant continues to be employed by, or provide approved service to, the
Employer from the Date of Grant until the applicable Vesting Date. The following table defines which date is assigned as the
annual vesting date (the “Designated Vesting Date”) based on the grant date.
Grant Date
Designated Vesting Date*
January 1 – March 31
February 15  of the next calendar year
April 1 – June 30
May 15   of the next calendar year
th
th 
2
DB1/ 119264074.2


July 1 – September 30
August 15 of the next calendar year
October 1 – December 30
November 15  of the next calendar year
    * If a Designated Vesting Date falls on a weekend, federal holiday or any other day the Nasdaq Global Market is closed for trading, such
Designated Vesting Date will become the next active trading day of the Company’s common stock.
(b)
The vesting of the Stock Units shall be cumulative, but shall not exceed 100% of the Stock Units. If the foregoing
schedule would produce fractional Stock Units, the number of Stock Units that vest shall be rounded down to the nearest whole
Stock Unit and the fractional Stock Units will be accumulated so that the resulting whole Stock Units will be included in the
number of Stock Units that become vested on the last Vesting Date.
(c)
If the Participant’s employment or service terminates on account of the Participant’s death or Disability before the
last Vesting Date, any unvested Stock Units shall become fully vested upon such termination of employment or service.
(d)
In the event of a Change of Control, the provisions of the Plan applicable to a Change of Control shall apply to the
Stock Units, and, in the event of a Change of Control, the Committee may take such actions as it deems appropriate as described
in the Plan.
In addition, if the Company is not the surviving corporation (or survives only as a subsidiary of another corporation) as a
result of a Change of Control and the Stock Units are assumed by, or replaced with an award with comparable terms by, the
surviving corporation (or parent or subsidiary of the surviving corporation) and the Participant’s employment or service is
terminated by the Employer without Cause or by the Participant for Good Reason (if applicable) upon or within 12 months
following a Change of Control and before the Stock Units are fully vested in accordance with the vesting schedule set forth in
Section 3(a) above, any unvested Stock Units shall become fully vested upon such termination of employment or service. In the
event that the surviving corporation (or a parent or subsidiary of the surviving corporation) does not assume or replace the Stock
Units with an award with comparable terms, and the Participant is employed by, or providing services to, the Employer on the
date of the Change of Control, any unvested Stock Units shall become fully vested upon the date of the Change of Control.
4.
Termination of Stock Units. If the Participant ceases to be employed by, or provide approved service to, the
Employer for any reason before all of the Stock Units vest, any unvested Stock Units shall automatically terminate and shall be
forfeited as of the date of the Participant’s termination of employment or service. No payment shall be made with respect to any
unvested Stock Units that terminate as described in this Section 4.
th 
th
3
DB1/ 119264074.2


5.
Payment of Stock Units.
(a)
If and when the Stock Units vest, the Company shall issue to the Participant one share of Company Stock for each
vested Stock Unit, subject to applicable Withholding Taxes (as defined below). Payment shall be made within 30 days after the
applicable Vesting Date.
(b)
All obligations of the Company under this Agreement shall be subject to the rights of the Employer as described in
the Plan to withhold amounts required by law to be withheld for any federal (including FICA), state, local and other taxes with
respect to the payment of the Stock Units (“Withholding Taxes”). The Participant irrevocably (i) has elected, as of the Date of
Grant, to sell shares of Company Stock in an amount having an aggregate Fair Market Value equal to the Withholding Taxes, and
to allow the Company’s designated broker (the “Broker”) to remit the cash proceeds of such sale to the Employer (a “Sell to
Cover”) and (ii) directs the Employer to make a cash payment to satisfy the Withholding Taxes from the cash proceeds of such
sale directly to the appropriate taxing authorities. To the extent the Sell to Cover does not cover all Withholding Taxes due, the
Participant shall be required to pay to the Employer, or make other arrangements satisfactory to the Employer to provide for the
payment of, any Withholding Taxes that the Employer is required to withhold with respect to the Stock Units.
(c)
The obligation of the Company to deliver Company Stock following vesting of the Stock Units shall be subject to
all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate by the
Committee, including such actions as Company counsel shall deem necessary or appropriate to comply with relevant securities
laws and regulations.
6.
No Stockholder Rights. Neither the Participant, nor any person entitled to receive payment in the event of the
Participant’s death, shall have any of the rights and privileges of a stockholder with respect to shares of Company Stock,
including voting, dividend rights or dividend equivalent rights, until certificates for shares have been issued upon payment of
Stock Units. The Participant acknowledges that no election under Section 83(b) of the Code is available with respect to Stock
Units.
7.
No Employment or Other Rights. The grant of the Stock Units shall not confer upon the Participant any right to be
retained by or in the employ or service of any Employer and shall not interfere in any way with the right of any Employer to
terminate the Participant’s employment or service at any time. The right of any Employer to terminate at will the Participant’s
employment or service at any time for any reason is specifically reserved.
8.
Assignment and Transfers. Except as the Committee may otherwise permit, the rights and interests of the
Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death
of the Participant, by will or by the laws of descent and distribution. In the event of any attempt by the Participant to alienate,
assign, pledge, hypothecate, or otherwise dispose of the Stock Units or any right hereunder, except as provided for in this
Agreement, or in the event of the levy or any attachment, execution or similar process upon the rights or interests hereby
conferred, the
4
DB1/ 119264074.2


Company may terminate the Stock Units by notice to the Participant, and the Stock Units and all rights hereunder shall thereupon
become null and void. The rights and protections of the Company hereunder shall extend to any successors or assigns of the
Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned by the Company without
the Participant’s consent.
9.
Applicable Law; Jurisdiction. The validity, construction, interpretation and effect of this Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of laws
provisions thereof. Any action arising out of, or relating to, any of the provisions of this Agreement shall be brought only in the
United States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will not accept
jurisdiction, in any court of general jurisdiction in Boston, Massachusetts, and the jurisdiction of such court in any such
proceeding shall be exclusive. Notwithstanding the foregoing sentence, on and after the date a Participant receives shares of
Company Stock hereunder, the Participant will be subject to the jurisdiction provision set forth in the Company’s bylaws.
10.
Notice. Any notice to the Company provided for in this instrument shall be addressed to the Company in care of
the Chief Financial Officer at the corporate headquarters of the Company, and any notice to the Participant shall be addressed to
such Participant at the current address shown on the payroll of the Employer, or to such other address as the Participant may
designate to the Employer in writing. Any notice shall be delivered by hand, or enclosed in a properly sealed envelope addressed
as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal
Service or by the postal authority of the country in which the Participant resides or to an internationally recognized expedited
mail courier.
11.
Company Policies. The Participant agrees that payment to the Participant shall be made in such manner and on
such terms and conditions as may be required by the Committee and the Employer shall be entitled to set off against the amount
of any such payment any amounts otherwise owed to the Participant by the Employer, to the extent permitted by applicable law.
In addition, the Participant agrees that the Stock Units shall be subject to any applicable clawback or recoupment policies, share
trading policies and other policies that may be implemented by the Board or imposed under applicable rule or regulation from
time to time.
12.
Application of Section 409A of the Code. This Agreement is intended to be exempt from section 409A of the
Code under the “short-term deferral” exception and to the extent this Agreement is subject to section 409A of the Code, it will in
all respects be administered in accordance with section 409A of the Code.
By electronic acceptance, the Participant hereby accepts the award of Stock Units described in this Agreement, and agrees
to be bound by the terms of this Agreement. The Participant hereby agrees that all decisions and determinations of the Committee
with respect to the Stock Units shall be final and binding.
5
DB1/ 119264074.2


Exhibit A
Vesting Schedule
Units Vesting
Vesting Date
6
DB1/ 119264074.2


7
DB1/ 119264074.2


EXECUTION VERSION
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT
THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and
between Replimune, Inc. (the “Company”) and Sushil Patel (the “Executive”) as of March 25, 2024.
WHEREAS, the Company and the Executive are parties to an Amended and Restated Employment Agreement dated May 3,
2021, as amended as of December 30, 2022, pursuant to which the Executive provided services to the Company as the Chief Strategy
Officer (the “Prior Agreement”); and
WHEREAS, the Executive has accepted the Company's offer of employment as the Company’s Chief Executive Officer; and
WHEREAS, Section 26 of the Prior Agreement provides that the Prior Agreement may be changed only by a written document
signed by the Executive and the Company; and
WHEREAS, the Executive and the Company desire to amend, restate, supersede and replace in its entirety the Prior Agreement
effective on the Effective Date (as defined below) in connection with Executive's employment with the Company as the Company’s
Chief Executive Officer.
NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the
Company and the Executive hereby agree as follows:
1.
Employment.
(a)
Term. The initial term of this Agreement shall begin on April 1, 2024 (the “Effective Date”), and shall continue until
this Agreement is terminated, such period is referred to herein as the “Term.”
(b)
Duties.
(i)
During the Term, the Executive shall serve as the Chief Executive Officer of the Company, with duties,
responsibilities, and authority commensurate therewith, and shall report to the Board of Directors of the Company (the “Board”).
The Executive shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to
the Executive by the Board. The Executive shall, if requested, also serve as an officer or director of any affiliate of the Company
for no additional compensation.
(c)
Best Efforts. During the Term, the Executive shall devote the Executive’s best efforts and full time and attention to
promote the business and affairs of the Company and its affiliated entities, and may be engaged in other business activities only to the
extent the Executive has received the prior written consent of the Nominating and Corporate Governance Committee of the Board and
such activities do not materially interfere or conflict with the Executive’s obligations to the Company hereunder, including, without
limitation, obligations pursuant to Section 15 below. The foregoing shall not be construed as preventing the Executive from (i) serving
on civic, educational, philanthropic or charitable boards or committees and (ii) managing personal investments, so long as
DB1/ 144654048.4


such activities are permitted under the Company’s code of conduct and employment policies and do not violate the provisions of
Section 15 below.
(d)
Principal Place of Employment. The Executive understands and agrees that the Executive’s principal place of
employment will be in the Company’s offices located in Woburn, MA, or elsewhere in the Boston, MA metropolitan area, and that the
Executive will be required to travel for business in the course of performing the Executive’s duties for the Company. It is
acknowledged that the Executive may work remotely or with flexibility in scheduling days on site per Company policies adopted,
modified and/or changed from time to time in response to the pandemic and other such factors.
2.
Compensation.
(a)
Base Salary. During the Term, the Company shall pay the Executive a base salary (“Base Salary”), at the annualized
rate of $600,000, which shall be paid in installments in accordance with the Company’s normal payroll practices. The Executive’s Base
Salary shall be reviewed annually by the Board, pursuant to the normal performance review policies for senior-level executives, and
may be adjusted from time to time as the Compensation Committee of the Board (the “Compensation Committee”) deems appropriate.
The Compensation Committee may take any actions of the Board pursuant to this Agreement.
(b)
Annual Bonus. The Executive shall be eligible to be awarded an annual discretionary bonus for each fiscal year during
the Term, based on the establishment and attainment of individual and corporate performance goals and targets established by the
Compensation Committee (“Annual Bonus”) in its sole discretion. The target amount of the Executive’s Annual Bonus for any fiscal
year during the Term is 60% of the Executive’s annual Base Salary, and the actual Annual Bonus awarded, if any, may be more or less
than the target amount, as determined by the Compensation Committee in its sole discretion. Any Annual Bonus awarded shall be paid
after the end of the fiscal year to which it relates, at the same time and under the same terms and conditions as the bonuses for other
executives of the Company; provided that the Executive must be employed in good standing on the date that the Executive’s Annual
Bonus is paid. The Annual Bonus shall be subject to the terms of the annual bonus plan that is applicable to other executives of the
Company, including the requirement as to continued employment in good standing, subject to the provisions of Section 7 below.
(c)
Equity Awards. During the Term, the Executive will be eligible for grants under the Replimune Group, Inc. 2018
Omnibus Incentive Compensation Plan, as it may be amended from time to time, or any successor plan (the “Plan”), as determined by
the Compensation Committee, from time to time. Any grant under the Plan will be issued under and be governed by the terms and
provisions of the Plan and the applicable award agreement.
3.
Retirement and Welfare Benefits. During the Term, the Executive shall be eligible to participate in the Company’s health, life
insurance, long-term disability, retirement and welfare benefit plans, and programs available to similarly-situated employees of the
Company, pursuant to their respective terms and conditions. Nothing in this Agreement shall preclude the Company or any
2
DB1/ 144654048.4


Affiliate (as defined below) of the Company from terminating or amending any employee benefit plan or program from time to time
after the Effective Date.
4.
Paid Time-Off. During the Term, the Executive shall be entitled to paid time-off, in accordance with the Company’s paid time-
off policy, as may be in effect from time to time. Pursuant to the Company’s current paid time-off policy, executive-level employees
(Vice President and above) have the flexibility to take time off as needed to achieve balance in their lives and to deliver exceptional
results when on the job. Such flexible time-off policy does not designate a set number of vacation days per year, but allows the
Executive to set a schedule that works for the Executive, as long as it does not disrupt Company operations or otherwise conflict with
Executive’s responsibilities and obligations pursuant to Paragraph 1(c).
5.
Business Expenses. The Company shall reimburse the Executive for all necessary and reasonable travel (which does not
include commuting) and other business expenses incurred by the Executive in the performance of the Executive’s duties hereunder in
accordance with such policies and procedures as the Company may adopt generally from time to time for executives.
6.
Termination Without Cause; Resignation for Good Reason. The Company may terminate the Executive’s employment at any
time without Cause (as defined below) upon 30 days’ advance written notice, subject to the Company’s right to suspend or relieve the
Executive of all duties, or to pay in lieu with respect to all or any portion of such notice period. The Executive may initiate a
termination of employment by resigning for Good Reason, as described below. Upon termination by the Company without Cause or
resignation by the Executive for Good Reason, whether before or after the Change of Control Protection Period (as defined below), if
the Executive executes and does not revoke a written Release (as defined below), the Executive shall be entitled to receive, in lieu of
any payments under any severance plan or program for employees or executives, the following:
(a)
The Company will pay the Executive an amount equal to the Executive’s Base Salary. Payment shall be made over the
12-month period following the termination date in installments in accordance with the Company’s normal payroll practices. Payment
will begin within 60 days following the termination date, and any installments not paid between the termination date and the date of the
first payment will be paid with the first payment.
(b)
Provided that the Executive is eligible for and timely elects continuation coverage under COBRA, the Company will
pay on the Executive’s behalf the COBRA premiums for continued health care coverage under the Company’s group health plans for
the Executive and the Executive’s eligible dependents (“COBRA Payments”). The Company will pay the COBRA Payments for the
period from the Executive’s termination date until the earliest to occur of (i) the end of the 12-month period following the Executive’s
termination date; (ii) the date the Executive becomes eligible for group health insurance coverage through a subsequent employer; or
(iii) the date the Executive ceases to be eligible for COBRA coverage for any reason, including the Executive ceasing to pay the
applicable COBRA premiums (each of the events described in (ii) or (iii) in this Section 6(b) shall be referred to herein as a
“Disqualifying Event”). The Executive is required to notify the Company within five days of becoming aware that a Disqualifying
Event has occurred or will occur. The COBRA health care continuation coverage period under section 4980B of the
3
DB1/ 144654048.4


Internal Revenue Code of 1986, as amended (the “Code”), shall run concurrently with the period during which the Company pays the
COBRA Payments.
(c)
The Company shall pay any other amounts earned, accrued, and owing but not yet paid under Section 2 above and any
benefits accrued and due under any applicable benefit plans and programs of the Company (“Accrued Obligations”), regardless of
whether the Executive executes or revokes the Release.
7.
Change of Control Termination. Notwithstanding the foregoing, upon termination by the Company without Cause or
resignation by the Executive for Good Reason, in each case on or within 12 months following a Change of Control (as defined in the
Plan, or a successor to the Plan) (the “Change of Control Protection Period”), and provided that the Executive executes and does not
revoke a written Release, then the Executive shall be entitled to receive, in lieu of any payments under Section 6 of this Agreement or
any severance plan or program for employees or executives, the following:
(a)
The Company will pay the Executive an aggregate amount equal to two times the sum of (x) the Executive’s Base
Salary, plus (y) the Executive’s target Annual Bonus for the year of termination. Payment shall be made over the 24-month period
following the termination date in installments in accordance with the Company’s normal payroll practices. Payment will begin within
60 days following the termination date, and any installments not paid between the termination date and the date of the first payment
will be paid with the first payment.
(b)
Provided that the Executive is eligible for and timely elects continuation coverage under COBRA, the Company will
pay the COBRA Payments for the period from the Executive’s termination date until the earliest to occur of (i) the end of the 24-month
period following the Executive’s termination date or (ii) a Disqualifying Event. The Executive is required to notify the Company
within five days of becoming aware that a Disqualifying Event has occurred or will occur. The COBRA health care continuation
coverage period under section 4980B of the Code shall run concurrently with the period during which the Company pays the COBRA
Payments.
(c)
The Company shall pay any Accrued Obligations, regardless of whether the Executive executes or revokes the Release.
8.
Cause. The Company may immediately terminate the Executive’s employment at any time for Cause upon written notice to the
Executive, in which event all payments under this Agreement shall cease, except for any Accrued Obligations.
9.
Voluntary Resignation Without Good Reason. The Executive may voluntarily terminate employment without Good Reason
upon 30 days’ prior written notice to the Company, subject to the Company’s right to suspend or relieve Executive of all duties, or to
pay in lieu with respect to all or any portion of such notice period. In such event, after the effective date of such termination, no
payments shall be due under this Agreement, except that the Executive shall be entitled to any Accrued Obligations.
4
DB1/ 144654048.4


10.
Disability. If the Executive incurs a Disability during the Term, in accordance with applicable law, the Company may terminate
the Executive’s employment on or after the date of Disability. If the Executive’s employment terminates on account of Disability, the
Executive shall be entitled to receive any Accrued Obligations. For purposes of this Agreement, the term “Disability” shall mean the
Executive is eligible to receive long-term disability benefits under the Company’s long-term disability plan; provided that if the
Executive is not covered under the Company’s long-term disability plan, “Disability” shall mean the Executive is unable to perform the
essential functions of the job, with or without reasonable accommodation, by reason of any medically determinable physical or mental
impairment that can be expected to last for a continuous period of not less than six months, subject to applicable law.
11.
Death. If the Executive dies during the Term, the Executive’s employment shall terminate on the date of death and the
Company shall pay any Accrued Obligations to the Executive’s executor, legal representative, administrator or designated beneficiary,
as applicable. Otherwise, the Company shall have no further liability or obligation under this Agreement to the Executive’s executors,
legal representatives, administrators, heirs or assigns or any other person claiming under or through the Executive.
12.
Resignation of Positions. Effective as of the date of any termination of employment for any reason, the Executive will be
automatically deemed to resign from all Company-related positions, including as an officer and director of the Company and its
parents, subsidiaries and Affiliates, as applicable, and shall execute all documentation necessary to effectuate such resignation(s).
13.
Definitions. For purposes of this Agreement, the following terms shall have the following meanings:
(a)
“Cause” shall mean a determination by the Board that the Executive (i) has breached this Agreement or any
confidentiality, non-solicitation, non-competition or inventions assignment agreement or obligations with the Company; (ii) committed
an act of dishonesty, fraud, embezzlement or theft; (iii) engaged in conduct that causes, or is likely to cause, material damage to the
property or reputation of the Company; (iv) failed to perform satisfactorily the material duties of the Executive’s position (other than
by reason of Disability) after receipt of a written warning from the Board; (v) committed a felony or any crime of moral turpitude; or
(vi) materially failed to comply with the Company’s code of conduct or employment policies.
(b)
“Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent, other than
on account of the Executive’s Disability:
(i)
A material diminution by the Company of the Executive’s authority, duties or responsibilities;
(ii)
A material and permanent change in the geographic location at which the Executive must perform services
under this Agreement (which, for purposes of this Agreement, means relocation of the offices of the Company at which the Executive
is principally employed to a location that increases the Executive’s commute to work by more than 50 miles);
5
DB1/ 144654048.4


(iii)
A material diminution in the Executive’s Base Salary, other than a general reduction in Base Salary that affects
all similarly-situated executives in substantially the same proportions;
(iv)
Any action or inaction that constitutes a material breach by the Company of this Agreement; or
(v)
The Company terminates this Agreement for any reason other than Cause or Disability and does not offer the
Executive continued employment on substantially similar terms as set forth in this Agreement.
The Executive must provide written notice of termination for Good Reason to the Company within 30 days after the event constituting
Good Reason. The Company shall have a period of 30 days in which it may correct the act or failure to act that constitutes the grounds
for Good Reason as set forth in the Executive’s notice of termination. If the Company does not correct the act or failure to act, the
Executive’s employment will terminate for Good Reason on the first business day following the Company’s 30-day cure period. If the
Executive does not provide written notice of termination for Good Reason to the Company within 30 days after an event constituting
Good Reason, then the Executive will be deemed to have waived the Executive’s right to terminate for Good Reason with respect to
such event.
(c)
“Release” shall mean a separation agreement and general release of any and all claims against the Company and all
related parties with respect to all matters arising out of the Executive’s employment by the Company, and the termination thereof (other
than claims for any entitlements under the terms of this Agreement or under any plans or programs of the Company under which the
Executive has accrued and is due a benefit). The Release will be in a standard form determined by and acceptable to the Company and
shall include the Restrictive Covenants set forth in Section 15.
14.
Section 409A.
(a)
This Agreement is intended to comply with section 409A of the Code, and its corresponding regulations, or an
exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A
of the Code, to the extent applicable. Severance benefits under this Agreement are intended to be exempt from section 409A of the
Code under the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation pay” exception, to
the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required by section 409A of the Code,
if the Executive is considered a “specified employee” for purposes of section 409A of the Code and if payment of any amounts under
this Agreement is required to be delayed for a period of six months after separation from service pursuant to section 409A of the Code,
payment of such amounts shall be delayed as required by section 409A of the Code, and the accumulated amounts shall be paid in a
lump-sum payment within 10 days after the end of the six-month period. If the Executive dies during the postponement period prior to
the payment of benefits, the amounts withheld on account of section 409A of the Code shall be paid to the personal representative of
the Executive’s estate within 60 days after the date of the Executive’s death.
6
DB1/ 144654048.4


(b)
All payments to be made upon a termination of employment under this Agreement may only be made upon a
“separation from service,” if required under section 409A of the Code. For purposes of section 409A of the Code, each payment
hereunder shall be treated as a separate payment, and the right to a series of installment payments under this Agreement shall be treated
as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the calendar year of a
payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of
the Release, directly or indirectly, result in the Executive’s designating the calendar year of payment of any amounts of deferred
compensation subject to section 409A of the Code, and if a payment that is subject to execution of the Release could be made in more
than one taxable year, payment shall be made in the later taxable year.
(c)
All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with
the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement be for expenses
incurred during the period specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits
provided, during a fiscal year not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other fiscal
year, (iii) the reimbursement of an eligible expense be made no later than the last day of the fiscal year following the year in which the
expense is incurred, and (iv) the right to reimbursement or in-kind benefits not be subject to liquidation or exchange for another
benefit.
15.
Restrictive Covenants.
(a)
Non-Competition.
(i)
The Executive agrees that during the Executive’s employment with the Company and its Affiliates and the one-
year period following the date on which the Executive’s employment terminates for any reason (the “Restriction Period”), the
Executive will not, without the Board’s express written consent, engage (directly or indirectly) in any Competitive Business in the
Restricted Area. The term “Competitive Business” means any activities or services conducted by any third party with respect to the
research, development, marketing, manufacturing or sale of oncolytic immunotherapies that are similar to the activities or services the
Executive has performed (or gained Proprietary Information about (as defined below)) at any time during the last two years of the
Executive’s employment with the Company. The term “Restricted Area” means the United States of America, Canada and countries
within Europe, in respect of which the Company or any of its Affiliates has material business operations as of the date on which the
Executive’s employment terminates and in which the Executive has provided services or had a material presence or influence at any
time during the last two years of the Executive’s employment with the Company or its Affiliates.
(ii)
The Executive agrees that the offer of employment to be Chief Executive Officer of the Company, and the Base
Salary provided for in Section 2(a), the Annual Bonus percentage opportunity provided for in Section 2(b), the separation benefits
provided for in Section 6 and the Change of Control Termination benefits provided for in Section 7, are fair and reasonable
consideration for the Executive’s compliance with this Section 15(a). The Executive understands and
7
DB1/ 144654048.4


agrees that, given the nature of the business of the Company and its Affiliates and the Executive’s position with the Company, the
foregoing geographic scope is reasonable and appropriate, that by virtue of the Executive’s position and scope of responsibilities, the
Executive has and will provide services and will have a material presence or influence within the Restricted Area, and that more
limited geographical limitations on this non-competition covenant are therefore not appropriate. For purposes of this Agreement, the
term “Affiliate” means the Company’s sole shareholder, any subsidiary of the Company or other entity under common control with the
Company.
(iii)
The Company shall not enforce this Section 15(a) if it terminates the Executive’s employment without Cause as
defined in Section 13(a). The Executive shall not be entitled to any payments under Sections 6 or 7, however, unless the Executive
executes and does not revoke a Release containing the Restrictive Covenants set forth in Section 15, including a one-year post-
employment non-compete restriction.
(b)
Non-solicitation of Company Personnel. The Executive agrees that during the Restriction Period, the Executive will
not, either directly or through others, hire or attempt to hire any employee, consultant or independent contractor of the Company or its
Affiliates, or solicit or attempt to solicit any such person to change or terminate such person’s relationship with the Company or an
Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other person or business entity,
unless more than 12 months shall have elapsed between the last day of such person’s employment or service with the Company or
Affiliate and the first day of such solicitation or hiring or attempt to solicit or hire. If any employee, consultant or independent
contractor is hired or solicited by any entity that has hired or agreed to hire the Executive, such hiring or solicitation shall be
conclusively presumed to be a violation of this subsection (b).
(c)
Non-solicitation of Business Partners. The Executive agrees that during the Restriction Period, the Executive will not,
either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate for the benefit of a
Competitive Business, any (i) business partner or (ii) prospective business partner of the Company or an Affiliate who is or was
identified through leads developed during the course of the Executive’s employment or service with the Company, in each case, with
whom the Executive was involved as part of the Executive’s job responsibilities during the Executive’s employment or service with the
Company, or regarding whom the Executive learned Proprietary Information (as defined below) during the Executive’s employment or
service with the Company.
(d)
Proprietary Information. At all times, the Executive will hold in strictest confidence and will not disclose, use, lecture
upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or
publication may be required in connection with the Executive’s work for the Company or as described in Section 15(e) below, or unless
the Company expressly authorizes such disclosure in writing. “Proprietary Information” shall mean any and all confidential and/or
proprietary knowledge, data or information of the Company and its Affiliates and shareholders, including but not limited to
information relating to financial matters, investments, budgets, business plans, marketing plans, personnel matters, business contacts,
products, processes, know-how, designs, methods, improvements, discoveries, inventions, ideas, data, programs, and other works of
authorship. Proprietary Information does not include information
8
DB1/ 144654048.4


which (i) was disclosed in response to a valid order by a court or other governmental body, where the Executive provided the Company
with prior written notice of such disclosure, (ii) was or becomes generally available to the public other than as a result of disclosure by
the Executive or any of the Executive’s agents, advisors or representatives, (iii) was within the Executive’s possession prior to its being
furnished to the Executive by or on behalf of the Company, provided that the source of the information was not bound by a
confidentiality agreement with the Company or otherwise prohibited from transmitting the information to the Executive by a
contractual, legal or fiduciary obligation, or (iv) was or becomes available to the Executive on a non-confidential basis from a source
other than the Company or its representatives, provided that such source is not bound by a confidentiality agreement with the Company
or otherwise prohibited from transmitting the information to the Executive by a contractual, legal or fiduciary obligation.
(e)
Reports to Government Entities. Nothing in this Agreement shall prohibit or restrict the Executive from initiating
communications directly with, responding to any inquiry from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or filing a claim or assisting with an investigation directly with a self-regulatory
authority or a government agency or entity, including the Equal Employment Opportunity Commission, the Massachusetts
Commission Against Discrimination, the Department of Labor, the National Labor Relations Board, the Department of Justice, the
Securities and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority,
or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. The
Executive does not need the prior authorization of the Company to engage in conduct protected by this subsection, and the Executive
does not need to notify the Company that the Executive has engaged in such conduct. Please take notice that federal law provides
criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose trade secrets to
their attorneys, courts, or government officials in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and
1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation
for reporting a suspected violation of the law.
(f)
Work Made for Hire; Inventions Assignment. The Executive agrees that all inventions, innovations, improvements,
developments, methods, designs, analyses, reports, and all similar or related information which relates to the Company’s or its
Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived,
developed or made by the Executive while employed by the Company (“Work Product”) belong to the Company. The Executive
acknowledges that, by reason of being employed by the Company at the relevant times, to the extent permitted by law, all of the Work
Product consisting of copyrightable subject matter is “work made for hire” as defined in 17 U.S.C. § 101 and such copyrights are
therefore owned by the Company. To the extent that the foregoing does not apply, the Executive hereby irrevocably assigns to the
Company, for no additional consideration, the Executive’s entire right, title, and interest in and to all Work Product and intellectual
property rights therein, including, without limitation, the right to sue, counterclaim, and recover for all past, present, and future
infringement, misappropriation, or dilution thereof, and all rights corresponding thereto throughout the world. The Executive will
promptly disclose such Work Product to the Board and perform all actions reasonably requested by the Board (whether during or after
the Term) to establish
9
DB1/ 144654048.4


and confirm such ownership (including, without limitation, executing assignments, consents, powers of attorney and other
instruments). If requested by the Company, the Executive agrees to execute any inventions assignment and confidentiality agreement
that is required to be signed by Company employees generally. Nothing contained in this Agreement shall be construed to reduce or
limit the Company’s rights, title, or interest in any Work Product or intellectual property rights so as to be less in any respect than that
the Company would have had in the absence of this Agreement. The Executive understands that this Agreement does not, and shall not
be construed to, grant the Executive any license or right of any nature with respect to any Work Product or intellectual property rights
or any Proprietary Information, materials, software, or other tools made available to the Executive by the Company.
(g)
Return of Company Property. Upon termination of the Executive’s employment with the Company for any reason, and
at any earlier time the Company requests, the Executive will (i) deliver to the person designated by the Company all originals and
copies of all documents and property of the Company or an Affiliate that is in the Executive’s possession or under the Executive’s
control or to which the Executive may have access, (ii) deliver to the person designated by the Company all Company property,
including keys, key cards, access cards, identification cards, security devices, employer credit cards, network access devices,
computers, cell phones, smartphones, PDAs, pagers, fax machines, equipment, manuals, reports, files, books, compilations, work
product, e-mail messages, recordings, disks, thumb drives or other removable information storage devices, hard drives, and data, and
(iii) to the extent that the Executive made use of the Executive’s personal electronics (e.g., laptop, iPad, telephone, thumb drives, etc.)
during employment with the Company, permit the Company to delete all Company property and information from such personal
devices. The Executive will not reproduce or appropriate for the Executive’s own use, or for the use of others, any property, Proprietary
Information or Work Product.
(h)
Future Cooperation. The Executive agrees that, following the termination of the Executive’s employment, the
Executive will cooperate fully with the Company, upon request, in relation to (i) transitioning the Executive’s job duties to the
Executive’s successor and any other operational issues that may arise in connection with the Executive’s separation from employment;
and (ii) the Company’s defense, prosecution or other involvement in any continuing or future claims, lawsuits, charges, arbitrations, or
internal or external investigations (or audits or reviews of any type) arising out of events or matters that occurred during the
Executive’s employment by the Company or to which the Executive is otherwise a relevant witness.
(i)
Tolling. Notwithstanding the foregoing, should the Executive violate any of the restrictive covenants in this Section 15,
then the period of the Executive’s breach of such covenant (“Violation Period”) shall stop the running of the corresponding Restriction
Period. Once the Executive resumes compliance with the restrictive covenant, the Restriction Period applicable to such covenant shall
be extended for a period equal to the Violation Period so that the Company enjoys the full benefit of the Executive’s compliance with
the restrictive covenant for the duration of the corresponding Restriction Period.
16.
Legal and Equitable Remedies.
10
DB1/ 144654048.4


(a)
Because the Executive’s services are personal and unique and the Executive has had and will continue to have access to
and has become and will continue to become acquainted with the Proprietary Information of the Company and its Affiliates, and
because any breach by the Executive of any of the restrictive covenants contained in Section 15 would result in irreparable injury and
damage for which money damages would not provide an adequate remedy, the Company shall have the right to enforce Section 15 and
any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other
rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set forth in Section 15.
The Executive agrees that in any action in which the Company seeks injunction, specific performance or other equitable relief, the
Executive will not assert or contend that any of the provisions of Section 15 are unreasonable or otherwise unenforceable.
(b)
The Executive irrevocably and unconditionally (i) agrees that any legal proceeding arising out of this Agreement shall
be brought solely in the United States District Court for the District of Massachusetts, or if such court does not have jurisdiction or will
not accept jurisdiction, in any court of general jurisdiction in the Commonwealth of Massachusetts, (ii) consents to the exclusive
jurisdiction of such court in any such proceeding, and (iii) waives any objection to the laying of venue of any such proceeding in any
such court. The Executive also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other
papers.
(c)
Notwithstanding anything in this Agreement to the contrary, if the Executive breaches any of the Executive’s
obligations under Section 15, the Company shall be obligated to provide only the Accrued Obligations, and all payments under Section
2, Section 6, or Section 7 hereof, as applicable, shall cease. In such event, and in addition to any legal and equitable remedies permitted
by law, the Company may require that the Executive repay all amounts theretofore paid to the Executive pursuant to Sections 6 and 7
hereof (other than Sections 6(c) and 7(c)), and in such case, the Executive shall promptly repay such amounts on the terms determined
by the Company.
17.
Survival. The respective rights and obligations of the parties under this Agreement (including, but not limited to, under
Sections 15 and 16) shall survive any termination of the Executive’s employment or termination or expiration of this Agreement to the
extent necessary to the intended preservation of such rights and obligations.
18.
No Mitigation or Set-Off. In no event shall the Executive be obligated to seek other employment or take any other action by
way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not
be reduced regardless of whether the Executive obtains other employment. The Company’s obligation to make the payments provided
for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without
limitation, any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Executive or others.
19.
Section 280G. In the event of a change in ownership or control under section 280G of the Code, if it shall be determined that
any payment or distribution in the nature of compensation (within the meaning of section 280G(b)(2) of the Code) to or for the benefit
of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a
“Payment”), would constitute an “excess parachute payment” within the meaning of section 280G of
11
DB1/ 144654048.4


the Code, the aggregate present value of the Payments under the Agreement shall be reduced (but not below zero) to the Reduced
Amount (defined below) if and only if the Accounting Firm (described below) determines that the reduction will provide the Executive
with a greater net after-tax benefit than would no reduction. No reduction shall be made unless the reduction would provide the
Executive with a greater net after-tax benefit. The determinations under this Section shall be made as follows:
(a)
The “Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present value of
Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below),
determined in accordance with section 280G(d)(4) of the Code. The term “Excise Tax” means the excise tax imposed under section
4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.
(b)
Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the
reduction in the economic value deliverable to the Executive. Where more than one payment has the same value for this purpose and
they are payable at different times, they will be reduced on a pro rata basis. Only amounts payable under this Agreement shall be
reduced pursuant to this Section.
(c)
All determinations to be made under this Section shall be made by an independent certified public accounting firm
selected by the Company and agreed to by the Executive immediately prior to the change-in-ownership or -control transaction (the
“Accounting Firm”). The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and
the Executive within 10 days of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company
and the Executive. All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section
shall be borne solely by the Company.
20.
Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in
connection herewith shall be in writing and shall be deemed to have been given when hand-delivered or mailed by registered or
certified mail, as follows (provided that notice of change of address shall be deemed given only when received):
If to the Company, to:
Replimune, Inc.
500 Unicorn Park Drive
Woburn, MA 01801
Attn: Legal
with a copy to:
Morgan, Lewis & Bockius LLP
One Federal Street
Boston, MA 02110
12
DB1/ 144654048.4


Attn: Benjamin Stein
If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or
the Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in
this Section.
21.
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall
withhold from any payments under this Agreement all federal, state, and local taxes as the Company is required to withhold pursuant to
any law or governmental rule or regulation. The Executive shall bear all expense of, and be solely responsible for, all federal, state, and
local taxes due with respect to any payment received by the Executive under this Agreement.
22.
Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any
other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this
Agreement or now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or power
under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.
23.
Assignment. All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be
enforceable by the respective heirs, executors, administrators, legal representatives, successors, and assigns of the parties hereto, except
that the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be assignable or
delegable in whole or in part by the Executive. The Company may assign its rights, together with its obligations hereunder, in
connection with any sale, transfer or other disposition of all or substantially all of its business and assets, and such rights and
obligations shall inure to, and be binding upon, any successor to the business or any successor to substantially all of the assets of the
Company, whether by merger, purchase of stock or assets or otherwise, which successor shall expressly assume such obligations, and
the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not limited to those under
Section 15, will continue to apply in favor of the successor.
24.
Company Policies. This Agreement and the compensation payable hereunder shall be subject to any applicable clawback or
recoupment policies, including the Replimune Group, Inc. Compensation Recoupment Policy, share trading policies, and other policies
that may be implemented by the Board from time to time with respect to officers of the Company.
25.
Indemnification. In the event the Executive is made, or threatened to be made, a party to any legal action or proceeding,
whether civil or criminal, including any governmental or regulatory proceedings or investigations, by reason of the fact that the
Executive is or was a director or officer of the Company or any of its Affiliates, the Executive shall be indemnified by the Company,
and the Company shall pay the Executive’s related expenses when and as incurred, to the fullest extent permitted by applicable law and
the Company’s articles of incorporation and bylaws; provided, however, the Executive shall not be entitled to indemnity to the extent
any such legal action,
13
DB1/ 144654048.4


proceeding or investigation arises out of or relates to any act or omission by the Executive determined to be the result of the
Executive’s own gross negligence, fraud, willful or intentional misconduct or your breach of any law or fiduciary obligations, or any
claims brought by the Executive against the Company or any of its Affiliates or any counterclaims brought by the Company or any of
its Affiliates against the Executive. During the Executive’s employment with the Company or any of its Affiliates and after termination
of employment for any reason, the Company shall cover the Executive under the Company’s directors’ and officers’ insurance policy
applicable to other officers and directors according to the terms of such policy. The Executive agrees to notify the Company promptly
upon becoming aware of any claim or potential claim asserted against the Executive arising from the Executive’s performance of the
Executive’s job duties.
26.
Entire Agreement; Amendment. This Agreement sets forth the entire agreement of the parties hereto and supersedes any and all
prior agreements and understandings concerning the Executive’s employment by the Company, including the Prior Agreement. This
Agreement may be changed only by a written document signed by the Executive and the Company.
27.
Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to
be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of
this Agreement, which can be given effect without the invalid or unenforceable provision or application, and shall not invalidate or
render unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable
with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.
28.
Governing Law; Forum. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive
and procedural laws of Massachusetts without regard to rules governing conflicts of law. Any lawsuit arising under this Agreement or
employment with the Company shall be brought solely in a state or federal court located in Massachusetts.
29.
Acknowledgements. The Executive acknowledges (a) that the Company hereby advises the Executive to consult with legal
counsel prior to signing this Agreement, (b) that the Executive has had a full and adequate opportunity to read and understand the
terms and conditions contained in this Agreement, (c) that the Executive has been provided with this Agreement a minimum of 10
business days prior to the date this Agreement becomes effective, and (d) that the post-employment non-competition and non-
solicitation provisions are supported by fair and reasonable consideration.
30.
Counterparts. This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of
which shall be an original, but all of which together shall constitute one instrument.
(Signature Page Follows)
14
DB1/ 144654048.4


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
REPLIMUNE, INC.
____/s/ Philip Astley-Sparke______
Name: Philip Astley-Sparke
Title: Chief Executive Officer
Date: March 25, 2024
EXECUTIVE
          /s/ Sushil Patel        
Name: Sushil Patel
Date: March 25, 2024
15
DB1/ 144654048.4


EXECUTION VERSION
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by
and between Replimune, Inc. (the “Company”) and Philip Astley-Sparke (the “Executive”) as of March 25, 2024.
WHEREAS, the Company and the Executive are parties to an Amended and Restated Employment Agreement dated
November 2, 2021 pursuant to which the Executive provided services to the Company as the Chief Executive Officer (the “Prior
Agreement”); and
WHEREAS, the Executive has accepted the Company's offer of employment as the Company’s Executive Chairman; and
WHEREAS, Section 26 of the Prior Agreement provides that the Prior Agreement may be changed only by a written
document signed by the Executive and the Company; and
WHEREAS, the Executive and the Company desire to amend, restate, supersede and replace in its entirety the Prior
Agreement effective on the Effective Date (as defined below) in connection with Executive's employment with the Company as
the Company’s Executive Chairman.
NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth,
the Company and the Executive hereby agree as follows:
1.
Employment.
(a)
Term. The initial term of this Agreement shall begin on April 1, 2024 (the “Effective Date”), and shall continue
until this Agreement is terminated, such period is referred to herein as the “Term.”
(b)
Duties.
(i)
During the Term, the Executive shall serve as the Executive Chairman of the Company on a part-time basis
and reporting to the Board of Directors of the Company (the “Board”). In such position, the Executive shall have such duties,
authority and responsibility as shall be determined from time to time by the Board, which duties, authority and responsibility are
consistent with the Executive’s position. The Executive shall, if requested, also serve as an officer or director of any affiliate of
the Company for no additional compensation. The Executive agrees and acknowledges that the Executive’s transition from Chief
Executive Officer to Executive Chairman does not constitute Good Reason under the Prior Agreement.
(c)
Best Efforts. During the Term, the Executive shall devote on average a minimum of 40% of the Executive’s
working hours per week (and in any event not less than 20 hours per week) to the Company. During this time, the Executive shall
devote the Executive’s best efforts and attention to promote the business and affairs of the Company and its affiliated entities, and
DB1/ 144657598.4


may be engaged in other business activities only to the extent the Executive has received the prior written consent of the
Nominating and Corporate Governance Committee of the Board and such activities do not materially interfere or conflict with the
Executive’s obligations to the Company hereunder, including, without limitation, obligations pursuant to Section 15 below. The
foregoing shall not be construed as preventing the Executive from (i) serving on civic, educational, philanthropic or charitable
boards or committees and (ii) managing personal investments, so long as such activities are permitted under the Company’s code
of conduct and employment policies and do not violate the provisions of Section 15 below.
(d)
Principal Place of Employment. The Executive understands and agrees that the Executive’s principal place of
employment will be in the Company’s offices located in Woburn, MA, or elsewhere in the Boston, MA metropolitan area, and
that the Executive will be required to travel for business in the course of performing the Executive’s duties for the Company. It is
acknowledged that the Executive may work remotely or with flexibility in scheduling days on site per Company policies adopted,
modified and/or changed from time to time in response to the pandemic and other such factors.
2.
Compensation.
(a)
Base Salary. During the Term, the Company shall pay the Executive a base salary (“Base Salary”), at the
annualized rate of $268,686, which shall be paid in installments in accordance with the Company’s normal payroll practices. The
Executive’s Base Salary shall be reviewed annually by the Board, pursuant to the normal performance review policies for senior-
level executives, and may be adjusted from time to time as the Compensation Committee of the Board (the “Compensation
Committee”) deems appropriate. The Compensation Committee may take any actions of the Board pursuant to this Agreement.
(b)
Annual Bonus. The Executive shall be eligible to be awarded an annual discretionary bonus for each fiscal year
during the Term, based on the establishment and attainment of individual and corporate performance goals and targets established
by the Compensation Committee (“Annual Bonus”) in its sole discretion. The target amount of the Executive’s Annual Bonus for
any fiscal year during the Term is 60% of the Executive’s annual Base Salary, and the actual Annual Bonus awarded, if any, may
be more or less than the target amount, as determined by the Compensation Committee in its sole discretion. Any Annual Bonus
awarded shall be paid after the end of the fiscal year to which it relates, at the same time and under the same terms and conditions
as the bonuses for other executives of the Company; provided that the Executive must be employed in good standing on the date
that the Executive’s Annual Bonus is paid. The Annual Bonus shall be subject to the terms of the annual bonus plan that is
applicable to other executives of the Company, including the requirement as to continued employment in good standing, subject
to the provisions of Section 7 below.
(c)
Equity Awards. During the Term, the Executive may be eligible for grants under the Replimune Group, Inc. 2018
Omnibus Incentive Compensation Plan, as it may be amended from time to time, or any successor plan (the “Plan”), as
determined by the Compensation
2
DB1/ 144657598.4


Committee, from time to time. Any grant under the Plan will be issued under and be governed by the terms and provisions of the
Plan and the applicable award agreement.
3.
Retirement and Welfare Benefits. During the Term, the Executive shall be eligible to participate in the Company’s health,
life insurance, long-term disability, retirement and welfare benefit plans, and programs available to similarly-situated employees
of the Company, pursuant to their respective terms and conditions. Nothing in this Agreement shall preclude the Company or any
Affiliate (as defined below) of the Company from terminating or amending any employee benefit plan or program from time to
time after the Effective Date.
4.
Paid Time-Off. During the Term, the Executive shall be entitled to paid time-off, in accordance with the Company’s paid
time-off policy, as may be in effect from time to time. Pursuant to the Company’s current paid time-off policy, executive-level
employees (Vice President and above) have the flexibility to take time off as needed to achieve balance in their lives and to
deliver exceptional results when on the job. Such flexible time-off policy does not designate a set number of vacation days per
year, but allows the Executive to set a schedule that works for the Executive, as long as it does not disrupt Company operations or
otherwise conflict with Executive’s responsibilities and obligations pursuant to Paragraph 1(c).
5.
Business Expenses. The Company shall reimburse the Executive for all necessary and reasonable travel (which does not
include commuting) and other business expenses incurred by the Executive in the performance of the Executive’s duties
hereunder in accordance with such policies and procedures as the Company may adopt generally from time to time for
executives.
6.
Termination Without Cause; Resignation for Good Reason. The Company may terminate the Executive’s employment at
any time without Cause (as defined below) upon 30 days’ advance written notice, subject to the Company’s right to suspend or
relieve the Executive of all duties, or to pay in lieu with respect to all or any portion of such notice period. The Executive may
initiate a termination of employment by resigning for Good Reason, as described below. Upon termination by the Company
without Cause or resignation by the Executive for Good Reason, whether before or after the Change of Control Protection Period
(as defined below), if the Executive executes and does not revoke a written Release (as defined below), the Executive shall be
entitled to receive, in lieu of any payments under any severance plan or program for employees or executives, the following:
(a)
The Company will pay the Executive an amount equal to the Executive’s Base Salary. Payment shall be made over
the 12-month period following the termination date in installments in accordance with the Company’s normal payroll practices.
Payment will begin within 60 days following the termination date, and any installments not paid between the termination date
and the date of the first payment will be paid with the first payment.
(b)
Provided that the Executive is eligible for and timely elects continuation coverage under COBRA, the Company
will pay on the Executive’s behalf the COBRA premiums for continued health care coverage under the Company’s group health
plans for the Executive and the Executive’s eligible dependents (“COBRA Payments”). The Company will pay the COBRA
3
DB1/ 144657598.4


Payments for the period from the Executive’s termination date until the earliest to occur of (i) the end of the 12-month period
following the Executive’s termination date; (ii) the date the Executive becomes eligible for group health insurance coverage
through a subsequent employer; or (iii) the date the Executive ceases to be eligible for COBRA coverage for any reason,
including the Executive ceasing to pay the applicable COBRA premiums (each of the events described in (ii) or (iii) in this
Section 6(b) shall be referred to herein as a “Disqualifying Event”). The Executive is required to notify the Company within five
days of becoming aware that a Disqualifying Event has occurred or will occur. The COBRA health care continuation coverage
period under section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”), shall run concurrently with the
period during which the Company pays the COBRA Payments.
(c)
The Company shall pay any other amounts earned, accrued, and owing but not yet paid under Section 2 above and
any benefits accrued and due under any applicable benefit plans and programs of the Company (“Accrued Obligations”),
regardless of whether the Executive executes or revokes the Release.
7.
Change of Control Termination. Notwithstanding the foregoing, upon termination by the Company without Cause or
resignation by the Executive for Good Reason, in each case on or within 12 months following a Change of Control (as defined in
the Plan, or a successor to the Plan) (the “Change of Control Protection Period”), and provided that the Executive executes and
does not revoke a written Release, then the Executive shall be entitled to receive, in lieu of any payments under Section 6 of this
Agreement or any severance plan or program for employees or executives, the following:
(a)
The Company will pay the Executive an aggregate amount equal to two times the sum of (x) the Executive’s Base
Salary, plus (y) the Executive’s target Annual Bonus for the year of termination. Payment shall be made over the 24-month period
following the termination date in installments in accordance with the Company’s normal payroll practices. Payment will begin
within 60 days following the termination date, and any installments not paid between the termination date and the date of the first
payment will be paid with the first payment.
(b)
Provided that the Executive is eligible for and timely elects continuation coverage under COBRA, the Company
will pay the COBRA Payments for the period from the Executive’s termination date until the earliest to occur of (i) the end of the
24-month period following the Executive’s termination date or (ii) a Disqualifying Event. The Executive is required to notify the
Company within five days of becoming aware that a Disqualifying Event has occurred or will occur. The COBRA health care
continuation coverage period under section 4980B of the Code shall run concurrently with the period during which the Company
pays the COBRA Payments.
(c)
The Company shall pay any Accrued Obligations, regardless of whether the Executive executes or revokes the
Release.
4
DB1/ 144657598.4


8.
Cause. The Company may immediately terminate the Executive’s employment at any time for Cause upon written notice
to the Executive, in which event all payments under this Agreement shall cease, except for any Accrued Obligations.
9.
Voluntary Resignation Without Good Reason. The Executive may voluntarily terminate employment without Good
Reason upon 30 days’ prior written notice to the Company, subject to the Company’s right to suspend or relieve Executive of all
duties, or to pay in lieu with respect to all or any portion of such notice period. In such event, after the effective date of such
termination, no payments shall be due under this Agreement, except that the Executive shall be entitled to any Accrued
Obligations.
10.
Disability. If the Executive incurs a Disability during the Term, in accordance with applicable law, the Company may
terminate the Executive’s employment on or after the date of Disability. If the Executive’s employment terminates on account of
Disability, the Executive shall be entitled to receive any Accrued Obligations. For purposes of this Agreement, the term
“Disability” shall mean the Executive is eligible to receive long-term disability benefits under the Company’s long-term disability
plan; provided that if the Executive is not covered under the Company’s long-term disability plan, “Disability” shall mean the
Executive is unable to perform the essential functions of the job, with or without reasonable accommodation, by reason of any
medically determinable physical or mental impairment that can be expected to last for a continuous period of not less than six
months, subject to applicable law.
11.
Death. If the Executive dies during the Term, the Executive’s employment shall terminate on the date of death and the
Company shall pay any Accrued Obligations to the Executive’s executor, legal representative, administrator or designated
beneficiary, as applicable. Otherwise, the Company shall have no further liability or obligation under this Agreement to the
Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through the
Executive.
12.
Resignation of Positions. Effective as of the date of any termination of employment for any reason, the Executive will be
automatically deemed to resign from all Company-related positions, including as an officer and director of the Company and its
parents, subsidiaries and Affiliates, as applicable, and shall execute all documentation necessary to effectuate such resignation(s).
13.
Definitions. For purposes of this Agreement, the following terms shall have the following meanings:
(a)
“Cause” shall mean a determination by the Board that the Executive (i) has breached this Agreement or any
confidentiality, non-solicitation, non-competition or inventions assignment agreement or obligations with the Company; (ii)
committed an act of dishonesty, fraud, embezzlement or theft; (iii) engaged in conduct that causes, or is likely to cause, material
damage to the property or reputation of the Company; (iv) failed to perform satisfactorily the material duties of the Executive’s
position (other than by reason of Disability) after receipt of a
5
DB1/ 144657598.4


written warning from the Board; (v) committed a felony or any crime of moral turpitude; or (vi) materially failed to comply with
the Company’s code of conduct or employment policies.
(b)
“Good Reason” shall mean the occurrence of one or more of the following without the Executive’s consent, other
than on account of the Executive’s Disability:
(i)
A material diminution by the Company of the Executive’s authority, duties or responsibilities;
(ii)
A material and permanent change in the geographic location at which the Executive must perform services
under this Agreement (which, for purposes of this Agreement, means relocation of the offices of the Company at which the
Executive is principally employed to a location that increases the Executive’s commute to work by more than 50 miles);
(iii)
A material diminution in the Executive’s Base Salary, other than a general reduction in Base Salary that
affects all similarly-situated executives in substantially the same proportions; or
(iv)
Any action or inaction that constitutes a material breach by the Company of this Agreement.
The Executive must provide written notice of termination for Good Reason to the Company within 30 days after the event
constituting Good Reason. The Company shall have a period of 30 days in which it may correct the act or failure to act that
constitutes the grounds for Good Reason as set forth in the Executive’s notice of termination. If the Company does not correct the
act or failure to act, the Executive’s employment will terminate for Good Reason on the first business day following the
Company’s 30-day cure period. If the Executive does not provide written notice of termination for Good Reason to the Company
within 30 days after an event constituting Good Reason, then the Executive will be deemed to have waived the Executive’s right
to terminate for Good Reason with respect to such event.
(c)
“Release” shall mean a separation agreement and general release of any and all claims against the Company and
all related parties with respect to all matters arising out of the Executive’s employment by the Company, and the termination
thereof (other than claims for any entitlements under the terms of this Agreement or under any plans or programs of the Company
under which the Executive has accrued and is due a benefit). The Release will be in a standard form determined by and
acceptable to the Company and shall include the Restrictive Covenants set forth in Section 15.
14.
Section 409A.
(a)
This Agreement is intended to comply with section 409A of the Code, and its corresponding regulations, or an
exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by section
409A of the Code, to the extent applicable. Severance benefits under this Agreement are intended to be exempt from section
6
DB1/ 144657598.4


409A of the Code under the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation
pay” exception, to the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required by
section 409A of the Code, if the Executive is considered a “specified employee” for purposes of section 409A of the Code and if
payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service
pursuant to section 409A of the Code, payment of such amounts shall be delayed as required by section 409A of the Code, and
the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period. If the
Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of section
409A of the Code shall be paid to the personal representative of the Executive’s estate within 60 days after the date of the
Executive’s death.
(b)
All payments to be made upon a termination of employment under this Agreement may only be made upon a
“separation from service,” if required under section 409A of the Code. For purposes of section 409A of the Code, each payment
hereunder shall be treated as a separate payment, and the right to a series of installment payments under this Agreement shall be
treated as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the calendar
year of a payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the
Executive’s execution of the Release, directly or indirectly, result in the Executive’s designating the calendar year of payment of
any amounts of deferred compensation subject to section 409A of the Code, and if a payment that is subject to execution of the
Release could be made in more than one taxable year, payment shall be made in the later taxable year.
(c)
All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance
with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement be
for expenses incurred during the period specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or
in-kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement, or in-kind benefits to be
provided, in any other fiscal year, (iii) the reimbursement of an eligible expense be made no later than the last day of the fiscal
year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits not be subject to
liquidation or exchange for another benefit.
15.
Restrictive Covenants.
(a)
Non-competition.
(i)
The Executive agrees that during the Executive’s employment with the Company and its Affiliates and the
one-year period following the date on which the Executive’s employment terminates for any reason (the “Restriction Period”),
the Executive will not, without the Board’s express written consent, engage (directly or indirectly) in any Competitive Business
in the Restricted Area. The term “Competitive Business” means any activities or services conducted by any third party with
respect to the research, development, marketing,
7
DB1/ 144657598.4


manufacturing or sale of oncolytic immunotherapies that are similar to the activities or services the Executive has performed (or
gained Proprietary Information about (as defined below)) at any time during the last two years of the Executive’s employment
with the Company. The term “Restricted Area” means the United States of America, Canada and countries within Europe, in
respect of which the Company or any of its Affiliates has material business operations as of the date on which the Executive’s
employment terminates and in which the Executive has provided services or had a material presence or influence at any time
during the last two years of the Executive’s employment with the Company or its Affiliates.
(ii)
The Executive agrees that the Base Salary provided for in Section 2(a), the Annual Bonus percentage
opportunity provided for in Section 2(b), the separation benefits provided for in Section 6 and the Change of Control Termination
benefits provided for in Section 7, are fair and reasonable consideration for the Executive’s compliance with this Section 15(a).
The Executive understands and agrees that, given the nature of the business of the Company and its Affiliates and the Executive’s
position with the Company, the foregoing geographic scope is reasonable and appropriate, that by virtue of the Executive’s
position and scope of responsibilities, the Executive has and will provide services and will have a material presence or influence
within the Restricted Area, and that more limited geographical limitations on this non-competition covenant are therefore not
appropriate. For purposes of this Agreement, the term “Affiliate” means the Company’s sole shareholder, any subsidiary of the
Company or other entity under common control with the Company.
(iii)
The Company shall not enforce this Section 15(a) if it terminates the Executive’s employment without
Cause as defined in Section 13(a). The Executive shall not be entitled to any payments under Sections 6 or 7, however, unless the
Executive executes and does not revoke a Release containing the Restrictive Covenants set forth in Section 15, including a one-
year post-employment non-compete restriction.
(b)
Non-solicitation of Company Personnel. The Executive agrees that during the Restriction Period, the Executive
will not, either directly or through others, hire or attempt to hire any employee, consultant or independent contractor of the
Company or its Affiliates, or solicit or attempt to solicit any such person to change or terminate such person’s relationship with
the Company or an Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other
person or business entity, unless more than 12 months shall have elapsed between the last day of such person’s employment or
service with the Company or Affiliate and the first day of such solicitation or hiring or attempt to solicit or hire. If any employee,
consultant or independent contractor is hired or solicited by any entity that has hired or agreed to hire the Executive, such hiring
or solicitation shall be conclusively presumed to be a violation of this subsection (b).
(c)
Non-solicitation of Business Partners. The Executive agrees that during the Restriction Period, the Executive will
not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate for the benefit of a
Competitive Business, any (i) business partner or (ii) prospective business partner of the Company or an Affiliate who is
8
DB1/ 144657598.4


or was identified through leads developed during the course of the Executive’s employment or service with the Company, in each
case, with whom the Executive was involved as part of the Executive’s job responsibilities during the Executive’s employment or
service with the Company, or regarding whom the Executive learned Proprietary Information (as defined below) during the
Executive’s employment or service with the Company.
(d)
Proprietary Information. At all times, the Executive will hold in strictest confidence and will not disclose, use,
lecture upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such
disclosure, use or publication may be required in connection with the Executive’s work for the Company or as described in
Section 15(e) below, or unless the Company expressly authorizes such disclosure in writing. “Proprietary Information” shall
mean any and all confidential and/or proprietary knowledge, data or information of the Company and its Affiliates and
shareholders, including but not limited to information relating to financial matters, investments, budgets, business plans,
marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods, improvements,
discoveries, inventions, ideas, data, programs, and other works of authorship. Proprietary Information does not include
information which (i) was disclosed in response to a valid order by a court or other governmental body, where the Executive
provided the Company with prior written notice of such disclosure, (ii) was or becomes generally available to the public other
than as a result of disclosure by the Executive or any of the Executive’s agents, advisors or representatives, (iii) was within the
Executive’s possession prior to its being furnished to the Executive by or on behalf of the Company, provided that the source of
the information was not bound by a confidentiality agreement with the Company or otherwise prohibited from transmitting the
information to the Executive by a contractual, legal or fiduciary obligation, or (iv) was or becomes available to the Executive on
a non-confidential basis from a source other than the Company or its representatives, provided that such source is not bound by a
confidentiality agreement with the Company or otherwise prohibited from transmitting the information to the Executive by a
contractual, legal or fiduciary obligation.
(e)
Reports to Government Entities. Nothing in this Agreement shall prohibit or restrict the Executive from initiating
communications directly with, responding to any inquiry from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or filing a claim or assisting with an investigation directly with a self-
regulatory authority or a government agency or entity, including the Equal Employment Opportunity Commission, the
Massachusetts Commission Against Discrimination, the Department of Labor, the National Labor Relations Board, the
Department of Justice, the Securities and Exchange Commission, Congress, any agency Inspector General or any other federal,
state or local regulatory authority, or from making other disclosures that are protected under the whistleblower provisions of state
or federal law or regulation. The Executive does not need the prior authorization of the Company to engage in conduct protected
by this subsection, and the Executive does not need to notify the Company that the Executive has engaged in such conduct.
Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret
misappropriation to individuals who disclose trade secrets to their attorneys, courts, or government officials in certain,
confidential circumstances that are set forth
9
DB1/ 144657598.4


at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in
connection with a lawsuit for retaliation for reporting a suspected violation of the law.
(f)
Work Made for Hire; Inventions Assignment. The Executive agrees that all inventions, innovations,
improvements, developments, methods, designs, analyses, reports, and all similar or related information which relates to the
Company’s or its Affiliates’ actual or anticipated business, research and development or existing or future products or services
and which are conceived, developed or made by the Executive while employed by the Company (“Work Product”) belong to the
Company. The Executive acknowledges that, by reason of being employed by the Company at the relevant times, to the extent
permitted by law, all of the Work Product consisting of copyrightable subject matter is “work made for hire” as defined in 17
U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that the foregoing does not apply, the
Executive hereby irrevocably assigns to the Company, for no additional consideration, the Executive’s entire right, title, and
interest in and to all Work Product and intellectual property rights therein, including, without limitation, the right to sue,
counterclaim, and recover for all past, present, and future infringement, misappropriation, or dilution thereof, and all rights
corresponding thereto throughout the world. The Executive will promptly disclose such Work Product to the Board and perform
all actions reasonably requested by the Board (whether during or after the Term) to establish and confirm such ownership
(including, without limitation, executing assignments, consents, powers of attorney and other instruments). If requested by the
Company, the Executive agrees to execute any inventions assignment and confidentiality agreement that is required to be signed
by Company employees generally. Nothing contained in this Agreement shall be construed to reduce or limit the Company’s
rights, title, or interest in any Work Product or intellectual property rights so as to be less in any respect than that the Company
would have had in the absence of this Agreement. The Executive understands that this Agreement does not, and shall not be
construed to, grant the Executive any license or right of any nature with respect to any Work Product or intellectual property
rights or any Proprietary Information, materials, software, or other tools made available to the Executive by the Company.
(g)
Return of Company Property. Upon termination of the Executive’s employment with the Company for any reason,
and at any earlier time the Company requests, the Executive will (i) deliver to the person designated by the Company all originals
and copies of all documents and property of the Company or an Affiliate that is in the Executive’s possession or under the
Executive’s control or to which the Executive may have access, (ii)  deliver to the person designated by the Company all
Company property, including keys, key cards, access cards, identification cards, security devices, employer credit cards, network
access devices, computers, cell phones, smartphones, PDAs, pagers, fax machines, equipment, manuals, reports, files, books,
compilations, work product, e-mail messages, recordings, disks, thumb drives or other removable information storage devices,
hard drives, and data, and (iii)  to the extent that the Executive made use of the Executive’s personal electronics (e.g., laptop,
iPad, telephone, thumb drives, etc.) during employment with the Company, permit the Company to delete all Company property
and information from such personal devices. The Executive will not reproduce or
10
DB1/ 144657598.4


appropriate for the Executive’s own use, or for the use of others, any property, Proprietary Information or Work Product.
(h)
Future Cooperation. The Executive agrees that, following the termination of the Executive’s employment, the
Executive will cooperate fully with the Company, upon request, in relation to (i) transitioning the Executive’s job duties to the
Executive’s successor and any other operational issues that may arise in connection with the Executive’s separation from
employment; and (ii) the Company’s defense, prosecution or other involvement in any continuing or future claims, lawsuits,
charges, arbitrations, or internal or external investigations (or audits or reviews of any type) arising out of events or matters that
occurred during the Executive’s employment by the Company or to which the Executive is otherwise a relevant witness.
(i)
Tolling. Notwithstanding the foregoing, should the Executive violate any of the restrictive covenants in this
Section 15, then the period of the Executive’s breach of such covenant (“Violation Period”) shall stop the running of the
corresponding Restriction Period. Once the Executive resumes compliance with the restrictive covenant, the Restriction Period
applicable to such covenant shall be extended for a period equal to the Violation Period so that the Company enjoys the full
benefit of the Executive’s compliance with the restrictive covenant for the duration of the corresponding Restriction Period.
16.
Legal and Equitable Remedies.
(a)
Because the Executive’s services are personal and unique and the Executive has had and will continue to have
access to and has become and will continue to become acquainted with the Proprietary Information of the Company and its
Affiliates, and because any breach by the Executive of any of the restrictive covenants contained in Section 15 would result in
irreparable injury and damage for which money damages would not provide an adequate remedy, the Company shall have the
right to enforce Section 15 and any of its provisions by injunction, specific performance or other equitable relief, without bond
and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the
restrictive covenants set forth in Section 15. The Executive agrees that in any action in which the Company seeks injunction,
specific performance or other equitable relief, the Executive will not assert or contend that any of the provisions of Section 15 are
unreasonable or otherwise unenforceable.
(b)
The Executive irrevocably and unconditionally (i) agrees that any legal proceeding arising out of this Agreement
shall be brought solely in the United States District Court for the District of Massachusetts, or if such court does not have
jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in the Commonwealth of Massachusetts, (ii)
consents to the exclusive jurisdiction of such court in any such proceeding, and (iii) waives any objection to the laying of venue
of any such proceeding in any such court. The Executive also irrevocably and unconditionally consents to the service of any
process, pleadings, notices or other papers.
11
DB1/ 144657598.4


(c)
Notwithstanding anything in this Agreement to the contrary, if the Executive breaches any of the Executive’s
obligations under Section 15, the Company shall be obligated to provide only the Accrued Obligations, and all payments under
Section 2, Section 6, or Section 7 hereof, as applicable, shall cease. In such event, and in addition to any legal and equitable
remedies permitted by law, the Company may require that the Executive repay all amounts theretofore paid to the Executive
pursuant to Sections 6 and 7 hereof (other than Sections 6(c) and 7(c)), and in such case, the Executive shall promptly repay such
amounts on the terms determined by the Company.
17.
Survival. The respective rights and obligations of the parties under this Agreement (including, but not limited to, under
Sections 15 and 16) shall survive any termination of the Executive’s employment or termination or expiration of this Agreement
to the extent necessary to the intended preservation of such rights and obligations.
18.
No Mitigation or Set-Off. In no event shall the Executive be obligated to seek other employment or take any other action
by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts
shall not be reduced regardless of whether the Executive obtains other employment. The Company’s obligation to make the
payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any
circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right which the Company
may have against the Executive or others.
19.
Section 280G. In the event of a change in ownership or control under section 280G of the Code, if it shall be determined
that any payment or distribution in the nature of compensation (within the meaning of section 280G(b)(2) of the Code) to or for
the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or
otherwise (a “Payment”), would constitute an “excess parachute payment” within the meaning of section 280G of the Code, the
aggregate present value of the Payments under the Agreement shall be reduced (but not below zero) to the Reduced Amount
(defined below) if and only if the Accounting Firm (described below) determines that the reduction will provide the Executive
with a greater net after-tax benefit than would no reduction. No reduction shall be made unless the reduction would provide the
Executive with a greater net after-tax benefit. The determinations under this Section shall be made as follows:
(a)
The “Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present
value of Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax
(defined below), determined in accordance with section 280G(d)(4) of the Code. The term “Excise Tax” means the excise tax
imposed under section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.
(b)
Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the
reduction in the economic value deliverable to the Executive.
12
DB1/ 144657598.4


Where more than one payment has the same value for this purpose and they are payable at different times, they will be reduced
on a pro rata basis. Only amounts payable under this Agreement shall be reduced pursuant to this Section.
(c)
All determinations to be made under this Section shall be made by an independent certified public accounting firm
selected by the Company and agreed to by the Executive immediately prior to the change-in-ownership or -control transaction
(the “Accounting Firm”). The Accounting Firm shall provide its determinations and any supporting calculations both to the
Company and the Executive within 10 days of the transaction. Any such determination by the Accounting Firm shall be binding
upon the Company and the Executive. All of the fees and expenses of the Accounting Firm in performing the determinations
referred to in this Section shall be borne solely by the Company.
20.
Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in
connection herewith shall be in writing and shall be deemed to have been given when hand-delivered or mailed by registered or
certified mail, as follows (provided that notice of change of address shall be deemed given only when received):
    If to the Company, to:
Replimune, Inc.
500 Unicorn Park Drive
Woburn, MA 01801
Attn: Legal
with a copy to:
Morgan, Lewis & Bockius LLP 
One Federal Street
Boston, MA 02110
Attn: Benjamin Stein
If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the
Company or the Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the
manner specified in this Section.
21.
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company
shall withhold from any payments under this Agreement all federal, state, and local taxes as the Company is required to withhold
pursuant to any law or governmental rule or regulation. The Executive shall bear all expense of, and be solely responsible for, all
federal, state, and local taxes due with respect to any payment received under this Agreement.
22.
Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of
any other remedy, and each and every such remedy shall be
13
DB1/ 144657598.4


cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in
equity. No delay or omission by a party in exercising any right, remedy or power under this Agreement or existing at law or in
equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to
time and as often as may be deemed expedient or necessary by such party in its sole discretion.
23.
Assignment. All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be
enforceable by the respective heirs, executors, administrators, legal representatives, successors, and assigns of the parties hereto,
except that the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be
assignable or delegable in whole or in part by the Executive. The Company may assign its rights, together with its obligations
hereunder, in connection with any sale, transfer or other disposition of all or substantially all of its business and assets, and such
rights and obligations shall inure to, and be binding upon, any successor to the business or any successor to substantially all of the
assets of the Company, whether by merger, purchase of stock or assets or otherwise, which successor shall expressly assume such
obligations, and the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not
limited to those under Section 15, will continue to apply in favor of the successor.
24.
Company Policies. This Agreement and the compensation payable hereunder shall be subject to any applicable clawback
or recoupment policies, including the Replimune Group, Inc. Compensation Recoupment Policy, share trading policies, and other
policies that may be implemented by the Board from time to time with respect to officers of the Company.
25.
Indemnification. In the event the Executive is made, or threatened to be made, a party to any legal action or proceeding,
whether civil or criminal, including any governmental or regulatory proceedings or investigations, by reason of the fact that the
Executive is or was a director or officer of the Company or any of its Affiliates, the Executive shall be indemnified by the
Company, and the Company shall pay the Executive’s related expenses when and as incurred, to the fullest extent permitted by
applicable law and the Company’s articles of incorporation and bylaws; provided, however, the Executive shall not be entitled to
indemnity to the extent any such legal action, proceeding or investigation arises out of or relates to any act or omission by the
Executive determined to be the result of the Executive’s own gross negligence, fraud, willful or intentional misconduct or your
breach of any law or fiduciary obligations, or any claims brought by the Executive against the Company or any of its Affiliates or
any counterclaims brought by the Company or any of its Affiliates against the Executive. During the Executive’s employment
with the Company or any of its Affiliates and after termination of employment for any reason, the Company shall cover the
Executive under the Company’s directors’ and officers’ insurance policy applicable to other officers and directors according to
the terms of such policy. The Executive agrees to notify the Company promptly upon becoming aware of any claim or potential
claim asserted against the Executive arising from the Executive’s performance of the Executive’s job duties.
14
DB1/ 144657598.4


26.
Entire Agreement; Amendment. This Agreement sets forth the entire agreement of the parties hereto and supersedes any
and all prior agreements and understandings concerning the Executive’s employment by the Company, including the Prior
Agreement. This Agreement may be changed only by a written document signed by the Executive and the Company.
27.
Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is
adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other
provision or application of this Agreement, which can be given effect without the invalid or unenforceable provision or
application, and shall not invalidate or render unenforceable such provision or application in any other jurisdiction. If any
provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force
and effect in all other circumstances.
28.
Governing Law; Forum. This Agreement shall be governed by, and construed and enforced in accordance with, the
substantive and procedural laws of Massachusetts without regard to rules governing conflicts of law. Any lawsuit arising under
this Agreement or employment with the Company shall be brought solely in a state or federal court located in Massachusetts.
29.
Acknowledgements. The Executive acknowledges (a) that the Company hereby advises the Executive to consult with
legal counsel prior to signing this Agreement, (b) that the Executive has had a full and adequate opportunity to read and
understand the terms and conditions contained in this Agreement, (c) that the Executive has been provided with this Agreement a
minimum of 10 business days prior to the date this Agreement becomes effective, and (d) that the post-employment non-
competition and non-solicitation provisions are supported by fair and reasonable consideration.
30.
Counterparts. This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of
which shall be an original, but all of which together shall constitute one instrument.
(Signature Page Follows)
15
DB1/ 144657598.4


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
                REPLIMUNE, INC.
                    /s/ Emily Hill        
                Name: Emily Hill
                Title: Chief Financial Officer
                Date: March 25, 2024
                
                EXECUTIVE
                    /s/ Philip Astley-Sparke    
                Name: Philip Astley-Sparke
                Date: March 25, 2024
R
li
I
16
DB1/ 144657598.4


Replimune Inc
500 Unicorn Park Dr.
Woburn, MA 01801
    
PERSONAL & CONFIDENTIAL                                                                        March 25, 2024
Robert Coffin
RE:    Separation and Transition Agreement
Dear Rob:
This letter of agreement and general release (“Agreement”) confirms our agreement regarding your transition from employment
with Replimune, Inc. (the “Company”) by mutual agreement, which is being treated as a termination by the Company without
Cause (as such term is defined in the Employment Agreement by and between you and the Company dated November 2, 2021
(the “Employment Agreement”), to a consulting role. You and the Company (the “Parties” and each, a “Party”) agree to the
following:
1.
Introduction: Nature of this Agreement. The Parties recognize your essential role as Company founder, inventor of all
Replimune products to date, the person who oversaw all research and development, and one of the two senior members of
the leadership team since the Company’s founding in 2015. At the same time, the Parties agree to the transitioning of your
role from employment and executive officer to consulting as Founder & Chief Scientist. This Agreement sets forth the
terms of the termination of your employment as a Company executive officer, and includes a customary release and the
terms of all payments to which you may be entitled from the Company, including under the Employment Agreement.
2.
Employment Separation Date and Transition to Consulting. Your last day of employment with the Company will be
March 31, 2024 (the “Last Day of Employment”) and you shall be eligible for the benefits set forth in Section 3 below.
Effective as of the date hereof, you shall continue to be available to the Company to complete certain projects and
transition your duties, as requested by the Chief Executive Officer of the Company (the “CEO”). You will continue to
receive your current base salary and benefits through the Last Day of Employment. Additionally, you will receive any
other amounts earned, accrued and owing but not yet paid through your Last Day of Employment, including any vested
benefits accrued and due under any applicable benefit plans and programs of the Company, pursuant to the Employment
Agreement, regardless of whether you execute or revoke this Agreement. You will also receive payment for approved
expenses within 30 days after receipt of the expense report. Your employment and your participation in and eligibility for
the Company’s employee benefit plans and programs will terminate on your Last Day of Employment. Except for
consulting services, in accordance with the Consulting Agreement described below, effective as of the Last Day of
Employment, you will automatically be deemed to resign from all Company-related positions, including as an officer of
the Company and its parents, subsidiaries and affiliates, as applicable, and shall execute all documentation necessary to
effectuate such resignation(s). You will
DB1/ 144801600.7


remain a member of the Board of Directors of the Company (the “Board”) until the Company’s next annual meeting of
shareholders slated for September 2024.
3.
Consideration in Exchange for Release.
(a)
Provided you timely execute and do not revoke this Agreement, you comply with your obligations under the
Employment Agreement, attached hereto as Exhibit A, and effectively transition your responsibilities, as and to
the extent necessary, through your Last Day of Employment: (i) you will be eligible to receive the severance
payments and benefits set forth in Section 3(b) below and (ii) the Company will enter into the consulting
agreement attached here as Exhibit B (the “Consulting Agreement”) with you, to be effective on April 1, 2024,
and the Company will provide the compensation described therein upon performance of the services described
therein.
(b)
Provided you have timely executed and not revoked this Agreement and provided you timely execute and do not
revoke the release attached as Exhibit C (“Second Release”) (which must be executed within 45 days of, and not
before, the Last Day of Employment) and otherwise comply with their terms, you shall receive the following
additional benefits:
(i)
An amount equal to $596,440.00, which is 12 months of your current base salary, shall be paid to you in
accordance with the following: (A) base salary amounts that would have been paid to you prior to March
15, 2025 if you had been employed by the Company during such time shall be paid in installments in
accordance with the Company’s normal payroll practices, commencing within 60 days following the Last
Day of Employment, provided that, any installments not paid between the Last Day of Employment and
the date of the first payment will be paid with the first payment, and (B) base salary amounts that would
have been paid to you between March 15, 2025 and March 31, 2025 if you had been employed by the
Company during such time shall be paid to you in a lump sum on March 14, 2025.
(ii)
The full amount of your Annual Bonus (as defined in the Employment Agreement) for the fiscal year
ending March 31, 2024 in the amount of $238,576 (the “Annual Bonus Payment”), shall be paid to you.
The Annual Bonus Payment will be paid when annual bonuses are paid to employees of the Company, not
later than 60 days following the Last Day of Employment.
(iii)
During the period beginning on the Last Day of Employment and ending on the earliest of (A) the date on
which you first become covered by any other “group health plan” as described in Section 4980B(g)(2) of
the Internal Revenue Code of 1986, as amended (the “Code”), (B) September
2
DB1/ 144801600.7


30, 2025, or (C) the date you cease to be eligible for continued coverage under the Consolidated Omnibus
Budget Reconciliation Act (“COBRA”) for any reason (such period, the “Coverage Period”), if you timely
elect to receive continued health coverage under the Company’s health plan pursuant to COBRA at a level
of coverage at your level of coverage in effect on the Last Day of Employment, the Company will pay
monthly COBRA premiums directly to the carrier(s) on your behalf. You agree to notify the Company
within five days of your coverage under an alternative health plan upon becoming covered by such
alternative plan, or your other ineligibility for continued coverage under COBRA upon becoming
ineligible. The COBRA health care continuation coverage period under Section 4980B of the Code shall
run concurrently with the Coverage Period.
4.
Release.
(a)
In consideration of the compensation and benefits set forth in Section 3(a) hereof, to the fullest extent permitted by
law you waive, release, and forever discharge the Company and each of its past and current parents, subsidiaries,
affiliates, and each of its and their respective past and current directors, officers, members, trustees, employees,
representatives, agents, attorneys, employee benefit plans and such plans’ administrators, fiduciaries, trustees,
recordkeepers and service providers, and each of its and their respective successors and assigns, each and all of
them in their personal and representative capacities (collectively the “Company Releasees”) from any and all
claims legally capable of being waived, agreements, causes of action, attorneys’ fees, costs, damages, or any right
to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by
contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which
you now have, ever have had, or may hereafter have, whether known or unknown to you, arising at any time up to
the date of your execution of this Agreement, arising out of or relating in any way to your employment with the
Company or the termination thereof.
Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to
the extent legally capable of being waived, based upon or arising under any federal, state or local fair employment
practices or equal opportunity laws, including, but not limited to, the Age Discrimination in Employment Act
(“ADEA”) (29 U.S.C. Section 621, et seq.), 42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the
Equal Pay Act, the Employee Retirement Income Security Act (“ERISA”) (including, but not limited to, claims
for breach of fiduciary duty under ERISA), the Americans With Disabilities Act, the Family and Medical Leave
Act of 1993, the Massachusetts Fair Employment Practices Act, the Massachusetts Civil Rights Act, the
Massachusetts Equal Rights Act, the Massachusetts Parental Leave Act, the Massachusetts Labor and Industries
Act, the Massachusetts right of privacy law, the Massachusetts Wage Act (as further explained below), the
Massachusetts
3
DB1/ 144801600.7


Earned Sick Time law, the Massachusetts Equal Pay Act, the Massachusetts Paid Family and Medical Leave Law,
and the Massachusetts Minimum Fair Wage Law, all as amended, as well as any claim or right under your
Employment Agreement unless provided herein.
Massachusetts Wage Act Waiver. By signing this Agreement, you acknowledge that this waiver includes any
claims against the Company Releasees under Mass. Gen. Laws ch. 149, § 148 et seq.,—the Massachusetts Wage
Act. These claims include, but are not limited to, claims for failure to pay earned wages, failure to pay overtime,
failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay,
failure to furnish appropriate pay stubs, improper wage deductions, and failure to provide proper check-cashing
facilities.
(b)
You acknowledge that you have not made any claims or allegations related to discrimination, harassment, sexual
abuse or retaliation, and none of the payments set forth as consideration in this Agreement or the Second Release,
are related to discrimination, harassment, sexual abuse or retaliation. In addition, nothing in this Agreement
precludes you from discussing or disclosing information about unlawful acts in the workplace, such as harassment,
discrimination, sexual assault or any other conduct that you have reason to believe is unlawful, including the
amount or fact of any settlement relating to such acts.
(c)
Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or
prevents you from making or asserting: (i) any claim or right you may have under COBRA; (ii) any claim or right
you may have for unemployment insurance or workers’ compensation benefits (other than for retaliation under
workers’ compensation laws); (iii) any claim to vested benefits under the written terms of a qualified employee
pension benefit plan; (iv) any claim for indemnity pursuant to Section 25 of the Employment Agreement, which is
incorporated herein by reference; (v) any medical claim incurred during your employment that is payable under
applicable medical plans or an employer-insured liability plan; (vi) any claim or right that may arise after the
execution of this Agreement; (vii) any claim or right you may have under this Agreement; (viii) any claim or right
you may have as a former officer of the Company under the Company’s D&O policy and any indemnification
agreement with the Company to which you are a party; or (ix) any claim that is not otherwise able to be waived
under applicable law.
(d)
In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment
Opportunity Commission (“EEOC”) or similar federal or state fair employment practices agency or interfere with
your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that
pursuant to Section 4(a) above, you are waiving any right to recover monetary damages or any other form of
personal relief from the
4
DB1/ 144801600.7


Company Releasees to the extent any such charge, complaint, investigation or proceeding asserts a claim subject
to the release in Section 4(a) above. To the extent you receive any such personal or monetary relief in connection
with any such charge, complaint, investigation or proceeding, the Company will be entitled to an offset for the
payments made pursuant to Section 3(b) of this Agreement to the fullest extent permitted by law.
5.
No Additional Entitlements. You agree and represent that other than as provided for in this Agreement, you have received
all entitlements due from the Company relating to your employment with the Company or under your Employment
Agreement, including but not limited to, all wages earned, including without limitation all commissions and bonuses, sick
pay, vacation pay, overtime pay, and any paid and unpaid personal leave for which you were eligible and entitled, and that
no other entitlements are due to you other than as set forth in this Agreement. Additionally, the Company agrees not to
contest any claim for unemployment benefits you may file; provided, however, that the Company may respond to any
inquiry from the unemployment compensation board to the extent you make any allegations of wrongdoing by the
Company. Except as expressly provided for herein, your Employment Agreement with the Company is hereby terminated.
6.
Protection of Confidential Information. Except as expressly permitted in Sections 4(b) and 8 of this Agreement or if
otherwise required by law, you agree that you will not at any time, directly or indirectly, use or disclose any trade secret,
confidential or proprietary information you have learned by reason of your employment with the Company and will
continue to abide by your confidentiality obligations pursuant to Section 15 of your Employment Agreement.
7.
Non-Disparagement. Except as expressly permitted in Sections 4(b) and 8 of this Agreement, you agree that you shall not
at any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the
Company and/or the Company Releasees and you shall not take any action that would cause or contribute to their being
held in disrepute. The Company agrees to direct its directors and officers not to at any time make any written or oral
comments or statements of a defamatory or disparaging nature regarding you or take any action that would cause or
contribute to you being held in disrepute. You and the Company agree to act reasonably and in good faith to prepare a
mutually acceptable internal communication plan for employees and to prepare a mutually acceptable press release and 8-
K SEC filing regarding your transition from employment to continued services as a consultant.
8.
Reports to Government Entities. Nothing in this Agreement restricts or prohibits you from initiating communications
directly with, responding to any inquiries from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with
a self-regulatory authority or a government agency, from making other disclosures that are protected under the
whistleblower provisions of federal, state, or local law or regulation, or engaging in the conduct set forth in Section 4(b)
of this Agreement. You do not need the prior authorization of the Company to engage in conduct protected by this
Section, and you do not need to notify the Company that you have engaged in such
5
DB1/ 144801600.7


conduct. Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade
secret misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in
certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or
investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected
violation of the law.
9.
Non-Admission. It is understood and agreed that neither the execution of this Agreement nor the terms of this Agreement
constitute an admission of liability to you by the Company or the Company Releasees, and such liability is expressly
denied. It is further understood and agreed that no person shall use this Agreement, or the consideration paid pursuant
thereto, as evidence of an admission of liability, in as much as such liability is expressly denied.
10.
Cooperation. You agree that upon the Company’s reasonable notice to you, and a reasonable request, you shall cooperate
with the Company and its counsel (including, if necessary, preparation for and appearance at depositions, hearings, trials
or other proceedings) with regard to matters that relate to or arise out of matters you have knowledge about or have been
involved with during your employment with the Company. In the event that such cooperation is required, you will be
reimbursed for any reasonable travel expenses incurred in connection therewith. In the event cooperation is requested
when you are no longer providing paid services under the Consulting Agreement, cooperation requiring your services or
counsel (including, if necessary, preparation for and appearance at depositions, hearings, trials or other proceedings) will
be compensated at $500 per hour.
11.
Confidentiality of the Agreement. Except as permitted in Sections 4(b) and 8 of this Agreement, as may be required
pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof, to enforce the terms
of this Agreement or if otherwise required by law, the Parties, including the Company, shall not disclose the terms of this
Agreement, or the circumstances giving rise to this Agreement, to any person other than their respective attorneys,
immediate family members, accountants, financial advisors or corporate employees who have a business need to know
such terms in order to approve or implement such terms.
12.
Restrictive Covenant Obligations.
(a)
Subject to Section 8 of this Agreement, you reaffirm and agree that you remain bound by Sections 15(b) through
(f), 16, and 17 of your Employment Agreement, which are incorporated herein by reference.
(b)
Non-Competition. You agree that during the one-year period following the Last Day of Employment, you will not,
without the express written consent of the Company’s Board of Directors, engage (directly or indirectly) in any
Competitive Business in the Restricted Area. The term “Competitive Business” means (i) during the Initial Term
(as defined in the Consulting Agreement), any activities or services conducted by any third party with respect to
the research, development,
6
DB1/ 144801600.7


marketing, manufacturing or sale of oncolytic immunotherapies that are similar to the activities or services you
have performed (or gained Proprietary Information (as defined in the Employment Agreement) about) at any time
during the last two years of your employment with the Company, and (ii) during the Final Term (as defined in the
Consulting Agreement), any activities or services conducted by any third party with respect to the research,
development, marketing, manufacturing or sale of HSV-based oncolytic immunotherapies that are similar to the
activities or services you have performed (or gained Proprietary Information about) at any time during the last two
years of your employment with the Company. The term “Restricted Area” means the United States of America,
Canada and countries within Europe, in respect of which the Company or any of its Affiliates has material
business operations as of the date on which your employment terminates and in which you have provided services
or had a material presence or influence at any time during the last two years of your employment with the
Company or its Affiliates. You agree that the benefits set forth in Section 3 of this Agreement are fair and
reasonable consideration for your compliance with this Section 12(b). You understand and agree that, given the
nature of the business of the Company and its Affiliates and your position with the Company, the foregoing
Restricted Area is reasonable and appropriate, that by virtue of your position and scope of responsibilities, you
provided services and had a material presence or influence within the Restricted Area, and that more limited
geographical limitations on this non-competition covenant are therefore not appropriate. For purposes of this
Agreement, the term “Affiliate” means the Company’s sole shareholder, any subsidiary of the Company or other
entity under common control with the Company. Unless otherwise specified herein, terms defined in the
Employment Agreement, as they are used in this Section 12(b), shall have the meanings set forth in the
Employment Agreement.
13.
Return of Company Property. By no later than the last day on which you provide consulting services under the Consulting
Agreement, you must (i) send to Camilo Garcia by overnight FedEx or by hand all originals and copies of all documents
and property of the Company or an affiliate that is in your possession or under your control or to which you may have
access, (ii) deliver to Camilo Garcia all Company property, including keys, key cards, access cards, identification cards,
security devices, employer credit cards, network access devices, computers, cell phones, smartphones, PDAs, pagers, fax
machines, equipment, manuals, reports, files, books, compilations, work product, e-mail messages, recordings, disks,
thumb drives or other removable information storage devices, hard drives, and data, and (iii) to the extent that you made
use of your personal electronics (e.g., laptop, iPad, telephone, thumb drives, etc.) during your employment with the
Company, delete all Company property and information from such personal devices; provided that you submit to the
Company for approval a list of any Company-related items on your personal electronics that you believe you should be
permitted to retain.
14.
Acknowledgments. You hereby acknowledge that:
7
DB1/ 144801600.7


(a)
The Company advises you to consult with an attorney before signing this Agreement (including all Exhibits
thereto);
(b)
You have obtained independent legal advice from an attorney of your own choice with respect to this Agreement
(including all Exhibits thereto), or you have knowingly and voluntarily chosen not to do so;
(c)
You freely, voluntarily and knowingly entered into this Agreement and all Exhibits thereto after due consideration;
(d)
You have had a minimum of forty-five (45) days to review and consider this Agreement (including all Exhibits
thereto) (the “Consideration Period”);
(e)
You and the Company agree that changes to the Company’s offer contained in this Agreement, whether material or
immaterial, will not restart the Consideration Period provided for in Section 14(d) above;
(f)
You have a right to revoke this Agreement, by notifying the undersigned representative in writing, via hand
delivery, facsimile or electronic mail, within seven (7) business days of your execution of this Agreement;
(g)
As required by federal law, you have received a listing (as Exhibit D hereto) of the ages and job titles of
employees in the Decisional Unit, described in Exhibit D, who were selected for termination and eligible to
receive severance pay and benefits in exchange for signing a release of claims, and the employees who were not
selected for termination and not eligible to receive severance pay and benefits in exchange for signing a release of
claims;
(h)
In exchange for your waivers, releases and commitments set forth herein, including your waiver and release of all
claims arising under the ADEA, the payments, benefits and other considerations that you are receiving pursuant to
this Agreement exceed any payment, benefit or other thing of value to which you would otherwise be entitled, and
are just and sufficient consideration for the waivers, releases and commitments set forth herein; and
(i)
No promise or inducement has been offered to you, except as expressly set forth herein, and you are not relying
upon any such promise or inducement in entering into this Agreement.
15.
Medicare Disclaimer. You acknowledge that you are not a Medicare Beneficiary as of the time you enter into this
Agreement. To the extent that you are a Medicare Beneficiary, you agree to contact a Company Human Resources
Representative for further instruction.
16.
Miscellaneous.
(a)
Entire Agreement. This Agreement (including the Second Release), together with the expressly incorporated
provisions of your Employment Agreement and the Consulting Agreement, sets forth the entire agreement
between you and the Company and replaces any other oral or written agreement between you and the Company
relating to the subject matter of this Agreement, including, without limitation, any prior offer letters and/or
employment agreements, but not
8
DB1/ 144801600.7


including the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, which remains in full force and
effect.
(b)
Governing Law. This Agreement shall be construed, performed, enforced and in all respects governed in
accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the principles of
conflicts of law thereof. Additionally, all disputes arising from or related to this Agreement shall be brought in a
state or federal court situated in the Commonwealth of Massachusetts, Suffolk County, and the Parties hereby
expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes.
(c)
Severability. Should any provision of this Agreement be held to be void or unenforceable, the remaining
provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions
were originally deleted.
(d)
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the
Company shall withhold from any payments under this Agreement all federal, state, and local taxes as the
Company is required to withhold pursuant to any law or governmental rule or regulation. You shall bear all
expense of, and be solely responsible for, the employee portion of all federal, state, and local taxes due with
respect to any payment received under this Agreement.
(e)
Legal Fees. The Company will pay directly to your attorney up to $15,000 of reasonable legal fees incurred in the
review and negotiation of this Agreement and the Consulting Agreement, following submission of an appropriate
invoice from the attorney.
(f)
Section 409A. This Agreement is intended to comply with Section 409A of the Code, and its corresponding
regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in
a manner permitted by Section 409A of the Code, to the extent applicable. To the extent that any provision of this
Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a
manner so that all payments hereunder comply with Section 409A of the Code. Severance benefits under this
Agreement are intended to be exempt from Section 409A of the Code under the “short-term deferral” exception, to
the maximum extent applicable, and then under the “separation pay” exception, to the maximum extent applicable.
All payments to be made upon a termination of employment under this Agreement may only be made upon a
“separation from service” to the extent required under Section 409A of the Code. For purposes of Section 409A of
the Code, each payment hereunder shall be treated as a separate payment, and the right to a series of installment
payments under this Agreement shall be treated as a right to a series of separate payments. In no event may you,
directly or indirectly, designate the calendar year of a payment. Notwithstanding any provision of this Agreement
to the contrary, in no event shall the timing of your execution of this Agreement or
9
DB1/ 144801600.7


the Second Release, directly or indirectly, result in your designating the calendar year of payment of any amounts
of deferred compensation subject to Section 409A of the Code. All reimbursements and in-kind benefits provided
under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the
Code. The Parties agree that this Agreement may be amended, as reasonably requested by either Party and as may
be necessary to comply with Section 409A of the Code and all related rules and regulations as mutually agreed-
upon by the Parties. The Parties intend that any such amendment will preserve the payments and benefits provided
hereunder without additional cost to either Party, to the extent practicable.
(g)
Amendments. This Agreement may not be modified or amended, except upon the express written consent of both
you and the Company.
(h)
Breach. You acknowledge that if you breach, in any material way, any of your commitments to the Company
agreed upon in Sections 6, 7, 9, 10, 11, 12, or 13, the Company may cease payment of any severance benefits
under Section 2 and require that you be subject to suit by the Company for damages and equitable relief relating to
such breach and your Consulting Agreement will terminate; provided that if your breach is curable the Company
shall provide you with prompt written notice and a reasonable opportunity to cure. If a court of competent
jurisdiction determines that you materially breached your commitments to the Company agreed upon in Sections
6, 7, 9, 10, 11, 12, or 13 and such breach was not cured, the Company may require you to forfeit all or part of the
severance benefits not yet paid to you and to repay all severance amounts previously paid to you. You further
acknowledge that any material breach by you of Section 6, 7, 9, 10, 11, 12, or 13 will cause irreparable damage to
the Company and that in the event of such breach, the Company shall have, in addition to any and all remedies at
law, the right to an injunction, specific performance or other equitable relief from a court of competent jurisdiction
to prevent and/or restrain such breach, without the necessity of posting a bond or undertaking.
(i)
Waiver. A waiver by either Party hereto of a breach of any term or provision of the Agreement shall not be
construed as a waiver of any subsequent breach.
(j)
Counterparts. This Agreement may be executed in one or more counterparts, and be transmitted by facsimile or
pdf, each of which shall be deemed an original, but all of which together shall constitute one and the same
agreement.
(k)
Assignment. In the event of a change of control, the Company will assign any surviving obligations in this
Agreement to the appropriate entity to the extent permitted by law. This Agreement shall inure to the benefit of the
Company and permitted successors and assigns. However, you may not assign this Agreement or any part hereof.
Any purported assignment by you shall be null and void from the initial date of purported assignment.
(l)
Effective Date. This Agreement will become effective and enforceable on the first day following the expiration of
the seven (7) business day revocation period
10
DB1/ 144801600.7


provided for in Section 14(f) above (the “Effective Date”). If you fail to return an executed original before the
expiration of the Consideration Period (or otherwise revoke this Agreement pursuant to Section 14(f) above), this
Agreement, including but not limited to the obligation of the Company to provide the compensation and benefits
provided in Section 3 above, shall be deemed automatically null and void.
[Signature Page Follows]
11
DB1/ 144801600.7


    If the above accurately states our agreement, including the separation, waiver and release, kindly sign below and return the
original Agreement to me.
Sincerely,
Replimune, Inc.
    /s/ Philip Astley-Sparke    
Name: Philip Astley-Sparke
Title: Chief Executive Officer
Date: March 25, 2024        
UNDERSTOOD, AGREED TO AND ACCEPTED WITH THE INTENTION TO
BE LEGALLY BOUND:
____/s/ Robert Coffin__________________________

Robert Coffin
Date: March 25, 2024
Signature Page to Separation and Release Agreement
DB1/ 144801600.7


SECOND RELEASE
In consideration of the payments, benefits and other compensation and benefits provided by Replimune, Inc. (the “Company”) as
set forth in the Separation and Transition Agreement dated March 25, 2024 (the “Transition Agreement”), which you
acknowledge and agree is just and sufficient consideration for the waivers, releases and commitments set forth herein, by
executing this agreement and release (“Second Release”) you hereby IRREVOCABLY AND UNCONDITIONALLY agree to
WAIVE, RELEASE AND FOREVER DISCHARGE the Company Releasees (as defined in Section 4 of the Transition
Agreement) from any and all claims legally capable of being waived, agreements, causes of action, attorneys’ fees, costs,
damages, or any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by
contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which you now have,
ever have had, or may hereafter have, whether known or unknown to you, arising at any time up to the date of your execution of
this Second Release, arising out of or relating in any way to your employment with the Company or the termination thereof.
Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to the extent
legally capable of being waived, based upon or arising under any federal, state or local fair employment practices or equal
opportunity laws, including, but not limited to, the Age Discrimination in Employment Act (“ADEA”) (29 U.S.C. Section 621, et
seq.), 42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the Equal Pay Act, the Employee Retirement Income
Security Act (“ERISA”) (including, but not limited to, claims for breach of fiduciary duty under ERISA), the Americans With
Disabilities Act, the Family and Medical Leave Act of 1993, the Massachusetts Fair Employment Practices Act, the
Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the Massachusetts Parental Leave Act, the Massachusetts
Labor and Industries Act, the Massachusetts right of privacy law, the Massachusetts Wage Act (as further explained below), the
Massachusetts Earned Sick Time law, the Massachusetts Equal Pay Act, the Massachusetts Paid Family and Medical Leave Law,
and the Massachusetts Minimum Fair Wage Law, all as amended, as well as any claim or right under your Employment
Agreement unless as provided herein.
Massachusetts Wage Act Waiver. By signing this Second Release, you acknowledge that this waiver includes any claims
against the Company Releasees under Mass. Gen. Laws ch. 149, § 148 et seq.,—the Massachusetts Wage Act. These claims
include, but are not limited to, claims for failure to pay earned wages, failure to pay overtime, failure to pay earned commissions,
failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, improper
wage deductions, and failure to provide proper check-cashing facilities.
Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you from
making or asserting: (i) any claim or right you may have under COBRA; (ii) any claim or right you may have for unemployment
insurance or workers’ compensation benefits (other than for retaliation under workers’ compensation laws); (iii) any claim to
vested benefits under the written terms of a qualified employee pension benefit plan; (iv) any claim for indemnity pursuant to
Section 25 of your Employment Agreement, which is incorporated herein by reference; (v) any medical claim incurred during
your employment that is payable under applicable medical plans or an employer-insured liability plan; (vi) any claim or
DB1/ 144801600.7


right that may arise after the execution of this Second Release; (vii) any claim or right you may have under this Second Release;
(viii) any claim or right you may have as a former officer of the Company under the Company’s D&O policy and any
indemnification agreement with the Company to which you are a party; (ix) any claim that is not otherwise able to be waived
under applicable law; (x) any claim or right that may arise after your execution of this Second Release; or (xi) any claim or right
you may have under this Second Release.
In addition, nothing in this Second Release shall prevent you from filing a charge or complaint with the Equal Employment
Opportunity Commission (“EEOC”) or similar federal or state fair employment practices agency or interfere with your ability to
participate in any investigation or proceeding conducted by such agency; provided, however, that you understand and agree that,
pursuant to the Transition Agreement (i) you are waiving any right to recover monetary damages or any other form of personal
relief in connection with any such charge, action, investigation or proceeding; and (ii) to the extent you receive any such personal
or monetary relief in connection with any such charge, complaint, investigation or proceeding, the Company will be entitled to an
offset for the payments made pursuant to Section 3(b) of the Transition Agreement to the fullest extent permitted by law.
By signing this Second Release, you understand and acknowledge that you were advised of and afforded the opportunity to take
advantage of each of the protections set forth in Section 14 of the Transition Agreement, including, but not limited to: (i)
consultation with an attorney before signing this Second Release; (ii) at least forty-five (45) days in which to consider this
Second Release; and (iii) at least seven (7) business days in which to revoke this Second Release after signature. You further
acknowledge that you have received a listing (as Exhibit D attached to the Transition Agreement) of the ages and job titles of
employees in the Decisional Unit, described in Exhibit D, who were selected for termination and eligible to receive severance
pay and benefits in exchange for signing a release of claims, and the employees who were not selected for termination and not
eligible to receive severance pay and benefits in exchange for signing a release of claims. You further acknowledge that you
freely, voluntarily and knowingly entered into this Second Release after due consideration.
This Second Release incorporates by reference, as if set forth fully herein, all terms and conditions of the Transition Agreement
between the Company and you, including the recitation of consideration provided by the Company. By signing this Second
Release, you waive, release and forever discharge any and all claims that may have arisen through the date of your execution of
this Second Release. It is not your intention to otherwise change, alter or amend any of the terms and conditions of the Transition
Agreement, for which you received adequate consideration, and which Transition Agreement remains in full force and effect. You
acknowledge and agree that you continue to be bound by the terms and conditions of the Transition Agreement.
This Second Release shall become effective on the first day following the expiration of the seven (7) business day revocation
period described above, provided you have not exercised your right to revoke. You understand and agree that, should you fail to
timely execute this Second Release, or if you timely execute but then revoke this Second Release, you shall not be eligible for
and
DB1/ 144801600.7


you shall not receive the severance benefits set forth in Section 3(b) of your Transition Agreement.
I UNDERSTAND AND ACKNOWLEDGE THAT I SHALL EXECUTE THIS SECOND RELEASE WITHIN 45 DAYS OF,
AND NOT BEFORE, MY SEPARATION DATE WITH THE COMPANY.
            UNDERSTOOD, AGREED TO
                    AND ACCEPTED WITH THE
                    INTENTION TO BE LEGALLY BOUND:
Date: ____4/1/2024____________    ___/s/ Robert Coffin___________________
                    Robert Coffin
DB1/ 144801600.7


CONSULTING AGREEMENT
This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 25, 2024, by and between Replimune, Inc.
(the “Company”) and Robert Coffin (the “Consultant,” together with the Company, the “Parties” and each, a “Party”). This
Agreement will be effective on April 1, 2024. For the avoidance of doubt, if the Consultant does not execute or revokes the
Second Release attached as Exhibit C to the Separation and Transition Agreement dated as of March 25, 2024, between the
Company and the Consultant (the “Transition Agreement”), this Agreement shall not become effective, the Term (as defined in
Section 3(a) below) of this Agreement shall not commence and this Agreement shall automatically terminate and become null
and void ab initio.
1.
Consulting Services.
(a)
Subject to and upon the terms and conditions set forth in this Agreement, effective on April 1, 2024 (the “Start
Date”), the Company hereby retains the Consultant, and the Consultant hereby agrees to be retained by the Company, to provide
consulting services including transition support and such other services as shall be determined and reasonably requested from
time to time by the Chief Executive Officer of the Company (the “Services”). The Consultant shall report to Chief Executive
Officer of the Company (the “CEO”), which is Sushil Patel as of the Start Date, and serve at his direction. The Consultant’s title
during his period of service shall be the Founder & Chief Scientist of the Company.
(b)
The amount of time that Consultant shall devote to the performance of the Services pursuant to this Agreement in
relation to the retainer set forth in Section 2 shall be: (i) for the period beginning on the Start Date and ending on the earlier of
March 31, 2025 or the date of the BLA filing (i.e., FDA acceptance) (the “Initial Term”), up to 125 hours per month; and (ii) in
relation to the reduced retainer for the period beginning on the first day following the end of the Initial Term and ending on the
earlier of the date of BLA approval and March 31, 2026 (the “Final Term”), up to 60 hours per month. The Consultant shall be
available to perform the Services pursuant to this Agreement during regular business hours, or as otherwise agreed, and either on
site or remotely.
(c)
The Consultant shall provide the Services under this Agreement at such times and locations as are mutually agreed
upon by the Consultant and the CEO. In rendering the Services under this Agreement, the Consultant shall act solely as an
independent contractor, the Consultant will not be eligible for any employee benefit plans or programs maintained by the
Company, and this Agreement shall not be construed to create any employee/employer relationship between the Consultant and
the Company.
(d)
During the Term of this Agreement, and except to the extent otherwise agreed upon in writing by the Consultant
and the Company, the Consultant will keep separate and not co-mingle (i) the Consultant’s Services for the Company, and (ii) any
contact information
DB1/ 144801600.7


obtained during the Consultant’s consulting relationship with the Company, with those provided, or pursuant, to any other
consulting arrangements.
(e)
It is understood and agreed that, subject to Section 12 of that certain Transition Agreement, the Consultant may be
involved in any capacity in other businesses, endeavors and undertakings, including, without limitation, participation in other
business opportunities and membership and work on advisory boards, boards of directors, and consulting for other companies, so
long as such activities and opportunities do not directly conflict with or detract from Consultant’s Services hereunder. The
Consultant agrees that the Consultant’s continuing obligations under Section 12 of the Transition Agreement shall remain in full
force and effect during the Term of this Agreement and are hereby incorporated by reference, provided, that, solely for purposes
of this Section 1(e), the terms of the Transition Agreement are hereby modified such that reference therein to the term of the
Consultant’s employment with the Company and termination thereof shall include reference to the Consultant’s consultancy
pursuant to this Agreement and the termination thereof such that, for example, the non-solicitation covenants set forth in the
Employment Agreement with the Company dated November 2, 2021 and incorporated into the Transition Agreement shall
continue during the Term of this Agreement and for the one-year period thereafter; provided that the non-competition covenants
set forth in the Transition Agreement shall only continue until the later of the end of the Term or the one-year period following
the Last Day of Employment (as defined in the Transition Agreement). As consideration for the payments and continued vesting
of the Options and RSUs (as each defined in Section 2(c) below), if applicable, the Consultant agrees to continue to abide by the
terms of the Transition Agreement as modified pursuant to the foregoing provisions of this Section 1(e).
2.
Compensation and Equity Awards.
(a)
Consulting Fees.
(i)
Subject to, and in accordance with, the terms and conditions set forth in this Agreement, during the Initial
Term, the Company will pay the Consultant a retainer to retain access to the Consultant’s historical
knowledge and expertise and for consulting services as set forth in Section 1 an amount equal to $50,000
per month and for the Final Term, the Company will pay Consultant an amount equal to $25,000 per
month. For the avoidance of doubt, nothing in this Agreement shall entitle the Consultant to be paid any
fees after the end of the Term.
(ii)
The retainer shall be paid at the end of each month during the Term. The Company will not withhold any
income or other employment taxes from the payments made to the Consultant under this Agreement. The
Company will issue Forms 1099 reporting income earned on account of services provided as a consultant.
The Consultant shall be obligated to timely pay all taxes due on the income paid to him by the Company
for his services as
2
DB1/ 144801600.7


a consultant. The Consultant will indemnify and hold the Company harmless against the claims of any
governmental taxing authority made in connection with the revenue derived by the Consultant under this
Agreement.
(b)
The Company shall reimburse the Consultant for any actual out-of-pocket business expenses incurred by the
Consultant while rendering or related to his Services under this Agreement so long as such expenses are reasonable and
necessary, and appropriately documented and in accordance with the Company’s standard practices. Without limiting the
generality of the foregoing, since the Consultant, as founder and inventor of the Company’s products may represent the scientific
advances and endeavors of the Company, to promote and to inspire interest and trust in the Company’s products, the Consultant
may be expected to attend media and industry events such as conferences, trade shows, summits, and webinars. In representing
the Company, the Consultant would attend in capacity as a visitor and/or as an active participant, including giving presentations,
joining panel discussions, providing Q&A and media interviews, with his expenses borne by the Company and his time involved
in such endeavors considered Services hereunder.
(c)
All of the Consultant’s stock options to purchase shares of Replimune Group, Inc.’s common stock (“Options”)
and restricted stock units on Replimune Group, Inc.’s common stock (“RSUs”) that are unvested as of the Last Day of
Employment (as defined in the Transition Agreement) will continue to vest in accordance with the terms of the governing plan
and award agreements (“Award Agreements”), until the end of the Term. The Consultant’s vested and exercisable Options shall
remain exercisable for the 180-day period following the date that is the earlier of the date of BLA approval and March 31, 2026
and the Options shall automatically terminate upon the expiration of such 180-day period; provided, however, that in no event
may the Options be exercised after the date that is immediately before the tenth anniversary of the applicable date of grant of
such Options. The Parties to this Agreement expressly agree that, if there is a Change of Control (as defined in the Replimune
Group, Inc. 2018 Omnibus Incentive Compensation Plan (the “Plan”)) before the end of the Term of this Agreement, any then-
outstanding Options and RSUs will be treated the same way that outstanding stock options and restricted stock units on
Replimune Group, Inc. stock held by departing senior level employees of the Company are treated in accordance with the terms
of the Plan and the Award Agreements. During the Term, the Consultant shall only sell shares of Replimune Group, Inc.’s
common stock in accordance with Replimune’s Insider Trading Policy, including under a 10b5-1 share sales plan put in place by
the Consultant where appropriate.
(d)
Except for the consulting fees described in Section 2(a), any expense reimbursement made in accordance with
Section 2(b) hereof, and any Option and RSU vesting arrangement set forth in Section 2(c), the Company shall have no
obligation to provide any compensation or benefits to the Consultant with respect to any Services rendered by the Consultant to
the Company pursuant to this Agreement. The compensation and benefits set forth in this Section 2 are separate and apart from
the severance benefits provided under the Transition Agreement.
3
DB1/ 144801600.7


3.
Term; Termination.
(a)
This Agreement shall take effect as of the Start Date and shall continue thereafter in full force and effect until the
last day of the Final Term, unless terminated earlier in accordance with the provisions of Sections 3(b), 3(c), 3(d) or 3(e) below,
whichever, if any, may first occur (the “Term”). Except as otherwise set forth in Sections 3(b), 3(c), 3(d) or 3(e) below, the
Company shall not terminate this Agreement prior to the expiration of the Final Term.
(b)
Upon a determination by the Company that the Consultant has materially breached this Agreement or the
Transition Agreement, including Section 5(a) of this Agreement and Section 7 of the Transition Agreement, or otherwise engaged
in any willful misconduct that has the effect, or potential effect, of causing material harm to the Company (monetarily,
reputationally or otherwise), the Company may terminate this Agreement after providing the Consultant with five days’ advanced
written notice of its intent to terminate this Agreement and a basis therefore. The Consultant shall have the opportunity within
such five-day notice period to demonstrate to the Company that the basis for such termination has been cured or explained to the
Company’s reasonable satisfaction, and if not cured or explained to the Company’s reasonable satisfaction, termination shall take
effect with the expiration of the five-day period. As a result of termination in accordance with this Section 3(b), the Term will end
with no further compensation due to the Consultant.
(c)
Upon a determination by the Consultant that the Company has materially breached this Agreement or the
Transition Agreement, or the Company is otherwise engaged in willful misconduct that has the effect, or potential effect, of
causing material harm to the Consultant (monetarily, reputationally or otherwise), the Consultant may terminate this Agreement
after providing the Company with five days’ advanced written notice of the Consultant’s intent to terminate this Agreement and a
basis therefore. The Company shall have the opportunity within such five-day notice period to demonstrate to the Consultant that
the basis for such termination has been cured or explained to the Consultant’s reasonable satisfaction, and if not cured or
explained to the Consultant’s reasonable satisfaction, termination shall take effect with the expiration of the five-day period. As a
result of termination in accordance with this Section 3(c), the Term will end with no further compensation due to the Consultant.
(d)
Upon notice from the Consultant or a determination by the Company that the Consultant has accepted a new full-
time position or other significant work position that demonstrably interferes with the Consultant’s ability to perform the Services
under this Agreement, including with respect to the required amount of time for which the Consultant is available to perform
such Services as agreed between the Consultant and the CEO in accordance with Section 1(b) above, the Company may terminate
this Agreement at any time following the first anniversary of the Start Date upon 30 days’ prior written notice to the Consultant
and the provision to the Consultant of an opportunity to cure or explain to the Company’s reasonable satisfaction within such 30-
day period. If there is no reasonably demonstrated and timely cure or explanation by the Consultant to the Company’s reasonable
satisfaction, termination shall take
4
DB1/ 144801600.7


effect with the expiration of the 30-day period. As a result of termination in accordance with this Section 3(d), the Term will end
with no further compensation due to the Consultant.
(e)
Following the first anniversary of the Start Date, either the Company or the Consultant may terminate this
Agreement for any reason upon 90 days’ prior written notice to the other Party. The Parties may also terminate this Agreement by
mutual agreement. Upon termination of this Agreement and the Services on 90-days notice or by mutual agreement, the
Company is only obligated to pay the Consultant any amounts owed for the Services performed through the date of termination.
This Agreement and the Services provided by the Consultant hereunder shall also terminate immediately upon the Consultant’s
death. As a result of termination in accordance with this Section 3(e), the Term will end with no further compensation due to the
Consultant.
(f)
The provisions of Sections 1(e), 3(c), 4, 5, 6 and 7 of this Agreement and the entirety of the Transition Agreement,
with Section 12 of that Transition Agreement modified by the provisions of Section 1(e) herein, shall survive the termination of
this Agreement.
(g)
Upon expiration or termination of this Agreement, the Consultant agrees that the Consultant will not represent to
third parties that the Consultant has continuing ongoing obligations to and with the Company (other than those obligations that
survive the termination of this Agreement, including those set out in Section 1(e) above), and will not represent that the
Consultant has a role with the Company or any authority to speak or act for or on behalf of the Company. However, this section
shall not limit Consultant’s rights to communicate his past services to the Company, including his role as founder and inventor.
4.
No Conflicting Obligation. The Consultant hereby represents that the Consultant is free to enter into this Agreement and
that the Consultant’s performance of all of the terms of this Agreement and of all of the Consultant’s duties as a consultant to the
Company do not and will not breach (i) any agreement to keep in confidence information acquired by the Consultant in
confidence or in trust, (ii) any agreement to assign to any third party inventions made by the Consultant, or (iii) any agreement
not to compete against the business of any third party. Consultant further represents that the Consultant has not made and will not
make any agreements in conflict with this Agreement.
5.
Mutual Non-Disparagement; No Use of Name, Etc.
(a)
Except as expressly permitted in Sections 4(b) and 8 of the Transition Agreement, the Consultant agrees that the
Consultant shall not at any time make any written or oral comments or statements of a defamatory or disparaging nature
regarding the Company and/or the Company Releasees (as defined in the Transition Agreement) and the Consultant shall not take
any action that would cause or contribute to their being held in disrepute. The Company agrees to direct its directors and officers
not to at any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the
Consultant or take any action that would cause or contribute to the Consultant being held in disrepute.
5
DB1/ 144801600.7


(b)
Without the prior written consent of the Company, the Consultant shall not at any time use, for the Consultant’s
benefit or on behalf of any other person, any name that is identical or similar to or likely to be confused with the name of the
Company or any of Affiliate of the Company (as defined in Section 7(c) below) or any product or service produced or provided
by the Company or any Affiliate of the Company.
(c)
The Consultant shall not hold the Consultant out as currently representing the Company without the prior written
consent of the Company, unless it is within the scope of the Services being provided for the Company. Matters and inquiries
outside the scope of the Services and relating to the Company should be directed to the Chief Executive Officer of the Company.
(d)
Nothing in this Agreement restricts or prohibits the Consultant from (i) accurately conveying to other parties the
Consultant’s past contributions as founder and inventor of the Company’s products, as well as the Consultant’s past service to the
Company, and to using the Company name and products in doing so, or (ii) initiating communications directly with, responding
to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or
regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government
agency, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or local law or
regulation. The Consultant does not need the prior authorization of the Company to engage in conduct protected by this Section,
and the Consultant does not need to notify the Company that the Consultant has engaged in such conduct. The Consultant should
take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to
individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential circumstances
that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of
the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
6.
Return of Property. The Consultant agrees to promptly return to the Company after the end of the Term, or sooner if
requested by the Company, all of its property, including, but not limited to, computers, files, and documents, including any
correspondence or other materials containing trade secrets of the Company, identification cards, credit cards, keys, equipment,
software and data, however stored other an as required to perform the consultancy services, as agreed with the Company. To the
extent the Consultant has any Company information or material stored on any PDA, personal computer, personal email, hard
drive, thumb drive, cloud or other electronic storage device, the Consultant agrees to permanently delete such information from
such devices, subject to any Company litigation preservation directive then in effect; provided that the Consultant agrees to
submit to the Company for approval a list of any Company-related items on the Consultant’s personal electronics that the
Consultant believes the Consultant should be permitted to retain.
7.
Miscellaneous.
6
DB1/ 144801600.7


(a)
This Agreement represents the entire Agreement of the Parties with respect to the arrangements contemplated
hereby. No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this
Agreement. This Agreement may be amended only by a written instrument executed in one or more counterparts by the Parties.
(b)
No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed
or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other
obligations hereunder. Failure on the part of either Party to complain of any act or failure to act of the other Party or to declare the
other Party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver
hereunder shall be effective unless it is in writing, executed by the Party waiving the breach or default hereunder.
(c)
This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors
and permitted assigns. This Agreement may be assigned by the Company to any Affiliate of the Company, with Consultant’s
prior written consent (as long as the Company remains secondarily liable for any payments or obligations hereunder) and to a
successor of its business to which this Agreement relates (whether by purchase or otherwise). “Affiliate of the Company” means
any person or entity which, directly or indirectly, controls or is controlled by or is under common control with the Company and,
for the purposes of this definition, “control” (including the terms “controlled by” and “under common control with”) shall mean
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of another
whether through the ownership of voting securities or holding of office in another, by contract or otherwise. The Consultant may
not assign or transfer any or all of the Consultant’s rights or obligations under this Agreement; provided, that, any amounts due
under this Agreement upon or following the Consultant’s death shall be paid to Consultant’s estate or beneficiaries, as applicable.
(d)
Unless otherwise provided herein, any notice, report, payment or document to be given by one Party to the other
shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid
(such mailed notice to be effective on the date which is three business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one business day after it is deposited with such courier),
or sent by email (such notice sent by email to be effective when sent, if confirmed by certified or registered mail or overnight
courier as aforesaid), or sent by telefax (such notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) addressed to the Party at the address set forth on the signature page to this
Agreement or to such other place as any Party may designate as to itself by written notice to the other Party. Either Party may
change its address for notices by means of a notice delivered in accordance with this Section 7(d). Notwithstanding the foregoing,
all such notices, reports, payments or documents provided by the Company to the Consultant shall be sent by email (in addition
to any other form of delivery chosen by the Company) to the Consultant at his personal email address on file with the Company.
7
DB1/ 144801600.7


(e)
This Agreement shall be governed by and construed in accordance with the substantive laws of the
Commonwealth of Massachusetts without reference to any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Section headings of this Agreement are for reference only and shall
not affect its interpretation. In the event that any provision of this Agreement should be held unenforceable by a court of
competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent
permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.
(f)
The Parties agree that any breach or threatened breach of Sections 1(e), 4, 5, 6 or 7 of this Agreement by the
Consultant may cause irreparable harm to the Company; and that money damages will not provide an adequate remedy. In the
event of a breach or threatened breach of Sections 1(e), 4, 5, 6 or 7 of this Agreement by the Consultant, the Company shall, in
addition to any other rights and remedies it may have, be entitled to an injunction, without the need to post bond.
(g)
In the event that the Consultant is made, or threatened to be made, a party to any legal action or proceeding,
whether civil or criminal, including any governmental or regulatory proceedings or investigations, arising out of, related to or
based upon any violation of law, rule or regulation by the Company, by reason of the fact that the Consultant is or was engaged
by the Company to perform the Services, the Consultant shall be indemnified by the Company to the fullest extent permitted by
law provided that notwithstanding the foregoing, no such indemnification shall apply if the Consultant has acted illegally,
fraudulently and/or in bad faith in connection with the Consultant’s Services and/or obligations hereunder.
(h)
This Agreement may be executed in counterparts, all of which together shall for all purposes constitute one
agreement binding on each of the Parties hereto notwithstanding that each such Party shall not have signed the same counterpart.
[Signature Page Follows]
8
DB1/ 144801600.7


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
REPLIMUNE, INC.
By:        /s/ Philip Astley-Sparke    
Name:    Philip Astley-Sparke
Title:    Chief Executive Officer
Address: 500 Unicorn Park Dr., 3  Floor
     Woburn, MA 01801
Email:
Date: March 25, 2024
CONSULTANT
By: ______/s/ Robert Coffin______
Robert Coffin
Address:
    
    
Email:
                    Date: March 25, 2024
R
li
I
rd
DB1/ 144801600.7


Replimune Inc
500 Unicorn Park Dr.
Woburn, MA 01801
    
PERSONAL & CONFIDENTIAL                                                                            March 26 , 2024
Pamela Esposito
RE:    Separation Agreement and Release
Dear Pamela:
This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of
your separation from employment with Replimune, Inc. (the “Company”) without Cause (as defined in the Employment
Agreement with the Company dated January 20, 2016 (the “Employment Agreement”). This Agreement provides for all
payments to which you may be entitled from the Company, including under the Employment Agreement. You and the Company
(the “Parties” and each, a “Party”) agree as follows:
1.
Separation Date and Transition Period. Your last day of employment with the Company will be March 31, 2024 (the “Last
Day of Employment”) and you shall be eligible for the benefits set forth in Section 2 below. Effective as of the date
hereof, you shall continue to be available to the Company to complete certain projects and transition your duties, as
reasonably requested by the Chief Executive Officer of the Company (the “CEO”). You will continue to receive your
current base salary and benefits through the Last Day of Employment. Additionally, you will receive any other amounts
earned, accrued and owing but not yet paid through your Last Day of Employment, including any vested benefits accrued
and due under any applicable benefit plans and programs of the Company, pursuant to the Employment Agreement,
regardless of whether you execute or revoke this Agreement. Consistent with prior Company practices, you will also
receive payment for approved expenses, which the Company recognizes are outstanding, within 30 days after receipt of
the expense report. Your employment and your participation in and eligibility for the Company’s employee benefit plans
and programs will terminate on your Last Day of Employment. Except for consulting services, in accordance with the
Consulting Agreement described below, effective as of the Last Day of Employment, you will automatically be deemed to
resign from all Company-related positions, including as an officer and director of the Company and its parents,
subsidiaries and affiliates, as applicable, and shall execute all documentation necessary to effectuate such resignation(s).
On your Last Day of Employment your Company email shall be disabled and have an automatic reply containing your
consulting email address (and telephone number if you request).
2.
Consideration in Exchange for Release.
(a)
Provided you timely execute and do not revoke this Agreement, you comply with your obligations under the
Employment Agreement, attached hereto as Exhibit A, and effectively transition your responsibilities prior to your
Last Day of
DB1/ 144798856.7


Employment: (i) you will be eligible to receive the severance payments and benefits set forth in Section 2(b)
below and (ii) the Company will enter into the consulting agreement attached here as Exhibit B (the “Consulting
Agreement”) with you, to be effective on April 1, 2024, and the Company will provide the compensation
described therein upon performance of the services described therein.
(b)
Provided you have timely executed and not revoked this Agreement and provided you timely execute and do not
revoke the release attached as Exhibit C (“Second Release”) (which must be executed within 45 days of, and not
before, the Last Day of Employment) and otherwise comply with their terms, you shall receive the following
additional benefits:
(i)
An amount equal to $435,240, which is 12 months of your current base salary, shall be paid to you in
installments in accordance with the Company’s normal payroll practices, commencing within 60 days
following the Last Day of Employment; provided that, any installments not paid between the Last Day of
Employment and the date of the first payment will be paid with the first payment.
(ii)
The full amount of your Annual Bonus (as defined in the Employment Agreement) for the fiscal year
ending March 31, 2024 in the amount of $147,981 (the “Annual Bonus Payment”), shall be paid to you.
The Annual Bonus Payment will be paid when annual bonuses are paid to other employees, not later than
60 days following the Last Day of Employment.
(iii)
During the period beginning on the Last Day of Employment and ending on the earliest of (A) the date on
which you first become covered by any other “group health plan” as described in Section 4980B(g)(2) of
the Internal Revenue Code of 1986, as amended (the “Code”), (B) March 31, 2025, or (C) the date you
cease to be eligible for continued coverage under the Consolidated Omnibus Budget Reconciliation Act
(“COBRA”) for any reason (such period, the “Coverage Period”), if you timely elect to receive continued
health coverage under the Company’s health plan pursuant to COBRA at a level of coverage at your level
of coverage in effect on the Last Day of Employment, the Company will pay monthly COBRA premiums
directly to the carrier(s) on your behalf. You agree to notify the Company within five days of your
coverage under an alternative health plan upon becoming covered by such alternative plan, or your other
ineligibility for continued coverage under COBRA upon becoming ineligible. The COBRA health care
continuation coverage period under Section 4980B of the Code shall run concurrently with the Coverage
Period.
2
DB1/ 144798856.7


3.
Release.
(a)
In consideration of the compensation and benefits set forth in Section 2(a) hereof, to the fullest extent permitted by
law you waive, release, and forever discharge the Company and each of its past and current parents, subsidiaries,
affiliates, and each of its and their respective past and current directors, officers, members, trustees, employees,
representatives, agents, attorneys, employee benefit plans and such plans’ administrators, fiduciaries, trustees,
recordkeepers and service providers, and each of its and their respective successors and assigns, each and all of
them in their personal and representative capacities (collectively the “Company Releasees”) from any and all
claims legally capable of being waived, agreements, causes of action, attorneys’ fees, costs, damages, or any right
to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by
contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which
you now have, ever have had, or may hereafter have, whether known or unknown to you, arising at any time up to
the date of your execution of this Agreement, arising out of or relating in any way to your employment with the
Company or the termination thereof.
Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to
the extent legally capable of being waived, based upon or arising under any federal, state or local fair employment
practices or equal opportunity laws, including, but not limited to, the Age Discrimination in Employment Act
(“ADEA”) (29 U.S.C. Section 621, et seq.), 42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the
Equal Pay Act, the Employee Retirement Income Security Act (“ERISA”) (including, but not limited to, claims
for breach of fiduciary duty under ERISA), the Americans With Disabilities Act, the Family and Medical Leave
Act of 1993, the New Hampshire Protective Legislation Law, the New Hampshire Unemployment Compensation Law,
the New Hampshire Uniform Trade Secrets Act, the New Hampshire Whistleblowers' Protection Act, the New
Hampshire Minimum Wage Act, the New Hampshire Public Employee Labor Relations Act, the New Hampshire
Safety and Health of Employees Law, the New Hampshire Law Against Discrimination, the Massachusetts Fair
Employment Practices Act, the Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the
Massachusetts Parental Leave Act, the Massachusetts Labor and Industries Act, the Massachusetts right of privacy
law, the Massachusetts Wage Act (as further explained below), the Massachusetts Earned Sick Time law, the
Massachusetts Equal Pay Act, the Massachusetts Paid Family and Medical Leave Law, and the Massachusetts
Minimum Fair Wage Law, all as amended, as well as any claim or right under your Employment Agreement
unless provided herein.
Massachusetts Wage Act Waiver. By signing this Agreement, you acknowledge that this waiver includes any
claims against the Company Releasees under Mass. Gen. Laws ch. 149, § 148 et seq.,—the Massachusetts Wage
Act. These claims include, but are not limited to, claims for failure to pay earned wages, failure to
3
DB1/ 144798856.7


pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or
holiday pay, failure to furnish appropriate pay stubs, improper wage deductions, and failure to provide proper
check-cashing facilities.
(b)
You acknowledge that you have not filed any claims or allegations that you have been the subject discrimination,
harassment, sexual abuse or retaliation, and none of the payments set forth as consideration in this Agreement or
the Second Release, are related to discrimination, harassment, sexual abuse or retaliation. In addition, nothing in
this Agreement precludes you from discussing or disclosing information about unlawful acts in the workplace,
such as harassment, discrimination, sexual assault or any other conduct that you have reason to believe is
unlawful, including the amount or fact of any settlement relating to such acts.
(c)
Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or
prevents you from making or asserting: (i) any claim or right you may have under COBRA; (ii) any claim or right
you may have for unemployment insurance or workers’ compensation benefits (other than for retaliation under
workers’ compensation laws); (iii) any claim to vested benefits under the written terms of a qualified employee
pension benefit plan; (iv) any right to indemnification and/or advancement that you may have as a former officer
of the Company; (v) any medical claim incurred during your employment that is payable under applicable medical
plans or an employer-insured liability plan; (vi) any claim or right that may arise after the execution of this
Agreement; (vii) any claim or right you may have under this Agreement; or (viii) any claim that is not otherwise
able to be waived under applicable law.
(d)
In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment
Opportunity Commission (“EEOC”) or similar federal or state fair employment practices agency or interfere with
your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that
pursuant to Section 3(a) above, you are waiving any right to recover monetary damages or any other form of
personal relief from the Company Releasees to the extent any such charge, complaint, investigation or proceeding
asserts a claim subject to the release in Section 3(a) above. To the extent you receive any such personal or
monetary relief in connection with any such charge, complaint, investigation or proceeding, the Company will be
entitled to an offset for the payments made pursuant to Section 2(b) of this Agreement to the fullest extent
permitted by law.
(e)
In consideration of the covenants set forth in this Agreement, to the fullest extent permitted by law, the Company,
on behalf of the Company and each of its past and current parents, subsidiaries and affiliates (“Executive
Releasees”), waives, releases, and forever discharges you the from any and all claims legally capable of being
waived, agreements, causes of action, attorneys’ fees, costs, damages, or
4
DB1/ 144798856.7


any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity,
by contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law,
which they now have, ever have had, or may hereafter have, whether known or unknown to them, arising at any
time up to the date of your execution of this Agreement, arising out of or relating in any way to your employment
with the Company or the termination thereof; provided that notwithstanding the foregoing, nothing contained in
this Agreement constitutes a release or waiver by the Company or any Executive Releasee, or prevents the
Company or any Executive Releasee from making or asserting any claims the Company or an Executive Releasee
may have against you, relating to any felony, fraud, or embezzlement.
4.
No Additional Entitlements. You agree and represent that other than as provided for in this Agreement, you have received
all entitlements due from the Company relating to your employment with the Company or under your Employment
Agreement, including but not limited to, all wages earned, including without limitation all commissions and bonuses, sick
pay, vacation pay, overtime pay, and any paid and unpaid personal leave for which you were eligible and entitled, and that
no other entitlements are due to you other than as set forth in this Agreement. Additionally, the Company agrees not to
contest any claim for unemployment benefits you may file; provided, however, that the Company may respond to any
inquiry from the unemployment compensation board to the extent you make any allegations of wrongdoing by the
Company. Except as expressly provided for herein, your Employment Agreement with the Company is hereby terminated.
5.
Protection of Confidential Information. Except as expressly permitted in Sections 3(b) and 7 of this Agreement or if
otherwise required by law, you agree that you will not at any time, directly or indirectly, use or disclose any trade secret,
confidential or proprietary information you have learned by reason of your employment with the Company and will
continue to abide by your confidentiality obligations pursuant to Section 6 of your Employment Agreement.
6.
Non-Disparagement. Except as expressly permitted in Sections 3(b) and 6 of this Agreement, you agree that you shall not
at any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the
Company and/or the Company Releasees and you shall not take any action that would cause or contribute to their being
held in disrepute. The Company’s directors and officers will not at any time make any written or oral comments or
statements of a defamatory or disparaging nature regarding you or take any action that would cause or contribute to you
being held in disrepute. You and the Company agree to prepare a mutually acceptable internal communication to
employees and third parties regarding your transition from employment and continued services as a consultant.
7.
Reports to Government Entities. Nothing in this Agreement restricts or prohibits you from initiating communications
directly with, responding to any inquiries from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with
a self-regulatory authority or a government agency, from making other disclosures that
5
DB1/ 144798856.7


are protected under the whistleblower provisions of federal, state, or local law or regulation, or engaging in the conduct
set forth in Section 3(b) of this Agreement. You do not need the prior authorization of the Company to engage in conduct
protected by this Section, and you do not need to notify the Company that you have engaged in such conduct. Please take
notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation
to individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential
circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a
suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
8.
Non-Admission. It is understood and agreed that neither the execution of this Agreement nor the terms of this Agreement
constitute an admission of liability to you by the Company or the Company Releasees, nor by you to the Company or the
Company Releasees, and such liability is expressly denied. It is further understood and agreed that no person shall use this
Agreement, or the consideration paid pursuant thereto, as evidence of an admission of liability, in as much as such
liability is expressly denied.
9.
Cooperation. You agree that upon the Company’s reasonable written notice to you, and a reasonable request, you shall
reasonably cooperate with the Company and its counsel (including, if necessary, preparation for and appearance at
depositions, hearings, trials or other proceedings) with regard to matters that relate to or arise out of matters you have
knowledge about or have been involved with during your employment with the Company. In the event that such
cooperation is required, you will be advanced for any reasonable travel expenses incurred in connection therewith. In
addition, the Company will cover your reasonable legal fees; to the extent a conflict or potential conflict exists with a
Company lawyer who would be representing you, you may retain separate mutually acceptable counsel.
10.
Confidentiality of the Agreement. Except as permitted in Sections 3(b) and 7 of this Agreement, as may be required
pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof, to enforce the terms
of this Agreement or if otherwise required by law, the Parties, including the Company, shall not disclose the terms of this
Agreement, or the circumstances giving rise to this Agreement, to any person other than their respective attorneys,
immediate family members, accountants, financial advisors or corporate employees who have a business need to know
such terms in order to approve or implement such terms.
11.
Restrictive Covenant Obligations. Subject to Section 7 of this Agreement, you reaffirm and agree that you remain bound
by Sections 7, 9, 10 and 22 of your Employment Agreement, which are incorporated herein by reference. Notwithstanding
the foregoing, the Company hereby amends:
(a)
The restriction set out in Section 7.1(a) of your Employment Agreement is hereby waived, effective as of the Last
Day of Employment.
6
DB1/ 144798856.7


(b)
Section 7.1(b) of your Employment Agreement is hereby amended to include “… for the purpose of leading any
person to cease …” instead of “…which may lead to any person to ceasing…”
(c)
Section 7.1(c) of your Employment Agreement to “solicit away” instead of “solicit;”
(d)
Section 7.1(d) of your Employment Agreement to “… where such dealing is for the purpose of leading any person
to cease …” instead of “…where such dealing may lead to any person to ceasing…”
12.
Return of Company Property. Subject to Section 10 of your Employment Agreement which permits you to retain one
copy of certain information for archival purposes, by no later than three days after the last day on which you provide
consulting services under the Consulting Agreement, you must certify that you have destroyed, or send to Camilo Garcia
by overnight FedEx: (i) all originals and copies of all documents and property of the Company or an affiliate that is in
your possession or under your control or to which you may have access, (ii) all Company property, including keys, key
cards, access cards, identification cards, security devices, employer credit cards, network access devices, computers, cell
phones, smartphones, PDAs, pagers, fax machines, equipment, manuals, reports, files, books, compilations, work product,
e-mail messages, recordings, disks, thumb drives or other removable information storage devices, hard drives, and data,
and (iii) to the extent that you made use of your personal electronics (e.g., laptop, iPad, telephone, thumb drives, etc.)
during your employment with the Company, permit the Company to delete all Company property and information from
such personal devices. For the avoidance of doubt, you may retain any Company issued telephone.
13.
Acknowledgments. You hereby acknowledge that:
(a)
The Company advises you to consult with an attorney before signing this Agreement (including all Exhibits
thereto);
(b)
You have obtained independent legal advice from an attorney of your own choice with respect to this Agreement
(including all Exhibits thereto), or you have knowingly and voluntarily chosen not to do so;
(c)
You freely, voluntarily and knowingly entered into this Agreement and all Exhibits thereto after due consideration;
(d)
You have had a minimum of forty-five (45) days to review and consider this Agreement (including all Exhibits
thereto) (the “Consideration Period”);
(e)
You and the Company agree that changes to the Company’s offer contained in this Agreement, whether material or
immaterial, will not restart the Consideration Period provided for in Section 13(d) above;
(f)
You have a right to revoke this Agreement, by notifying the undersigned representative in writing, via hand
delivery, facsimile or electronic mail, within seven (7) business days of your execution of this Agreement;
7
DB1/ 144798856.7


(g)
As required by federal law, you have received a listing (as Exhibit D hereto) of the ages and job titles of
employees in the Decisional Unit, described in Exhibit D, who were selected for termination and eligible to
receive severance pay and benefits in exchange for signing a release of claims, and the employees who were not
selected for termination and not eligible to receive severance pay and benefits in exchange for signing a release of
claims;
(h)
In exchange for your waivers, releases and commitments set forth herein, including your waiver and release of all
claims arising under the ADEA, the payments, benefits and other considerations that you are receiving pursuant to
this Agreement exceed any payment, benefit or other thing of value to which you would otherwise be entitled, and
are just and sufficient consideration for the waivers, releases and commitments set forth herein; and
(i)
No promise or inducement has been offered to you, except as expressly set forth herein, and you are not relying
upon any such promise or inducement in entering into this Agreement.
14.
Medicare Disclaimer. You acknowledge that you are not a Medicare Beneficiary as of the time you enter into this
Agreement. To the extent that you are a Medicare Beneficiary, you agree to contact a Company Human Resources
Representative for further instruction.
15.
Miscellaneous.
(a)
Entire Agreement. This Agreement (including the Second Release), together with the expressly incorporated
provisions of your Employment Agreement and the Consulting Agreement, sets forth the entire agreement
between you and the Company and unless otherwise indicated replaces any other oral or written agreement
between you and the Company, including, without limitation, any prior offer letters and/or employment
agreements, but not including the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, which
remains in full force and effect.
(b)
Governing Law. This Agreement shall be construed, performed, enforced and in all respects governed in
accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the principles of
conflicts of law thereof. Additionally, all disputes arising from or related to this Agreement shall be brought in a
state or federal court situated in the Commonwealth of Massachusetts, Suffolk County, and the Parties hereby
expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes.
(c)
Severability. Should any provision of this Agreement be held to be void or unenforceable, the remaining
provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions
were originally deleted.
(d)
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the
Company shall withhold from any payments under this Agreement all federal, state, and local taxes as the
Company is required
8
DB1/ 144798856.7


to withhold pursuant to any law or governmental rule or regulation. You shall bear all expense of, and be solely
responsible for, the employee portion of all federal, state, and local taxes due with respect to any payment received
under this Agreement.
(e)
Legal Fees. The Company will pay your attorney up to $15,000 of reasonable legal fees incurred in the review of
this Agreement and the Consulting Agreement, following submission of an appropriate invoice. This payment will
be reported on a Form 1099-MISC.
(f)
Section 409A. This Agreement is intended to comply with Section 409A of the Code, and its corresponding
regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in
a manner permitted by Section 409A of the Code, to the extent applicable. To the extent that any provision of this
Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a
manner so that all payments hereunder comply with Section 409A of the Code. Severance benefits under this
Agreement are intended to be exempt from Section 409A of the Code under the “short-term deferral” exception, to
the maximum extent applicable, and then under the “separation pay” exception, to the maximum extent applicable.
All payments to be made upon a termination of employment under this Agreement may only be made upon a
“separation from service” to the extent required under Section 409A of the Code. The Parties agree that as of the
Termination Date, you will have incurred a “separation from service” with the Company and following the
Termination Date you will be providing 20% or less of the average level of bona fide services you provided to the
Company and its affiliates over the immediately preceding 36-month period prior to the Termination Date. For
purposes of Section 409A of the Code, each payment hereunder shall be treated as a separate payment, and the
right to a series of installment payments under this Agreement shall be treated as a right to a series of separate
payments. In no event may you, directly or indirectly, designate the calendar year of a payment. Notwithstanding
any provision of this Agreement to the contrary, in no event shall the timing of your execution of this Agreement
or the Second Release, directly or indirectly, result in your designating the calendar year of payment of any
amounts of deferred compensation subject to Section 409A of the Code. All reimbursements and in-kind benefits
provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of
the Code. The Parties agree that this Agreement may be amended, as reasonably requested by either Party and as
may be necessary to comply with Section 409A of the Code and all related rules and regulations as mutually
agreed-upon by the Parties. The Parties intend that any such amendment will preserve the payments and benefits
provided hereunder without additional cost to either Party, to the extent practicable.
(g)
Section 280G. Your rights under Section 5.8 of the Employment Agreement shall continue until March 31, 2025.
9
DB1/ 144798856.7


(h)
Amendments. This Agreement may not be modified or amended, except upon the express written consent of both
you and the Company.
(i)
Breach. You acknowledge that if you materially breach your commitments to the Company agreed upon in
Sections 5, 6, 8, 9, 10, 11, or 12, the Company may cease payment of any severance benefits under Section 2 and
require that you be subject to suit by the Company for damages and equitable relief relating to such breach and
your Consulting Agreement will terminate; provided that if your breach is curable the Company shall provide you
with prompt written notice and a reasonable opportunity to cure. If a court of competent jurisdiction determines
that you materially breached your commitments to the Company agreed upon in Sections 5, 6, 8, 9, 10, 11, or 12
and such breach was not cured, you may be required to forfeit all or part of the severance benefits not yet paid to
you and to repay all severance amounts previously paid to you. You further acknowledge that any material breach
by you of Sections 5, 6, 8, 9, 10, 11, or 12 will cause irreparable damage to the Company and that in the event of
such breach, the Company shall have, in addition to any and all remedies at law, the right to an injunction, specific
performance or other equitable relief from a court of competent jurisdiction to prevent and/or restrain such breach,
without the necessity of posting a bond or undertaking.
(j)
Waiver. A waiver by either Party hereto of a breach of any term or provision of the Agreement shall not be
construed as a waiver of any subsequent breach.
(k)
Counterparts. This Agreement may be executed in one or more counterparts, and be transmitted by facsimile or
pdf, each of which shall be deemed an original, but all of which together shall constitute one and the same
agreement.
(l)
Assignment. In the event of a change of control, the Company will assign any surviving obligations in this
Agreement to the appropriate entity to the extent permitted by law. This Agreement shall inure to the benefit of the
Company and permitted successors and assigns. However, you may not assign this Agreement or any part hereof.
Any purported assignment by you shall be null and void from the initial date of purported assignment.
(m)
Effective Date. This Agreement will become effective and enforceable on the first day following the expiration of
the seven (7) business day revocation period provided for in Section 13(f) above (the “Effective Date”). If you fail
to return an executed original before the expiration of the Consideration Period (or otherwise revoke this
Agreement pursuant to Section 13(f) above), this Agreement, including but not limited to the obligation of the
Company to provide the compensation and benefits provided in Section 2 above, shall be deemed automatically
null and void.
[Signature Page Follows]
10
DB1/ 144798856.7


    If the above accurately states our agreement, including the separation, waiver and release, kindly sign below and return the
original Agreement to me.
Sincerely,
Replimune, Inc.
    /s/ Philip Astley-Sparke    
Name: Philip Astley-Sparke
Title: Chief Executive Officer
Date: March 26, 2024        
    
UNDERSTOOD, AGREED TO AND ACCEPTED WITH THE INTENTION TO
BE LEGALLY BOUND:
___/s/ Pamela Esposito__________________________

Pamela Esposito
Date: March 26, 2024
Signature Page to Separation and Release Agreement
DB1/ 144798856.7


SECOND RELEASE
In consideration of the payments, benefits and other compensation and benefits provided by Replimune, Inc. (the “Company”) as
set forth in the Separation Agreement and Release dated March 26, 2024 (the “Separation Agreement”), which you acknowledge
and agree is just and sufficient consideration for the waivers, releases and commitments set forth herein, by executing this
agreement and release (“Second Release”) you hereby IRREVOCABLY AND UNCONDITIONALLY agree to WAIVE,
RELEASE AND FOREVER DISCHARGE the Company Releasees (as defined in Section 3 of the Separation Agreement) from
any and all claims legally capable of being waived, agreements, causes of action, attorneys’ fees, costs, damages, or any right to
any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort, law of trust
or pursuant to federal, state or local statute, regulation, ordinance or common law, which you now have, ever have had, or may
hereafter have, whether known or unknown to you, arising at any time up to the date of your execution of this Second Release,
arising out of or relating in any way to your employment with the Company or the termination thereof.
Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to the extent
legally capable of being waived, based upon or arising under any federal, state or local fair employment practices or equal
opportunity laws, including, but not limited to, the Age Discrimination in Employment Act (“ADEA”) (29 U.S.C. Section 621, et
seq.), 42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the Equal Pay Act, the Employee Retirement Income
Security Act (“ERISA”) (including, but not limited to, claims for breach of fiduciary duty under ERISA), the Americans With
Disabilities Act, the Family and Medical Leave Act of 1993, the New Hampshire Protective Legislation Law, the New
Hampshire Unemployment Compensation Law, the New Hampshire Uniform Trade Secrets Act, the New Hampshire
Whistleblowers' Protection Act, the New Hampshire Minimum Wage Act, the New Hampshire Public Employee Labor Relations
Act, the New Hampshire Safety and Health of Employees Law, the New Hampshire Law Against Discrimination, the
Massachusetts Fair Employment Practices Act, the Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the
Massachusetts Parental Leave Act, the Massachusetts Labor and Industries Act, the Massachusetts right of privacy law, the
Massachusetts Wage Act (as further explained below), the Massachusetts Earned Sick Time law, the Massachusetts Equal Pay
Act, the Massachusetts Paid Family and Medical Leave Law, and the Massachusetts Minimum Fair Wage Law, all as amended, as
well as any claim or right under the Employment Agreement, unless as provided herein.
Massachusetts Wage Act Waiver. By signing this Second Release, you acknowledge that this waiver includes any claims
against the Company Releasees under Mass. Gen. Laws ch. 149, § 148 et seq.,—the Massachusetts Wage Act. These claims
include, but are not limited to, claims for failure to pay earned wages, failure to pay overtime, failure to pay earned commissions,
failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, improper
wage deductions, and failure to provide proper check-cashing facilities.
Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you from
making or asserting: (i) any claim or right you may have under COBRA; (ii) any claim or right you may have for unemployment
insurance or workers’
DB1/ 144798856.7


compensation benefits (other than for retaliation under workers’ compensation laws); (iii) any claim to vested benefits under the
written terms of a qualified employee pension benefit plan; (iv) any right to indemnification and/or advancement that you may
have as a former officer of the Company; (v) any medical claim incurred during your employment that is payable under
applicable medical plans or an employer-insured liability plan; (vi) any claim or right that may arise after the execution of this
Second Release; (vii) any claim or right you may have under this Second Release; (viii) any claim that is not otherwise able to be
waived under applicable law; (ix) any claim or right that may arise after your execution of this Second Release; or (x) any claim
or right you may have under this Second Release.
In addition, nothing in this Second Release shall prevent you from filing a charge or complaint with the Equal Employment
Opportunity Commission (“EEOC”) or similar federal or state fair employment practices agency or interfere with your ability to
participate in any investigation or proceeding conducted by such agency; provided, however, that you understand and agree that,
pursuant to the Separation Agreement (i) you are waiving any right to recover monetary damages or any other form of personal
relief in connection with any such charge, action, investigation or proceeding; and (ii) to the extent you receive any such personal
or monetary relief in connection with any such charge, complaint, investigation or proceeding, the Company will be entitled to an
offset for the payments made pursuant to Section 2(b) of the Separation Agreement to the fullest extent permitted by law.
By signing this Second Release, you understand and acknowledge that you were advised of and afforded the opportunity to take
advantage of each of the protections set forth in Section 13 of the Separation Agreement, including, but not limited to: (i)
consultation with an attorney before signing this Second Release; (ii) at least forty-five (45) days in which to consider this
Second Release; and (iii) at least seven (7) business days in which to revoke this Second Release after signature. You further
acknowledge that you have received a listing (as Exhibit D attached to the Separation Agreement) of the ages and job titles of
employees in the Decisional Unit, described in Exhibit D, who were selected for termination and eligible to receive severance
pay and benefits in exchange for signing a release of claims, and the employees who were not selected for termination and not
eligible to receive severance pay and benefits in exchange for signing a release of claims. You further acknowledge that you
freely, voluntarily and knowingly entered into this Second Release after due consideration.
This Second Release incorporates by reference, as if set forth fully herein, all terms and conditions of the Separation Agreement
between the Company and you, including the recitation of consideration provided by the Company. By signing this Second
Release, you waive, release and forever discharge any and all claims that may have arisen through the date of your execution of
this Second Release. It is not your intention to otherwise change, alter or amend any of the terms and conditions of the Separation
Agreement, for which you received adequate consideration, and which Separation Agreement remains in full force and effect.
You acknowledge and agree that you continue to be bound by the terms and conditions of the Separation Agreement.
This Second Release shall become effective on the first day following the expiration of the seven (7) business day revocation
period described above, provided you have not exercised your right
DB1/ 144798856.7


to revoke. You understand and agree that, should you fail to timely execute this Second Release, or if you timely execute but then
revoke this Second Release, you shall not be eligible for and you shall not receive the severance benefits set forth in Section 2(b)
of your Separation Agreement.
I UNDERSTAND AND ACKNOWLEDGE THAT I SHALL EXECUTE THIS SECOND RELEASE WITHIN 45 DAYS OF,
AND NOT BEFORE, MY SEPARATION DATE WITH THE COMPANY.
UNDERSTOOD, AGREED TO AND ACCEPTED WITH THE INTENTION TO BE LEGALLY BOUND:
Date: ___April 11, 2024_________    __/s/ Pamela Esposito__________________________
                    Pamela Esposito
DB1/ 144798856.7


    
CONSULTING AGREEMENT
This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 26, 2024 by and between Replimune, Inc.
(the “Company”) and Pamela Esposito (the “Consultant,” together with the Company, the “Parties” and each, a “Party”). This
Agreement will be effective on April 1, 2024. For the avoidance of doubt, if the Consultant does not execute or revokes the
Second Release attached as Exhibit C to the Separation Agreement and Release, dated as of March 26, 2024, between the
Company and the Consultant (the “Separation Agreement”), this Agreement shall not become effective, the Term (as defined in
Section 3(a) below) of this Agreement shall not commence and this Agreement shall automatically terminate and become null
and void ab initio.
1.
Consulting Services.
(a)
Subject to and upon the terms and conditions set forth in this Agreement, effective on April 1, 2024 (the “Start
Date”), the Company hereby retains the Consultant, and the Consultant hereby agrees to be retained by the Company, to provide
consulting services consistent with Schedule 1 attached hereto (the “Services”).
(b)
The Consultant shall devote up to 32 hours per month (and no less than eight hours per month) to the performance
of the Services pursuant to this Agreement. The Consultant shall be available to perform the Services pursuant to this Agreement
during regular business hours.
(c)
The Consultant shall provide the Services under this Agreement at such times and locations as are mutually agreed
upon by the Consultant and the Company, which may include representing the Company externally. In rendering the Services
under this Agreement, the Consultant shall act solely as an independent contractor, the Consultant will not be eligible for any
employee benefit plans or programs maintained by the Company, and this Agreement shall not be construed to create any
employee/employer relationship between the Consultant and the Company.
(d)
During the Term of this Agreement, and except to the extent otherwise agreed upon in writing by the Consultant
and the Company, the Consultant will keep separate and not co-mingle (i) the Consultant’s Services for the Company, and (ii) any
contact information obtained during the Consultant’s consulting relationship with the Company, with those provided, or pursuant,
to any other consulting arrangements.
(e)
It is understood and agreed that, subject to Section 11 of that certain Separation Agreement, the Consultant may be
involved in any capacity in other businesses, endeavors and undertakings. The Consultant agrees to promptly notify the Company
if the Consultant has accepted full-time employment or a contract to perform services for a third party (“Alternative Work”). The
Consultant further agrees that such Alternative Work shall not interfere with the
DB1/ 144798856.7


Consultant’s ability to perform the Services under this Agreement, including with respect to the required amount of time for
which the Consultant is available to perform such Services as set forth in Section 1(b) and the Consultant shall use the
Consultant’s reasonable efforts to ensure that such interference shall not occur. The Consultant agrees that the Consultant’s
continuing obligations under Section 11 of the Separation Agreement shall remain in full force and effect during the Term of this
Agreement and are hereby incorporated by reference, provided, that, solely for purposes of this Section 1(e), the terms of the
Separation Agreement are hereby modified such that reference therein to the term of the Consultant’s employment with the
Company and termination thereof shall include reference to the Consultant’s consultancy pursuant to this Agreement and the
termination thereof such that, for example, the non-solicitation covenants set forth in the Employment Agreement with the
Company dated January 20, 2016 (“Employment Agreement”) and incorporated into the Separation Agreement shall continue
during the Term of this Agreement and for the one-year period thereafter, as modified herein or in the Separation Agreement. As
consideration for the payments and continued vesting of the Options and RSUs (as each defined in Section 2(c) below), if
applicable, the Consultant agrees to continue to abide by the terms of the Separation Agreement as modified pursuant to the
foregoing provisions of this Section 1(e).
2.
Compensation and Equity Awards.
(a)
Consulting Fees.
(i)
Subject to, and in accordance with, the terms and conditions set forth in this Agreement, during the Term,
the Consultant will be eligible for a consulting fee in an amount equal to $400 per hour of Services
provided by the Consultant. For the avoidance of doubt, nothing in this Agreement shall entitle the
Consultant to the consulting fee after the end of the Term.
(ii)
Consulting fees shall be paid in monthly installments within 30 days following the Consultant’s submission
to the Company of a monthly invoice. The Company will not withhold any income or other employment
taxes from the payments due to the Consultant under this Agreement. The Consultant hereby agrees that
the Consultant will timely pay all taxes and fees upon the income paid by the Company hereunder, and will
indemnify and hold the Company harmless against the claims of any governmental taxing authority made
in connection with the revenue derived by the Consultant under this Agreement.
(b)
The Company shall reimburse the Consultant or, at the Company’s option advance funds, for any actual out-of-
pocket business expenses incurred by the Consultant while rendering Services under this Agreement so long as such expenses are
reasonable and necessary, and appropriately documented and consistent with the Company’s standard practices. Without limiting
the generality of the foregoing, any out-of-pocket travel expenses as well as any out-of-pocket expenses that, individually or in
the aggregate, exceed $500.00, shall be reimbursed, by
2
DB1/ 144798856.7


the Company (or, advanced at the Company’s option) only if approved by the Company in advance of such out-of-pocket
expenses being incurred by the Consultant.
(c)
All of the Consultant’s stock options to purchase shares of Replimune Group, Inc.’s common stock (“Options”)
and restricted stock units on Replimune Group, Inc.’s common stock (“RSUs”) that are unvested as of the Last Day of
Employment (as defined in the Separation Agreement) will continue to vest in accordance with the terms of the governing plan
and award agreements (“Award Agreements”), until the end of the Term. Upon termination of this Agreement for any reason, the
Consultant’s Options shall remain exercisable for the later of the 180-day period following the last day of the Term or December
31, 2025. The Options shall automatically terminate upon the expiration of such 180-day period; provided, however, that in no
event may the Options be exercised after the date that is immediately before the tenth anniversary of the applicable date of grant
of such Options. The Parties to this Agreement expressly agree that, if there is a Change of Control (as defined in the Replimune
Group, Inc. 2018 Omnibus Incentive Compensation Plan (the “Plan”)) before the end of the Term of this Agreement, the Options
and RSUs will be treated in accordance with the terms of the Plan and the Award Agreements. During the Term, the Consultant
shall only sell the number of shares of Replimune Group, Inc.’s common stock as provided for under the Consultant’s share sales
plan . For the avoidance of doubt, (i) following the first anniversary of the Start Date, in the event the Company terminates this
Agreement for any reason upon 90 days’ prior written notice as set forth in Section 3(b), the Consultant’s outstanding Options
and RSUs will continue to vest during such 90-day notice period and (ii) to the extent any of Consultant’s Options expire during
the Term (i.e., hit their tenth anniversary during the Term), such options may be exercised at any time until such tenth anniversary
subject to compliance with the share sales plan.
(d)
Except for the consulting fees described in Section 2(a), any expense reimbursement made in accordance with
Section 2(b) hereof, and any Option and RSU vesting arrangement set forth in Section 2(c), the Company shall have no
obligation to provide any compensation or benefits to the Consultant with respect to any Services rendered by the Consultant to
the Company pursuant to this Agreement. The compensation and benefits set forth in this Section 2 are separate and apart from
the severance benefits provided under the Separation Agreement.
3.
Term; Termination.
(a)
This Agreement shall take effect as of the Start Date and shall continue thereafter in full force and effect until
December 31, 2025, unless terminated earlier in accordance with the provisions of Section 3(b) hereof (the “Term”). The
Consultant shall begin providing the Services to the Company on the Start Date.
(b)
Except as otherwise set forth in this Section 3(b), the Company shall not terminate this Agreement prior to the
expiration of the Term. If the Consultant has materially breached this Agreement or the Separation Agreement, including Section
5(a) of this Agreement and Section 6 of the Separation Agreement, or otherwise engaged in any willful misconduct that has the
effect,
3
DB1/ 144798856.7


or potential effect, of causing material harm to the Company (monetarily, reputationally or otherwise), and following prompt
written notice to the Consultant and the Consultant’s failure to cure such breach or misconduct within five days, the Company
may terminate this Agreement immediately. If the Company has materially breached this Agreement or the Separation Agreement
or otherwise engaged in willful misconduct that has the effect, or potential effect, of causing material harm to the Consultant
(monetarily, reputationally or otherwise), and following prompt written notice to the Company and the Company’s failure to cure
such breach or misconduct within five days, the Consultant may terminate this Agreement immediately. Repeated breaches of the
same type shall not be curable. Upon notice from the Consultant or a determination by the Company that the Consultant has
accepted Alternative Work that interferes with the Consultant’s ability to perform the Services under this Agreement, including
with respect to the required amount of time for which the Consultant is available to perform such Services as set forth in Section
1(b), the Company may terminate this Agreement at any time following the first anniversary of the Start Date upon 30 days’ prior
written notice to the Consultant and the provision to the Consultant of an opportunity to cure within such 30-day period.
Following the first anniversary of the Start Date, the Company may terminate this Agreement for any reason upon 90 days’ prior
written notice. The Parties may also terminate this Agreement by mutual agreement. This Agreement and the Services provided
by the Consultant hereunder shall terminate immediately upon the Consultant’s death. Upon termination of this Agreement and
the Services for any reason, the Company is only obligated to pay the Consultant any amounts owed for the Services performed
through the date of termination. The provisions of Sections 1(e), 3(c), 4, 5, 6 and 7 of this Agreement and the entirety of the
Separation Agreement, with Section 11 of that Agreement modified by the provisions of Section 1(e) herein, shall survive the
termination of this Agreement.
(c)
Upon expiration or termination of this Agreement, the Consultant agrees that the Consultant will not represent to
third parties that the Consultant has continuing ongoing obligations to and with the Company (other than those obligations that
survive the termination of this Agreement, including those set out in Section 1(e) above), and will not represent that the
Consultant has a role with the Company or any authority to speak or act for or on behalf of the Company.
4.
No Conflicting Obligation. The Consultant hereby represents that the Consultant is free to enter into this Agreement and
that the Consultant’s performance of all of the terms of this Agreement and of all of the Consultant’s duties as a consultant to the
Company do not and will not breach (i) any agreement to keep in confidence information acquired by the Consultant in
confidence or in trust, (ii) any agreement to assign to any third party inventions made by the Consultant, or (iii) any agreement
not to compete against the business of any third party. Consultant further represents that the Consultant has not made and will not
make any agreements in conflict with this Agreement.
5.
Mutual Non-Disparagement; No Use of Name, Etc.
4
DB1/ 144798856.7


(a)
Except as expressly permitted in Sections 3(b) and 7 of the Separation Agreement, the Consultant agrees that the
Consultant shall not at any time make any written or oral comments or statements of a defamatory or disparaging nature
regarding the Company and/or the Company Releasees (as defined in the Separation Agreement) and the Consultant shall not
take any action that would cause or contribute to their being held in disrepute. The Company’s directors and officers will not at
any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the Consultant or take
any action that would cause or contribute to the Consultant being held in disrepute.
(b)
Without the prior written consent of the Company, the Consultant shall not at any time use, for the Consultant’s
benefit or on behalf of any other person, any name that is identical or similar to or likely to be confused with the name of the
Company or any of Affiliate of the Company (as defined in Section 7(c) below) or any product or service produced or provided
by the Company or any Affiliate of the Company.
(c)
The Consultant shall not hold the Consultant out as currently representing the Company without the prior written
consent of the Company, unless it is within the scope of the Services being provided for the Company. Matters and inquiries
outside the scope of the Services and relating to the Company should be directed to the Chief Executive Officer of the Company.
(d)
Nothing in this Agreement restricts or prohibits the Consultant from initiating communications directly with,
responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations
of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a
government agency, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or
local law or regulation. The Consultant does not need the prior authorization of the Company to engage in conduct protected by
this Section, and the Consultant does not need to notify the Company that the Consultant has engaged in such conduct. The
Consultant should take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret
misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain,
confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of
a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
6.
Return of Property. Subject to Section 10 of Employment Agreement, the Consultant agrees to promptly return to the
Company after the end of the Term, or sooner if requested by the Company, all of the Company’s property, including, but not
limited to, computers, files, and documents, including any correspondence or other materials containing trade secrets of the
Company, identification cards, credit cards, keys, equipment, software and data, however stored other an as required to perform
the consultancy services, as agreed with the Company. To the extent the Consultant has any Company information or material
stored on any PDA, personal computer, personal email, hard drive, thumb drive, cloud or other electronic storage device, the
5
DB1/ 144798856.7


Consultant agrees to then cooperate with the Company in permanently deleting such information from such devices, subject to
any Company litigation preservation directive then in effect.
7.
Miscellaneous.
(a)
This Agreement and the Separation Agreement represent the entire agreement of the Parties with respect to the
arrangements contemplated hereby. No prior agreement, whether written or oral, shall be construed to change, amend, alter,
repeal or invalidate this Agreement. This Agreement may be amended only by a written instrument executed in one or more
counterparts by the Parties.
(b)
No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed
or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other
obligations hereunder. Failure on the part of either Party to complain of any act or failure to act of the other Party or to declare the
other Party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver
hereunder shall be effective unless it is in writing, executed by the Party waiving the breach or default hereunder.
(c)
This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors
and permitted assigns. This Agreement may be assigned by the Company to any Affiliate of the Company (as long as the
Company remains secondarily liable for any payments or obligations hereunder) and to a successor of its business to which this
Agreement relates (whether by purchase or otherwise). “Affiliate of the Company” means any person or entity which, directly or
indirectly, controls or is controlled by or is under common control with the Company and, for the purposes of this definition,
“control” (including the terms “controlled by” and “under common control with”) shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of another whether through the ownership
of voting securities or holding of office in another, by contract or otherwise. The Consultant may not assign or transfer any or all
of the Consultant’s rights or obligations under this Agreement; provided, that, any amounts due under this Agreement upon or
following the Consultant’s death shall be paid to Consultant’s estate or beneficiaries, as applicable.
(d)
Unless otherwise provided herein, any notice, report, payment or document to be given by one Party to the other
shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid
(such mailed notice to be effective on the date which is three business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one business day after it is deposited with such courier),
or sent by email (such notice sent by email to be effective when sent, if confirmed by certified or registered mail or overnight
courier as aforesaid), or sent by telefax (such notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) addressed to the Party at the address set forth on the signature page to this
Agreement or to such other place as any Party may designate as to
6
DB1/ 144798856.7


itself by written notice to the other Party. Either Party may change its address for notices by means of a notice delivered in
accordance with this Section 7(d). Notwithstanding the foregoing, all such notices, reports, payments or documents provided by
the Company to the Consultant shall be sent by email (in addition to any other form of delivery chosen by the Company) to the
Consultant at his personal email address on file with the Company.
(e)
This Agreement shall be governed by and construed in accordance with the substantive laws of the
Commonwealth of Massachusetts without reference to any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Section headings of this Agreement are for reference only and shall
not affect its interpretation. In the event that any provision of this Agreement should be held unenforceable by a court of
competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent
permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.
(f)
The Parties agree that any material breach or threatened material breach of Sections 1(e), 4, 5, 6 or 7 of this
Agreement by the Consultant may cause irreparable harm to the Company; and that money damages will not provide an adequate
remedy. In the event of such a breach or threatened breach of Sections 1(e), 4, 5, 6 or 7 of this Agreement by the Consultant, the
Company shall, in addition to any other rights and remedies it may have, be entitled to an injunction, without the need to post
bond.
(g)
In the event that the Consultant is made, or threatened to be made, a party to any legal action or proceeding,
whether civil or criminal, including any governmental or regulatory proceedings or investigations by reason of the fact that the
Consultant is or was engaged by the Company to perform the Services, the Consultant shall be indemnified by the Company to
the fullest extent permitted by law provided that notwithstanding the foregoing, no such indemnification shall apply if the
Consultant has acted illegally, fraudulently and/or in bad faith in connection with the Consultant’s Services and/or obligations
hereunder. The Company further agrees that it shall have the Consultant covered as insured and/or an additional insured under
Company insurance policies to the extent permitted under the applicable policy.
(h)
This Agreement may be executed in counterparts, all of which together shall for all purposes constitute one
agreement binding on each of the Parties hereto notwithstanding that each such Party shall not have signed the same counterpart.
[Signature Page Follows]
7
DB1/ 144798856.7


IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first written above.
REPLIMUNE, INC.
By:     /s/ Philip Astley-Sparke
Name:    Philip Astley-Sparke
Title:    Chief Executive Officer
Address: 500 Unicorn Park Dr., 3  Floor
     Woburn, MA 01801
Date: March 26, 2024
CONSULTANT
By: /s/ Pamela Esposito    
Pamela Esposito
Date: March 26, 2024
rd
DB1/ 144798856.7


Schedule 1
Consulting Services
 
•
Partner Meeting Preparation/Participation 
•
Messaging for documents
•
Strategic Consulting
•
Coaching
•
Special projects as directed by the Chief Executive Officer, Executive Chairman or Chief Financial Officer of the
Company
 
R
li
I
DB1/ 144798856.7


Replimune Inc
500 Unicorn Park Dr.
Woburn, MA 01801
    
PERSONAL & CONFIDENTIAL                                                                            March 31, 2024
Tanya Lewis
RE:    Separation Agreement and Release
Dear Tanya:
This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of
your separation from employment with Replimune, Inc. (the “Company”) without Cause (as defined in the Employment
Agreement with the Company dated May 10, 2021 (the “Employment Agreement”). This Agreement provides for all payments to
which you may be entitled from the Company, including under the Employment Agreement. You and the Company (the “Parties”
and each, a “Party”) agree as follows:
1.
Separation Date and Transition Period. Your last day of employment with the Company will be March 31, 2024 (the “Last
Day of Employment”) and you shall be eligible for the benefits set forth in Section 2 below. Effective as of the date
hereof, you shall continue to be available to the Company to complete certain projects and transition your duties, as
reasonably requested by the Chief Executive Officer of the Company (the “CEO”). The Company will continue to pay
you your current base salary, and benefits through the Last Day of Employment. Additionally, the Company will pay you
a total sum of $147,097, representing the full amount of your Annual Bonus for fiscal year ending March 31, 2024. The
Company will also pay you any other amounts earned, accrued and owing but not yet paid through your Last Day of
Employment, including all other vested benefits accrued and due under any applicable benefit plans and programs of the
Company, pursuant to the Employment Agreement, regardless of whether you execute or revoke this Agreement. The
Company will also reimburse you for approved expenses within 30 days after receipt of the expense report. Approval of
such expenses shall not be unreasonably withheld. Your employment and your participation in and eligibility for the
Company’s employee benefit plans and programs will terminate on your Last Day of Employment. Except for consulting
services, in accordance with the Consulting Agreement described below, effective as of the Last Day of Employment, you
will automatically be deemed to resign from all Company-related positions, including as an officer and director of the
Company and its parents, subsidiaries and affiliates, as applicable, and shall execute all documentation necessary to
effectuate such resignation(s).
2.
Consideration in Exchange for Release.
(a)
Provided you timely execute and do not revoke this Agreement, you comply with your obligations under the
Employment Agreement, attached hereto as Exhibit A, and cooperate with the Company in the transition your
responsibilities prior to your Last Day of Employment: (i) the Company will pay you the severance
DB1/ 144956535.8


payments and provide you the benefits set forth in Section 2(b) below and (ii) the Company will enter into the
consulting agreement attached here as Exhibit B (the “Consulting Agreement”) with you, to be effective on April
1, 2024, and the Company will provide the compensation described therein upon performance of the services
described therein.
(b)
Provided you have timely executed and not revoked this Agreement and otherwise comply with their terms, you
shall receive an amount equal to $459,680, which is 12 months of your current base salary. Such amount shall be
paid to you in installments in accordance with the Company’s normal payroll practices, commencing within 60
days following the Last Day of Employment, provided that, any installments not paid between the Last Day of
Employment and the date of the first payment will be paid with the first payment.
3.
Release.
(a)
In consideration of the compensation and benefits set forth in Section 2(a) hereof, to the fullest extent permitted by
law you waive, release, and forever discharge the Company and each of its past and current parents, subsidiaries,
affiliates, and each of its and their respective past and current directors, officers, members, trustees, employees,
representatives, agents, attorneys, employee benefit plans and such plans’ administrators, fiduciaries, trustees,
recordkeepers and service providers, and each of its and their respective successors and assigns, each and all of
them in their representative capacities (collectively the “Company Releasees”) from any and all claims legally
capable of being waived, agreements, causes of action, attorneys’ fees, costs, damages, or any right to any
monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort,
law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which you now
have, ever have had, or may hereafter have, whether known or unknown to you, arising at any time up to the date
of your execution of this Agreement, arising out of or relating in any way to your employment with the Company
or the termination thereof.
Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to
the extent legally capable of being waived, based upon or arising under any federal, state or local fair employment
practices or equal opportunity laws, including, but not limited to, the Age Discrimination in Employment Act
(“ADEA”) (29 U.S.C. Section 621, et seq.), 42 U.S.C. Section 1981, Title VII of the Civil Rights Act of 1964, the
Equal Pay Act, the Employee Retirement Income Security Act (“ERISA”) (including, but not limited to, claims
for breach of fiduciary duty under ERISA), the Americans With Disabilities Act, the Family and Medical Leave
Act of 1993, the Massachusetts Fair Employment Practices Act, the Massachusetts Civil Rights Act, the
Massachusetts Equal Rights Act, the Massachusetts Parental Leave Act, the Massachusetts Labor and Industries
Act, the Massachusetts right of privacy law, the Massachusetts Wage Act (as further explained below), the
Massachusetts
2
DB1/ 144956535.8


Earned Sick Time law, the Massachusetts Equal Pay Act, the Massachusetts Paid Family and Medical Leave Law,
and the Massachusetts Minimum Fair Wage Law, all as amended, as well as any claim or right under your
Employment Agreement unless provided herein.
Massachusetts Wage Act Waiver. By signing this Agreement, you acknowledge that this waiver includes any
claims against the Company Releasees under Mass. Gen. Laws ch. 149, § 148 et seq.,—the Massachusetts Wage
Act. These claims include, but are not limited to, claims for failure to pay earned wages, failure to pay overtime,
failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay,
failure to furnish appropriate pay stubs, improper wage deductions, and failure to provide proper check-cashing
facilities.
(b)
You acknowledge that you have not filed any claims related to discrimination, harassment, sexual abuse or
retaliation, and none of the payments set forth as consideration in this Agreement are related to discrimination,
harassment, sexual abuse or retaliation. In addition, nothing in this Agreement precludes you from discussing or
disclosing information about unlawful acts in the workplace, such as harassment, discrimination, sexual assault or
any other conduct that you have reason to believe is unlawful, including the amount or fact of any settlement
relating to such acts.
(c)
Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or
prevents you from making or asserting: (i) any claim or right you may have under COBRA; (ii) any claim or right
you may have for unemployment insurance or workers’ compensation benefits (other than for retaliation under
workers’ compensation laws); (iii) any claim to vested benefits under the written terms of a qualified employee
pension benefit plan (including, but not limited to, the Company’s 401(k) plan; (iv) any claim for indemnity
pursuant to Section 25 of the Employment Agreement, which is incorporated herein by reference; (v) any medical
claim incurred during your employment that is payable under applicable medical plans or an employer-insured
liability plan; (vi) any claim or right that may arise after the execution of this Agreement; (vii) any claim or right
you may have under this Agreement; or (viii) any claim that is not otherwise able to be waived under applicable
law.
(d)
In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment
Opportunity Commission (“EEOC”) or similar federal or state fair employment practices agency or interfere with
your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that
pursuant to Section 3(a) above, you are waiving any right to recover monetary damages or any other form of
personal relief from the Company Releasees to the extent any such charge, complaint, investigation or proceeding
asserts a claim subject to the release in Section 3(a) above. To the
3
DB1/ 144956535.8


extent you receive any such personal or monetary relief in connection with any such charge, complaint,
investigation or proceeding, the Company will be entitled to an offset for the payments made pursuant to Section
2(b) of this Agreement to the fullest extent permitted by law.
(e)
The Company, on its own behalf and on behalf of each of its current and former affiliates, parents, and
subsidiaries, hereby waives, releases and discharges you from any and all claims, causes of action, costs, damages,
attorneys’ fees, or rights to any monetary recovery, whether known or unknown, whether based in law or in equity,
in contract or tort, or under federal, state, or local laws or regulations, or at common law, arising out of or relating
to your employment with the Company. Notwithstanding the generality of the foregoing, nothing herein
constitutes a release or waiver by the Company of, or prevents the Company from making or asserting: (i) any
claim or right that may arise after the execution of this Agreement; (ii) any claim or right the Company may have
under this Agreement; or (iii) any claim that is not otherwise able to be waived under applicable law.
4.
No Additional Entitlements. You agree and represent that other than as provided for in this Agreement and in the
Consulting Agreement, you have received all entitlements due from the Company relating to your employment with the
Company or under your Employment Agreement, including but not limited to, all wages earned, including without
limitation all commissions and bonuses, sick pay, vacation pay, overtime pay, and any paid and unpaid personal leave for
which you were eligible and entitled, and that no other entitlements are due to you other than as set forth in this
Agreement. Additionally, the Company agrees not to contest any claim for unemployment benefits you may file;
provided, however, that the Company may respond to any inquiry from the unemployment compensation board to the
extent you make any allegations of wrongdoing by the Company. Except as expressly provided for herein, your
Employment Agreement with the Company is hereby terminated.
5.
Protection of Confidential Information. Except as expressly permitted in Sections 3(b) and 7 of this Agreement or if
otherwise required by law, you agree that you will not at any time, directly or indirectly, use or disclose any trade secret,
confidential or proprietary information you have learned by reason of your employment with the Company and will
continue to abide by the confidentiality obligations set forth in Section 15(d) of your Employment Agreement.
6.
Non-Disparagement. Except as expressly permitted in Sections 3(b) and 7 of this Agreement, you agree that you shall not
at any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the
Company and its officers and directors. The Company agrees that the Company and its directors and officers, serving in
such roles as of the Last Day of Employment, will not, at any time, make any written or oral comments or statements of a
defamatory or disparaging nature regarding you. The Company agrees to take reasonable efforts to instruct its senior vice
presidents, vice presidents, executive directors, senior directors and directors, serving in such roles as of the Last Day of
Employment, to not, at any time, make any written or
4
DB1/ 144956535.8


oral comments or statements of a defamatory or disparaging nature regarding you. You and the Company agree to prepare
a mutually acceptable internal communication to employees and third parties regarding your separation. The Company
agrees to respond to any future inquiries from prospective employers by confirming only your dates of employment and
position(s) held.
7.
Reports to Government Entities. Nothing in this Agreement restricts or prohibits you from initiating communications
directly with, responding to any inquiries from, providing testimony before, providing confidential information to,
reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with
a self-regulatory authority or a government agency, from making other disclosures that are protected under the
whistleblower provisions of federal, state, or local law or regulation, or engaging in the conduct set forth in Section 3(b)
of this Agreement. You do not need the prior authorization of the Company to engage in conduct protected by this
Section, and you do not need to notify the Company that you have engaged in such conduct. Please take notice that
federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to
individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential
circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a
suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
8.
Non-Admission. It is understood and agreed that neither the execution of this Agreement nor the terms of this Agreement
constitute an admission of liability to you by the Company or the Company Releasees, and such liability is expressly
denied. It is further understood and agreed that no person shall use this Agreement, or the consideration paid pursuant
thereto, as evidence of an admission of liability, in as much as such liability is expressly denied.
9.
Cooperation. You agree that upon the Company’s reasonable notice to you, and a reasonable request, you shall cooperate
with the Company and its counsel (including, if necessary, preparation for and appearance at depositions, hearings, trials
or other proceedings) with regard to matters that relate to or arise out of matters you have knowledge about or have been
involved with during your employment with the Company. In the event that such cooperation is required, you will be
reimbursed for any reasonable expenses incurred in connection therewith, including but not limited to travel expenses. In
addition, the Company will cover your reasonable legal fees; to the extent a conflict or potential conflict exists with a
Company lawyer who would be representing you, you may retain separate mutually acceptable counsel.
10.
Confidentiality of the Agreement. Except as permitted in Sections 3(b) and 7 of this Agreement, as may be required
pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof, to enforce the terms
of this Agreement or if otherwise required by law, the parties, including the Company, shall not disclose the terms of this
Agreement, or the circumstances giving rise to this Agreement, to any person other than their respective attorneys,
immediate family members, accountants,
5
DB1/ 144956535.8


financial advisors or corporate employees who have a business need to know such terms in order to approve or implement
such terms.
11.
Restrictive Covenant Obligations. Subject to Section 7 of this Agreement, you reaffirm and agree that you remain bound
by Sections 15(b) through (f) and 17 of your Employment Agreement, which are incorporated herein by reference, subject
to the following: (a) The noncompetition provision set forth in Section 15(a) of the Employment Agreement has been
waived and, therefore, does not survive termination of the Employment Agreement; and (b) Section 15(b) of the
Employment Agreement shall be replaced with the following language: The Executive agrees that during the Restriction
Period, the Executive will not either directly or through others, hire or attempt to hire any employee, consultant or
independent contractor of the Company, or solicit or attempt to solicit any such person for the purpose of persuading him
or her to change or terminate his or her relationship with the Company or otherwise to become an employee, consultant or
independent contractor to, for or of any other person or business entity, unless more than 12 months shall have elapsed
between the last day of such person’s employment or service with the Company and the first day of such solicitation or
hiring or attempt to solicit or hire.
12.
Return of Company Property. By no later than the last day on which you provide consulting services under the Consulting
Agreement, you must (i) send to Camilo Garcia by overnight FedEx all originals and copies of all documents and property
of the Company or an affiliate that is in your possession or under your control or to which you may have access, (ii)
deliver to Camilo Garcia all Company property, including keys, key cards, access cards, identification cards, security
devices, employer credit cards, network access devices, computers, cell phones, smartphones, PDAs, pagers, fax
machines, equipment, manuals, reports, files, books, compilations, work product, e-mail messages, recordings, disks,
thumb drives or other removable information storage devices, hard drives, and data, and (iii) to the extent that you made
use of your personal electronics (e.g., laptop, iPad, telephone, thumb drives, etc.) during your employment with the
Company, permit the Company to delete all Company property and information from such personal devices.
13.
Acknowledgments. You hereby acknowledge that:
(a)
The Company advises you to consult with an attorney before signing this Agreement (including all Exhibits
thereto);
(b)
You have obtained independent legal advice from an attorney of your own choice with respect to this Agreement
(including all Exhibits thereto), or you have knowingly and voluntarily chosen not to do so;
(c)
You freely, voluntarily and knowingly entered into this Agreement and all Exhibits thereto after due consideration;
(d)
You have had a minimum of forty-five (45) days to review and consider this Agreement (including all Exhibits
thereto) (the “Consideration Period”);
6
DB1/ 144956535.8


(e)
You and the Company agree that changes to the Company’s offer contained in this Agreement, whether material or
immaterial, will not restart the Consideration Period provided for in Section 13(d) above;
(f)
You have a right to revoke this Agreement, by notifying the undersigned representative in writing, via hand
delivery, facsimile or electronic mail, within seven (7) business days of your execution of this Agreement;
(g)
As required by federal law, you have received a listing (as Exhibit C hereto) of the ages and job titles of
employees in the Decisional Unit, described in Exhibit C, who were selected for termination and eligible to
receive severance pay and benefits in exchange for signing a release of claims, and the employees who were not
selected for termination and not eligible to receive severance pay and benefits in exchange for signing a release of
claims;
(h)
In exchange for your waivers, releases and commitments set forth herein, including your waiver and release of all
claims arising under the ADEA, the payments, benefits and other considerations that you are receiving pursuant to
this Agreement exceed any payment, benefit or other thing of value to which you would otherwise be entitled, and
are just and sufficient consideration for the waivers, releases and commitments set forth herein; and
(i)
No promise or inducement has been offered to you, except as expressly set forth herein, and you are not relying
upon any such promise or inducement in entering into this Agreement.
14.
Medicare Disclaimer. You acknowledge that you are not a Medicare Beneficiary as of the time you enter into this
Agreement. To the extent that you are a Medicare Beneficiary, you agree to contact a Company Human Resources
Representative for further instruction.
15.
Miscellaneous.
(a)
Entire Agreement. Except as otherwise provided herein, this Agreement, together with the expressly incorporated
provisions of your Employment Agreement and the Consulting Agreement, sets forth the entire agreement
between you and the Company and replaces any other oral or written agreement between you and the Company
relating to the subject matter of this Agreement, including, without limitation, any prior offer letters and/or
employment agreements, but not including the Replimune Group, Inc. 2018 Omnibus Incentive Compensation
Plan, which remains in full force and effect.
(b)
Governing Law. This Agreement shall be construed, performed, enforced and in all respects governed in
accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the principles of
conflicts of law thereof. Additionally, all disputes arising from or related to this Agreement shall be brought in a
state or federal court situated in the Commonwealth of Massachusetts, Suffolk County, and the parties hereby
expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes.
7
DB1/ 144956535.8


(c)
Severability. Should any provision of this Agreement be held to be void or unenforceable, the remaining
provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions
were originally deleted.
(d)
Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the
Company shall withhold from any payments under this Agreement all federal, state, and local taxes as the
Company is required to withhold pursuant to any law or governmental rule or regulation. You shall bear all
expense of, and be solely responsible for, the employee portion of all federal, state, and local taxes due with
respect to any payment received under this Agreement.
(e)
Legal Fees. The Company will pay your attorneys up to $15,000 of your reasonable legal fees incurred in the
review of this Agreement and the Consulting Agreement, within ten (10) business days following your submission
of an invoice.
(f)
Section 409A. This Agreement is intended to comply with Section 409A of the Code, and its corresponding
regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in
a manner permitted by Section 409A of the Code, to the extent applicable. To the extent that any provision of this
Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a
manner so that all payments hereunder comply with Section 409A of the Code. Severance benefits under this
Agreement are intended to be exempt from Section 409A of the Code under the “short-term deferral” exception, to
the maximum extent applicable, and then under the “separation pay” exception, to the maximum extent applicable.
All payments to be made upon a termination of employment under this Agreement may only be made upon a
“separation from service” to the extent required under Section 409A of the Code. The Parties agree that as of the
Termination Date, you will have incurred a “separation from service” with the Company and following the
Termination Date you will be providing 20% or less of the average level of bona fide services you provided to the
Company and its affiliates over the immediately preceding 36-month period prior to the Termination Date. For
purposes of Section 409A of the Code, each payment hereunder shall be treated as a separate payment, and the
right to a series of installment payments under this Agreement shall be treated as a right to a series of separate
payments. In no event may you, directly or indirectly, designate the calendar year of a payment. Notwithstanding
any provision of this Agreement to the contrary, in no event shall the timing of your execution of this Agreement,
directly or indirectly, result in your designating the calendar year of payment of any amounts of deferred
compensation subject to Section 409A of the Code. All reimbursements and in-kind benefits provided under this
Agreement shall be made or provided in accordance with the requirements of Section 409A of the Code. The
Parties agree that this Agreement may be amended, as reasonably requested by either Party and
8
DB1/ 144956535.8


as may be necessary to comply with Section 409A of the Code and all related rules and regulations as mutually
agreed-upon by the Parties. The Parties intend that any such amendment will preserve the payments and benefits
provided hereunder without additional cost to either Party, to the extent practicable.
(g)
Section 280G. The Company agrees that the rights afforded to you under in Section 19 of the Employment
Agreement shall survive termination of the Employment Agreement.
(h)
Amendments. This Agreement may not be modified or amended, except upon the express written consent of both
you and the Company.
(i)
Breach. You acknowledge that if you breach, in any material way, any of your commitments to the Company
agreed upon in Sections 5, 6, 8, 9. 10, 11 or 12, the Company may cease payment of any severance benefits not yet
paid to you under Section 2 and you may be subject to suit by the Company for damages and equitable relief
relating to such breach, and your Consulting Agreement will terminate; provided that if your breach is curable the
Company shall provide you with prompt written notice and a reasonable opportunity to cure. Such opportunity to
cure shall not be unreasonably withheld. If a court of competent jurisdiction determines that you materially
breached your commitments to the Company agreed upon in Sections 5, 6, 8, 9. 10, 11 or 12 and such breach was
not cured, the Company may seek a court order determining that you have forfeited all or part of the severance
benefits not yet paid to you. You further acknowledge that any material breach by you of Section 5, 6, 8, 9. 10, 11
or 12 will cause irreparable damage to the Company and that in the event of such breach, the Company shall have,
in addition to any and all remedies at law, the opportunity to seek to an injunction, specific performance or other
equitable relief from a court of competent jurisdiction to prevent and/or restrain such breach, without the necessity
of posting a bond or undertaking.
(j)
Waiver. A waiver by either Party hereto of a breach of any term or provision of the Agreement shall not be
construed as a waiver of any subsequent breach.
(k)
Counterparts. This Agreement may be executed in one or more counterparts, and be transmitted by facsimile or
pdf, each of which shall be deemed an original, but all of which together shall constitute one and the same
agreement.
(l)
Assignment. In the event of a change of control, the Company will assign any surviving obligations in this
Agreement to the appropriate entity to the extent permitted by law. This Agreement shall inure to the Parties and
their permitted successors and assigns. However, neither party may assign its rights or obligations under this
Agreement without the prior written consent of the other party, which consent shall not be unreasonably withheld
or delayed.
(m)
Effective Date. This Agreement will become effective and enforceable on the first day following the expiration of
the seven (7) business day revocation period provided for in Section 13(f) above (the “Effective Date”). If you fail
to return an executed original before the expiration of the Consideration Period (or otherwise
9
DB1/ 144956535.8


revoke this Agreement pursuant to Section 13(f) above), this Agreement, including but not limited to the
obligation of the Company to provide the compensation and benefits provided in Section 2 above, shall be deemed
automatically null and void.
[Signature Page Follows]
10
DB1/ 144956535.8


    If the above accurately states our agreement, including the separation, waiver and release, kindly sign below and return the
original Agreement to me.
Sincerely,
Replimune Inc.
____/s/ Philip Astley-Sparke______________________
Name: Philip Astley-Sparke
Title: Chief Executive Officer
Date: March 31, 2024        
        
UNDERSTOOD, AGREED TO AND ACCEPTED WITH THE INTENTION TO
BE LEGALLY BOUND:
____/s/ Tanya Lewis_____________________________

Tanya Lewis
Date: March 31, 2024
Signature Page to Separation and Release Agreement
DB1/ 144956535.8


DB1/ 144956535.8


CONSULTING AGREEMENT
This CONSULTING AGREEMENT (this “Agreement”) is dated as of March 31, 2024, by and between Replimune, Inc.
(the “Company”) and Tanya Lewis (the “Consultant,” together with the Company, the “Parties” and each, a “Party”). This
Agreement will be effective on April 1, 2024. For the avoidance of doubt, if the Consultant does not execute or revokes the
Separation Agreement and Release, dated as of March 31, 2024, between the Company and the Consultant (the “Separation
Agreement”), this Agreement shall not become effective, the Term (as defined in Section 3(a) below) of this Agreement shall not
commence and this Agreement shall automatically terminate and become null and void ab initio.
1.
Consulting Services.
(a)
Subject to and upon the terms and conditions set forth in this Agreement, effective on April 1, 2024 (the “Start
Date”), the Company hereby retains the Consultant, and the Consultant hereby agrees to be retained by the Company, to provide
strategic consulting services to the Company (the “Services”).
(b)
The amount of time that Consultant shall devote to the performance of the Services pursuant to this Agreement
shall be: (i) for the period beginning on the Start Date and ending on the earlier of the BLA acceptance date (i.e., FDA
acceptance) and December 31, 2024 (the “Initial Term”), four hours per week; and (ii) for the period beginning on the first day
following the end of the Initial Term and ending on the earlier of the date of BLA approval and December 31, 2025 (the “Final
Term”), up to two hours per week. The Consultant shall be available to perform the Services pursuant to this Agreement during
regular business hours, or as otherwise agreed, and either on site or remotely.
(c)
In rendering the Services under this Agreement, the Consultant shall act solely as an independent contractor, the
Consultant will not be eligible for any employee benefit plans or programs maintained by the Company, and this Agreement shall
not be construed to create any employee/employer relationship between the Consultant and the Company.
(d)
The Consultant will keep separate and not co-mingle (i) the Consultant’s Services for the Company, and (ii) any
contact information obtained during the Consultant’s consulting relationship with the Company, with those provided, or pursuant,
to any other consulting arrangements.
2.
Compensation and Equity Awards.
(a)
Consulting Fees.
(i)
Subject to, and in accordance with, the terms and conditions set forth in this Agreement, from April 1,
2024 through the end of the Final Term, the Consultant will be paid a consulting fee in an amount equal to
$500 for each hour of Service provided by the Consultant (the “Consulting Fee”).
DB1/ 144956535.8


For the avoidance of doubt, nothing in this Agreement shall entitle the Consultant to the Consulting Fee
after the end of the Final Term.
(ii)
In addition to the Consultant Fee, the Company shall pay Consultant the cost of any travel required to the
Company’s offices or for other business conducted on behalf of the Company, as required to render the
Services.
(iii)
The Company will not withhold any income or other employment taxes from the payments due to the
Consultant under this Agreement. The Consultant hereby agrees that the Consultant will timely pay all
taxes and fees upon the income paid by the Company hereunder, and will indemnify and hold the
Company harmless against the claims of any governmental taxing authority made in connection with the
revenue derived by the Consultant under this Agreement.
(b)
The Company shall reimburse the Consultant for any actual out-of-pocket expenses incurred by the Consultant
under this Agreement so long as such expenses are reasonable and necessary, and appropriately documented and approved per the
Company’s standard practices. Such expenses include transportation and lodging costs. Without limiting the generality of the
foregoing, any out-of-pocket travel expenses as well as any out-of-pocket expenses that, individually or in the aggregate, exceed
$500.00, shall be reimbursed by the Company only if approved by the Company in advance of such out-of-pocket expenses being
incurred by the Consultant. The Company agrees that such approval shall not be unreasonably withheld or delayed.
(c)
All of the Consultant’s stock options to purchase shares of Replimune Group, Inc.’s common stock (“Options”)
and restricted stock units on Replimune Group, Inc.’s common stock (“RSUs”) that are unvested as of the Last Day of
Employment (as defined in the Separation Agreement) will continue to vest in accordance with the terms of the governing plan
and award agreements (“Award Agreements”), until the end of the Final Term (and, in any case, through May 2025). Upon
termination of this Agreement for any reason, the Consultant’s Options shall remain exercisable for the later of the 180-day
period following the last day of the Final Term or December 31, 2025. The Options shall automatically terminate upon the
expiration of such 180-day period; provided, however, that in no event may the Options be exercised after the date that is
immediately before the tenth anniversary of the applicable date of grant of such Options. The Parties to this Agreement expressly
agree that, if there is a Change of Control (as defined in the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan
(the “Plan”)) before the end of the Final Term of this Agreement, the Options and RSUs will be treated in accordance with the
terms of the Plan and the Award Agreements. During the Term, the Consultant shall only sell the number of shares of Replimune
Group, Inc.’s common stock as provided for under the Consultant’s share sales plan. For the avoidance of doubt, following the
first anniversary of the Start Date, in the event the Company terminates this Agreement for any reason upon 90 days’ prior
written notice as set forth in Section 3(b), the Consultant’s outstanding Options and RSUs will continue to vest during such 90-
day notice period.
2
DB1/ 144956535.8


(d)
Except for the Consulting Fees described in Section 2(a), any expense reimbursement made in accordance with
Section 2(b) hereof, and any Option and RSU vesting arrangement set forth in Section 2(c), the Company shall have no
obligation to provide any compensation or benefits to the Consultant for any Services rendered by the Consultant to the Company
pursuant to this Agreement. The Consultant shall have no obligation to provide any services beyond those to which the
Consultant and the Company have agreed pursuant to this Agreement. The compensation and benefits set forth in this Section 2
are separate and apart from the severance benefits provided under the Separation Agreement.
3.
Term; Termination.
(a)
This Agreement shall take effect as of the Start Date and shall continue thereafter in full force and effect until the
end of the Final Term, unless terminated earlier in accordance with the provisions of Section 3(b) hereof (the “Term”). The
Consultant shall begin providing the Services to the Company on the Start Date.
(b)
Except as otherwise set forth in this Section 3(b), the Company shall not terminate this Agreement prior to the
expiration of the Final Term. Upon a determination by the Company that the Consultant has materially breached this Agreement
or the Separation Agreement, including Section 5(a) of this Agreement and Section 6 of the Separation Agreement, the Company
may terminate this Agreement immediately. Upon a determination by the Consultant that the Company has breached this
Agreement or the Separation Agreement, the Consultant may terminate this Agreement immediately. Upon notice from the
Consultant or a determination by the Company that the Consultant has accepted alternative work that interferes with the
Consultant’s ability to perform the Services under this Agreement, the Company shall provide the Consultant with 30 days’ prior
written notice of the Company’s intent to terminate this Agreement and an opportunity to cure within such 30-day period.
Following the first anniversary of the Start Date, the Company may terminate this Agreement for any reason upon 90 days’ prior
written notice (delivered after the first anniversary of the Start Date). The Parties may also terminate this Agreement by mutual
written agreement. This Agreement and the Services provided by the Consultant hereunder shall terminate immediately upon the
Consultant’s death. Upon termination of this Agreement, the Company shall pay the Consultant any amounts owed for the
Services performed through the date of termination. The provisions of Sections 3(c), 5, 6 and 7 of this Agreement and the entirety
of the Separation Agreement shall survive the termination of this Agreement.
(c)
Upon expiration or termination of this Agreement, the Consultant agrees that the Consultant will not represent to
third parties that the Consultant has a role with the Company or any authority to speak or act for or on behalf of the Company.
4.
No Conflicting Obligation. The Consultant hereby represents that the Consultant is free to enter into this Agreement and
that the Consultant’s performance of all of the terms of this Agreement and of all of the Consultant’s duties as a consultant to the
Company do not and will not breach (i) any agreement to keep in confidence information acquired by the Consultant in
3
DB1/ 144956535.8


confidence or in trust, (ii) any agreement to assign to any third party inventions made by the Consultant, or (iii) any agreement
not to compete against the business of any third party. Consultant further represents that the Consultant has not made and will not
make any agreements in conflict with this Agreement.
5.
Non-Disparagement; No Use of Name, Etc.
(a)
Except as expressly permitted in Sections 3(b) and 7 of the Separation Agreement, the Consultant agrees that she
shall not at any time make any written or oral comments or statements of a defamatory or disparaging nature regarding the
Company and its officers and directors. The Company agrees that the Company and its directors and officers, serving in such
roles as of the Start Date, will not, at any time, make any written or oral comments or statements of a defamatory or disparaging
nature regarding the Consultant. The Company agrees to take reasonable efforts to instruct its senior vice presidents, vice
presidents, executive directors, senior directors and directors, serving in such roles as of the Start Date, to not, at any time, make
any written or oral comments or statements of a defamatory or disparaging nature regarding the Consultant.
(b)
Without the prior written consent of the Company, the Consultant shall not at any time knowingly use, for the
Consultant’s benefit or on behalf of any other person, any name that is identical or similar to or reasonably likely to be confused
with the name of the Company or any of Affiliate of the Company (as defined in Section 7(c) below) or any product or service
produced or provided by the Company or any Affiliate of the Company.
(c)
The Consultant shall not hold the Consultant out as currently representing the Company without the prior written
consent of the Company, unless it is within the scope of the Services being provided for the Company. Matters and inquiries
outside the scope of the Services and relating to the Company should be directed to the Chief Executive Officer of the Company.
(d)
Nothing in this Agreement restricts or prohibits the Consultant from initiating communications directly with,
responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations
of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a
government agency, or from making other disclosures that are protected under the whistleblower provisions of federal, state, or
local law or regulation. The Consultant does not need the prior authorization of the Company to engage in conduct protected by
this Section, and the Consultant does not need to notify the Company that the Consultant has engaged in such conduct. The
Consultant should take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret
misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain,
confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of
a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.
4
DB1/ 144956535.8


6.
Return of Property. The Consultant agrees to promptly return to the Company after the end of the Term or sooner if
requested by Company all of its property, including, but not limited to, computers, files, and documents, including any
correspondence or other materials containing trade secrets of the Company, identification cards, credit cards, keys, equipment,
software and data, however stored other an as required to perform the consultancy services, as agreed with the Company. To the
extent the Consultant has any Company information or material stored on any PDA, personal computer, personal email, hard
drive, thumb drive, cloud or other electronic storage device, the Consultant agrees to cooperate with the Company in permanently
deleting such information from such devices, subject to any Company litigation preservation directive then in effect.
7.
Indemnification. The Company agrees to defend, indemnify and hold the Consultant harmless from and against all third-
party suits, actions, claims, demands, damages or losses, expenses and/or costs of every kind (including reasonable attorneys’
fees) (collectively, “Claims”) to which the Consultant may be subjected as a result of the Consultant’s performance of services to
the Company under this Agreement, except Claims arising out of any gross negligence or willful misconduct of the Consultant.
The Company further agrees that it will have the Consultant covered under the Company’s insurance policies for the duration of
the consulting engagement, to the extent permitted under the applicable policies.
8.
Miscellaneous.
(a)
This Agreement represents the entire Agreement of the parties with respect to the arrangements contemplated
hereby. No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this
Agreement. This Agreement may be amended only by a written instrument executed in one or more counterparts by the parties.
(b)
No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed
or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other
obligations hereunder. Failure on the part of either party to complain of any act or failure to act of the other party or to declare the
other party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver
hereunder shall be effective unless it is in writing, executed by the party waiving the breach or default hereunder.
(c)
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and permitted assigns. This Agreement may be assigned by the Company to any Affiliate of the Company (as long as the
Company remains secondarily liable for any payments or obligations hereunder) and to a successor of its business to which this
Agreement relates (whether by purchase or otherwise). “Affiliate of the Company” means any person or entity which, directly or
indirectly, controls or is controlled by or is under common control with the Company and, for the purposes of this definition,
“control” (including the terms “controlled by” and “under common control with”) shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of
5
DB1/ 144956535.8


another whether through the ownership of voting securities or holding of office in another, by contract or otherwise. The
Consultant may not assign or transfer any or all of the Consultant’s rights or obligations under this Agreement; provided, that,
any amounts due under this Agreement upon or following the Consultant’s death shall be paid to Consultant’s estate or
beneficiaries, as applicable.
(d)
Unless otherwise provided herein, any notice, report, payment or document to be given by one Party to the other
shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage prepaid
(such mailed notice to be effective on the date which is three business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one business day after it is deposited with such courier),
or sent by email (such notice sent by email to be effective when sent, if confirmed by certified or registered mail or overnight
courier as aforesaid), or sent by telefax (such notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) addressed to the Party at the address set forth on the signature page to this
Agreement or to such other place as any Party may designate as to itself by written notice to the other Party. Either Party may
change its address for notices by means of a notice delivered in accordance with this Section 7(d). Notwithstanding the foregoing,
all such notices, reports, payments or documents provided by the Company to the Consultant shall be sent by email (in addition
to any other form of delivery chosen by the Company) to the Consultant at his personal email address on file with the Company.
(e)
This Agreement shall be governed by and construed in accordance with the substantive laws of the
Commonwealth of Massachusetts without reference to any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Additionally, all disputes arising from or related to this Agreement
shall be brought in a state or federal court situated in the Commonwealth of Massachusetts, Suffolk County, and the parties
hereby expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes. Section headings of
this Agreement are for reference only and shall not affect its interpretation. In the event that any provision of this Agreement
should be held unenforceable by a court of competent jurisdiction, such court is hereby authorized to amend such provision so as
to be enforceable to the fullest extent permitted by law, and all remaining provisions shall continue in full force without being
impaired or invalidated in any way.
(f)
The parties agree that any breach or threatened breach of Sections 4, 5, 6, 7 or 8 of this Agreement by the
Consultant or the Company may cause irreparable harm to the other party; and that money damages will not provide an adequate
remedy. In the event of a breach or threatened breach of Sections 4, 5, 6, 7 or 8 of this Agreement by either party, the other party
may, in addition to any other rights and remedies it may have, request an injunction, without the need to post bond.
6
DB1/ 144956535.8


(g)
This Agreement may be executed in counterparts, all of which together shall for all purposes constitute one agreement
binding on each of the parties hereto notwithstanding that each such Party shall not have signed the same counterpart.
[Signature Page Follows]
7
DB1/ 144956535.8


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.
REPLIMUNE, INC.
By:     /s/ Philip Astley-Sparke
Name:    Philip Astley Sparke
Title:    Chief Executive Officer
Address: 500 Unicorn Park, Suite 303
     Woburn, MA 01801
Date: March 31, 2024
CONSULTANT
By: /s/ Tanya Lewis    
Tanya Lewis
                            Date: March 31, 2024
DB1/ 144956535.8


REPLIMUNE GROUP, INC.
CLAWBACK POLICY
Article I.

PURPOSE AND GENERAL TERMS
Section 1.
Purpose.
(a)
Replimune Group, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to implement a
mandatory clawback policy in the event of a Restatement in compliance with the applicable rules of the Nasdaq Stock Market (“Nasdaq”),
which is set forth in Article 2 of this Policy.
(b)
Any capitalized terms used but not immediately defined in this Policy have the meanings set forth in Section 7 of this Article
I.
Section 2.
Administration.
(a)
This Policy shall be administered in the sole discretion of the Committee. The Committee shall have the discretion to
interpret the Policy and make all determinations with respect to this Policy, consistent with applicable law and this Policy. Without limiting
the foregoing, Article II of this Policy shall be interpreted in a manner that is consistent with the requirements of the Applicable Rules, and
compliance with this Policy shall not be waived by the Committee, the Board or the Company in any respect.
(b)
Any interpretations and determinations made by the Committee shall be final and binding on all affected individuals.
Section 3.
Effective Date; Term. This Policy is effective as of October 2, 2023 (the “Effective Date”). Article II of this Policy applies to
Incentive-Based Compensation that is Received by any Executive Officer on or after the Effective Date as described in Section 3 of Article II
below.
Section 4.
Amendment. The Committee may amend this Policy from time to time in its discretion, subject to any limitations under
applicable law or listing standards, including, in the case of Article II, the Applicable Rules. Without limiting the forgoing, the Committee
may amend this Policy as it deems necessary to reflect any amendment of the Applicable Rules or regulations or guidance issued under the
Applicable Rules.
Section 5.
No Substitution of Rights; Non-Exhaustive Rights.
(a)
Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights that may be
available to the Company pursuant to (a) the Company’s equity incentive plans, including the Company’s 2017 Equity Compensation Plan,
the Company’s 2018 Omnibus Incentive Compensation Plan and the Company’s Employee Stock Purchase Plan or any successor plan
thereto, or any other incentive plan of the Company or any of its subsidiaries, (b) the terms of any recoupment policy or provision in any
employment agreement, compensation agreement or arrangement, or other agreement, or (c) any other legal remedies available to the
Company under applicable law.
(b)
In addition to recovery of compensation as provided for in this Policy, the Company may take any and all other actions as it
deems necessary, appropriate and in the Company’s best interest in
EU1/ 502027227.2
Adopted Nov. 20, 2023

connection with the Committee determining that this Policy should apply, including termination of the employment of, or initiating legal
action against, an Executive Officer, and nothing in this Policy limits the Company’s rights to take any such appropriate actions.
Section 6.
Governing Law. This Policy and all determinations made and actions taken pursuant hereto, to the extent not otherwise
governed by mandatory provisions of the Applicable Rules, shall be governed by and construed in accordance with the laws of the State of
Delaware without regard to choice of law principles. If any provision of this Policy shall be held illegal or invalid for any reason, such
illegality or invalidity shall not affect the remaining parts of this Policy, but this Policy shall be construed and enforced as if the illegal or
invalid provision had never been included in this Policy.
Section 7.
Defined Terms. The following capitalized terms used in this Policy have the following meanings:
“Applicable Rules” means Section 10D of the Exchange Act and Rule 10D-1 promulgated thereunder and Listing Rule 5608
of the Listing Rules of Nasdaq.
“Board” means the Board of Directors of the Company.
“Committee” means the Compensation Committee of the Board, or, in the absence of such committee, a majority of
independent directors serving on the Board.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Executive Officer” means each officer of the Company who is identified as an executive officer for the purposes of 17 CFR
§ 229.401(b), which is defined as the Company’s president, principal financial officer, principal accounting officer (or if there is no such
accounting officer, the controller), any vice president of the Company in charge of a principal business unit, division or function (such as
sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar
significant policy-making functions for the Company, as determined under 17 CFR §229.401(b).
“Financial Reporting Measures” means (i) measures that are determined and presented in accordance with the accounting
principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures, (ii)
the Company’s stock price, and (iii) total shareholder return in respect of the Company. A “Financial Reporting Measure” need not be
presented within the financial statements or included in a filing with the SEC.
“Incentive-Based Compensation” means any compensation that is granted, earned, or vested, based wholly or in part upon
the attainment of a Financial Reporting Measure. Incentive-Based Compensation does not include, among other forms of compensation,
equity awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus
awards that are discretionary or based on subjective goals or goals unrelated to Financial Reporting Measures, as determined to be subject to
repayment pursuant to this Policy.
“Received” Incentive-Based Compensation is deemed “Received” for the purposes of this Policy in the Company’s fiscal
period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation award is attained, even if the payment
or grant of the Incentive-Based Compensation occurs after the end of that period.
2
EU1/ 502027227.2
Adopted Nov. 20, 2023

“Recovery Period” means the three completed fiscal years immediately preceding the date on which the Company is
required to prepare a Restatement, which date is the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the
Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is
required to prepare a Restatement, or (ii) a date that a court, regulator or other legally authorized body directs the Company to prepare a
Restatement.
“Regulators” means, as applicable, the Securities and Exchange Commission and Nasdaq.
“Restatement” means that the Company is required to prepare an accounting restatement due to a material noncompliance of
the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an
error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a
material misstatement if the error were corrected in the current period or left uncorrected in the current period.
Article II.

DODD-FRANK RECOUPMENT POLICY FOR EXECUTIVE OFFICERS
Section 1.
Recovery on a Restatement.
(a)
In the event that the Company is required to prepare a Restatement, the Company shall reasonably promptly recover from an
Executive Officer the amount of any erroneously awarded Incentive-Based Compensation that is Received by such Executive Officer during
the Recovery Period. The amount of erroneously Received Incentive-Based Compensation will be the excess of the Incentive-Based
Compensation Received by the Executive Officer (whether in cash or shares) based on the erroneous data in the original financial statements
over the Incentive-Based Compensation (whether in cash or in shares) that would have been Received by the Executive Officer had such
Incentive-Based Compensation been based on the restated results, without respect to any tax liabilities incurred or paid by the Executive
Officer.
(b)
Recovery of any erroneously awarded compensation under this Article II is not dependent on fraud or misconduct by any
Executive Officer in connection with a Restatement.
(c)
Without limiting the foregoing, for Incentive-Based Compensation based on the Company’s stock price or total shareholder
return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in
the Restatement, (i) the amount shall be based on the Company’s reasonable estimate of the effect of the Restatement on the stock price or
total shareholder return upon which the Incentive-Based Compensation was Received, and (ii) the Company shall maintain documentation of
the determination of that reasonable estimate and provide such estimate to Nasdaq as required by the Applicable Rules.
Section 2.
Covered Executive Officers and Covered Incentive-Based Compensation.
(a)
This Article II covers all persons who are Executive Officers at any time during the Recovery Period for which Incentive-
Based Compensation is Received or during the performance period applicable to such Incentive-Based Compensation. Incentive-Based
Compensation shall not be recovered under this Article II to the extent Received by any person before the date the person served as an
Executive Officer. Subsequent changes in an Executive Officer’s employment status, including retirement
3
EU1/ 502027227.2
Adopted Nov. 20, 2023

or termination of employment, do not affect the Company’s right to recover Incentive-Based Compensation pursuant to this Article II.
(b)
Article II of this Policy shall apply to Incentive-Based Compensation that is Received by any Executive Officer on or after
the Effective Date and that results from attainment of a Financial Reporting Measure based on or derived from financial information for any
fiscal period ending on or after the Effective Date. For the avoidance of doubt, this will include Incentive-Based Compensation that may have
been approved, awarded, or granted to an Executive Officer on or before the Effective Date if such Incentive-Based Compensation is
Received on or after the Effective Date.
Section 3.
Methods of Recovery; Limited Exceptions.
(a)
The Committee shall determine, in its sole discretion, the method of recovering any Incentive-Based Compensation Received
pursuant to this Article II, consistent with applicable law, which may include, without limitation, the methods of recovery described in Article
III.
(b)
No recovery shall be required if any of the following conditions are met and the Committee determines that, on such basis,
recovery would be impracticable:
(i)
the direct expense paid to a third party to assist in enforcing this Article II would exceed the amount to be recovered;
provided that prior to making a determination that it would be impracticable to recover any Incentive-Based Compensation based on the
expense of enforcement, the Company shall (x) have made a reasonable attempt to recover the Incentive-Based Compensation, (y) have
documented such reasonable attempts to recover, and (z) provide the documentation to Nasdaq;
(ii)
recovery would violate home country law where that law was adopted prior to November 28, 2022; provided that,
prior to making a determination that it would be impracticable to recover any Incentive-Based Compensation based on a violation of home
country law, the Company shall (x) have obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in
such violation, and (y) provide a copy of such opinion to Nasdaq; or
(iii)
recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to
employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended (the
“Code”), and U.S. Treasury regulations promulgated thereunder.
Section 4.
Reporting; Disclosure; Monitoring. The Company shall make all required disclosures and filings with the Regulators with
respect to this Policy in accordance with the requirements of the Applicable Rules, and any other requirements applicable to the Company,
including the disclosures required in connection with SEC filings.
Article III.

METHODS OF RECOVERY
Section 1.
Methods of Recovery. Subject to the limited exceptions set forth in Section [4] of Article II, in the event that the Committee
determines that this Policy should apply, to the extent permitted by applicable law, the Company shall, as determined by the Committee in its
sole discretion, take any such actions as it deems necessary or appropriate to recover Incentive-Based Compensation. The actions may
include, without limitation (and as applicable):
4
EU1/ 502027227.2
Adopted Nov. 20, 2023

(a)
forfeit, reduce or cancel any Incentive-Based Compensation (whether vested or unvested) that has not been distributed or
otherwise settled;
(b)
seek recovery of any Incentive-Based Compensation that was previously paid to the Executive Officer;
(c)
seek recovery of any amounts realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any
Incentive-Based Compensation;
(d)
recoup any amount in respect of Incentive-Based Compensation that was contributed or deferred to a plan that takes into
account Incentive-Based Compensation (excluding certain tax-qualified plans, but including deferred compensation plans, and supplemental
executive retirement plans, and insurance plans to the extent otherwise permitted by applicable law, including Section 409A of the Code) and
any earnings accrued on such Incentive-Based Compensation;
(e)
except as otherwise required by Article II, determine whether Incentive-Based Compensation should be recouped on a pre-
tax or after-tax basis;
(f)
offset, withhold, eliminate or cause to be forfeited any amount that could be paid or awarded to the Executive Officer after
the date of determination; and
(g)
take any other remedial and recovery action permitted by law, as determined by the Committee.
(h)
In addition, (i) the Committee may authorize legal action for breach of fiduciary duty or other violation of law and take such
other actions to enforce the obligations of the Executive Officer to the Company as the Committee deems appropriate, or (ii) in the event that
an Executive Officer fails to repay or reimburse erroneously awarded compensation that is subject to recovery, the Committee may require an
Executive Officer to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in
recovering erroneously awarded compensation under this Policy.
Section 2.
Notice. Before the Company takes action to seek recovery of compensation pursuant to this Policy against an Executive
Officer the Company shall take commercially reasonable steps to provide such individual with advance written notice of such clawback;
provided that this notice requirement shall not in any way delay the reasonably prompt recovery of any erroneously awarded Incentive-Based
Compensation pursuant to Article II.
Section 3.
No Indemnification. The Company shall not indemnify any current or former Executive Officer against the loss of
erroneously awarded compensation, and shall not pay or reimburse any such person for premiums incurred or paid for any insurance policy to
fund such person’s potential recovery obligations.
5
EU1/ 502027227.2
Adopted Nov. 20, 2023

EXHIBIT 21.1
Subsidiaries of Replimune Group, Inc.
Name of Subsidiary
Jurisdiction
Replimune, Inc.
Delaware
Replimune Limited
United Kingdom
Replimune Securities Corporation
Massachusetts
Replimune (Ireland) Limited
Ireland
EU1/ 55029326.1


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-265805) and Form S-8 (Nos. 333-
226323, 333-256314 and 333-272031) of Replimune Group, Inc. of our report dated May 16, 2024 relating to the financial statements, which
appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
May 16, 2024

Exhibit 31.1
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Sushil Patel, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Replimune Group, Inc.;
2.
 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: May 16, 2024
By:
/s/ SUSHIL PATEL
Sushil Patel
Chief Executive Officer
(Principal Executive Officer)

Exhibit 31.2
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Emily Hill, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Replimune Group, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal
control over financial reporting.
Date: May 16, 2024
By:
/s/ EMILY HILL
Emily Hill
Chief Financial Officer
(Principal Financial Officer)

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Replimune Group, Inc. (the "Company") for the fiscal year ended March 31, 2024, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Sushil Patel, Chief Executive Officer of the Company,
hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his
knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 16, 2024
By:
/s/ SUSHIL PATEL
Sushil Patel
Chief Executive Officer
(Principal Executive Officer)

Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Replimune Group, Inc. (the "Company") for the fiscal year ended March 31, 2024, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Emily Hill, Chief Financial Officer of the Company,
hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her
knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 16, 2024
By:
/s/ EMILY HILL
Emily Hill
Chief Financial Officer
(Principal Financial Officer)